AU2013221970A1 - Inhibitors of poly(ADP-ribose)polymerase - Google Patents

Abstract

INHIBITORS OF POLY(ADP-RIBOSE)POLYM ERASE Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.

Description

INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE RELATED APPLICATIONS This application claims priority to U.S. Application No. 60/882,317, filed December 28, 2006. FIELD OF THE INVENTION This invention relates to inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them. BACKGROUND OF THE INVENTION Poly(ADP-ribose)polymerase (PARP) is essential for facilitating DNA repair, controlling RNA transcription, mediating cell death and regulating immune response. This activity makes PARP inhibitors targets for a number of disorders. PARP inhibitors have shown utility for treating diseases such as ischemia reperfusion injury, inflammatory disease, retroviral infections, ischemia reperfusion injury, myocardial infarction, stroke and other neural trauma, organ transplantation, reperfusion of the eye, kidney, gut and skeletal muscle, arthritis, gout, inflammatory bowel disease, CNS inflammation such as MS and allergic encephalitis, sepsis, septic shock, hemmorhagic shock, pulmonary fibrosis, and uveitis, diabetes and Parkinsons disease, liver toxicity following acetominophen overdose, cardiac and kidney toxicities from doxorubicin and platinum-based antineoplastic agents and skin damage secondary to sulfur mustards. PARP inhibitors have also been shown to potentiate radiation and chemotherapy by increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals. US 2002/0183325 Al describes phtalazinone derivatives as PARP inhibitors. US 2004/0023968 Al describes phtalazinone derivatives as PARP inhibitors. US 2005/0085476 Al describes fused pyridazine derivatives as PARP inhibitors. US 2005/0059663 Al describes phtalazinone derivatives as PARP inhibitors. US 2006/0063767 Al describes phtalazinone derivatives as PARP inhibitors. US 2006/0142293 Al describes phtalazinone derivatives as PARP inhibitors. US 2006/0149059 Al describes phtalazinone derivatives as PARP inhibitors. US 2007/0093489 Al describes phtalazinone derivatives as PARP inhibitors. 1 There is therefore a need in the therapeutic arts for PARP inhibitors. Such compounds can be used to treat subjects suffering from cancer, and can further expand the range of treatment options available for such subjects. SUMMARY OF THE INVENTION One embodiment of this invention, therefore, pertains to compounds that inhibit the activity of poly(ADP-ribose) polymerase and have formula I 0 A NH - N

A

2 (I), and pharmaceutically acceptable salts thereof, wherein A' is R 1 or R 2 , wherein A' is unsubstituted or substituted with one or two OH, CN, C1-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, C 5 -alkyl, cycloalkane, OR or NRRA; R is H or alkyl;

R

1 is cycloalkane or cycloalkene each of which is unfused or fused with RiA RiA is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 is heterocycloalkane or heterocycloalkene; each of which is unfused or fused with R2A.

R

2 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; A2 is OR 4 , NHR 4 , N(R 4

)

2 , SR 4 , S(O)R 4 , S0 2

R

4 or R ; wherein each R 4 is C1-alkyl, C 2 -alkyl or C 3 -alkyl; each of which is substituted with R 1; 2

R

5 is CI-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl or C 5 -alkyl; each of which is substituted with R 10 , and further unsubstituted or substituted with one or two or three of independently selected OR 10 , NHR 10 , N(R 0

)

2 , SR 10 , S(O)R 10 , S0 2

R

1 0 or CF 3 ; wherein each R 10 is R10A, R10B or R10C; each of which must be attached at a carbon atom; R 1A is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; N" R10B is 'IN NN s / oro/ ; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R10C is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein each R 10 is independently unsubstituted or substituted with one or two or three of independently selected, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , NHR", N(R 11

)

2 ,

C(O)R

11 , C(O)OR 11 , C(O)NH 2 , C(O)NHR 11 , C(O)N(R 1 )2, NHC(O)R 11 , NR 11

C(O)R

11 ,

NHSO

2 R", NR"IS0 2 R", NHC(O)OR 11 , NR 11

C(O)OR

11 , NHSO 2

NH

2 , NHSO 2

NHR

11 ,

NHSO

2

N(R

1

)

2 , SO 2

NH

2 , SO 2

NHR

11 , SO 2

N(R

11

)

2 , NHC(O)NH 2 , NHC(O)NHR 1 , 3 NHC(O)N(R")2, NR"C(O)N(R") 2 , NO 2 , OH, (0), C(O)H, C(O)OH, CN, CF 3 , OCF 3 ,

CF

2

CF

3 , F, Cl, Br or I; wherein each R 11 is R 12 , R 13 , R 14 or R1;

R

12 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

13 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

14 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rio, ORi 6 , SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 16

)

2 , C(O)Rio, C(O)NH 2 , C(O)NHRio, C(O)N(R 16

)

2 , NHC(O)Rio, NR 16

C(O)R

16 , NHC(O)ORio

NR

1 6

C(O)OR

1 6 , OH, F, Cl, Br or I; wherein each R 16 is R" or Rl 7

A

R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rs , C(O)OH, NH 2 , NHR 1 or N(R )2, C(O)R", C(O)NH 2 , C(O)NHR", C(O)N(R )2, NHC(O)R 8 , NR 8

C(O)R

8 , F, Cl, Br or I; R 1A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 4 wherein each R 18 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein each of the moieties represented by R", R", R", R 7 , and R 18 are independently unsubstituted or substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR19, 19 1 9 1 91 91

NH

2 , NHR , N(R 9)2, NHC(O)R 9, NR19C(O)R 9, NHS(O) 2 R 9, NR19S(O) 2 R'9, NHC(O)OR 9, NR19C(O)OR 9, NHC(O)NH 2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR19C(O)NHR 9, NR19C(O)N(R 9)2, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R 9, C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 ,

CF

3 , CF 2

CF

3 , OCF 3 , OCF 2

CF

3 , F, Cl, Br or I; wherein each R 19 is R 20 , R 21 , R 22 or R ; R20 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 1 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected R 24, OR24, SR 24, S(O) 2 R24, C(O)OH, NH 2 , NHR24 N(R 24)2, 5 C(O)R24, C(O)NH 2 , C(O)NHR24, C(O)N(R 24)2, NHC(O)R24 , NR 2 4

C(O)R

2 4 , NHC(O)OR24 NR24C(O)OR24 , NHS(O) 2 R24 , NR 2 4

S(O)

2

R

2 4 , OH, F, Cl, Br or I; wherein each R 2 4 is R 2 4 A or R 2 4 B. R24A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 24 is alkyl, alkenyl or alkynyl each of which is unsubstituted or substituted with one or two of independently selected R , OR , SR 25 , S(O) 2

R

2 5 , C(O)OH, NH 2 , NHR N(R 2 5

)

2 ,

C(O)R

25 , C(O)NH 2 , C(O)NHR 25 , C(O)N(R 2 5

)

2 , NHC(O)R 25 , NR 25

C(O)R

2 5 , NHC(O)OR 25 , NR C(O)OR , OH, F, Cl, Br or I; wherein each R 25 is alkyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl ; each of which is unsubstituted or substituted with

NH

2 , NH(CH 3 ), N(CH 3

)

2 , OH or OCH 3 ; wherein each of the moieties represented by R 20 , R 2 1 , R 2 2 , and R 2 4 A are independently unsubstituted or substituted with one or two of independently selected R 26 , OR 26 , alkenyl, alkynyl, phenyl, OH, (0), C(O)OH, CN, CF 3 , OCF 3 , CF 2

CF

3 , F, Cl, Br or I; and R26 is alkyl. Still another embodiment comprises pharmaceutical compositions comprising a compound having formula I and an excipient. Still another embodiment comprises methods of inhibiting PARP in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. 6 Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I 0 A NH

-

N

A

2 (I), or a salt thereof, wherein A' is R 1 or R 2 , wherein A' is unsubstituted or substituted with one or two OH, CN, CI-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, C 5 -alkyl, cycloalkane, OR or NRRA; R is H or alkyl;

R

1 is cycloalkane or cycloalkene each of which is unfused or fused with RIA RiA is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 is heterocycloalkane or heterocycloalkene; each of which is unfused or fused with R2A.

R

2 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; A2 is OR 4 , NHR 4 , N(R 4

)

2 , SR 4 , S(O)R 4 , S0 2

R

4 or R ; wherein each R 4 is CI-alkyl, C 2 -alkyl or C 3 -alkyl; each of which is substituted with Ri; 7

R

5 is CI-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl or C 5 -alkyl; each of which is substituted with R 10 , and further unsubstituted or substituted with one or two or three of independently selected OR 10 , NHR 10 , N(R 0

)

2 , SR 10 , S(O)R 10 , S0 2

R

1 0 or CF 3 ; wherein each R 10 is R10A, R10B or R10C; each of which must be attached at a carbon atom; R 1A is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; N" R10B is 'IN NN s / oro/ ; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R10C is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein each R 10 is independently unsubstituted or substituted with one or two or three of independently selected, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , NHR", N(R 11

)

2 ,

C(O)R

11 , C(O)OR 11 , C(O)NH 2 , C(O)NHR 11 , C(O)N(R 1 )2, NHC(O)R 11 , NR 11

C(O)R

11 ,

NHSO

2 R", NR"IS0 2 R", NHC(O)OR 11 , NR 11

C(O)OR

11 , NHSO 2

NH

2 , NHSO 2

NHR

11 ,

NHSO

2

N(R

1

)

2 , SO 2

NH

2 , SO 2

NHR

11 , SO 2

N(R

11

)

2 , NHC(O)NH 2 , NHC(O)NHR 1 , 8 NHC(O)N(R")2, NR"C(O)N(R") 2 , NO 2 , OH, (0), C(O)H, C(O)OH, CN, CF 3 , OCF 3 ,

CF

2

CF

3 , F, Cl, Br or I; wherein each R 11 is R 12 , R 13 , R 14 or R1;

R

12 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

13 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

14 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rio, ORi 6 , SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 16

)

2 , C(O)Rio, C(O)NH 2 , C(O)NHRio, C(O)N(R 16

)

2 , NHC(O)Rio, NR 16

C(O)R

16 , NHC(O)ORio

NR

1 6

C(O)OR

1 6 , OH, F, Cl, Br or I; wherein each R 16 is R" or Rl 7

A

R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rs , C(O)OH, NH 2 , NHR 1 or N(R )2, C(O)R", C(O)NH 2 , C(O)NHR", C(O)N(R )2, NHC(O)R 8 , NR 8

C(O)R

8 , F, Cl, Br or I; R 1A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 9 wherein each R 18 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein each of the moieties represented by R", R", R", R 7 A, and R18 are independently unsubstituted or substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR19, 19 1 9 1 91 91

NH

2 , NHR , N(R 9)2, NHC(O)R 9, NR19C(O)R 9, NHS(O) 2 R 9, NR19S(O) 2 R'9, NHC(O)OR 9, NR19C(O)OR 9, NHC(O)NH 2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR19C(O)NHR 9, NR19C(O)N(R 9)2, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R 9, C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 ,

CF

3 , CF 2

CF

3 , OCF 3 , OCF 2

CF

3 , F, Cl, Br or I; wherein each R 19 is R 20 , R 21 , R 22 or R ; R20 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 1 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected R 24, OR24, SR 24, S(O) 2 R24, C(O)OH, NH 2 , NHR24 N(R 24)2, 10 C(O)R24, C(O)NH 2 , C(O)NHR24, C(O)N(R 24)2, NHC(O)R24 , NR 2 4

C(O)R

2 4 , NHC(O)OR24 NR24C(O)OR24 , NHS(O) 2 R24 , NR 2 4

S(O)

2

R

2 4 , OH, F, Cl, Br or I; wherein each R 2 4 is R 2 4 A or R 2 4 B. R24A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 24 is alkyl, alkenyl or alkynyl each of which is unsubstituted or substituted with one or two of independently selected R , OR , SR 25 , S(O) 2

R

2 5 , C(O)OH, NH 2 , NHR N(R 2 5

)

2 ,

C(O)R

25 , C(O)NH 2 , C(O)NHR 25 , C(O)N(R 2 5

)

2 , NHC(O)R 25 , NR 25

C(O)R

2 5 , NHC(O)OR 25 , NR C(O)OR , OH, F, Cl, Br or I; wherein each R 25 is alkyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl ; each of which is unsubstituted or substituted with

NH

2 , NH(CH 3 ), N(CH 3

)

2 , OH or OCH 3 ; wherein each of the moieties represented by R 20 , R, R, and R 2 4 A are independently unsubstituted or substituted with one or two of independently selected R 26 , OR 26 , alkenyl, alkynyl, phenyl, OH, (0), C(O)OH, CN, CF 3 , OCF 3 , CF 2

CF

3 , F, Cl, Br or I; and R26 is alkyl. Still another embodiment comprises methods for decreasing tumor volume in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I Still another embodiment comprises the use of a compound of Formula I for the preparation of a medicament for the treatment of cancer. 11 Still another embodiment comprises a method of treating leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast or cervical carcinomas in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises the use of a compound of Formula I for the preparation of a medicament for the treatment of leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast or cervical carcinomas. Still another embodiment comprises methods for potentiation of cytotoxic cancer therapy in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods for potentiation of radiation therapy in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating ischemia reperfusion injury associated with myocardial infarction, stroke, neural trauma or organ transplantation in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating reperfusion of the eye, kidney, gut or skeletal muscle in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treatingarthritis, gout, inflammatory bowel disease, CNS inflammation, multiple sclerosis, allergic encephalitis, sepsis, septic shock, hemmorhagic shock, pulmonary fibrosis or uveitis in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. 12 Still another embodiment comprises a method of treating rheumatoid arthritis or septic shock in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating diabetes or Parkinsons disease in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating hypoglycemia in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating retroviral infection in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating liver toxicity following acetominophen overdose in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises a method of treating cardiac or kidney toxicities from doxorubicin or platinum based antineoplastic agents in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises methods of treating skin damage secondary to sulfur mustards in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having formula I. Still another embodiment comprises the compounds 2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid; 4-(3-amino-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 13 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)amino)-4 oxobutanoic acid; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5 dione; 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-(aminomethyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-((dimethylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(4-fluoro-3-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-((cyclohexylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(4-fluoro-3-((tetrahydro-2H-pyran-4-ylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(4-fluoro-3-((methyl((1-methylpyrrolidin-3-yl)methyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -((methyl(((2R)- 1 -methylpyrrolidin-2-yl)methyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -(morpholin-4-ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -(pyrrolidin- 1 -ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((cyclohexylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((methylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((ethylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-methylpiperidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3-(((2-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((cyclohexyl(methyl)amino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((2-ethylpyrrolidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-(morpholin-4-ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-(pyrrolidin- 1 -ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((cyclohexylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 14 4-(4-((4-phenylpiperidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((methylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((ethylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((4-methylpiperidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-(((2-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(4-((cyclohexyl(methyl)amino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((2-methylpyrrolidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-((4-methyl- 1,4-diazepan- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-methyl-1,4-diazepan- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -pyrimidin-2-ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -pyridin-3 -ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -pyridin-4-ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N,N-diethyl-2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1 '-biphenyl 2-carboxamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3-piperidin- 1 ylpropanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3-(4 methylpiperazin- 1 -yl)propanamide; 2-amino-N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 3 -cyclohexyl-N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)piperidine-3 carboxamide; 4-(4-fluoro-3 -(2-oxopyrrolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)azetidine-3 carboxamide; N-(2-(isopropylamino)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-morpholin-4 ylacetamide; 15 N-(2-morpholin-4-ylethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-pyrrolidin- 1 ylethyl)benzamide; 4-(3-((2-methylpyrrolidin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-azepan-1-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; 4-(3-(piperazin- 1 -ylcarbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-azetidin-3-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-piperidin-3-ylbenzamide; N-(4-(dimethylamino)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-methylpiperazin- 1 -yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 4-(3-((4-(isoxazol-5-ylcarbonyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-phenylpiperidin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(piperidin-2-ylmethyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(piperidin-4-ylmethyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-piperidin- 1 -ylethyl)benzamide; N-(1 -methylazetidin-3 -yl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; methyl 4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate; N-methyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide; 4-((2-(methylthio)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-(methylsulfonyl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-(methylsulfinyl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((3-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((6-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; methyl 6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate; N-ethyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide; 16 N-isopropyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide; N-cyclohexyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide; N-((1 -methylpiperidin-2-yl)methyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-((1 -methylpiperidin-4-yl)methyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-methyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide; N-ethyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide; N-isopropyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide; N-cyclopropyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide; N-cyclohexyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide; methyl 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate; methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate; 4-((5-bromothien-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-((3-bromothien-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-aminobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-bromobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(thien-2-ylmethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)thiophene-2-carboxylate; N-methyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide; N-ethyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide; N-methyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide; N-ethyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide; N,N-dimethyl-N'-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)sulfamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-piperidin-1 ylpropanamide; 4-chloro-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)butanamide; 17 4-(3-(2-oxopyrrolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-(2-oxoazetidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-(2-oxopyrrolidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((2-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((6-(2-oxopyrrolidin- 1 -yl)pyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((6-(2-oxoazetidin- 1 -yl)pyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)benzamide; N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)isonicotinamide; N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)nicotinamide; 4-((5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-2,2'-bipyridin-5-yl)methyl) 5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-methyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)thiophene-2-carboxamide; Nl-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)glycinamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-2-carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-3-carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)methanesulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)propane-2-sulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzenesulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyridine-3-sulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)furan-2-sulfonamide; 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-imidazole 4-sulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)thiophene-2-sulfonamide; 4-cyano-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzenesulfonamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)naphthalene-1 sulfonamide; 4-((6-bromopyridin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((6-(2-oxopyrrolidin- 1 -yl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)benzamide; 4-((3'-((isopropylamino)methyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 18 4-((3'-((cyclopentylamino)methyl)- 1,1 '-biphenyl-3 -yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-((3'-((2-methylpyrrolidin- 1 -yl)methyl)- 1,1 '-biphenyl-3 -yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-((3'-((cyclopropylamino)methyl)- 1,1 '-biphenyl-3 -yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-((3'-((cyclobutylamino)methyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-((2-bromo- 1 -oxidopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-((1 -oxido-2-(2-oxopyrrolidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)thiophene-3-carboxylate; 4-(3-((4-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-1,4-diazepan-1-yl)carbonyl)-4 fluorobenzyl)phthalazin- 1 (2H)-one; 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)cyclopropanecarboxamide; 2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)cyclopropanecarboxamide; 3 -ethoxy-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)propanamide; 5 -oxo-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-L-prolinamide; 5 -oxo-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-D-prolinamide; N -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)cyclopropane-1,1 dicarboxamide; 2-(benzyloxy)-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)acetamide; N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 -phenylpropanamide; 3 -(2,5 -dimethoxyphenyl)-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1 phenylcyclopropanecarboxamide; (2S)-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 phenylbutanamide; N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4-phenylbutanamide; 19 2-(3-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 2-(2-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 2-(4-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; (2R)-2-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 phenylacetamide; (2S)-2-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 phenylacetamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-phenoxypropanamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4-thien-2-ylbutanamide; 1 -acetyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)piperidine-4 carboxamide; 2-(3,5-difluorophenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 2 N -acetyl-N 1 -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-L leucinamide; N -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N 2

,N

2 -dipropyl-L alaninamide; 4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4 phenylbutanamide; N-(2-oxo-2-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenylamino)ethyl)benzamide; 3-(3-methoxyphenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide; 3-(4-methoxyphenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide; 2-(3,4-dimethylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; (2R)-2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4 phenylbutanamide; 20 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-phenoxybutanamide; 4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4-thien-2 ylbutanamide; 2-((4-methylpyrimidin-2-yl)thio)-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 3-(2-chlorophenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)propanamide; 3-(4-chlorophenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)propanamide; 3-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 phenylpentanamide; 2-(4-chloro-2-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-N' phenylpentanediamide; 4-(4-methoxyphenyl)-4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)butanamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2,2-diphenylacetamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3 (phenylsulfonyl)propanamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-(3 phenoxyphenyl)acetamide; 4-ethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 3-fluoro-2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 5-fluoro-2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 3-fluoro-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 2,3-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 2,4-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 2,5-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 21 3,5-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-propylbenzamide; 4-isopropyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 2-ethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide; 4-isopropoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 4-(diethylamino)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 4-butoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 2-fluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 (trifluoromethyl)benzamide; 2-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 (trifluoromethyl)benzamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-furamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-furamide; 2,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3-furamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-2-carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-3-carboxamide; 3-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)thiophene-2 carboxamide; 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)thiophene-2 carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-pyrrole-2 carboxamide; 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-pyrrole-2 carboxamide; 2,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)- 1 H-pyrrole 3-carboxamide; 1,2,5-trimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)- 1H pyrrole-3-carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-2 carboxamide; 22 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-4 carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-5 carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)isoxazole-5-carboxamide; 3,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)isoxazole-4 carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)nicotinamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)isonicotinamide; 3-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)pyridine-2 carboxamide; 2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)nicotinamide; 6-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)nicotinamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-pyridin-2-ylacetamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-pyridin-3-ylacetamide; 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)pyrazine-2 carboxamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-indole-3 carboxamide; 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1-phenyl-1H pyrazole-4-carboxamide; 6-chloro-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2H-chromene 3-carboxamide;

N

3

,N

3 -dimethyl-N -(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-beta alaninamide; 4-(2-(3 -bromophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2-(3 -bromo-4-fluorophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2,2,2-trifluoro- 1 -phenylethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 2-hydroxy-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide; 4-acetyl-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 23 3-methoxy-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide; 4-ethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide; 3-fluoro-4-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1-naphthamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-naphthamide; 5-chloro-2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide; 4-tert-butyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 4-(acetylamino)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-propoxybenzamide; 1 -hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 naphthamide; 2-chloro-5-(methylthio)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 3,4-diethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 2-benzyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide; 2-anilino-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide; 2-benzoyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-(2 phenylethyl)benzamide; 5-bromo-2-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide; 2-(4-methylbenzoyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide; 2-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 3-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; 4-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide; N-(2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1 '-biphenyl-3 yl)acetamide; 24 4-((6-fluoro-3'-(methylsulfonyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-((6-fluoro-3'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-((6-fluoro-4'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3 -yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1 '-biphenyl-3 carboxamide; 2'-fluoro-N,N-dimethyl-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1' biphenyl-4-carboxamide; 4-(3,3,3-trifluoro-2-phenylpropyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2-phenylethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2-(3 -bromophenyl)propyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)piperazine-1-carboxylate; 4-benzyl 1-tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)piperazine-1,4 dicarboxylate; 4-(2-(3-nitrophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(2-(3-aminophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(piperazin-2-ylmethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2-(3 -(2-oxopyrrolidin- 1 -yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(3 -(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)phenyl)-2-phenoxyacetamide; 4-(2-(6-fluoro-3'-(morpholin-4-ylcarbonyl)- 1,1 '-biphenyl-3 -yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; methyl 3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoate; methyl 3-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoate; 4-(2-(6-fluoro-4'-(morpholin-4-ylcarbonyl)-1,1'-biphenyl-3-yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(2-(6-fluoro-2'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3 -yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(2-(6-fluoro-3'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3 -yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 25 N-cyclopropyl-2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-carboxamide; N-(2-(dimethylamino)ethyl)-2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)- 1,1 '-biphenyl-3-carboxamide; 2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 carboxamide; N-(2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 yl)methanesulfonamide; N-(2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 yl)acetamide; 4-(2-(6-fluoro-3'-(morpholin-4-ylcarbonyl)- 1,1 '-biphenyl-3-yl)propyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(2-(6-fluoro-3'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3 -yl)propyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; N-cyclopropyl-2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl) 1,1 '-biphenyl-3-carboxamide; 4-(3-amino-4-chlorobenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3-amino-4-methoxybenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3-amino-4-hydroxybenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3-amino-4-methylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(2-(dimethylamino)ethyl)-3'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)- 1,1 '-biphenyl-3-carboxamide; 3'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 carboxamide; N-(3'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 yl)acetamide; 3'-(1 -(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 -carboxamide; N-(3'-(1 -(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 -yl)acetamide; N-(2-(dimethylamino)ethyl)-3'-(1 -(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-carboxamide; 3-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoic acid; 26 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4-(4 methoxyphenyl)-4-oxobutanamide; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3,4-dimethyl 1H-pyrrole-2,5-dione; 3-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 azabicyclo(3. 1.0)hexane-2,4-dione; 4-((4-(phenoxyacetyl)piperazin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(2-(3-bromo-4-fluorophenyl)propyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-oxo-N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)phenyl)-4 phenylbutanamide; 2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1 '-biphenyl-3 carboxamide; N-(2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-yl)acetamide; N-((2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-yl)methyl)methanesulfonamide; 2-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)hexahydro- 1 H isoindole- 1,3(2H)-dione; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3,3 dimethylpyrrolidine-2,5-dione; 4-(4-fluoro-3-(2-methyl-5-oxopyrrolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxo- 1,3-oxazolidin-3-yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3-(2-oxoazepan- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)piperidine-2,6 dione; 4-(4-fluoro-3-(2-oxoimidazolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3-(1,1 -dioxidoisothiazolidin-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxoazetidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3-(2-oxopiperidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N-(3-furylmethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; 27 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(thien-2-ylmethyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(thien-3-ylmethyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(pyridin-3-ylmethyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(pyridin-4-ylmethyl)benzamide; N-(2-(dimethylamino)ethyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-(dimethylamino)propyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(3-pyrrolidin- 1 ylpropyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(3-piperidin- 1 ylpropyl)benzamide; N-(3-morpholin-4-ylpropyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(1 H-indol-3-yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N- 1,3-thiazol-2-ylbenzamide; benzyl 2-oxo-2-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)ethyl)phenylamino)ethylcarbamate; 4-oxo-N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)phenyl)-4-(4 phenoxyphenyl)butanamide; benzyl 3-(((3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)ethyl)phenyl)amino)carbonyl)piperidine- 1 -carboxylate; 2-(4-methylphenoxy)-N-(3 -(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)phenyl)acetamide; 2-(4-methoxyphenoxy)-N-(3 -(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)phenyl)acetamide; 4-(4-fluoro-3 -(3 -methyl-2-oxoimidazolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3 -(2-oxotetrahydropyrimidin- 1 (2H)-yl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 28 4-(3-(3-tert-butyl-2-oxoimidazolidin- 1 -yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(4-fluoro-3-((1 S,4R)-3-oxo-2-azabicyclo(2.2. 1)hept-2-yl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; N-(2-ethylphenyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-(3 -ethylphenyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-(4-ethylphenyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-propylphenyl)benzamide; N-(2-isopropylphenyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-(4-isopropylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; N-(3-tert-butylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; N-(4-tert-butylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; N- 1,1 '-biphenyl-4-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-(2-fluoro-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3 -fluoro-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(4-fluoro-2-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(4-fluoro-3-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3 -chloro-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(4-chloro-3-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-bromo-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(4-bromo-3-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-fluoro-4-methoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 29 N-(3 -methoxy-5-(trifluoromethyl)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-hydroxy-6-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-hydroxy-2-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-hydroxy-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-methoxy-5-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-methoxy-4-methylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3-hydroxy-4-methoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(2-ethoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(4-propoxyphenyl)benzamide; N-(5-tert-butyl-2-methoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(5 -(acetylamino)-2-methoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-2,3-dihydro- 1,4-benzodioxin-6-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(5 -chloro-2,4-dimethoxyphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(3 -(methylthio)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(4-(methylthio)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(4-piperidin- 1 ylphenyl)benzamide; N-(4-morpholin-4-ylphenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 30 N-(2-anilinophenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-(4-((4-methoxyphenyl)amino)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-quinolin-6-ylbenzamide; N-(5-hydroxy- 1 -naphthyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-i H-indazol-6-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; 8-(4-fluorobenzyl)pyrido(2,3-d)pyridazin-5(6H)-one; 8-(3-chloro-4-fluorobenzyl)pyrido(2,3-d)pyridazin-5(6H)-one; (3aR)-8-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-2,3,3a,4-tetrahydro- 1 H pyrrolo(2, 1 -c)(1,4)benzoxazin- 1-one; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N methylmethanesulfonamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-hydroxy-2 methylpropanamide; (3 aS)-8-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-2,3,3 a,4-tetrahydro- 1 H pyrrolo(2, 1 -c)(1,4)benzoxazin- 1-one; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-phenylethyl)benzamide; N-(2-(2-methylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3 -methylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-methylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-pyridin-2-ylethyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-pyridin-3 -ylethyl)benzamide; 3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-pyridin-4-ylethyl)benzamide; N-(2-(2-methoxyphenyl)ethyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3 -methoxyphenyl)ethyl)-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 31 N-(2-(4-methoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2-fluorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3-fluorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-fluorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2-chlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3-chlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-chlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3-bromophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-bromophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(1,1 '-biphenyl-4-yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-(3 (trifluoromethyl)phenyl)ethyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-(4 (trifluoromethyl)phenyl)ethyl)benzamide; 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-(4 phenoxyphenyl)ethyl)benzamide; N-(2-(3,4-dimethylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(2-(2,4-dimethylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(2-(2,5-dimethylphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; 32 N-(2-(3-ethoxy-4-methoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(4-ethoxy-3-methoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2,3-dimethoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2,4-dimethoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(2-(2,5-dimethoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3,4-dimethoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide; N-(2-(3,5-dimethoxyphenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(1,3-benzodioxol-5-yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2,3-dichlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(3,4-dichlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-(2-(2,6-dichlorophenyl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; (3aS,4R,7S,7aR)-5-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)-2,2-dimethyltetrahydro-4,7-methano(1,3)dioxolo(4,5-c)pyridin-6(3aH) one; 4-(1-(3-bromo-4-fluorophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(1-(4-fluoro-3-(2-oxopyrrolidin- 1 -yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 8-(4-fluorobenzyl)-2,3,4,6-tetrahydropyrido(2,3 -d)pyridazin-5 (1 H)-one; 8-(3-bromo-4-fluorobenzyl)pyrido(2,3-d)pyridazin-5(6H)-one; N-(2-(dimethylamino)ethyl)-N-ethyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 33 N-(2-(diethylamino)ethyl)-N-methyl-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-benzyl-N-ethyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N-benzyl-N-isopropyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; N-benzyl-N-butyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzamide; N,N-dibenzyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide; N-benzyl-N-(2-hydroxyethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; N-methyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)-N-(2-pyridin-2 ylethyl)benzamide; N-(2-(3,4-dimethoxyphenyl)ethyl)-N-methyl-3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide; 4-(3-((4-hydroxypiperidin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 1-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzoyl)piperidine-3 carboxamide; 1-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzoyl)piperidine-4 carboxamide; 4-(3-((4-(2-oxo-2,3-dihydro- 1 H-benzimidazol- 1 -yl)piperidin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-methylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-ethylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzoyl)piperazine- 1 carbaldehyde; 4-(3 -((4-acetylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-(2-hydroxyethyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(3 -((4-phenylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-pyridin-2-ylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(3 -((4-pyrimidin-2-ylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 34 4-(3-((4-(2-(2-hydroxyethoxy)ethyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(3 -((4-(2-fluorophenyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(3 -((4-(4-fluorophenyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(3 -((4-(2-chlorophenyl)piperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(3 -((4-methyl-1,4-diazepan- 1 -yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(3 -(1,1 -dioxido- 1,2-thiazinan-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 8-(4-fluoro-3 -(2-oxoazetidin- 1 -yl)benzyl)pyrido(2,3 -d)pyridazin-5 (6H)-one; 8-(3 -chloro-4-fluorobenzyl)-2,3,4,6-tetrahydropyrido(2,3 -d)pyridazin-5 (1 H)-one; 4-(1-(4-fluoro-3 -(2-oxoazetidin- 1 -yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 1-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)pyrrolidine-2,5 -dione; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-(2 oxopyrrolidin- 1 -yl)acetamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 -methyl-I phenyl- 1 H-pyrazole-4-carboxamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 oxohexanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 methoxypropanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N' phenylpentanediamide; benzyl 2-(dimethylamino)-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenylcarbamate; 8-(4-fluoro-3-(2-oxoazetidin-1-yl)benzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H) one; 4-(3-bromo-4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(4-fluoro-3-(2-oxoazetidin-1-yl)phenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 2-fluoro-5-((5-oxo-5,6-dihydropyrido(2,3-d)pyridazin-8-yl)methyl)benzamide; 35 8-(3-amino-4-fluorobenzyl)pyrido(2,3-d)pyridazin-5(6H)-one; 8-(4-fluoro-3-(2-oxopyrrolidin- 1 -yl)benzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1 H) one; methyl 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzoate; 8-(3-amino-4-fluorobenzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H)-one; 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)benzoic acid; N-ethyl-2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; N-cyclobutyl-2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)-N-(2 pyrrolidin- 1 -ylethyl)benzamide; 8-(4-fluoro-3 -((4-(morpholin-4-ylcarbonyl)piperazin- 1 -yl)carbonyl)benzyl)-2,3,4,6 tetrahydropyrido(2,3 -d)pyridazin-5 (1 H)-one; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-N' phenylpentanediamide; 1-(2-fluoro-5 -((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8 yl)methyl)phenyl)pyrrolidine-2,5-dione; N-(2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)phenyl)-3 methoxypropanamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-5 oxohexanamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-3 phenoxypropanamide; N-(2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)phenyl)-4 oxo-4-phenylbutanamide; 2-(4-(benzyloxy)phenoxy)-N-(2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3 d)pyridazin-8-yl)methyl)phenyl)acetamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-2 (4-methoxyphenoxy)acetamide; 36 N-cyclopropyl-2-fluoro-5-((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; 8-(3-((4-(2-ethoxyethyl)piperazin- 1 -yl)carbonyl)-4-fluorobenzyl)-2,3,4,6 tetrahydropyrido(2,3 -d)pyridazin-5 (1 H)-one; 2-fluoro-5-((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)-N-(2-piperidin 1 -ylethyl)benzamide; 2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(3,2-d)pyridazin-8-yl)methyl)-N-(2-oxo-2 (piperidin- 1 -yl)ethyl)benzamide; 4-(4-fluoro-3 -((4-pyrimidin-2-ylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin-1(2H)-one; and 4-(4-fluoro-3 -(2-oxopyrrolidin- 1 -yl)phenyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; and therapeutically salts, prodrugs, esters, amides, salts of prodrugs, salts of esters and salts of amides thereof. DETAILED DESCRIPTION OF THE INVENTION Variable moieties of compounds herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied. It is meant to be understood that proper valences are maintained for all combinations herein, that monovalent moieties having more than one atom are attached through their left ends. It is also meant to be understood that a specific embodiment of a variable moiety may be the same or different as another specific embodiment having the same identifier. Abbreviations which have been used in the descriptions of the schemes and the examples that follow are: BOC is Di-tert-butyl dicarbonate C-18 is dimethyl-octadecylsilane DCI for chemical ionization for direct introduction, DME for 1,2-dimethoxyethane, DMSO for dimethylsulfoxide, ESI for electrospray ionization, HATU for O-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 37 HPLC for high performance liquid chromatography, MS for mass spectrometry, TFA for trifluoroacetic acid, As used in reference to 1 H NMR, the symbol "6" refers to a 1 H NMR chemical shift. As used in reference to 1 H NMR, the abbreviation "br" refers to a broad 1 H NMR signal. As used in reference to 1 H NMR, the abbreviation "d" refers to a doublet 1 H NMR peak. As used in reference to 1H NMR, the abbreviation "dd" refers to a doublet of doublets 1H NMR peak. As used in reference to 1H NMR, the abbreviation "m" refers to a multiplet 1H NMR peak. As used in reference to 1H NMR, the abbreviation "q" refers to a quartet 1 H NMR peak. As used in reference to 1H NMR, the abbreviation "s" refers to a singlet 1 H NMR peak. As used in reference to 1H NMR, the abbreviation "t" refers to a triplet 1 H NMR peak. The term "alkenyl," as used herein, means monovalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as

C

2 -alkenyl, C 3 -alkenyl, C 4 -alkenyl, C 5 -alkenyl, C 6 -alkenyl and the like. The term "alkyl," as used herein, means monovalent, saturated, straight or branched chain hydrocarbon moieties, such as CI-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, C 5 -alkyl, C 6 -alkyl and the like. The term "alkynyl," as used herein, means monovalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon triple bonds, such as

C

2 -alkynyl, C 3 -alkynyl, C 4 -alkynyl, C 5 -alkynyl, C 6 -alkynyl and the like. The term "cycloalkane," as used herein, means saturated cyclic or bicyclic hydrocarbon moieties, such as C 4 -cycloalkane, C 5 -cycloalkane, C 6 -cycloalkane,

C

7 -cycloalkane, Cs-cycloalkane, C 9 -cycloalkane, Cio-cycloalkane, C 1 i-cycloalkane,

C

1 2 -cycloalkane and the like. The term "cycloalkyl," as used herein, means monovalent, saturated cyclic and bicyclic hydrocarbon moieties, such as C 3 -cycloalkyl, C 4 -cycloalkyl, C 5 -cycloalkyl, 38

C

6 -cycloalkyl, C 7 -cycloalkyl, Cs-cycloalkyl, C 9 -cycloalkyl, Cio-cycloalkyl, Cii-cycloalkyl,

C

1 2 -cycloalkyl and the like. The term "cycloalkene," as used herein, means cyclic and bicyclic hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C 5 -cycloalkene,

C

6 -cycloalkene, C 7 -cycloalkene, Cs-cycloalkene, C 9 -cycloalkene, Cio-cycloalkene, C11-cycloalkene, C 12 -cycloalkene and the like. The term "cycloalkenyl," as used herein, means monovalent, cyclic hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C 4 -cycloalkenyl,

C

5 -cycloalkenyl, C 6 -cycloalkenyl, C 7 -cycloalkenyl, Cs-cycloalkenyl, C 9 -cycloalkenyl, Cio-cycloalkenyl, C 11 -cycloalkenyl, C 1 2 -cycloalkenyl and the like. The term "heteroarene," as used herein, means furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, 1,3,4-thiadiazole, thiophene, triazine and 1,2,3-triazole. The term "heteroaryl," as used herein, means furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, 1,2,3-thiadiazoyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiophenyl, triazinyl and 1,2,3-triazolyl. The term "heterocycloalkane," as used herein, means cycloalkane having one or two or three CH 2 moieties replaced with independently selected 0, S, S(O), SO 2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkane having one or two or three CH 2 moieties unreplaced or replaced with independently selected 0, S, S(O),

SO

2 or NH and one or two CH moieties replaced with N. The term "heterocycloalkene," as used herein, means cycloalkene having one or two or three CH 2 moieties replaced with independently selected 0, S, S(O), SO 2 or NH and one or 39 two CH moieties unreplaced or replaced with N and also means cycloalkene having one or two or three CH 2 moieties unreplaced or replaced with independently selected 0, S, S(O),

SO

2 or NH and one or two CH moieties replaced with N. The term "heterocycloalkyl," as used herein, means cycloalkyl having one or two or three CH 2 moieties replaced with independently selected 0, S, S(O), S02 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkyl having one or two or three CH 2 moieties unreplaced or replaced with independently selected 0, S, S(O), S02 or NH and one or two CH moieties replaced with N. The term "heterocycloalkenyl," as used herein, means cycloalkenyl having one or two or three CH 2 moieties replaced with independently selected 0, S, S(O), SO 2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkenyl having one or two or three CH 2 moieties unreplaced or replaced with independently selected 0, S, S(O),

SO

2 or NH and one or two CH moieties replaced with N. The term "cyclic moiety," as used herein, means benzene, cycloalkane, cycloalkyl, cycloalkene, cycloalkenyl, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and phenyl. Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms "R" and "S" are as defined in Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those atoms. Atoms having excess of one configuration over the other are assigned the configuration in excess, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace racemic mixtures, relative and absolute diastereoisomers and the compounds thereof. Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term "Z" represents 40 the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double bond and the term "E" represents the larger two substituents on opposite sides of a carbon carbon or carbon-nitrogen double bond. The compounds of this invention may also exist as a mixture of "Z" and "E" isomers. Compounds of this invention containing NH, C(O)H, C(O)OH, C(O)NH 2 , OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed NH, C(O)H, C(O)OH, C(O)NH 2 , OH or SH in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance. Metabolites of compounds having Formula I, produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases caused or exacerbated by unregulated or overexpressed poly(ADP-ribose)polymerase. Certain precursor compounds of compounds having Formula I may be metabolized in vitro or in vivo to form compounds having Formula I and may thereby also have utility for treating diseases caused or exacerbated by unregulared or overexpressed poly(ADP ribose)polymerase. Compounds having Formula I may exist as acid addition salts, basic addition salts or zwitterions. Salts of compounds having Formula I are prepared during their isolation or following their purification. Acid addition salts are those derived from the reaction of a compound having Formula I with acid. Accordingly, salts including the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate and undecanoate 41 salts of the compounds having Formula I are meant to be embraced by this invention. Basic addition salts of compounds are those derived from the reaction of the compounds having Formula I with the bicarbonate, carbonate, hydroxide, or phosphate of cations such as lithium, sodium, potassium, calcium and magnesium. Compounds having Formula I may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperintoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally and vaginally. Therapeutically effective amounts of a compound having Formula I depend on recipient of treatment, disease treated and severity thereof, composition comprising it, time of administration, route of administration, duration of treatment, potency, rate of clearance and whether or not another drug is co-administered. The amount of a compound having Formula I used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.001 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof. Compounds having Formula I may be administered with or without an excipient. Excipients include, for example, encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof. Compounds having Formula I may be radiolabeled with a radioactive isotope such as carbon (i.e. 13 C), hydrogen (i.e. 3 H), nitrogen (i.e. 15 N), phosphorus (i.e. 3 2 P), sulfur (i.e. 35 S), iodide (i.e. mI) and the like. Radioactive isotopes may be incorporated into the compounds having Formula I by reacting the same and a radioactive derivitizing agent or by incorporating a radiolabeled intermediate into their syntheses. The radiolabeled compounds of Formula I are useful for both prognostic and diagnostic applications and for in vivo and in vitro imaging. 42 Compounds having Formula I may be incorporated into devices such as, but not limited to, arterio-venous grafts, billiary stents, by-pass grafts, catheters, central nervous system shunts, coronary stents, drug delivery balloons, peripheral stents and ureteural stents, each of which may be used in areas such as, but not limited to, the vasculature for introduction of a compound having Formula I into selected tissues or organs in the body. One measure of the effectivness of compounds having Formula I is reduction or elimination of device-associated thrombi and complications associated therewith. Compounds having Formula I can used as a radiosensitizers which enhance the efficacy of radiotherapy. Examples of radiotherapy include, but are not limited to, external beam radiotherapy, teletherapy, brachtherapy and sealed and unsealed source radiotherapy. Excipients for preparation of compositions comprising a compound having Formula I to be administered orally include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered ophthalmically or orally include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered osmotically include, for example, chlorofluoro-hydrocarbons, ethanol, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be 43 administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof Excipients for preparation of compositions comprising a compound having Formula I to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof. Compounds having formula I are also expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, aurora kinase inhibitors, Bcr-Abl kinase inhibitors, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors inhibitors, hormonal therapies, immunologicals, intercalating antibiotics, kinase inhibitors, mammalian target of rapomycin inhibitors, mitogen-activated extracellular signal-regulated kinase inhibitors, non-steroidal anti-inflammatory drugs (NSAID's), platinum chemotherapeutics, polo-like kinase inhibitors, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, topoisomerase inhibitors and the like. Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CloretazineTM (VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, treosulfan, trofosfamide and the like. Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) 44 inhibitors, thrombospondin analogs v r e owth factor receptor tyrosn kiae(EF inhibitors and the like. Aurora kinase inhibitors include AZD-1 152, MLN-8054, VX-680 and the like. Bcr-Abl kinase inhibitors include DASATINIB* (BMS-354825), GLEEVEC* (imatinib) and the like. CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like. COX-2 inhibitors include ABT-963, ARCOXIA* (etoricoxib), BEXTRA* (valdecoxib), BMS347070, CELEBREX TM (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX* (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4 sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX* (rofecoxib) and the like. EGFR inhibitors include ABX-EGF, anti-EGFr immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA* (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB* (lapatinib) and the like. ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), Herceptin* (trastuzumab), TYKERB* (lapatinib), OMNITARG* (2C4, petuzumab), TAK-165, GW-572016 (ionafamib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like. Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like. 45 HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB*, NCS-683664, PU24FCl, PU 3, radicicol, SNX-2112, STA-9090 VER49009 and the like. MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like. mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus and the like. Non-steroidal anti-inflammatory drugs include AMIGESIC* (salsalate), DOLOBID* (diflunisal), MOTRIN* (ibuprofen), ORUDIS® (ketoprofen), RELAFEN* (nabumetone), FELDENE® (piroxicam) ibuprofin cream, ALEVE® and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN* (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE* (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like. PDGFR inhibitors include C-451, CP-673, CP-868596 and the like. Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin and the like. Polo-like kinase inhibitors include BI-2536 and the like. Thrombospondin analogs include ABT-5 10, ABT-567, ABT-898, TSP-1 and the like. VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788,

ANGIOZYME

TM

, axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, Macugen (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), (PTK-787, ZK-2225 84), SUTENT® (sunitinib, SU- 11248), VEGF trap, vatalanib, ZACTIMA TM (vandetanib, ZD-6474) and the like. 46 Antimetabolites include ALIMTA* (premetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA* (capecitabine), carmofur, LEUSTAT* (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflomithine, EICAR, enocitabine, ethnylcytidine, fludarabine, hydroxyurea, 5 fluorouracil (5-FU) alone or in combination with leucovorin, GEMZAR* (gemcitabine), hydroxyurea, ALKERAN*(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like. Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE* (bleomycin), daunorubicin, CAELYX* or MYOCET* (doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS* (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR* (valrubicin), zinostatin and the like. Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR* (irinotecan hydrochloride), camptothecin, CARDIOXANE* (dexrazoxine), diflomotecan, edotecarin, ELLENCE* or PHARMORUBICIN* (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like. Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT 1/B, denosumab, ERBITUX* (cetuximab), HUMAX-CD4* (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX* (edrecolomab), RENCAREX* (WX G250), RITUXAN* (rituximab), ticilimumab, trastuzimab and and the like. Hormonal therapies include ARIMIDEX* (anastrozole), AROMASIN* (exemestane), arzoxifene, CASODEX* (bicalutamide), CETROTIDE* (cetrorelix), degarelix, deslorelin, DESOPAN* (trilostane), dexamethasone, DROGENIL*, (flutamide), EVISTA* (raloxifene), fadrozole, FARESTON* (toremifene), FASLODEX® (fulvestrant),FEMARA*, (letrozole), 47 formestane, glucocorticoids, HECTOROL* or RENAGEL* (doxercalciferol), lasofoxifene, leuprolide acetate, MEGACE* (megesterol), MIFEPREX* (mifepristone), NILANDRON TM (nilutamide), NOLVADEX* (tamoxifen citrate), PLENAXIS TM (abarelix), predisone, PROPECIA* (finasteride), rilostane, SUPREFACT* (buserelin), TRELSTAR* (luteinizing hormone releasing hormone (LHRH)), vantas, VETORYL*, (trilostane or modrastane), ZOLADEX* (fosrelin, goserelin) and the like. Deltoids and retinoids include seocalcitol (EB 1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN* (aliretinoin), ATRAGEN*(liposomal tretinoin), TARGRETIN*(bexarotene), LGD-1550 and the like. Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like. Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like. Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-la, ACTIMMUNE* (interferon gamma-lb), or interferon gamma-ni, combinations thereof and the like. Other agents include ALFAFERONE®, BAM-002, BEROMUN* (tasonermin), BEXXAR* (tositumomab), CamPath® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE* (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010, melanoma vaccine, mitumomab, molgramostim, MYLOTARGTM (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OvaRex* (oregovomab), pemtumomab (Y-muHMFGi), PROVENGE®, sargaramostim, sizofilan, teceleukin, TheraCys*, ubenimex, VIRULIZIN*, Z-100, WF-10, PROLEUKIN* (aldesleukin), ZADAXIN* (thymalfasin), ZENAPAX* (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like. Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells 48 to direct them to have anti-tumor activity and include include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like. Pyrimidine analogs include cytarabine (ara C), cytosine arabinoside, doxifluridine, FLUDARA* (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR* (gemcitabine), TOMUDEX* (ratitrexed), TROXATYL TM (triacetyluridine troxacitabine) and the like. Purine analogs include LANVIS* (thioguanine) and PURI-NETHOL* (mercaptopurine). Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4 hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE* (docetaxel), PNU100940 (109881), patupilone, XRP-988 1, vinflunine, ZK-EPO and the like. Compounds of the present invention are also intended to be used as a radiosensitizer that enhances the efficacy of radiotherapy. Examples of radiotherapy include, but are not limited to, external beam radiotherapy, teletherapy, brachtherapy and sealed and unsealed source radiotherapy. Additionally, compounds having formula I may be combined with other chemptherapeutic agents such as ABRAXANE TM (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN*, ALTOCOR* or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN TM (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotne), AVE-8062, BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CeaVacTM (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX TM (human papillomavirus vaccine), CHOP* (C: CYTOXAN* (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); 0: Vincristine (ONCOVIN*); P: prednisone), CyPat

TM

, combrestatin A4P, DAB(389)EGF or TransMID-107RTM (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone 4-acetic acid (DMXAA), eniluracil, EVIZON TM (squalamine lactate), DIMERICINE* (T4N5 49 liposome lotion), discodermolide, DX-895 If (exatecan mesylate), enzastaurin, EP0906, GARDASIL* (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), gastrimmune, genasense, GMK (ganglioside conjugate vaccine), GVAX* (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL 13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-a, interferon-y, JUNOVANTM or MEPACTTM (mifamurtide), lonafarnib, 5,10 methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT*(AE 941), NEUTREXIN* (trimetrexate glucuronate), NIPENT* (pentostatin), ONCONASE" (a ribonuclease enzyme), ONCOPHAGE* (melanoma vaccine treatment), OncoVAX (IL-2 Vaccine), ORATHECIN TM (rubitecan), OSIDEM* (antibody-based cell drug), OvaRex* MAb ( murine monoclonal antibody), paditaxel, PANDIMEX T M (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC*-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB* (catumaxomab), REVLIMID* (lenalidomide), RSR13 (efaproxiral), SOMATULINE* LA (lanreotide), SORIATANE* (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN* (bexarotene), Taxoprexin* (DHA-paclitaxel), TELCYTA TM (TLK286), temilifene, TEMODAR* (temozolomide), tesmilifene, thalidomide, THERATOPE* (STn KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFeradeTM (adenovector: DNA carrier conitainiiig the gene for Tumor necrosis factor-u), TRACLEER* or ZAVESCA* (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX* (arsenic trioxide), VIRULIZIN*, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN* (motexafin gadolinium), XINLAY TM (atrasentan), XYOTAX TM (paclitaxel poliglumex), YONDELIS TM (trabectedin), ZD-6126, ZINECARD* (dexrazoxane), zometa (zolendronic acid), zorubicin and the like. In one embodiment, compounds having Formula I are used in a method of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound of claim 1 in combination with a chemotherapeutic agent selected from temozolomide, dacarbazine, cyclophosphamide, carmustine, melphalan, lomustine, 50 carboplatin, cisplatin, 5-FU +/- leucovorin, gemcitabine, methotrexate, bleomycin, irinotecan, camptothecin, or topotecan. It is expected that compounds having formula I would also inhibit growth of cells derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like (commonly-owned United States Application Ser No. 10/988,338), Cancer Res., 2000, 60, 6101-10); and autoimmune disorders include, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, thrombocytopenia and the like (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 Sep; 110(3): 584-90; Blood 2000 Feb 15;95(4):1283-92; and New England Journal of Medicine 2004 Sep; 351(14): 1409-1418). PARP Enzyme Inhihition Assay Nicotinamide[2,5',8-3H]adenine dinucleotide and strepavidin SPA beads were purchased from Amersham Biosiences. Recombinant Human Poly(ADP-Ribose) Polymerase (PARP), purified from E.coli and 6-Biotin-17-NAD*, were purchase from Trevigen. NAD*, histone, aminobenzamide, 3-amino benzamide and Calf Thymus DNA (dcDNA) were purchased from Sigma. Stem loop oligonucleotide containing MCAT sequence was obtained from Qiagen. The oligos were dissoloved to 1 mM in annealing buffer containing 10 mM Tris HCl pH 7.5, 1 mM EDTA, and 50 mM NaCl, incubated for 5 minutes at 95'C, and annealed at 45'C for 45 minutes. Histone HI (95% electrophoretically pure) was purchased from Roche. Biotinylated histone HI was prepared by treating the protein with Sulfo-NHS 51 LC-Biotin from Pierce. The biotinylation reaction was conducted by slowly and intermittently adding 3 equivalents of 10mM Sulfo-NHS-LC-Biotin to 100tM Histone HI in phosphate-buffered saline, pH 7.5, at 4'C with gentle vortexing over 1 minute followed by subsequent 4'C incubation for 1 hour. Streptavidin coated (FlashPlate Plus) microplates were purchased from Perkin Elmer. PARPI assay was conducted in PARP assay buffer containing 50 mM Tris pH 8.0, 1mM DTT, 4 mM MgCl 2 . PARP reactions contained 1.5 tM [ 3 H]-NAD* (1.6uCi/mmol), 200 nM biotinylated histone HI, 200 nM slDNA, and 1 nM PARP enzyme. Auto reactions utilizing SPA bead-based detection were carried out in 100 tL volumes in white 96 well plates. Reactions were initiated by adding 50 tl of 2X NAD+ substrate mixture to 50 tL of 2X enzyme mixture containing PARP and DNA. These reactions were terminated by the addition of 150 tL of 1.5 mM benzamide (~1000-fold over its IC50). 170 tL of the stopped reaction mixtures were transferred to streptavidin Flash Plates, incubated for 1 hour, and counted using a TopCount microplate scintillation counter. The EC 5 os for exemplified compounds of this invention are provided in Table 1. Cellular PARP assay: C41 cells were treated with a compound of this invention for 30 minutes in 96 well plate. PARP was then activated by damaging DNA with 1 mM H 2 0 2 for 10 minutes. The cells were then washed with ice-cold PBS once and fixed with pre-chilled methanol:acetone (7:3) at -20'C for 10 minutes. After air-drying, the plates were rehydrated with PBS and blocked 5% non-fat dry milk in PBS-TWEEN20@ (Sigma, St. Louis, MO) (0.05%) (blocking solution) for 30 minutes at room temperature. The cells were incubated with anti-PAR antibody I0H (1:50) in Blocking solution at 37 0 C for 60 minutes followed by washing with PBS- TWEEN20@ 5 times, and incubation with goat anti-mouse fluorescein 5(6) isothiocyanate-coupled antibody (1:50) and 1 pig/ml 4',6-diamidino-2-phenylindole (DAPI) in blocking solution at 37 0 C for 60 minutes. After washing with PBS- TWEEN20@ 5 times, the analysis was performed using an FMAX FLUORESCENCE MICROPLATE READER@ (Molecular Devices, Sunnyvalle, CA), set at the excitation wavelength of 490 nm and emission wavelength of 528 nm fluorescein 5(6)-isothiocyanate (FITC) or the excitation 52 wavelength of 355 nm and emission wavelength of 460 nm (DAPI). The PARP activity (FITC signal) was normalized with cell numbers (DAPI). The cellular assay measures the formation of poly ADP-ribose by PARP within cells and demonstrates that compounds of this invention penetrate cell membranes and inhibit PARP in intact cells. Due to variability in the cellular assay, 2-(1-propylpiperidin-4-yl)-1H benzimidazole-4-carboxamide was run as a comparator in each assay and data reported as the ratio of test compound EC 50 relative to the EC 5 o of 2-(1-propylpiperidin-4-yl)-1H benzimidazole-4-carboxamide obtained in that particular assay. The mean EC 5 0 of 2-(1 propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide for all assays carried out was 0.0032 gM (n=270) and generally ranged from 0.001 to 0.013 gM. (ratio EC 5 0 = EC 5 0 test compound / EC50 comparator compound). The EC 5 o data (nM) are shown in TABLE 1. TABLE 1 Inhibition of PARP by Compounds Having Formula I PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 5 o, nM (Ki, nM) EC 5 o, nM 1 91 18 83 2 44 19 75 278 3 3 >300 20 480 4 1.5 0.5 21 148 5 1.1 17 22 372 6 108 23 562 7 534 24 794 8 862 25 1610 9 319 26 1720 10 411 27 2110 11 1489 28 682 12 963 29 516 13 225 30 766 14 173 31 700 15 390 32 1960 16 307 33 347 17 283 34 1030 53 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 35 1820 64 40 11 36 2130 65 82 37 673 66 87 >1000 38 6 75 67 50 700 39 48 >300 68 351 40 23 >300 69 40 43 41 1010 70 101 42 20 13 71 639 43 8 2.3 72 144 44 2 13 73 86 45 14 >300 74 102 46 42 75 56 >1000 47 1.2 1.2 76 473 48 0.7 49 77 195 49 20 59 78 165 50 19 >300 79 18 121 51 47 80 47 570 52 13 15 81 123 53 10 15 82 691 54 205 83 126 55 1 15 84 617 56 5 >300 85 396 57 60 86 390 58 51 373 87 56 59 24 69 88 96 60 3 6.9 89 111 61 6 12 90 68 62 42 91 70 63 23 >1000 92 167 54 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 93 840 122 644 94 856 123 121 95 1260 125 47 798 96 2610 126 286 97 390 127 14 13 98 286 128 43 99 44 179 129 41 53 100 39 110 130 24 57 101 21 162 131 32 102 26 148 132 1040 103 1050 133 724 104 1230 134 133 105 725 135 16 106 290 136 76 107 216 137 69 108 576 138 22 62 109 609 139 206 110 372 140 60 111 12 61 141 77 112 136 142 11 41 113 6 662 143 78 114 65 286 144 125 115 157 145 57 116 578 146 678 117 477 147 41 118 2030 148 74 119 703 149 22 262 120 626 150 16 140 121 776 151 531 55 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 152 741 181 212 153 6 95 182 292 154 56 183 166 155 126 184 154 156 25 185 250 157 124 186 160 158 1590 187 1250 159 4 30 188 185 160 11 40 189 175 161 64 190 263 162 51 191 31 143 163 35 192 43 164 28 98 193 100 165 14 244 194 61 166 5 40 195 177 167 56 196 286 168 127 197 146 169 99 198 403 170 1700 199 196 171 56 200 158 172 3 5 201 570 173 2 32 202 93 174 655 203 103 175 21 215 204 203 176 43 205 176 177 156 206 18 212 178 462 208 22 423 179 238 209 395 180 159 210 56 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 211 98 240 285 212 65 241 1450 213 82 242 610 214 7 238 243 92 215 85 244 2340 216 82 245 963 217 5 44 246 52 218 86 247 48 219 9 38 248 2 43 220 14 137 249 85 221 1540 250 210 222 248 251 446 223 206 252 19 >1000 224 9220 253 229 225 41 254 4120 226 40 >1000 255 335 227 60 256 346 228 98 257 2280 229 49 258 1770 230 96 259 91 231 110 260 243 232 12 >1000 261 556 233 158 262 304 234 57 263 144 235 198 264 662 236 4 >1000 265 58 >1000 237 68 266 19 >1000 238 47 267 534 239 554 268 638 57 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 269 1050 298 2 2.7 270 487 299 4 5.5 271 1140 300 2 1.2 272 204 301 6 26 273 257 302 2 2.6 274 222 303 0.8 0.4 275 471 304 17 26 276 943 305 3 4 277 436 306 6 23 278 185 307 2 4 279 467 308 30 280 303 309 29 281 309 310 26 282 1710 311 58 283 442 312 131 284 2210 313 95 285 150 314 32 286 58 >1000 315 23 10 287 771 316 34 288 431 317 25 39 289 0.7 16 318 28 290 1 6 319 94 291 0.7 0.2 320 165 292 116 321 223 293 338 322 556 294 204 323 237 295 912 324 131 296 683 325 5 36 297 1440 326 70 58 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 327 1630 356 180 328 7 48 357 402 329 789 358 66 330 99 359 151 331 140 360 94 332 635 361 76 333 892 362 185 334 191 363 132 335 122 364 316 336 363 365 120 337 124 366 23 105 338 136 367 45 339 120 368 56 340 279 369 4210 341 154 370 4310 342 134 371 14 51 343 87 372 1570 344 194 373 22 211 345 149 374 27 346 33 158 375 51 347 337 376 173 348 259 377 42 349 55 378 28 350 143 379 20 173 351 277 380 71 352 154 381 67 353 59 382 79 354 363 383 44 355 92 384 40 59 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 385 42 414 119 386 33 415 3200 387 44 418 34 388 88 419 16 2.1 389 48 420 21 390 31 421 68 391 44 422 105 392 30 423 120 393 70 424 31 394 22 426 14 28 395 38 427 22 132 396 83 428 5 14 397 50 429 19 398 82 430 5 226 399 65 434 6 6.3 400 22 435 20 13 401 48 436 10 1.8 402 86 437 4 403 56 438 3 6.4 404 55 439 8 9.4 405 19 135 440 3 3.4 406 42 441 3 2 407 22 659 442 0.8 0.9 408 69 443 16 14 409 33 444 4 410 242 445 6 2.3 411 8 4.6 446 10 16 412 324 447 10 4 413 18 51 448 694 60 PARP-1 Cell, Ratio PARP-1 Cell, Ratio (Ki, nM) EC 50 , nM (Ki, nM) EC 50 , nM 449 103 481 12 33 450 122 483 5 16 451 56 484 14 18 452 2 2.5 485 14 53 453 14 486 15 9.6 454 16 487 10 41 455 1.3 0.9 490 0.7 0.7 456 5 14 491 191 457 0.7 0.2 458 2490 459 3 7 460 580 461 404 462 163 463 1880 464 5 3.1 465 3.5 13 467 116 468 249 470 18 10 471 51 472 9 25 473 2 106 474 1.4 4 475 1.4 13 476 12 30 477 4 6 478 2 15 479 1.3 3.5 61 Selected compounds of Formula I wherein A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is CI-alkyl were run in the PARP Enzyme Inhihition Assay and the PARP Cellular Assay described above. Compounds outside of 5 Formula I wherein at the position of A 2 is instead a bond also were run in the PARP Enzyme Inhihition Assay and the PARP Cellular Assay described above. The results of the assays are described in TABLE 2, below: TABLE 2 A2 is R5, wherein R5 is PARP Cell No A2 PARP Cell

C

1 -alkyl -1 (Ki, Ratio -1 (Ki, Ratio nM) EC 50 nM) EC 50 H 6 16.4 H 291 - F 0N, N N 0 F H 1.2 0.85 H 191 N, F N, F O 0 Selected compounds of Formula I wherein A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is C1-alkyl wherein R 5 is substituted with R 10 , wherein R 10 is phenyl, either with a para-subsituted F, as shown in Formula (Is): 0 NH /NR1 01 R02

R

10 5 F R104 (Is), or without a para-subsituted F were run in the PARP Enzyme Inhihition Assay and the PARP Cellular Assay described above. 62 Cell Cell PARP-1 PARP-1 Hydrogen analogs Ratio Fluoro Analogs Ratio (Ki, nM) (Ki, nM) EC 5 0 ECso Es o 122 50NH 2 H2 2.9 5.8 N1 NH NH H H ONH F 0 6.3 4(. 0.7 34.4 N NU H I H N H .1.9 2 0.7 2.6 3. 3.0 .6 03 HH 0 NH F 39.6 40.9 1.2 0.85 N63 H H 0 N F N2 1.7 ~N1.1 0.19 0 0 0 N ) N' 3.2 3.2' NYN ) 0.6 0.34 H 0 H 00 NH F 0 N N N N ~A NI. 63 Cell Cell PARP-1 PARP-1 Hydrogen analogs Ratio Fluoro Analogs Ratio (Ki, nM) (Ki, nM) EC 5 0 ECso Es HF H N 0 N N 0 N k N > S N 280 H 18.4 5.6 HNN N N N_ Fl 0~ ~ N' 0.8 0.93 0.7 0.3 As PARP inhibitors, the compounds of this invention have numerous therapeutic applications related to ischemia reperfusion injury, inflammatory diseases, degenerative diseases, protection from adverse effects of cytotoxic compounds, and potentiation of 5 cytotoxic cancer therapy. In particular, compounds of this invention potentiate radiation and chemotherapy by increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing mammals. Compounds having fomula I can treat leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast, and cervical carcinomas. 10 Other therapeutic applications include retroviral infection, arthritis, gout, inflammatory bowel disease, CNS inflammation, multiple sclerosis, allergic encephalitis, 64 sepsis, septic shock, hemmorhagic shock, pulmonary fibrosis, uveitis, diabetes, Parkinsons disease, myocardial infarction, stroke, other neural trauma, organ transplantation, reperfusion of the eye, reperfusion of the kidney, reperfusion of the gut, reperfusion of skeletal muscle, liver toxicity following acetominophen overdose, cardiac and kidney toxicities from 5 doxorubicin and platinum based antineoplastic agents, and skin damage secondary to sulfur mustards. (G. Chen et al. Cancer Chemo. Pharmacol. 22 (1988), 303; C. Thiemermann et al., Proc. Natl. Acad. Sci. USA 94 (1997), 679-683 D. Weltin et al. Int. J. Immunopharmacol. 17 (1995), 265- 271; H. Kr6ger et al. Inflammation 20 (1996), 203-215; W. Ehrlich et al. Rheumatol. Int. 15 (1995), 171-172; C. Szabo et al., Proc. Natl. Acad. Sci. USA 95 (1998), 0 3867-3872; S. Cuzzocrea et al. Eur. J. Pharmacol. 342 (1998), 67-76; V. Burkhart et al., Nature Medicine (1999), 5314-19). Compounds of Formula I In one embodiment of formula I 0 All NH - N 5

A

2 (I), or a salt thereof, wherein Al is R 1 or R 2 , wherein Al is unsubstituted or substituted with one or two OH, CN, 20 C1-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, C 5 -alkyl, cycloalkane, OR or NRRA; R is H or alkyl;

R

1 is cycloalkane or cycloalkene each of which is unfused or fused with RIA 25 RiA is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 is heterocycloalkane or heterocycloalkene; each of which is unfused or fused with 30 R2A. 65

R

2 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 5 A 2 is OR 4 , NHR 4 , N(R 4

)

2 , SR 4 , S(O)R 4 , S0 2

R

4 or R5; wherein each R4 is CI-alkyl, C 2 -alkyl or C 3 -alkyl; each of which is substituted with R ;0 0 R 5 is CI-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl or C 5 -alkyl; each of which is substituted with R 10 , and further unsubstituted or substituted with one or two or three of independently selected OR 10 , NHR 10 , N(R 0

)

2 , SR 10 , S(O)R 10 , S0 2

R

1 0 or CF 3 ; wherein each R 10 is R10A, R10B or R10C; each of which must be attached at a carbon 5 atom; R 1A is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or '0 heterocycloalkene; N N N N N N R10B s , O O o each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which are unfused or fused with benzene, 25 heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 66 RioC is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 5 wherein each R 10 is independently unsubstituted or substituted with one or two or three of independently selected R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2

R

1 1 , NH 2 , NHR 11 , N(R 11

)

2 ,

C(O)R

11 , C(O)OR 11 , C(O)NH 2 , C(O)NHR 11 , C(O)N(R 1 )2, NHC(O)R 11 , NR 11

C(O)R

11 ,

NHSO

2

R

11 , NR"ISO 2

R

11 , NHC(O)OR 11 , NR 11

C(O)OR

11 , NHSO 2

NH

2 , NHSO 2

NHR

11 ,

NHSO

2

N(R

1

)

2 , SO 2

NH

2 , SO 2

NHR

11 , SO 2

N(R

11

)

2 , NHC(O)NH 2 , NHC(O)NHR 1 , 0 NHC(O)N(R 1 )2, NR"C(O)N(R 1

)

2 , NO 2 , OH, (O), C(O)H, C(O)OH, CN, CF 3 , OCF 3 ,

CF

2

CF

3 , F, Cl, Br or I; wherein each R 11 is R 12 , R 13 , R 14 or R ; 5 R 12 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

13 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, '0 cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

14 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane 25 or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rio, OR 6 , SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 16

)

2 , 30 C(O)Rio, C(O)NH 2 , C(O)NHRio, C(O)N(R 16

)

2 , NHC(O)Rio, NR 16

C(O)R

16 , NHC(O)ORio

NR

1 6

C(O)OR

1 6 , OH, F, Cl, Br or I; wherein each R 16 is R" or Rl 7

A

67 R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rs , C(O)OH, NH 2 , NHR 1 or N(R 8)2, C(O)R 8, C(O)NH 2 , C(O)NHR 8, C(O)N(R 8)2, NHC(O)R 8 , NR 18

C(O)R

8 , F, Cl, Br or I; 5 R 1A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 0 wherein each R 18 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein each of the moieties represented by R , R", R", R 7 A, and R 18 are independently unsubstituted or substituted with one or two or three or four of independently 5 selected R 19 , OR 9, SR 9, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR19, 19 1 9 1 91 91

NH

2 , NHR , N(R 9)2, NHC(O)R 9, NR19C(O)R 9, NHS(O) 2 R 9, NR19S(O) 2 R'9, NHC(O)OR 9, NR19C(O)OR 9, NHC(O)NH 2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR19C(O)NHR 9, NR19C(O)N(R 9)2, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R 9, C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, '0 C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 ,

CF

3 , CF 2

CF

3 , OCF 3 , OCF 2

CF

3 , F, Cl, Br or I; wherein each R 19 is R 20 , R 21 , R 22 or R ; 25 R20 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R

2 1 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, 30 cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 68 R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 5 R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected R 24, OR24, SR 24, S(O) 2 R24, C(O)OH, NH 2 , NHR24 N(R 24)2, C(O)R24, C(O)NH 2 , C(O)NHR24, C(O)N(R 24)2, NHC(O)R24 , NR 2 4

C(O)R

2 4 , NHC(O)OR24 NR24C(O)OR24 , NHS(O) 2 R24 , NR 2 4

S(O)

2

R

2 4 , OH, F, Cl, Br or I; 0 wherein each R 2 4 is R 2 4 A or R24. R24A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, 5 cycloalkene, heterocycloalkane or heterocycloalkene; R 24 is alkyl, alkenyl or alkynyl each of which is unsubstituted or substituted with one or two of independently selected R , OR , SR 25 , S(O) 2

R

2 5 , C(O)OH, NH 2 , NHR N(R 2 5

)

2 ,

C(O)R

25 , C(O)NH 2 , C(O)NHR 25 , C(O)N(R 2 5

)

2 , NHC(O)R 25 , NR 25

C(O)R

25 , NHC(O)OR 25 , '0 NR C(O)OR , OH, F, Cl, Br or I; wherein each R 25 is alkyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl ; each of which is unsubstituted or substituted with

NH

2 , NH(CH 3 ), N(CH 3

)

2 , OH or OCH 3 ; 25 wherein each of the moieties represented by R 20 , R 2 1 , R 2 2 , and R 2 4 A are 266 independently unsubstituted or substituted with one or two of independently selected R2 OR 26, alkenyl, alkynyl, phenyl, OH, (0), C(O)OH, CN, CF 3 , OCF 3 , CF 2

CF

3 , F, Cl, Br or I; and 30 R26 is alkyl. 69 Embodiments of Formula I Selected subclasses of compounds of interest that fall within the scope of the compounds of formula I are shown in the various embodiments described below, wherein A', R1, RA, R , R2, R2A, A2, R, R', R , R 10B, R 10c, R", R1, R1, R1, R, R16, R , R 1A, ,R 9, R20 5 R , R2, R2, R24, R24A, R24B, R and R 26 can be as defined for the compounds of Formula I and as defined in the various embodiments described throughout this specification. Embodiments of A In one embodiment of formula I, A1 is R 1 or R 2 , wherein R 1 is an unfused cycloalkane and R 2 0 is an unfused heterocycloalkane, wherein A is unsubstituted or is substituted with one or two OH, CN, C1-alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, Cs-alkyl, cycloalkane, ORA or NRARA; wherein RA is H or alkyl. In another embodiment of formula I, A is R 1 or R 2 , wherein R 1 is cyclohexane and R 2 is piperidinyl, wherein A 1 is unsubstituted or is substituted with one or two C1-alkyl, C 2 -alkyl or C 3 -alkyl. In another embodiment of formula I, A is R 1 or R 2 , 5 wherein R1 is unsubstituted cyclohexane and R2 is unsubstituted piperidinyl. In another embodiment of formula I, A 1 is R 1 , and R 1 is unsubstituted cyclohexane, as shown in formula (Ta): 0 NH A2 (Ta). Embodiments of A 2 20 In one embodiment of formula I, A 2 is OR 4 , NHR 4 , N(R 4

)

2 , SR 4 , S(O)R 4 , S0 2

R

4 or R wherein each R4 is C1-alkyl, C 2 -alkyl or C 3 -alkyl; each of which is substituted with R 10 as described in Formula I; and R 5 is C1-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted as described in formula I. In another embodiment of formula I, A 2 is R 5 , and R 5 is C1-alkyl, C 2 alkyl or C 3 -alkyl wherein R 5 is substituted as described in formula I. In another embodiment 25 of formula I, A 2 is R 5 , wherein R 5 is C1-alkyl, which is substituted with R 1 0 , and further unsubstituted or substituted with one or two or three of independently selected NHR 10 , N(R 0)2, SR 10 , S(O)R 10 , S0 2

R

10 or CF 3 , wherein R 10 is as described in formula I. In another embodiment of formula I, A 2 is R 5 , wherein R 5 is C1-alkyl, substituted with R 10 as described in Formula I and further unsubstituted as shown in formula (Ib): 70 0 NH

R

10 (Ib). In another embodiment of formula I, A 2 is R 5 , wherein R 5 is C 2 -alkyl, substituted with R 10 as described in Formula I and further unsubstituted as shown in formulas (Ic) and (Id): 0 0 C NH S N A' NH / N

R

10 (Ic) R 10 (Id). In another embodiment of formula I, A 2 is R , 5 wherein R 5 is C 3 -alkyl, substituted with R 1 0 as described in Formula I and further unsubstituted. In another embodiment of formula I, A 2 is R 5 , wherein R 5 is C1-alkyl or C 2 alkyl; each of which are substituted with R 10 as described in Formula I and further substituted with CF 3 . 0 Embodiments of R 10 In one embodiment of formula I, R is R 0A, R10B or RioC, wherein R10^ is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, R10B is N N O sr and RioC is heterocycloalkyl, which is unfused, wherein R 10 is optionally substituted as described in Formula I. In another embodiment of 15 formula I, R 10 is R0A, R10B or RiOC, wherein ROA is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, R10B is N N O N"' s sand RioC is heterocycloalkyl, which is unfused; wherein R1 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR1, SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , 20 C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 1 , 71

NHSO

2

N(R")

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br, wherein R 11 is as described in Formula I. In another embodiment of formula I, R 10 is R10A, R10B or Ro c, wherein R1OA is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, R 10Bis N N ON , and RioC is heterocycloalkyl, which is unfused; 5 wherein R 10 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR1, SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 1 , C(O)OR 11 ,

C(O)NHR

11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R 11 is R , R", R4 or R"; wherein R is phenyl which is unfused or fused with benzene, heteroarene, 0 heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; R 14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two of independently selected Ri, OR1, SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHR 16

N(R

1 6

)

2 , C(O)Rio 5 C(O)NHR 16 , NHC(O)Rio, NHC(O)OR 16 , OH, F, Cl, Br or I, wherein Rio is as described in Formula I. In another embodiment of formula I, R is R 1A, R10B or Rioc, wherein R 0 is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, N'N N- N N N R10B is or and RioC is heterocycloalkyl, which is unfused; wherein R is substituted with F and further unsubstituted or substituted with one or 20 two of independently selected R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2

R

1 1 , NH 2 , N(R 1 1

)

2 , C(O)R 11 ,

C(O)OR

1 , C(O)NHR 1 , C(O)N(R 1 )2, NHC(O)R 1 , NHSO 2

R

11 , NR 1 S0 2

R

11 , NHC(O)OR 1 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R 11 is R , R , R14 or R1; wherein R is phenyl which is unfused or fused with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; 25 R 14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two 16 16 16 16 16 16 of independently selected R , OR , SR , S(O) 2 R , C(O)OH, NH 2 , NHR N(R1 )2, C(O)R i, C(O)NHR 16, NHC(O)R i, NHC(O)OR 16, OH, F, Cl, Br or I; wherein each Ri1 is 72 R or R 7 ; R 1 is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; and R 18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties represented by R", R", R4, R A, and R 18 are independently 5 unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR19, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I, wherein R19 is as described in Formula I. In another embodiment of formula I, R 10 is R10 , RiOB or Rioc wherein R10^ is phenyl which is unfused or fused with heterocycloalkane, which is fused N N N 0 heterocycloalkane, RiOB is 'o , ,and R oC is heterocycloalkyl, which is unfused; wherein R 10 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR", SR 11 ,

S(O)R

11 , S0 2

R

11 , NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 ,

NHSO

2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or 5 Br; wherein each R 11 is R , R , R4 or R ; wherein R 12 is phenyl which is unfused or fused with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; R14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused '0 or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two of independently selected Rio, OR 6 , SRio, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 1 6

)

2 ,

C(O)R

1 6 , C(O)NHR 16 , NHC(O)R 16 , NHC(O)OR 1 6 , OH, F, Cl, Br or I; wherein each R 16 is R or R 7 ; R 1 is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or 25 fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is 12 13 14 17A unfused; wherein the moieties represented by R , R , R , R A, and R 18 are independently unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR 9, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 19 19 19 20 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R 30 R2, R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R2 is cycloalkyl or heterocycloalkyl; each of which is unfused or fused with benzene; and R2 is 73 alkyl which is unsubstituted or substituted with R 2 4 , OR 2 4 , NHR 2 4 N(R24 )2, NHS(O) 2 R24 or OH, wherein R 2 4 is as described in Formula I. In another embodiment of formula I, R 10 R 1O, RioB or Rioc, wherein RlOA is phenyl which is unfused or fused with heterocycloalkane, which NN is fused heterocycloalkane, RioB is Q jor / , and RioC is 5 heterocycloalkyl, which is unfused; wherein R 10 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR", SR",

S(O)R

11 , S0 2

R

1 1 , NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 ,

NHSO

2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R 11 is R , R", R14 or R ; wherein R 12 is phenyl which is unfused or fused 0 with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; R14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two 5 of independently selected Rio, ORi 6 , SRio, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 1 6

)

2 ,

C(O)R

16 , C(O)NHR 16 , NHC(O)R 16 , NHC(O)OR 1 6 , OH, F, Cl, Br or I; wherein each R 16 is R or R 7 ; R 1 is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is 12 13 14 17A '0 unfused; wherein the moieties represented by R , R , R , R A, and R 18 are independently unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR 9, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 19 19 19 20 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R2 is 25 cycloalkyl or heterocycloalkyl; each of which is unfused or fused with benzene; and R2 is alkyl which is unsubstituted or substituted with R 2 4 , OR 2 4 , NHR 2 4 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R 2 4 is R 24 A or R 2 4 B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR , OH, F, Cl, Br or I; R 25 is alkyl, which is unsubstituted 30 or substituted with NH 2 ; wherein the moieties represented by R 20 , R, R, and R 24 Are independently unsubstituted or substituted with one or two of independently selected R 26 74

OR

2 6 (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of formula I, R 1 0 is R 0, 0 0 N' 'N oN H NN R10 orR Ro,wherein R 1 is ,O orO ,R0 N N O1CNH1 is ,and ROC is , wherein R 10 is optionally substituted as described in Formula I. In another embodiment of formula I, R 10 is 10A 10 5 R , wherein R10 is phenyl which is unfused, wherein R is optionally substituted as described in Formula I. In another embodiment of formula I, R 10 is R10, wherein R 1 0 is phenyl which is unfused, wherein R 10 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR1, SR 11 , S(O)R 11 , S0 2 R", NH 2 ,

N(R

11 )2, C(O)R 1 , C(O)OR 1 , C(O)NHR 1 , C(O)N(R 1

)

2 , NHC(O)R 1 , NHSO 2

R

1 , 0 NR 1 S0 2

R

11 , NHC(O)OR 1 , NHSO 2

N(R

11

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R" is R , R , R14 or R 15 ; wherein R 12 is phenyl which is unfused or fused with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused;

R

1 4 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused 5 with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two 16 16 16 16 16 16 of independently selected R , OR , SR , S(O) 2 R , C(O)OH, NH 2 , NHR N(R1 )2, C(O)R i, C(O)NHR 16, NHC(O)R i, NHC(O)OR 16, OH, F, Cl, Br or I; wherein each Ri1 is R or R 7 ; R 1 is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, 20 heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is 12 13 14 17A unfused; wherein the moieties represented by R , R , R , R A, and R 18 are independently unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR 9, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 19 19 19 20 25 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R2 is cycloalkyl or heterocycloalkyl; each of which is unfused or fused with benzene; and R2 is alkyl which is unsubstituted or substituted with R 2 4 , OR 2 4 , NHR 2 4 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R 2 4 is R 24 A or R 2 4 B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or 75 heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR , OH, F, Cl, Br or I; R2 5 is alkyl, which is unsubstituted or substituted with NH 2 ; wherein the moieties represented by R 20 , R , R , and R 2 4 Are independently unsubstituted or substituted with one or two of independently selected R 2 6 5 OR26 (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of formula I, R1 0 is R 0A, wherein R10^ is phenyl which is unfused, wherein R is substituted with F and further 15 16 substituted with NHC(O)R 1 wherein R 11 is R , wherein R is optionally substituted as described in Formula I. In another embodiment of formula I, R 10 is R10A, wherein R 1 0 is phenyl which is unfused, wherein R 10 is substituted with F and further substituted with R 11 , 11 12 14 1 0 wherein R" is R or R , wherein R 4 is heterocycloalkyl which is unsubstituted or substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I, wherein R19 is as described in Formula I. In another embodiment of formula I, R 10 is R10^, wherein R 1 0 is 5 phenyl which is unfused, wherein R 10 is substituted with F and further substituted with R 11 , wherein R 11 is phenyl, pyrrolidinyl, azabicylclo(3.1.O)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2. 1)hept-2-yl; each of which are independently unsubstituted or substituted with one or two or three or four of independently selected R 19 , * 19 19 19 19 19 19 1 91 '0 OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R'9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R19 is as described in Formula I. In another embodiment of formula I, R is R10^, wherein R 0 is phenyl which is unfused, wherein R 10 is substituted with F and further substituted with R 11 , wherein R 11 is phenyl, pyrrolidinyl, azabicylclo(3.1.O)hexanyl, hexahydro-1H-isoindolyl, 25 oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2.1 )hept-2-yl; each of which are independently 1A substituted with one or two (0). In another embodiment of formula I, R1 0 is R10 , wherein R 1A is phenyl which is unfused, wherein R 10 is substituted with F and further substituted with R 11 , wherein R 11 is R 14 , wherein R 14 is heterocycloalkyl which is unsubstituted or 30 substituted with one or two (0). In another embodiment of formula I, R1 0 is R10^, wherein R 1A is phenyl which is unfused, wherein R 10 is substituted with F and further substituted with R 11 , wherein R 11 is R 14 , wherein R 14 is pyrrolidinyl which is substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, S0 2

R

19 , C(O)R 19 , CO(O)R19, 76 19 1 91 91 NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R 19 is as described in Formula I and wherein R 14 is substituted with at least one (0). In another embodiment of formula I, R" is R"1O, wherein R 1A is phenyl which is unfused, wherein R 10 is substituted with F and further substituted 5 with R 11 , wherein R 11 is R", wherein R" is pyrrolidinyl which is substituted with one or two (0). Embodiments of Multiple Substituents The following are additional embodiments of the compounds of Formula I. Unless 0 otherwise specified, substituents are as described in Formula I. In one embodiment of Formula I, R 1 is cycloalkane, which is unfused; R 2 is heterocycloalkane, which is unfused, and A 2 is R'. Embodiments where A' is Cyclohexane, A2 is R5 In one embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which 5 is unfused, and A 2 is R , which is as described in Formula I. In another embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R ,

R

5 is Ci-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted as described in Formula I. In another embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R , R 5 is Ci-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 10 is ROA, wherein is ,0 R 10 is phenyl which is unfused and substituted with F, and further substituted with NHC(O)R, wherein R" is R". In another embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is Ci-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 10 is R10A, wherein is ROA is phenyl which is unfused and substituted with F, and further substituted with NHC(O)R 1 1, wherein R 11 is R 1 5 wherein R 15 is alkyl, which is 25 unsubstituted or substituted with one or two of independently selected Rio, ORi 6 , SRio 16 16 16 16 16 16 16

S(O)

2 R , C(O)OH, NH 2 , NHR N(R )2, C(O)Ri, C(O)NHR , NHC(O)R , NHC(O)OR OH, F, Cl, Br or I; wherein each R is R or R 17; R is alkyl, which is unsubstituted or substituted with one or two of independently selected R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with 30 benzene or heterocycloalkane; wherein each R 18 is phenyl or heterocycloalkyl; wherein each of the moieties represented by R1 7 A and R 18 are independently unsubstituted or substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 19 , N(R 1 9

)

2 , NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, 77 C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R20, R , R2 or R ; R20 is phenyl which is unfused; R 2 1 is heteroaryl which is unfused; R 22 is cycloalkyl or heterocycloalkyl; each of which are unfused or fused with benzene; R 2 is alkyl, which is 24 24 2 unsubstituted or substituted with one or two of independently selected R 24 , OR , NHR 24 5 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R24 is R24A or R24 ; R24A is unsubstituted phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with heterocycloalkane; R 24 is alkyl, which is unsubstituted or substituted with one or two of independently selected OR or OH; wherein each R 25 is alkyl unsubstituted or substituted with NH 2 ; wherein each R20 is unsubstituted or substituted with one or two of independently 0 selected R 26 , OR 2 6 , (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is C 1 alkyl, C 2 -alkyl or C 3 -alkyl wherein R 10 is substituted with F, and further substituted with R 14 wherein each R 10 is independently unsubstituted or substituted with one or two or three of independently selected R 11 , OR, SR 11 , S(O)R 11 , S0 2 R", NH 2 , NHR", N(R 1

)

2 , C(O)R 11 , 5 C(O)OR 11 , C(O)NH 2 , C(O)NHR 11 , C(O)N(R 1 )2, NHC(O)R 11 , NR 11

C(O)R

11 , NHSO 2

R

11 , NR"IS0 2 R", NHC(O)OR 11 , NR 11

C(O)OR

11 , NHSO 2

NH

2 , NHSO 2

NHR

11 , NHSO 2

N(R

1

)

2 ,

SO

2

NH

2 , SO 2

NHR

1 , SO 2

N(R

11

)

2 , NHC(O)NH 2 , NHC(O)NHR 1 , NHC(O)N(R 1

)

2 ,

NR"C(O)N(R

1

)

2 , NO 2 , OH, (0), C(O)H, C(O)OH, CN, CF 3 , OCF 3 , CF 2

CF

3 , F, Cl, Br or I; wherein R 14 is pyrrolidinyl, azetidinyl, pyrrolyl, 1,3-oxazolidinyl, azepanyl, piperidinyl, '0 imidazolidinyl, tetrahydropyrimidin(2H)-yl, azabicyclo(2.2.1 )heptyl or 1,6-dihydropyridazyl; each of which unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and wherein the moiety represented by R 14 is substituted with one or two (0) substituents. In another 25 embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is C1-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted with R 1 0 , and further unsubstituted or substituted with one or two or three of independently selected NHR , N(R 0

)

2 , SR 10 , S(O)R 10 , S0 2

R

10 or CF 3 , wherein R 10 is as described in formula I. In another embodiment of Formula I, A' is R 1 , wherein R 1 is unsubstituted cyclohexane which is 30 unfused, and A 2 is R 5 , R 5 is C1-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted with R 1 0 , and further unsubstituted or substituted with one CF 3 , wherein R 1 0 is as described in formula I. In another embodiment of Formula I, A 1 is R 1 , wherein R 1 is unsubstituted cyclohexane 78 which is unfused, and A 2 is R 5 selected from the following Formulas (Ie), (If), (Ig), (Ih), (Ii) or (Ij): o 0 0 NH NH NH N NN 11Y 4 R10 R10 (le) Ri10 (if) (Ig) ( 0 0 NH NH H F F F F Rio (Ih) (Ii) (Ij). In one 10 1A 10B bC 5 embodiment of Formula(Ii), R is R0 , R or R10; each of which must be attached at a carbon atom; ROA is phenyl which is unfused or fused with heterocycloalkane, which is fused N' N N N Or with heterocycloalkane; R10B is ' ; R10C is heterocycloalkyl, which is unfused; wherein R 10 is substituted with C(O)R 11 , C(O)NHR 1 , C(O)N(R"1)2or NHC(O)R 1 , and is further unsubstituted or substituted with one or two or 0 three of independently selected R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 11 ,

C(O)OR

11 , C(O)NHR 11 , C(O)N(R 1 )2, NHC(O)R 1 , NHSO 2

R

1 , NR 11 S0 2

R

1 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl, Br or I; wherein each R 11 is R , R", R" or R1; R 12 is phenyl which is unfused or fused with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; R 14 is cycloalkyl, heterocycloalkyl or 15 heterocycloalkenyl; each of which is unfused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; R 15 is alkyl, which is unsubstituted or substituted with one or two of independently selected Rio 1i, 1i, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 16

)

2 , C(O)Rio, C(O)NHR 16 , NHC(O)Rio 1616 17 17A 1 NHC(O)OR , OH, F, Cl, Br or I; wherein each Rio is R or R ; R" is alkyl, which is 20 unsubstituted or substituted with R 8; R 17 is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; 182 R18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties represented by R, 79 13 14 17A R , R , R , and R 18 are independently unsubstituted or substituted with one or two 19 19 19 1919 19 19 1 independently selected R19, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R 19 is R20, R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is 5 heteroaryl, which is unfused; R 22 is cycloalkyl,or heterocycloalkyl each of which is unfused or fused with benzene; R 23 is alkyl which is unsubstituted or substituted with one or two of independently selected R 24, OR24 , NHR24 N(R24 )2, NHS(O) 2 R 24, OH, F, Cl, Br or I; wherein each R24 is R24A or R 24B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with heterocycloalkane; R24B is alkyl which is unsubstituted 0 or substituted with OR, OH, F, Cl, Br or I; R is alkyl each of which is unsubstituted or substituted with NH 2 ; wherein the moieties represented by R 20 , R 21 , R 2 2 , and R 2 4 A are independently unsubstituted or substituted with one or two of independently selected R 2 6

OR

2 6 , (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula I, A is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is C1-alkyl 5 wherein R 5 is substituted with R 10 , wherein R 10 is as described in formula I, as described in 0 NH R10 Formula (Ie) (Ie). In another embodiment of Formula I, A is R 1 , wherein R 1 is unsubstituted cyclohexane which is unfused, and A 2 is R 5 , R 5 is unbranched C 2 alkyl wherein R 5 is substituted with R 10 , wherein R 10 is as described in formula I, as 0 NH described in Formula (If) Rio 0. 20 Embodiments of Formula (Ie) 10 1A 10B lCA In one embodiment of Formula (Ie), R is R10 , R or Rio , wherein R1OA is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, R10B is 80 N rN N N N N N N / N /N, , or / s s / O, 0- 0~ , and RioC is heterocycloalkyl, which is unfused; wherein R 10 is substituted as described in formula I. In another embodiment of Formula (Ie), R is R 0A, R10B or Rioc, wherein R0A is phenyl which is unfused or fused with heterocycloalkane, which is fused heterocycloalkane, R10B is N N O 5 so, and RioC is heterocycloalkyl, which is unfused; wherein R is substituted with one or two of independently selected R 11 , OR", SR",

S(O)R

11 , S0 2

R

11 , NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 ,

NHSO

2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R 11 is as described in Formula I. In another embodiment of Formula (Ie), R 10 is 0 R 1A, R10B or RioC, wherein R10^ is phenyl which is unfused or fused with heterocycloalkane, NO which is fused heterocycloalkane, R 10Bis SS - , or 0 RioC is heterocycloalkyl, which is unfused; wherein R 10 is substituted with F and further unsubstituted or substituted with one or two of independently selected R 11 , OR", SR 11 ,

S(O)R

11 , S0 2

R

11 , NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , 15 NHSO 2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R 11 is as described in Formula I. In another embodiment of Formula (Ie), R 10 is R 1A, R10B or RioC, wherein R10^ is phenyl which is unfused or fused with heterocycloalkane, N N which is fused heterocycloalkane, R 10Bis S I ord RioC is heterocycloalkyl, which is unfused; wherein R 10 is substituted with F and further 20 unsubstituted or substituted with one or two of independently selected R 11 , OR", SR",

S(O)R

11 , S0 2

R

11 , NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 ,

NHSO

2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or 12 13 14 15 12 Br; wherein R 11 is R 1 , R , R or R ; R is phenyl which is unfused or fused with benzene, 81 heteroarene, heterocycloalkane or heterocycloalkene; R" is heteroaryl, which is unfused; R 14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene; R 15 is alkyl which is unsubstituted or substituted with one or two of 5 independently selected Rio, OR1, SRi 6 , S(O) 2

R

16 , C(O)OH, NH 2 , NHR 16

N(R

1 6

)

2 , C(O)Rio 16 16 16 16 17 1A C(O)NHR , NHC(O)R , NHC(O)OR , OH, F, Cl, Br or I; wherein each R is R" or R R is alkyl which is unsubstituted or substituted with R"; R 17 is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is unfused; wherein 0 the moieties represented by R 1 , R 1 , R, Rl 7 A, and R 18 are independently unsubstituted or substituted with one or two of independently selected R19, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 19 , N(R 1 9

)

2 , NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R20, R , R2 or R ; R20 is phenyl, which is unfused; R 2 1 is heteroaryl, which is unfused; R 22 is cycloalkyl or 5 heterocycloalkyl; each of which is unfused or fused with benzene; R 2 is alkyl which is unsubstituted or substituted with R 24, OR24 , NHR24 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R24 is R24A or R 24B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR, OH, F, Cl, Br or I; R is alkyl, which is unsubstituted or substituted '0 with NH 2 ; wherein the moieties represented by R 2 0 , R 21 , R 22 , and R 2 4 A are independently unsubstituted or substituted with one or two of independently selected R 26 , OR 26 (0), F, Cl, 10 10A 10B bC Br or I; and R 26 is alkyl. In another embodiment of Formula (Ie), R is R , R or Rio 0 0 N N HH 10A Hor 10B wherein R is phenyl which is unfused, 0 0 , R i N' N~N or , and ROC is HN , wherein R 10 is optionally 25 substituted as described in Formula I. In another embodiment of Formula (Ie), R 10 is R10A, RioB or Rioc as described in Formulas (1k), (Il), (Im), (In), (Io) or (Ip) 82 0 0 0 H H H N 1N ~N R101 R 1 2 0 N R o2 N RN'o '0

R

10 5 1 R10 R1 0 3 R 1 05

R

10 R105 R1 0 0 0 NH NH N H INHN N R 10 2 S R-0 R101

R

10 5 N N R (In) R 1 02 (Io) or R10 (Ip), wherein 101 102 103 1040511 1 R , R , R , R 4 , and R , are independently selected from R", OR", SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , 5 NHSO 2 R", NR 11 S0 2

R

11 , NHC(O)OR 11 , NHSO 2

N(R

1 )2, NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R 11 is as described in Formula I. In another embodiment of Formula (Ie), R is R 0 or R10B, as described in Formulas (1k), (Il), (Im), (In), (Io) or (Ip). In another embodiment of Formula (Je), R 10 is phenyl, as shown 0 NH

R

101

R

1 02

R

1 0 5

R

10 3 in Formula (1k): R1"4 (1k), wherein R , R 2, R 3, R 4, and R 10 5 , 10 are independently selected from H, R 11 , OR1, SR 11 , S(O)R 11 , S0 2

R

1 , NH 2 , N(R 11

)

2 , 11 C(O)R"1, C(O)OR"1, C(O)NHR"1, C(O)N(R"1)2, NHC(O)R"1, NHSO2R"1, NR"1SO2R",

NHC(O)OR

11 , NHSO 2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R" is as described in Formula I. In another embodiment of Formula (1k), at least one of R 101 , R 1 02 103 10405 R , R 4 , and R are F, and at least one is R 11 , wherein R 11 is phenyl, pyrrolyl, 15 azabicylclo(3. 1.0)hexanyl, hexahydro-1H-isoindolyl, 1,3-oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, 1,6-dihydropyridazyl, tetrahydropyrimidin(2H)-yl or azabicylo(2.2.1 )hept-2-yl; each of which are independently 83 unsubstituted or substituted with one or two or three of independently selected R 19 , OR 19 , SR19, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 9, N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 19 19 19 20 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R2 is 5 cycloalkyl,or heterocycloalkyl each of which is unfused or fused with benzene; R 2 is alkyl which is unsubstituted or substituted with one or two of independently selected R 2 4 , OR 2 4 , NHR24 N(R24 )2, NHS(O) 2 R 9, OH, F, Cl, Br or I; wherein each R24 is R24A or R 24; R24A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with heterocycloalkane; R 24 B is alkyl which is unsubstituted or substituted with OR, OH, F, 0 Cl, Br or I; R is alkyl each of which is unsubstituted or substituted with NH 2 ; wherein the 20 212A moieties represented by R , R , R 2 2 , and R24A are independently unsubstituted or substituted with one or two of independently selected R 26, OR 26, (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula (1k), R , R 4 and R 5 are H, and R 1 02 is R 11 , wherein R 11 is selected from pyrrolidinyl, oxazolyl, imidazolidinyl, isothiazolidinyl, 5 piperidinyl, and azepanyl, wherein R102 is substituted with one or two (0) substituents. In another embodiment of Formula (1k), R 101 , R 10 4 and R 10 5 are H, and R 10 2 is R 11 , wherein R 11 is pyrrolidinyl. Further Embodiments of Formula (1k) 10 In one embodiment of Formula (1k), R102 is NHC(O)R 11 , as described in Formula (Iq): 0 NH NR101 H NR11

R

1 05

R

103 101 103 104 10 (Iq) wherein R , R , R and R 5 are independently selected from H, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 ,

C(O)NHR

11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R 11 is as described in Formula 15 16 25 I. In one embodiment of Formula (Iq), R 11 is R", wherein R is optionally substituted as described in Formula I and R 101 , R 10 3 , R 10 4 and R 10 5 are as described in Formula (Iq). In another embodiment of Formula (Iq), R03 is F, and R 10 , R 4 and R 10 5 are independently 84 selected from H, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R 11 , C(O)OR 11 ,

C(O)NHR

11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; and R 11 is R 15 , wherein R 16 is optionally substituted as described in Formula I. In another embodiment of Formula (Iq), one 0 103 1010156 5 of R 1 , R , R 4 and R 5 is F, R 11 is R", wherein Rio is optionally substituted as described in Formula I. In another embodiment of Formula (Iq), R 101 , R 10 4 and R 10 5 is F. In another embodiment of Formula (Iq), R03 is F. In another embodiment of Formula (Iq), one of R 101 , 103 10405156 R , R 4 and R is F, R 11 is R, wherein Rio is alkyl, which is unsubstituted or substituted with one or two of independently selected Rio, OR 6 , SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio 0 N(R 1 6

)

2 , C(O)Rio, C(O)NHR 16 , NHC(O)Rio, NHC(O)OR 16 , OH, F, Cl, Br or I; wherein each R i is R" or R ; R is alkyl, which is unsubstituted or substituted with one or two of independently selected R ; R 17 is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; wherein each R 18 is phenyl or heterocycloalkyl; wherein each of the moieties represented by 5 R 1A and R 18 are independently unsubstituted or substituted with one or two or three or four 19 19 19 1919 19 19 1 of independently selected R19, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R 19 is R20, R , R2 or R ; R 2 0 is phenyl which is unfused; R 21 is heteroaryl which is unfused; R 22 is cycloalkyl or heterocycloalkyl; each of which are unfused '0 or fused with benzene; R 23 is alkyl, which is unsubstituted or substituted with one or two of independently selected R 24, OR24 , NHR24 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R24 is R24A or R 24A; R24A is unsubsituted phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with heterocycloalkane; R 24 is alkyl, which is unsubstituted or substituted with one or two of independently selected OR 25 or OH; wherein 25 each R 25 is alkyl unsubstituted or substituted with NH 2 ; wherein each R 2 0 is unsubstituted or substituted with one or two of independently selected R 26, OR 26, (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula (Iq), R03 is F, and R 101 , R 10 4 and R05 are each H, 1 5 16 R" is R 1 , wherein R is optionally substituted as described in Formula I. In another embodiment of Formula (Iq), R 11 is R or R 14 , wherein R 14 is heterocycloalkyl which is 30 unsubstituted or substituted with one or two or three or four of independently selected R 19 , 19 19 19 19 19 19 1 91 OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R'9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein R19 is as described in Formula I. In another embodiment of Formula (Iq), R 11 is selected from 85 phenyl, pyrrolidinyl, azabicylclo(3.1.0)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl or azabicylo(2.2.1 )hept-2-yl; each of which are independently unsubstituted or substituted with one or two or three or four of independently selected R 19 , 19 19 19 19 19 19 1 91 5 OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O)2R'9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein R19 is as described in Formula I. In one embodiment of Formula (1k), R102 is R", wherein R 11 is pyrrolidinyl as 0 NH

R

202 H R201 R0 N NR101 _RM N

R

1 05

R

1 03 R24 described in Formula (Ir): R1 (Ir) wherein R 101 , R 3 , R 4 , and 0 R 5 , are independently selected from H, R 1

OR"

1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 ,

C(O)R

11 , C(O)OR 11 , C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2 R,

NHC(O)OR

11 , NHSO 2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R" is as described in Formula I, and R 201 , R 202, R203 , and R 204 are independently H, R19, OR 9, SR 1, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 5 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein R19 is as 103 11 104 described in Formula I. In one embodiment of Formula (Ir), R1 is F, and R , R , and R 5 are H, wherein R 201, R202, R203, and R 204 are independently H, R19, OR 9, SR 9, SO 2 R 1, 19 19 ~19 191199 C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein R 1 9 is as described in 20 Formula I. In one embodiment of Formula (Ir), one or two of R 20 1 , R 202 , R 203 , and R 20 4 is (0). In another embodiment of Formula (Ir), two of R 20 1 , R 202 , R 203 , and R 204 are (0). In another embodiment of Formula (Ir), R201 and R 204 are (0) and R 202 and R203 are H, as described in Formula (Iri): 86 0 NH N R1R 10301 10 R105 R103 R104 (Ir). In one embodiment of Formula (Iri), R 3 is F and R 1 , R14, and R 105 , are independently selected from H, R 11 ,OR11, SR 11 , S(O)R 11 , S0 2 R", NH 2 ,

N(R

11 )2, C(O)R 1 , C(O)OR 1 , C(O)NHR 1 , C(O)N(R 1

)

2 , NHC(O)R 1 , NHSO 2

R

1 ,

NR

1 S0 2

R

11 , NHC(O)OR 1 , NHSO 2

N(R

11

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein 5 R 11 is as described in Formula I. In one embodiment of Formula (1k), R 3 is F, as described in Formula (Is): 0 NH /NR1 01 R102

R

10 5 F 1010 102 14105 (Is), wherein R 1 2, R R 4 , and R , are independently selected from H, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R, C(O)OR 11 , 0 C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein R 11 is as described in Formula 1 102 10405 I. In another embodiment of Formula (Is), R , R , R 4 , and R , are independently selected from H, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R, C(O)OR 11 ,

C(O)NHR

11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 11 S0 2

R

11 , NHC(O)OR 11 , 15 NHSO 2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R 11 is R , R , R14 or R1; wherein R is phenyl which is unfused or fused with benzene, heteroarene, heterocycloalkane or heterocycloalkene; R 13 is heteroaryl, which is unfused; R14 is cycloalkyl, heterocycloalkyl or heterocycloalkenyl; each of which is unused or fused with benzene, cycloalkane, heterocycloalkane or heterocycloalkene; each of which ofusedis unfused 20 or fused with benzene; and R 15 is alkyl which is unsubstituted or substituted with one or two of independently selected Rio, OR 6 , SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 1 6

)

2 ,

C(O)R

16 , C(O)NHR 16 , NHC(O)R 1 6 , NHC(O)OR 1 6 , OH, F, Cl, Br or I; wherein each R 16 is 87 R or R 7 ; R 1 is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties represented by R", R", R", R A, and R 18 are independently 5 unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR 9, 19 19 19 19 1 91

SO

2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , 19 19 19 20 C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R2 is cycloalkyl or heterocycloalkyl; each of which is unfused or fused with benzene; and R2 is 0 alkyl which is unsubstituted or substituted with R 2 4 , OR 2 4 , NHR 2 4 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R 2 4 is R 24 A or R 2 4 B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR , OH, F, Cl, Br or I; R 25 is alkyl, which is unsubstituted or substituted with NH 2 ; wherein the moieties represented by R 2 0 , R, R, and R 2 4 Are 226 5 independently unsubstituted or substituted with one or two of independently selected R2 OR26 (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula (Is), R 11 is selected from phenyl, pyrrolidinyl, azabicylclo(3. 1.0)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl or azabicylo(2.2.1 )hept-2-yl; each of which are independently '0 unsubstituted or substituted with one or two or three or four of independently selected R 19 , OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 1, N(R 9)2, NHC(O)R 9, NHS(O) 2 R'9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein R19 is as described in Formula I. In another embodiment of Formula (Is), R102 is R 11 , wherein R" is selected from pyrrolidinyl, oxazolyl, imidazolidinyl, isothiazolidinyl, piperidinyl, 25 piperazinyl and azepanyl, wherein R 1 0 2 is substituted with one or two (0) substituents. In another embodiment of Formula (Is), R102 is R 11 , wherein R 11 is selected from pyrrolidinyl substituted with one or two (0) substituents. In another embodiment of Formula (Is), R 101 , R 10 4 and R 10 5 are H, and R 1 0 2 is selected from R 11 , OR 1 , NHC(O)R 1 , or C(O)NHR 1 ; wherein R 11 is as described in Formula I. In another embodiment of Formula (Is), wherein 30 R 101 , R 10 4 and R 10 5 are H, and R 1 0 2 is selected from R 11 , OR 1 , NHC(O)R 1 , or C(O)NHR 1 ; wherein R 11 is phenyl, pyrrolidinyl, azabicylclo(3.1.O)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2. 1)hept-2-yl; each of which are independently 88 unsubstituted or substituted with one or two or three or four of independently selected R 9 , OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 1, N(R 9)2, NHC(O)R 9, NHS(O)2R 9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R19 is as described in Formula I. In another embodiment of Formula (Is), wherein R 101 , R 10 4 and 5 R 105 are H, and R 1 0 2 is selected from R 1 ", OR 1 , NHC(O)R 1 , or C(O)NHR 1 ; wherein R 11 is phenyl, pyrrolidinyl, azabicylclo(3.1.0)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2. 1)hept-2-yl; each of which are independently unsubstituted or substituted with one or two of independently selected R 19 , OR 9, SR19, 19 19 19 19 1 91 0 SO2R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O)2R 9, C(O)NH2, C(O)NHR 9, C(O)N(RI9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R19 is as described in Formula I. In another embodiment of Formula (Is), wherein R 1 01 , R 10 4 and R 10 5 are H, and R 1 0 2 is selected from R 1 ", OR 1 , NHC(O)R 1 , or C(O)NHR 1 ; wherein R 11 is R 15 and R 15 is alkyl which is unsubstituted or substituted with one or two of independently 5 selected Rio, OR 6 , SR1, S(O) 2

R

1 6 , C(O)OH, NH 2 , NHRio N(R 1 6

)

2 , C(O)Rio, C(O)NHRio 16 16 167A 17 NHC(O)Ri, NHC(O)OR , OH, F, Cl, Br or I; wherein each Rio is R or R" ; R is alkyl which is unsubstituted or substituted with R 18 ; R1 7 A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene or heterocycloalkane; R18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties 12 13 14 17A '0 represented by R , R , R , R , and R 18 are independently unsubstituted or substituted with one or two of independently selected R 1 9, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R19, 19 1 91 91 NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R 19 is R 20, R2, R2 or R ; R 20 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R 22 is cycloalkyl or heterocycloalkyl; 25 each of which is unfused or fused with benzene; and R 23 is alkyl which is unsubstituted or substituted with R 24 , OR 24 , NHR 24

N(R

24

)

2 , NHS(O) 2

R

24 or OH; wherein each R 24 is R 2 4 A or

R

24 B; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR, 2 5 OH, F, Cl, Br or I; R 25 is alkyl, which is unsubstituted or substituted with NH 2 ; wherein the 30 moieties represented by R 20, R2, R 2 2 , and R24A are independently unsubstituted or substituted with one or two of independently selected R 26, OR26 (0), F, Cl, Br or I; and R 26 is alkyl. In one embodiment, the compound of Formula (Is) is selected from: 89 2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid; 4-(3-amino-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)amino)-4 oxobutanoic acid; 5 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5 dione; 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-(aminomethyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-((dimethylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 0 4-(4-fluoro-3-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(3-((cyclohexylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; 4-(4-fluoro-3-((tetrahydro-2H-pyran-4-ylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(4-fluoro-3-((methyl((1-methylpyrrolidin-3-yl)methyl)amino)methyl)benzyl)-5,6,7,8 5 tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -((methyl(((2R)- 1 -methylpyrrolidin-2-yl)methyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -pyrimidin-2-ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3 -pyridin-3 -ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 0 4-(4-fluoro-3 -pyridin-4-ylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; N,N-diethyl-2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1 '-biphenyl 2-carboxamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3-piperidin- 1 ylpropanamide; 25 N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3-(4 methylpiperazin- 1 -yl)propanamide; 2-amino-N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 3 -cyclohexyl-N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 30 yl)methyl)phenyl)propanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)piperidine-3 carboxamide; 4-(4-fluoro-3 -(2-oxopyrrolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 90 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)azetidine-3 carboxamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-morpholin-4 ylacetamide; 5 N-(2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1 '-biphenyl-3 yl)acetamide; 4-((6-fluoro-3'-(methylsulfonyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-((6-fluoro-3'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8 0 tetrahydrophthalazin- 1 (2H)-one; 4-((6-fluoro-4'-(pyrrolidin- 1 -ylcarbonyl)- 1,1 '-biphenyl-3 -yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; N,N-diethyl-2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-1,1' biphenyl-3-carboxamide; 5 2'-fluoro-N,N-dimethyl-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1' biphenyl-4-carboxamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-4-(4 methoxyphenyl)-4-oxobutanamide; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3,4-dimethyl '0 1H-pyrrole-2,5-dione; 3-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 azabicyclo(3. 1.0)hexane-2,4-dione; 2-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 -yl)methyl)phenyl)hexahydro- 1H isoindole- 1,3(2H)-dione; 25 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 -yl)methyl)phenyl)-3,3 dimethylpyrrolidine-2,5-dione; 4-(4-fluoro-3-(2-methyl-5-oxopyrrolidin-1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxo-1,3-oxazolidin-3-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1 (2H)-one; 30 4-(4-fluoro-3-(2-oxoazepan-1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 -yl)methyl)phenyl)piperidine-2,6 dione; 4-(4-fluoro-3-(2-oxoimidazolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1 (2H)-one; 91 4-(3-(1,1 -dioxidoisothiazolidin-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxoazetidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 4-(4-fluoro-3-(2-oxopiperidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 5 4-(4-fluoro-3-(3 -methyl-2-oxoimidazolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxotetrahydropyrimidin- 1 (2H)-yl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 4-(3-(3-tert-butyl-2-oxoimidazolidin- 1 -yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin 0 1(2H)-one; 4-(4-fluoro-3-((1 S,4R)-3-oxo-2-azabicyclo(2.2. 1)hept-2-yl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N methylmethanesulfonamide; 5 N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-hydroxy-2 methylpropanamide; (3 aS,4R,7S,7aR)-5 -(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)-2,2-dimethyltetrahydro-4,7-methano(1,3)dioxolo(4,5-c)pyridin-6(3aH) one; 0 4-(3 -(1,1 -dioxido- 1,2-thiazinan-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2-(2 oxopyrrolidin- 1 -yl)acetamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 -methyl-I 25 phenyl- 1 H-pyrazole-4-carboxamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-5 oxohexanamide; N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 methoxypropanamide; 30 N-(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N' phenylpentanediamide; 4-(4-fluoro-3 -((4-pyrimidin-2-ylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin-1(2H)-one; or 92 4-(4-fluoro-3-(2-oxopyrrolidin- 1 -yl)phenyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one. In another embodiment, the compound of Formula (Is) is selected from 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)amino)-4 5 oxobutanoic acid; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5 dione; 4-(4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-(4 0 methylpiperazin- 1 -yl)propanamide; 3 -(2-fluoro-5 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 azabicyclo(3. 1.0)hexane-2,4-dione; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 -yl)methyl)phenyl)-3,3 dimethylpyrrolidine-2,5-dione; 5 4-(4-fluoro-3-(2-oxo-1,3-oxazolidin-3-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1 (2H)-one; 4-(4-fluoro-3-(3-methyl-2-oxoimidazolidin- 1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H) one; 4-(4-fluoro-3-(2-oxoazepan-1 -yl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one; 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 -yl)methyl)phenyl)piperidine-2,6 '0 dione; 4-(3-(1,1 -dioxidoisothiazolidin-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1 (2H) one; 4-(4-fluoro-3-(2-oxopiperidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one; or 4-(4-fluoro-3-((4-pyrimidin-2-ylpiperazin-1-yl)carbonyl)benzyl)-5,6,7,8 25 tetrahydrophthalazin- 1 (2H)-one. In one embodiment of Formula (1k), R is C(O)R 11 , as described in Formula (It): 93 0 NH N 101 O

R

105

R

10 3 R104 (It), wherein R" is as described in Formula I. In one embodiment of Formula (It), R , R ", R 10 4 and R 10 5 are H. In another embodiment of Formula (It), R is F and R 101 , R 10 4 and R 10 5 are H. In another embodiment of Formula (It), R" is R 15 and R 15 is alkyl which is unsubstituted or substituted with one or two of independently selected Rio 5 OR1, SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHRio N(R 16

)

2 , C(O)Rio, C(O)NHR 16 , NHC(O)Rio 1616 17 17A 1 NHC(O)OR , OH, F, Cl, Br or I; wherein each Rio is R or R ; R" is alkyl which is unsubstituted or substituted with R ; R 17 is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties represented by R, 12 13 14 17A 0 R , R , R , and R 18 are independently unsubstituted or substituted with one or two of 19 19 19 1919 19 19 1 independently selected R19, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R 19 is R20, R , R2 or R ; R 2 0 is phenyl, which is unfused; R 21 is heteroaryl, which is unfused; R 22 is cycloalkyl or heterocycloalkyl; each of which is unfused 5 or fused with benzene; and R 2 3 is alkyl which is unsubstituted or substituted with R 2 4 , OR24 NHR24 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R 2 4 is R24A or R 24; R24A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which is unfused or fused with heterocycloalkane; R 24 is alkyl, which is unsubstituted or substituted with OR , OH, F, Cl, Br or I; R 25 is alkyl, which is unsubstituted or substituted with NH 2 ; wherein the moieties 20 212A 20 represented by R , R , R 22 , and R24A are independently unsubstituted or substituted with one or two of independently selected R 26 , OR 26 (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula (It), R 11 is phenyl, pyrrolidinyl, azabicylclo(3. 1.0)hexanyl, hexahydro- 1 H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2.1 )hept-2-yl; each of which are 25 independently unsubstituted or substituted with one or two of independently selected R19, 19 19 19 19 19 19 1 91 OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR , N(R 9)2, NHC(O)R 9, NHS(O) 2 R'9,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R19 is as described in Formula I. 94 In one embodiment of Formula (1k), R102 is C(O)NHR 11 , as described in Formula 0 NH

R

10 1 0 iN R11 R105 RiM (Iu): R104 (Iu), wherein R 11 is as described in Formula I. In one 101 103 104 0 embodiment of Formula (Iu), R , R , R and R 1 5 are H. In another embodiment of 5 Formula (Iu), R03 is F and R 101 , R 10 4 and R 10 5 are H. In another embodiment of Formula (Iu), R" is R 15 and R 15 is alkyl which is unsubstituted or substituted with one or two of independently selected Ri, OR1, SR1, S(O) 2

R

16 , C(O)OH, NH 2 , NHR 16

N(R

1 6

)

2 , C(O)Ri 6 16 16 16 16 17 1A C(O)NHR , NHC(O)R , NHC(O)OR , OH, F, Cl, Br or I; wherein each R is R" or R R is alkyl which is unsubstituted or substituted with R"; R 17 is phenyl, heteroaryl, 0 cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene or heterocycloalkane; R 18 is phenyl or heterocycloalkyl, which is unfused; wherein the moieties represented by R 1 , R 1 , R, Rl 7 A, and R 18 are independently unsubstituted or substituted with one or two of independently selected R19, OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 19 , N(R 1 9

)

2 , NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, 5 C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; wherein each R19 is R 20, R , R2 or R ; R20 is phenyl, which is unfused; R 2 1 is heteroaryl, which is unfused; R 22 is cycloalkyl or heterocycloalkyl; each of which is unfused or fused with benzene; and R 23 is alkyl which is unsubstituted or substituted with R 24, OR24 , NHR24 N(R24 )2, NHS(O) 2 R24 or OH; wherein each R24 is R24A or R 24; R 2 4 A is phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, 20 which is unfused or fused with heterocycloalkane; R 2 4 B is alkyl, which is unsubstituted or substituted with OR, OH, F, Cl, Br or I; R is alkyl, which is unsubstituted or substituted with NH 2 ; wherein the moieties represented by R 2 0 , R 21 , R 22 , and R 2 4 A are independently unsubstituted or substituted with one or two of independently selected R 26 , OR26 (0), F, Cl, Br or I; and R 26 is alkyl. In another embodiment of Formula (Iu), R" is phenyl, pyrrolidinyl, 25 azabicylclo(3. 1.0)hexanyl, hexahydro-1H-isoindolyl, oxazolidinyl, azepanyl, piperidinyl, imidazolidinyl, thiazolidinyl, thiazinyl, azetidinyl, tetrahydropyrimidinyl, or azabicylo(2.2.1)hept-2-yl; each of which are independently unsubstituted or substituted with 19 1 19 9 19 19 one or two of independently selected R 19 , OR 9, SR 9, SO 2 R19, C(O)R 9, CO(O)R 9, NHR 95 N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I wherein R 19 is as described in Formula I. In one embodiment of Formula (1k), R 1 0 2 is phenyl which is unsubstituted or 5 substituted with one or two or three or four of independently selected R 19 , OR 9, SR19, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR 9, NH 2 , NHR 9, N(R 9)2, NHC(O)R 9, NR19C(O)R 9, NHS(O) 2 R 9, NR19S(O) 2 R 9, NHC(O)OR 9, NR19C(O)OR'9,

NHC(O)NH

2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR 19 C(O)NHR 9, NR19C(O)N(R 9)2,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R'9, 0 C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 , CF 3 , CF 2

CF

3 , OCF 3 ,

OCF

2

CF

3 , F, Cl, Br or I; wherein R 19 is as described in Formula I. In one embodiment of Formula (1k), R 1 0 2 is heterocycloalkyl which is unsubstituted or 5 substituted with one or two or three or four of independently selected R 19 , OR 9, SR19, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR 9, NH 2 , NHR 9, N(R 9)2, NHC(O)R 9, NR19C(O)R 9, NHS(O) 2 R 9, NR19S(O) 2 R 9, NHC(O)OR 9, NR19C(O)OR'9,

NHC(O)NH

2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR 19 C(O)NHR 9, NR19C(O)N(R 9)2,

C(O)NH

2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R'9, '0 C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 , CF 3 , CF 2

CF

3 , OCF 3 ,

OCF

2

CF

3 , F, Cl, Br or I; wherein R 19 is as described in Formula I. Embodiments where A' is Piperidine, A 2 is R 5 25 In one embodiment of Formula (I) A' is R 2 , wherein R 2 is unsubstituted piperidine which is unfused, and A 2 is R , which is as described in Formula I. In another embodiment of Formula I, A' is R 2 , wherein R 2 is unsubstituted piperidine which is unfused, and A 2 is R 5 , R 5 is Ci-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted with R 10 , and further unsubstituted or substituted with one or two or three of independently selected NHR 1 0 , N(R 0

)

2 , SR , 30 S(O)R 10 , S0 2

R

10 or CF 3 , wherein R 1 0 is as described in formula I. In another embodiment of Formula I, A' is R 2 , wherein R 2 is unsubstituted piperidine which is unfused, and A 2 is R 5 , R 5 is Ci-alkyl, C 2 -alkyl or C 3 -alkyl wherein R 5 is substituted with R 10 , and further unsubstituted or substituted with one CF 3 , wherein R 1 0 is as described in formula I. In another embodiment 96 of Formula I, A' is R 2 , wherein R 2 is unsubstituted piperidine which is unfused, A 2 is Ci alkyl, and R 10 is phenyl, as shown in Formula (Iv): 0 NH N N R 1 01

R

102

R

105 R103 1014 102 103 104 0 (Iv), wherein R , R , R , R , and R 1 5 , are independently selected from H, R 11 , OR 1 , SR 11 , S(O)R 11 , S0 2 R", NH 2 , N(R 1

)

2 , C(O)R, C(O)OR 11 , 5 C(O)NHR 11 , C(O)N(R 1

)

2 , NHC(O)R 11 , NHSO 2

R

11 , NR 1

"SO

2

R

11 , NHC(O)OR 11 ,

NHSO

2

N(R

1

)

2 , NO 2 , OH, (0), C(O)OH, F, Cl or Br; wherein each R 11 is R , R , R or R1; R is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 13 is 0 heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R1 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or 5 heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 15 is alkyl, alkenyl or alkynyl; each of 16 16 which is unsubstituted or substituted with one or two of independently selected Rio, OR S6, S(O) 2

R

16 , C(O)OH, NH 2 , NHRi N(R 1 6

)

2 , C(O)Rio, C(O)NH 2 , C(O)NHRio

C(O)N(R

1 6

)

2 , NHC(O)Rio, NR 16

C(O)R

1 6 , NHC(O)OR 1 6 , NR 16

C(O)OR

16 , OH, F, Cl, Br or I; 20 wherein each R is R" or R A; R " is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected R 18 , C(O)OH, NH 2 , NHR or N(R )2, C(O)R", C(O)NH 2 , C(O)NHR", C(O)N(R )2, NHC(O)R", NR C(O)R , F, Cl, Br or I; R 17 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, 25 heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein each R18 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; 12 13 14 17A wherein each of the moieties represented by R , R , R , R , and R 18 are independently 97 unsubstituted or substituted with one or two or three or four of independently selected R' 9 , OR 9, SR 9, S(O)R 9, SO2R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR 9, NH 2 , NHR19, N(R 9)2, NHC(O)R 9, NR 19

C(O)R

9 , NHS(O) 2

R

9 , NR 19

S(O)

2

R

9 , NHC(O)OR 9, NR19C(O)OR 9, NHC(O)NH 2 , NHC(O)NHR 9, NHC(O)N(R 9)2, NR19C(O)NHR 9, 5 NR19C(O)N(R 9)2, C(O)NH 2 , C(O)NHR 9, C(O)N(RI9)2, C(O)NHOH, C(O)NHOR 9,

C(O)NHSO

2 R 9, C(O)NR19SO 2 R 9, SO 2

NH

2 , SO 2 NHR19, SO 2 N(RI9)2, C(O)H, C(O)OH,

C(N)NH

2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 , CF 3 ,

CF

2

CF

3 , OCF 3 , OCF 2

CF

3 , F, Cl, Br or I; wherein each R19 is R 2, R , R or R ; R21 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, 0 heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 2 1 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 22 is 5 cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 23 is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected R 2 4 , OR 2 4 , .0 SR24, S(O) 2 R 24, C(O)OH, NH 2 , NHR24 N(R)2, C(O)R24, C(O)NH 2 , C(O)NHR24 C(O)N(R 24)2, NHC(O)R 24, NR 24C(O)R24 , NHC(O)OR 24, NR 24C(O)OR24 , NHS(O) 2

R

2 4 , NR24 S(O) 2 R24, OH, F, Cl, Br or I; wherein each R 2 4 is R24A or R24B; R24A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or 25 heterocycloalkene; R 24 is alkyl, alkenyl or alkynyl each of which is unsubstituted or substituted with one or two of independently selected R , OR , SR 25 , S(O) 2

R

2 5 , C(O)OH,

NH

2 , NHR2 N(R 25

)

2 , C(O)R 25 , C(O)NH 2 , C(O)NHR 25 , C(O)N(R )2, NHC(O)R 25 , NR C(O)R 2 5 , NHC(O)OR , NR C(O)OR , OH, F, Cl, Br or I; wherein each R 2 5 is alkyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl ; each of 30 which is unsubstituted or substituted with NH 2 , NH(CH 3 ), N(CH 3

)

2 , OH or OCH 3 ; wherein 20 21 22 24A each of the moieties represented by R20, R , R, and R are independently unsubstituted or substituted with one or two of independently selected R 26 , OR 26 , alkenyl, alkynyl, phenyl, 98 OH, (0), C(O)OH, CN, CF 3 , OCF 3 , CF 2

CF

3 , F, Cl, Br or I; and R 26 is alkyl. In another embodiment, the compound of Formula (Iv) is selected from 8-(4-fluorobenzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H)-one; 8-(4-fluoro-3-(2-oxoazetidin-1-yl)benzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H) 5 one; 8-(3-chloro-4-fluorobenzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H)-one 8-(4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl)-2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H) one; methyl 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 0 yl)methyl)benzoate; 8-(3-amino-4-fluorobenzyl)- 2,3,4,6-tetrahydropyrido(2,3-d)pyridazin-5(1H)-one; 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)benzoic acid; N-ethyl-2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; 5 N-cyclobutyl-2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)-N-(2 pyrrolidin- 1 -ylethyl)benzamide; 8-(4-fluoro-3 -((4-(morpholin-4-ylcarbonyl)piperazin- 1 -yl)carbonyl)benzyl)-2,3,4,6 0 tetrahydropyrido(2,3 -d)pyridazin-5 (1 H)-one; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-N' phenylpentanediamide; 1-(2-fluoro-5 -((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8 yl)methyl)phenyl)pyrrolidine-2,5-dione; 25 N-(2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)phenyl)-3 methoxypropanamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-5 oxohexanamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-3 30 phenoxypropanamide; N-(2-fluoro-5 -((5 -oxo- 1,2,3,4,5,6-hexahydropyrido(2,3 -d)pyridazin-8-yl)methyl)phenyl)-4 oxo-4-phenylbutanamide; 99 2-(4-(benzyloxy)phenoxy)-N-(2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3 d)pyridazin-8-yl)methyl)phenyl)acetamide; N-(2-fluoro-5-((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)phenyl)-2 (4-methoxyphenoxy)acetamide; 5 N-cyclopropyl-2-fluoro-5-((5-oxo- 1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8 yl)methyl)benzamide; 8-(3-((4-(2-ethoxyethyl)piperazin- 1 -yl)carbonyl)-4-fluorobenzyl)-2,3,4,6 tetrahydropyrido(2,3-d)pyridazin-5(1H)-one; or 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido(2,3-d)pyridazin-8-yl)methyl)-N-(2-piperidin 0 1 -ylethyl)benzamide. Schemes The starting materials used herein are commercially available or may be prepared by routine methods well known to those of ordinary skill in the art. The compounds of the 5 present invention may be prepared using the methods illustrated in the general synthetic schemes and experimental procedures detailed below. The general synthetic schemes are presented for purposes of illustration and are not intended to be limiting. Scheme 1 RIA -o, . I o o 0 NfC" 6 4 O OH P*Bu 3 Br 1 2 3 0 0 0 8 11 0 Rll <COOH R R 100 As shown in Scheme 1, the bicyclic anhydride (1) can be reduced to the alcohol (2) using a reducing agent such as but not limited to sodium borohydride. The reaction is typically conducted in a solvent such as but not limited to tetrahydrofuran at below room temperature to reflux. Conversion of (2) to the phosphonium salt (3) may be carried out by 5 reacting the former with a trialkyl phosphine such as but not limited to tri-n-butyl phosphine in the presence of hydrobromic acid. The reaction is typically conducted in a solvent such as but not limited to acetic acid at reflux. Reaction of (3) with a nitrobenzaldehyde of Formula (4), wherein R 1 'A is a substituent on R 10 as described herein, in the presence of a base such as but not limited to triethylamine will provide a lactone of Formula (5). The reaction is 0 typically conducted in a solvent such as but not limited to dichloromethane at room temperature. Reduction of the nitro group of a compound of Formula (5) with a reducing agent such as but not limited to iron powder and NH 4 Cl will provide the corresponding aniline of Formula (6). The reaction is typically conducted in a solvent such as but not limited to ethanol at reflux. Reaction of the aniline of Formula (6) with hydrazine will 5 provide a tetrahydrophthalazinone of Formula (7). The reaction is typically conducted in a solvent such as but not limited to ethanol at an elevated temperature. Reaction of a compound of Formula (7) with either an anhydride of Formula (8) or with an acid of Formula (11) under standard peptide coupling conditions known to those skilled in the art and widely available in the literature will provide compounds of Formula (9) and (12), respectively. An acid of '0 Formula (9) may be further modified to an imide of Formula (10) using standard peptide coupling conditions including the use of 1,1 '-carbonyldiimidazole (CDI) as the coupling agent. Scheme 2 RilA OC I H O O NC 13 CHOON NH P*Bu 3 Br- OH 3 14 HN(Riik 16 0 0 0 NH I NH NH -N -N -N 0

N(R

1 6

)

2

NH

2 N(Riik 19 R11IA 18 RlA 17 R1 A 101 Alternatively, as shown in Scheme 2, the phosphonium salt (3) can be reacted with a cyanobenzaldehyde of Formula (13) to provide a lactone of Formula (14). The reaction is typically conducted under basic conditions in a solvent such as but not limited to dichloromethane at room temperature. Hydrolysis of the nitrile of Formula (14) to the 5 corresponding acid, followed by addition of hydrazine will provide the tetrahydrophthalazinone of Formula (15). The hydrolysis step is typically conducted with an aqueous base such as but not limited to sodium hydroxide at elevated temperatures. The second step is also conducted under aqueous conditions at elevated temperatures. Coupling the acid of Formula (15) with an amine of Formula (16), wherein each R" is as described in 0 Formula I herein or is H or is a heterocyclic amine R , under standard peptide coupling conditions known to those skilled in the art and widely available in the literature, will provide an amide of Formula (17). Alternatively, a compound of Formula (14) can be converted to a tetrahydrophthalazinone using hydrazine as previously described, followed by reduction to the primary amine of Formula (18) under standard Raney-nickel reduction conditions. 5 Treatment of compounds of Formula (18) under standard reductive amination conditions with an aldehyde R 16 CHO or ketone R 16

C(O)R

1 6 and then optionally with a second aldehyde Ri 6 CHO or ketone RioC(O)Rio, will provide secondary or tertiary amines of Formula (19) (wherein each R 16 can be H or as defined in Formula (I)). Scheme 3 RilA 0 20 (R11B) 2 HC CHO 20 H(OR11B)2 P Bu 3 Br- R 0\ 3 21 RilA 0 AlNHR 1 6

R

16 0

SNR

16

R

1 6 23H 19 R1i1A CHO 20 22 Ri1A In a manner similar to the procedure described in Scheme 1, the phosphonium salt (3) can be reacted with a benzaldehyde of Formula (20), wherein RiiB is alkyl such as but not limited to ethyl and R 1 lA is as previously defined in Scheme 1. Reaction of a compound of Formula (21) with hydrazine as described in Scheme 1, followed by hydrolysis using an 25 aqueous acid such as but not limited to sulfuric acid will provide a compound of Formula 102 (22). The reaction is typically performed at elevated temperatures in a solvent such as but not limited tot ethanol. Reaction of a compound of Formula (22) with an amine of Formula (23) under reductive amination conditions known to those skilled in the art and widely available in the literature will provide a tetrahydrophthalazinone of Formula (19). 5 Scheme 4 RilA 0 1 0 BO O'CH0 0 24 C Br P*Bu 3 Br- \ 3 25 RiIA R"SnR 3 27 0 or 0 NH R B(OH) 2 NH -N 28 , R" Br 29 R11A 26 RIA As shown in Scheme 4, the phosphonium salt (3) can be reacted with a bromobenzaldehyde of Formula (24) to provide a compound of Formula (25) using the 0 conditions described in Scheme 1. Reaction of a compound of Formula (25) with hydrazine as described in Scheme 1 will provide a tetrahydrophthalazinone of Formula (26), which can be coupled with stannane of Formula (27) or a borate of Formula (28) to provide a compound of Formula (29) wherein R 11 is a substituted or unsubstituted phenyl or heteroaryl. Coupling conditions include those known by those skilled in the art and widely available in the 15 literature for Suzuki and Stille type couplings. 103 Scheme 5 R1IA 0 1) Mg, ether N Br 0 Br N Br 2) Br 30 N R 00 NH |N NH N NH NI -NN -N - 36I~ NH 2 N~ CONH 2 s COOCH 3 R 35 0 00 NH NH N N N NH H H

NH

2 COOH N 0H 3 R R 00 NH NH N -N N NH H H 1N N R 11 H HH 38 RilA 4 RIA A benzylic bromide of Formula (30) wherein R" 1 is as described herein, can be converted to a Grignard reagent and then added to a diester (31) to give a keto-ester of 5 Formula (32) as shown in Scheme 5. The addition of the Grignard reagent is typically performed at cold temperatures, before warming up the reaction to room temperature. The reaction is typically performed in a solvent such as but not limited to tetrahydrofuran, ether and the like, or mixtures thereof. The Grignard reagent may be purchased commercially or prepared from Mg using standard conditions available in the literature. The addition of 10 hydrazine to a compound of Formula (32) under conditions described in Scheme 1 at room temperature will provide a phthalazinone of Formula (33). The bromide can be converted to an ester of Formula (34) under palladium catalyzed carboxylation conditions. The transformation typically requires the use of a palladium catalyst and a base, such as but not limited to triethylamine, in addition to carbon monoxide and methanol. Typical palladium 15 catalysts include [1,1 '-bis(diphenylphosphino)ferrocene] dichloropalladium(II) 104 dichloromethane and the like. The reaction is typically conducted at elevated temperatures and may require the use of a solvent such as but not limited to N,N-dimethylformamide. The ester of Formula (34) can be converted to a primary amide of Formula (35) using ammonia, followed by a Hoffman rearrangement with bromine and aqueous potassium hydroxide to 5 provide an aniline of Formula (36). The first step typically requires an elevated temperature, and the second step typically requires a decreased temperature for the additions, followed by heating. The pyridine ring can be reduced under catalytic conditions, such as but not limited to the use of hydrogen gas and platinum on carbon to provide a compound of Formula (37). Amide formation using either an acid chloride of Formula R 11 C(O)Cl or an acid of Formula 0 R 11 C(O)OH under standard peptide coupling conditions known to those skilled in the art and widely available in the literature will provide compounds of Formula (38). Alternatively, an ester of Formula (34) can be reduced to a compound of Formula (39) using the conditions described above, followed by hydrolysis to provide an acid of Formula (40). Typical hydrolysis conditions include but are not limited to using an aqueous base such as lithium 5 hydroxide at elevated temperatures. Amide formation using a primary or secondary amine of Formula NH 2 R"I or NH(R 1

)

2 employing standard peptide coupling conditions known to those skilled in the art and widely available in the literature, will provide an amide of Formula (41). 10 The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. The exemplified compounds were named using ACD/ChemSketch Version 5.06 (05 June 2001, Advanced Chemistry Development Inc. ,Toronto, Ontario), except for Examples 160, 320 and 487, which were named using ChemDraw@ Ver. 9.0.5 25 (CambridgeSoft, Cambridge, MA). Intermediates were named using IUPAC standards. EXAMPLE 1 2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid EXAMPLE 1A 30 3-hydroxy-4,5,6,7-tetrahydro-2-benzofuran-1(3H)-one To a solution of 1 -cyclohexene- 1,2-dicarboxylic anhydride (25.2 g) in tetrahydrofuran (125 mL) at 0 0 C was added sodium borohydride (1.51 g). The mixture was warmed to ambient temperature for 30 minutes, heated at reflux for 5 hours, cooled, treated with IN 105 hydrochloric acid and concentrated. The concentrate was partitioned between ethyl acetate and brine, and the organic layer was washed with brine and water and concentrated. The concentrate was purified by flash chromatography with 50% ethyl acetate in hexane. EXAMPLE 1B 5 tributyl(3 -oxo- 1,3,4,5,6,7-hexahydro-2-benzofuran- 1 -yl)phosphonium bromide A solution of EXAMPLE 1A (3 g) in acetic acid (10 mL) at ambient temperature was treated with tri-n-butyl phosphine (4.81 mL) and 33% hydrobromic acid in acetic acid (3.34 mL), heated at reflux for 21 hours, cooled and concentrated. The concentrate was purified by flash chromatography on silica gel with 10% methanol in dichloromethane. 0 EXAMPLE IC 2-fluoro-5-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H)-ylidene)methyl)benzonitrile To a solution of EXAMPLE 1B (3.05 g) in dichloromethane (30 mL) was added 2 fluoro-5-formylbenzonitrile (1.08 g) and triethylamine (1.02 mL). The mixture was stirred at ambient temperature for 16 hours and concentrated. The concentrate was partitioned between 5 ethyl acetate and brine. The organic layer was washed with brine and concentrated. The concentrate was purified by flash chromatography on silica gel with 50% ethyl acetate in hexane. EXAMPLE ID 2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid 10 To a suspension of EXAMPLE IC (1.46 g) in water (15 mL) was added 50% sodium hydroxide. The mixture was heated at 90 0 C for 1 hour. After cooling to 70 0 C, hydrazine monohydrate (0.54 mL) was added, and the solution was stirred at 70 0 C for 17 hours. The solution was cooled to ambient temperature and brought to pH 4 with 6N hydrochloric acid. The precipitate was filtered, washed with water and dried. 'H NMR (DMSO-d 6 ) 61.55-1.69 25 (m, 4H), 2.31-2.42 (m, 4H), 3.93 (s, 2H), 7.24 (dd, J=10.8, 8.5 Hz, 1H), 7.40-7.48 (m, 1H), 7.68 (dd, J=6.9, 2.2 Hz, 1H), 12.61 (s, 1H), 13.22 (brs, 1H). EXAMPLE 2 4-(3-amino-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 2A 30 3-(4-fluoro-3-nitrobenzylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one This example was prepared as described in EXAMPLE IC by substituting 4-fluoro-3 nitrobenzaldehyde for 2-fluoro-5-formylbenzonitrile. EXAMPLE 2B 106 3-(3-amino-4-fluorobenzylidene)-4,5,6,7-tetrahydroisobenzofuran- 1 (3H)-one A solution of EXAMPLE 2A (2.25 g) and ammonium chloride (0.83 g) in ethanol (35 mL) and water (25 mL) at 70 0 C was treated with iron powder (4.35 g), stirred for 3 hours and filtered through diatomaceous earth (CELITE*, World Minerals, Santa Barbara, CA) with hot 5 ethanol. The filtrate was concentrated, and the concentrate was stirred with water for 30 minutes and filtered. The solid was washed with water and dried. EXAMPLE 2C 4-(3-amino-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 2B (1.42 g) in ethanol (10 mL) was added hydrazine 0 monohydrate (0.27 mL). The mixture stirred at reflux for 1 hour, cooled to 0 0 C, and filtered. The solid was washed with water and dried. 1 H NMR (CD 3 0D) 6 1.63-1.75 (m, 4H), 2.36 2.45 (m, 2H), 2.46-2.53 (m, 2H), 3.84 (s, 2H), 6.42-6.49 (m, 1H), 6.64 (dd, J=8.6, 2.2 Hz, 1H), 6.86 (dd, J=11.2, 8.1 Hz, 1H). EXAMPLE 3 5 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)amino)-4 oxobutanoic acid To a solution of EXAMPLE 2 (872 mg) in acetonitrile was added succinic anhydride (370 mg). The mixture was heated at reflux for 17 hours, cooled and concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent '0 Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.l1% trifluoroacetic acid). H NMR (DMSO-d 6 ) 61.53-1.66 (m, 4H), 2.30-2.43 (m, 4H), 2.55-2.67 (m, 2H), 3.26-3.31 (m, 2H), 3.85 (s, 2H), 6.85-6.99 (m, 1H), 7.15 (dd, J=10.8, 8.5 Hz, 1H), 7.74 (d, J=6.4 Hz, 1H), 9.70 (brs, 1H), 12.09 (brs, 1H), 12.61 (s, 1H). EXAMPLE 4 25 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-vl)methyl)phenvll)pyrrolidine-2,5 dione To EXAMPLE 3 (905 mg) in dichloromethane (30 mL) and N,N-dimethylformamide (6 mL) was added 1,1'-carbonyldiimidazole (785 mg). The mixture was stirred at ambient temperature for 3 hours and concentrated. The concentrate was purified by HPLC (Zorbax@ 30 C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.10% trifluoroacetic acid). 1 H NMR (DMSO-d 6 ): 6 1.57-1.69 (m, 4H), 2.32-2.42 (m, 4H), 2.78-2.89 (m, 4H), 3.93 (s, 2H), 7.09-7.13 (m, 1H), 7.32-7.33 (m, 1H), 7.34 (d, J=1.2 Hz, 1H), 12.62 (s, 1H). 107 EXAMPLE 5 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 5A tert-butyl 4-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoyl)-1,4 5 diazepane- 1 -carboxylate To EXAMPLE 1 (294 mg) in 1:1 N,N-dimethylformamide/pyridine (6 mL) was added 1,1'-carbonyldiimidazole (166 mg). The mixture was stirred at ambient temperature for 30 minutes, and tert-butyl 1-homopiperazine carboxylate (189 ptL) was added. The mixture was stirred for 18 hours and concentrated. The concentrate was purified by flash 0 chromatography on silica gel with 5% methanol in ethyl acetate. EXAMPLE 5B 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 5A (330 mg) in dichloromethane (8 mL) at 0 0 C was added trifluoroacetic acid (8 mL). The solution was warmed to ambient temperature, and 5 acetonitrile was added. The mixture was concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0 100% acetonitrile/water with 0.l1% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and treated with 1 M hydrochloric acid in diethyl ether and filtered to give the title compound as the hydrochloride salt. 1 H NMR (CD 3 0D) 6 1.70-1.76 (m, 4H), '0 2.02-2.11 (m, 2H), 2.52 (d, J=27.5 Hz, 4H), 3.32-3.36 (m, 2H), 3.40-3.46 (m, 2H), 3.51 (t, J=6.1 Hz, 2H), 3.95-4.01 (m, 2H), 4.06 (s, 2H), 7.19 (t, J=9.0 Hz, 1H), 7.29-7.34 (m, 1H), 7.36-7.41 (m, 1H). EXAMPLE 6 4-(3-(aminomethyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 25 EXAMPLE 6A This example was prepared as described in EXAMPLE 2C by substituting EXAMPLE IC for EXAMPLE 2B. EXAMPLE 6B 4-(3-(aminomethyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 30 To a solution of EXAMPLE 6A (1.5 g) in 20% ammonia in methanol (150 mL) was added Raney nickel (15 g). The mixture was shaken under hydrogen (60 psi) at ambient temperature for 2 hours, filtered, and concentrated. The concentrate was purified by HPLC (Zorbax@ C- 18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% 108 acetonitrile/water with 0.1% trifluoroacetic acid) to give the title compound as the trifluoroacetate salt. 'H NMR (CD 3 0D) 61.55-1.65 (m, 4H), 2.33-2.41 (m, 4H), 3.90 (s, 2H), 4.04 (s, 2H), 7.21-7.25 (m, 1H), 7.27-7.29 (m, 1H), 7.31 (d, J=7.0 Hz, 1H), 8.20-8.27 (brs, 2H). 5 EXAMPLE 7 4-(3-((dimethylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 6 (75 mg) in methanol (8 mL) was added 37 wt% formaldehyde in water (39 ptL) and triethylamine (36 ptL). The solution was stirred at ambient temperature for 1 hour. Sodium cyanoborohydride (49 mg) and zinc chloride (35 0 mg) were added, and the mixture was stirred for 60 hours and was concentrated. The concentrate was dissolved in trifluoroacetic acid/methanol and purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.l1% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and treated with 1 M hydrochloric acid in diethyl ether to give the 5 title compound as the hydrochloride salt. 'H NMR (CD 3 0D) 61.68-1.80 (m, 4H), 2.50-2.60 (m, 4H), 2.88 (s, 6H), 4.10 (s, 2H), 4.39 (s, 2H), 7.22-7.27 (m, 1H), 7.40-7.44 (m, 1H), 7.46 (dd, J=6.9, 2.0 Hz, 1H). EXAMPLE 8 4-(4-fluoro-3-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 10 This example was prepared as the hydrochloride salt as described in EXAMPLE 7 by substituting acetone for formaldehyde. 1 H NMR (CD 3 0D) 61.39 (d, J=6.7 Hz, 6H), 1.68-1.77 (m, 4H), 2.43-2.59 (m, 4H), 3.41-3.50 (m, 1H), 4.05 (s, 2H), 4.24 (s, 2H), 7.18-7.24 (m, 1H), 7.35-7.38 (m, 1H), 7.38-7.42 (m, 1H). EXAMPLE 9 25 4-(3-((cyclohexylamino)methyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 7 by substituting cyclohexanone for formaldehyde. 1H NMR (CD 3 0D) 6 1.32-1.46 (m, 4H), 1.68 1.81 (m, 6H), 1.84-1.94 (m, 2H), 2.13-2.22 (m, 2H), 2.43-2.61 (m, 4H), 3.08-3.18 (m, 1H), 4.07 (s, 2H), 4.26 (s, 2H), 7.18-7.23 (m, 1H), 7.35-7.39 (m, 1H), 7.40-7.43 (m, 1H). 30 EXAMPLE 10 4-(4-fluoro-3-((tetrahydro-2H-pyran-4-ylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one 109 This example was prepared as the hydrochloride salt as described in EXAMPLE 7 by substituting tetrahydro-4H-pyran-4-one for formaldehyde. 'H NMR (CD 3 0D) 6 1.66-1.76 (m, 6H), 2.04-2.14 (m, 2H), 2.40-2.57 (m, 4H), 3.40-3.51 (m, 3H), 4.03 (s, 2H), 4.05 (d, J=4.6 Hz, 2H), 4.29 (s, 2H), 7.18-7.25 (m, 1H), 7.36-7.39 (m, 1H), 7.40 (d, J=1.8 Hz, 1H). 5 EXAMPLE 11 4-(4-fluoro-3-((methyl((1 -methylpyrrolidin-3-yl)methyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one To a solution of EXAMPLE 6 (75 mg) in methanol (8 mL) was added 3-formyl pyrrolidine-1-carboxylic acid tert-butyl ester (104 mg) and triethylamine (36 ptL). The 0 mixture was stirred at ambient temperature for 1 hour. Sodium cyanoborohydride (49 mg) and zinc chloride (35 mg) were added. The mixture was stirred for 60 hours and trifluoracetic acid was added and the mixture stirred for one hour and was concentrated. The concentrate was dissolved in water/acetonitrile and was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.10% 5 trifluoroacetic acid). The residue was treated as described above with with 37 wt% formaldehyde in water (39 ptL), followed by treatment with IM hydrochloric acid in diethyl ether to obtain the title compound as the HCl salt. 1 H NMR (CD 3 0D) 61.69-1.74 (m, 6H), 1.80-1.88 (m, 3H), 2.10-2.20 (m, 2H), 2.44-2.58 (m, 6H), 3.10 (dd, J=11.4, 7.5 Hz, 2H), 3.22 3.26 (m, 1H), 3.34-3.38 (m, 2H), 3.52-3.56 (m, 1H), 4.03 (s, 2H), 4.31 (s, 2H), 7.18-7.23 (m, '0 1H), 7.35-7.39 (m, 1H), 7.49 (dd, J=6.9, 2.0 Hz, 1H). EXAMPLE 12 4-(4-fluoro-3-((methyl(((2R)-1-methylpyrrolidin-2-yl)methyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 11 25 by substituting N-(tert-butoxycarbonyl)-D-prolinal for 3 -formyl-pyrrolidine- 1 -carboxylic acid tert-butyl ester. 1 H NMR (CD 3 0D) 6 1.74-1.83 (m, 4H), 1.95-2.07 (m, 1H), 2.10-2.28 (m, 2H), 2.52-2.70 (m, 5H), 2.91 (s, 3H), 3.04 (s, 3H), 3.21-3.29 (m, 1H), 3.63-3.69 (m, 1H), 3.73-3.81 (m, 1H), 3.90-4.00 (m, 1H), 4.05-4.13 (m, 1H), 4.20 (s, 2H), 4.50-4.62 (m, 2H), 7.27 (t, J=9.1 Hz, 1H), 7.44-7.49 (m, 1H), 7.64 (d, J=5.2 Hz, 1H). 30 EXAMPLE 13 4-(3-((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 13A 3-(3-(diethoxymethyl)benzylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 110 This example was prepared as described in EXAMPLE 1 C by substituting 3-(diethoxymethyl)benzaldehyde for 2-fluoro-5-formylbenzonitrile. EXAMPLE 13B 4-(3-(diethoxymethyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 This example was prepared as described in EXAMPLE 2C by substituting EXAMPLE 13A for EXAMPLE 2B. EXAMPLE 13C 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzaldehyde To a solution of EXAMPLE 13B (681 mg) in a 1:1 mixture of ethanol/water (20 mL) 0 was added concentrated sulfuric acid (0.4 mL). The mixture was refluxed for 16 hours. The mixture was cooled and concentrated, and the concentrate was triturated with saturated sodium bicarbonate. The solid was filtered, washed with water and dried. EXAMPLE 13D 4-(3-((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 A solution of EXAMPLE 13C (80 mg) and cyclopropylamine (51 mg) in methanol (8 mL) was stirred at ambient temperature for 1 hour. Sodium cyanoborohydride (57 mg) was added, and the solution was stirred for 18 hours and was concentrated. The concentrate was dissolved in methanol/trifluoroacetic acid and was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with '0 0.1% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and was treated with 1 M hydrochloric acid in diethyl ether and concentrated to give the title compound as the hydrochloride salt. 1H NMR (CD 3 0D) 6 0.82-0.92 (m, 4H), 1.65-1.77 (m, 4H), 2.41-2.60 (m, 4H), 2.69-2.79 (m, 1H), 4.11 (s, 2H), 4.28 (s, 2H), 7.31 (d, J=6.7 Hz, 1H), 7.34-7.40 (m, 2H), 7.41-7.45 (m, 1H). 25 EXAMPLE 14 4-(3-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting isopropylamine for cyclopropylamine. 1 H NMR (CD 3 0D) 61.38 (d, J=6.7 Hz, 6H), 1.68-1.79 (m, 4H), 2.41-2.65 (m, 4H), 3.38-3.48 (m, 1H), 4.12 (s, 2H), 4.17 (s, 2H), 7.31 30 (d, J=7.1 Hz, 1H), 7.35-7.38 (m, 1H), 7.38-7.41 (m, 1H), 7.41-7.46 (m, 1H). EXAMPLE 15 4-(3-(morpholin-4-ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 111 This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting morpholine for cyclopropylamine. 1H NMR (CD 3 0D) 61.67-1.78 (m, 4H), 2.39-2.57 (m, 4H), 3.13-3.24 (m, 2H), 3.32-3.39 (m, 2H), 3.71-3.80 (m, 2H), 4.03 (dd, J=13.3, 3.2 Hz, 2H), 4.08 (s, 2H), 4.34 (s, 2H), 7.37 (d, J=6.7 Hz, 1H), 7.39-7.42 (m, 1H), 5 7.41-7.44 (m, 1H), 7.44-7.48 (m, 1H). EXAMPLE 16 4-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting pyrrolidine for cyclopropylamine. H NMR (CD 3 0D) 61.67-1.79 (m, 4H), 0 1.95-2.07 (m, 2H), 2.11-2.24 (m, 2H), 2.44-2.65 (m, 4H), 3.09-3.26 (m, 2H), 3.41-3.54 (m, 2H), 4.15 (s, 2H), 4.35 (s, 2H), 7.32-7.37 (m, 1H), 7.39-7.47 (m, 3H). EXAMPLE 17 4-(3-((cyclohexylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 5 by substituting cyclohexylamine for cyclopropylamine. 1H NMR (CD 3 0D) 61.20-1.27 (m, 1H), 1.31-1.45 (m, 4H), 1.66-1.78 (m, 5H), 1.85-1.93 (m, 2H), 2.12-2.20 (m, 2H), 2.45-2.60 (m, 4H), 3.08 (dd, J=14.6, 7.6 Hz, 1H), 4.11 (s, 2H), 4.19 (s, 2H), 7.32 (d, J=7.0 Hz, 1H), 7.34-7.38 (m, 1H), 7.38-7.42 (m, 1H), 7.41-7.45 (m, 1H). EXAMPLE 18 10 4-(3-((methylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting 2M methylamine in methanol for cyclopropylamine. 1H NMR (CD 3 0D) 61.69-1.78 (m, 4H), 2.45-2.59 (m, 4H), 2.70 (s, 3H), 4.13 (s, 2H), 4.16 (s, 2H), 7.30-7.33 (m, 1H), 7.33-7.37 (m, 1H), 7.37-7.40 (m, 1H), 7.43 (t, J=7.4 Hz, 1H). 25 EXAMPLE 19 4-(3-((ethylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting 2M ethylamine in methanol for cyclopropylamine. 1H NMR (CD 3 0D) 61.33 (t, J=7.2 Hz, 3H), 1.66-1.80 (m, 4H), 2.42-2.62 (m, 4H), 3.10 (q, J=7.4 Hz, 2H), 4.13 (s, 2H), 30 4.16 (s, 2H), 7.31 (d, J=7.1 Hz, 1H), 7.34-7.37 (m, 1H), 7.38-7.40 (m, 1H), 7.41-7.45 (m, 1H). EXAMPLE 20 4-(3-((4-methylpiperidin-1-yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 112 This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting 4-methylpiperidine for cyclopropylamine. 'H NMR (CD 3 0D) 60.99 (d, J=6.4 Hz, 3H), 1.39-1.54 (m, 2H), 1.67-1.76 (m, 5H), 1.83-1.95 (m, 2H), 2.44-2.63 (m, 4H), 2.92 3.04 (m, 2H), 3.35-3.46 (m, 2H), 4.15 (s, 2H), 4.26 (s, 2H), 7.34-7.37 (m, 1H), 7.40-7.44 (m, 5 2H), 7.44-7.47 (m, 1H). EXAMPLE 21 4-(3-(((2-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 0 by substituting 3-(trifluoromethyl)phenethylamine for cyclopropylamine. 1 H NMR (CD 3 0D) 61.64-1.72 (m, 4H), 2.40-2.57 (m, 4H), 3.06-3.14 (m, 2H), 3.27-3.29 (m, 2H), 4.07 (s, 2H), 4.22 (s, 2H), 7.33 (d, J=7.3 Hz, 1H), 7.35-7.38 (m, 1H), 7.38-7.42 (m, 1H), 7.44 (t, J=7.5 Hz, 1H), 7.55 (d, J=0.9 Hz, 1H), 7.55-7.58 (m, 1H), 7.59 (d, J=5.2 Hz, 1H), 7.60-7.62 (m, 1H). EXAMPLE 22 5 4-(3-((cyclohexyl(methyl)amino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 by substituting N-methyl cyclohexylamine for cyclopropylamine. 1H NMR (CD 3 0D) 61.23 1.40 (m, 3H), 1.53-1.65 (m, 2H), 1.67-1.79 (m, 5H), 1.90-2.00 (m, 2H), 2.02-2.18 (m, 2H), 2.40-2.49 (m, 2H), 2.49-2.58 (m, 2H), 2.71 (s, 3H), 3.16-3.28 (m, 1H), 4.07 (s, 2H), 4.17 (d, '0 J=12.9 Hz, 1H), 4.45 (d, J=13.2 Hz, 1H), 7.34-7.36 (m, 1H), 7.37-7.39 (m, 1H), 7.41 (s, 1H), 7.43-7.49 (m, 1H). EXAMPLE 23 4-(3-((2-ethylpyrrolidin-1-yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13 25 by substituting 2-ethylpyrrolidine for cyclopropylamine. 1H NMR (CD 3 0D) 60.94 (t, J=7.5 Hz, 3H), 1.52-1.63 (m, 1H), 1.69-1.77 (m, 4H), 1.78-1.87 (m, 2H), 1.91-2.04 (m, 1H), 2.05 2.17 (m, 1H), 2.31-2.44 (m, 1H), 2.45-2.64 (m, 4H), 3.19-3.28 (m, 1H), 3.34-3.47 (m, 2H), 4.15 (s, 2H), 4.21 (d, J=12.9 Hz, 1H), 4.50 (d, J=13.2 Hz, 1H), 7.33-7.38 (m, 1H), 7.40-7.44 (m, 2H), 7.44-7.48 (m, 1H). 30 EXAMPLE 24 4-(4-((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one EXAMPLE 24A 3-(4-(diethoxymethyl)benzylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 113 This example was prepared as described in EXAMPLE 1 C by substituting 4 (diethoxymethyl)benzaldehyde for 2-fluoro-5-formylbenzonitrile. EXAMPLE 24B 4-(4-(diethoxymethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 5 This example was prepared as described in EXAMPLE 2C by substituting EXAMPLE 24A for EXAMPLE 2B. EXAMPLE 24C 4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)benzaldehyde This example was prepared as described in EXAMPLE 13C by substituting EXAMPLE 24B 0 for EXAMPLE 13B. EXAMPLE 24D 4-(4-((cyclopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C. H NMR (CD 3 0D) 60.82-0.88 (m, 2H), 5 0.89-0.94 (m, 2H), 1.62-1.77 (m, 4H), 2.35-2.44 (m, 2H), 2.45-2.55 (m, 2H), 2.70-2.82 (m, 1H), 4.02 (s, 2H), 4.27 (s, 2H), 7.30 (d, J=8.3 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H). EXAMPLE 25 4-(4-((isopropylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D '0 by substituting EXAMPLE 24C for EXAMPLE 13C and 2-propylamine for cyclopropylamine. 'H NMR (CD 3 0D) 61.38 (d, J=6.4 Hz, 6H), 1.65-1.72 (m, 4H), 2.37-2.45 (m, 2H), 2.46-2.52 (m, 2H), 3.39-3.50 (m, 1H), 4.01 (s, 2H), 4.17 (s, 2H), 7.31 (d, J=8.3 Hz, 2H), 7.44 (d, J=8.0 Hz, 2H). EXAMPLE 26 25 4-(4-(morpholin-4-ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and morpholine for cyclopropylamine. H NMR (CD 3 0D) 61.65-1.76 (m, 4H), 2.43-2.48 (m, 2H), 2.49-2.58 (m, 2H), 3.13-3.24 (m, 2H), 3.33-3.37 (m, 2H), 3.36-3.41 (m, 1H), 3.70-3.80 (m, 2H), 3.99-4.03 (m, 1H), 4.06 (s, 30 2H), 4.34 (s, 2H), 7.35 (d, J=8.0 Hz, 2H), 7.49 (d, J=8.0 Hz, 2H). EXAMPLE 27 4-(4-(pyrrolidin- 1 -ylmethyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 114 This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and pyrrolidine for cyclopropylamine. I H NMR (CD 3 0D) 61.63-1.76 (m, 4H), 1.94-2.06 (m, 2H), 2.10-2.24 (m, 2H), 2.37-2.46 (m, 2H), 2.46-2.55 (m, 2H), 3.11-3.23 (m, 2H), 3.38-3.58 (m, 2H), 4.02 (s, 2H), 4.34 (s, 2H), 7.33 5 (d, J=7.7 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H). EXAMPLE 28 4-(4-((cyclohexylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and cyclohexylamine for 0 cyclopropylamine. 1 H NMR (CD 3 0D) 61.21-1.29 (m, 1H), 1.33-1.43 (m, 4H), 1.64-1.75 (m, 5H), 1.86-1.93 (m, 2H), 2.13-2.21 (m, 2H), 2.37-2.44 (m, 2H), 2.49 (t, J=4.9 Hz, 2H), 3.05 3.16 (m, 1H), 4.01 (s, 2H), 4.18 (s, 2H), 7.30 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H). EXAMPLE 29 4-(4-((4-phenylpiperidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 5 This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 4-phenylpiperidine for cyclopropylamine. 1H NMR (CD 3 0D) 61.64-1.76 (m, 4H), 1.93-2.03 (m, 2H), 2.05-2.15 (m, 2H), 2.40-2.49 (m, 2H), 2.48-2.55 (m, 2H), 2.81-2.94 (m, 1H), 3.10-3.23 (m, 2H), 3.54-3.64 (m, 2H), 4.04 (s, 2H), 4.33 (s, 2H), 7.19-7.22 (m, 1H), 7.24 (d, J=7.1 Hz, 2H), 7.28-7.33 (m, '0 2H), 7.36 (d, J=8.0 Hz, 2H), 7.51 (d, J=7.7 Hz, 2H). EXAMPLE 30 4-(4-((methylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 2M methylamine in methanol for 25 cyclopropylamine. 1H NMR (CD 3 0D) 61.64-1.73 (m, 4H), 2.38-2.44 (m, 2H), 2.47-2.54 (m, 2H), 2.71 (s, 3H), 4.02 (s, 2H), 4.15 (s, 2H), 7.31 (d, J=8.3 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H). EXAMPLE 31 4-(4-((ethylamino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D 30 by substituting EXAMPLE 24C for EXAMPLE 13C and 2M ethylamine in methanol for cyclopropylamine. 1H NMR (CD 3 0D) 61.32 (t, J=7.4 Hz, 3H), 1.64-1.72 (m, 4H), 2.37-2.44 (m, 2H), 2.45-2.52 (m, 2H), 3.10 (q, J=7.4 Hz, 2H), 4.01 (s, 2H), 4.15 (s, 2H), 7.30 (d, J=8.3 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H). 115 EXAMPLE 32 4-(4-((4-methylpiperidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 4-methylpiperidine for 5 cyclopropylamine. 'H NMR (CD 3 0D) 60.99 (d, J=6.4 Hz, 3H), 1.33-1.48 (m, 2H), 1.66-1.75 (m, 5H), 1.85-1.95 (m, 2H), 2.40-2.48 (m, 2H), 2.48-2.57 (m, 2H), 2.90-3.05 (m, 2H), 3.44 (d, J=12.3 Hz, 2H), 4.04 (s, 2H), 4.25 (s, 2H), 7.33 (d, J=8.0 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H). EXAMPLE 33 4-(4-(((2-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)benzyl)-5,6,7,8 0 tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 3-(trifluoromethyl)phenethylamine for cyclopropylamine. 1 H NMR (CD 3 0D) 61.62-1.72 (m, 4H), 2.38-2.44 (m, 2H), 2.46-2.52 (m, 2H), 3.06-3.14 (m, 2H), 3.27-3.35 (m, 2H), 4.02 (s, 2H), 4.22 (s, 2H), 7.31 (d, J=8.3 Hz, 5 2H), 7.45 (d, J=8.3 Hz, 2H), 7.53-7.57 (m, 2H), 7.57-7.62 (m, 2H). EXAMPLE 34 4-(4-((cyclohexyl(methyl)amino)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and N-methylcyclohexylamine for '0 cyclopropylamine. I H NMR (CD 3 0D) 61.20-1.31 (m, 1H), 1.32-1.44 (m, 2H), 1.54-1.63 (m, 2H), 1.65-1.75 (m, 5H), 1.91-2.01 (m, 2H), 2.05-2.18 (m, 2H), 2.39-2.46 (m, 2H), 2.47-2.53 (m, 2H), 2.71 (s, 3H), 3.23-3.29 (m, 1H), 4.03 (s, 2H), 4.13 (d, J=13.2 Hz, 1H), 4.47 (d, J=13.2 Hz, 1H), 7.34 (d, J=8.3 Hz, 2H), 7.43-7.46 (m, 2H). EXAMPLE 35 25 4-(4-((2-methylpyrrolidin- 1 -yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 2-methylpyrrolidine for cyclopropylamine. 1 H NMR (CD 3 0D) 61.39 (d, J=6.7 Hz, 3H), 1.66-1.78 (m, 5H), 1.93-2.02 (m, 1H), 2.03-2.13 (m, 1H), 2.29-2.38 (m, 1H), 2.39-2.45 (m, 2H), 2.47-2.53 (m, 2H), 3.15 30 3.27 (m, 1H), 3.34-3.40 (m, 1H), 3.51-3.62 (m, 1H), 4.02 (s, 2H), 4.09-4.17 (m, 1H), 4.43 4.55 (m, 1H), 7.33 (d, J=8.0 Hz, 2H), 7.46 (d, J=8.3 Hz, 2H). EXAMPLE 36 4-(4-((4-methyl-1,4-diazepan-1-yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 116 This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting EXAMPLE 24C for EXAMPLE 13C and 1-methylhomopiperazine for cyclopropylamine. 'H NMR (CD 3 OD) 61.68-1.79 (m, 4H), 2.29-2.42 (m, 2H), 2.46-2.53 (m, 2H), 2.53-2.62 (m, 2H), 2.97 (s, 3H), 3.35-3.44 (m, 1H), 3.47-3.65 (m, 2H), 3.67-3.96 (m, 5 5H), 4.11 (s, 2H), 4.46 (s, 2H), 7.35 (d, J=8.0 Hz, 2H), 7.59 (d, J=8.0 Hz, 2H). EXAMPLE 37 4-(3-((4-methyl-1,4-diazepan-1-yl)methyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 13D by substituting 1-methylhomopiperazine for cyclopropylamine. 'H NMR (CD 3 0D) 61.68 0 1.81 (m, 4H), 2.29-2.41 (m, 2H), 2.44-2.53 (m, 2H), 2.55-2.64 (m, 2H), 2.98 (s, 3H), 3.33 3.40 (m, 1H), 3.40-3.56 (m, 2H), 3.58-3.72 (m, 1H), 3.73-3.97 (m, 4H), 4.15 (s, 2H), 4.46 (s, 2H), 7.37 (d, J=7.7 Hz, 1H), 7.46 (t, J=7.8 Hz, 1H), 7.51 (d, J=6.1 Hz, 2H). EXAMPLE 38 4-(4-fluoro-3-pyrimidin-2-ylbenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 EXAMPLE 38A 3-(3-bromo-4-fluorobenzylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one This example was prepared as described in EXAMPLE IC by substituting 3-bromo-4 fluorobenzaldehyde for 2-fluoro-5-formylbenzonitrile. EXAMPLE 38B 10 4-(3-bromo-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as described in EXAMPLE 2D by substituting EXAMPLE 38A for EXAMPLE 2B. EXAMPLE 38C 4-(4-fluoro-3-pyrimidin-2-ylbenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 25 To EXAMPLE 38B (75 mg) in N,N-dimethylformamide (8 mL) was added 2 tributylstannylpyrimidine (81 mg), tris(dibenzylidineacetone)dipalladium(O) (20 mg), tri-o tolylphosphine (20 mg) and triethylamine (92 iL). The mixture was stirred at 70 0 C for 17 hours. After cooling, the mixture was filtered, and the filtrate was concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent 30 Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.l1% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and treated with IM hydrochloric acid in diethyl ether and concentrated to provide the title compound as the hydrochloride salt. H NMR (CD 3 0D) 61.69-1.78 (m, 4H), 2.48-2.60 (m, 4H), 4.11 (s, 2H), 7.27 (dd, J=10.8, 8.5 117 Hz, 1H), 7.43-7.50 (m, 1H), 7.61 (t, J=5.1 Hz, 1H), 7.87 (dd, J=7.1, 2.4 Hz, 1H), 9.01 (d, J=5.1 Hz, 2H). EXAMPLE 39 4-(4-fluoro-3-pyridin-3-ylbenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 To EXAMPLE 38B (75 mg), 3-pyridineboronic acid (54 mg) and dichlorobis(triphenylphosphine)palladium (II) (28 mg) in 7:3:2 1,2-dimethoxyethane/ water/ethanol (3 mL) was added 2M sodium carbonate (0.22 mL). The mixture was stirred in a CEM Explorer@ microwave reactor (Matthews, NC) for 10 minutes at 150 0 C. After cooling, the mixture was filtered, and the filtrate was concentrated. The concentrate was 0 purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.10% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and was treated with 1 M hydrochloric acid in diethyl ether and concentrated to provide the title compound as the hydrochloride salt. 1 H NMR (CD 3 0D) 61.70-1.80 (m, 4H), 2.50-2.62 (m, 4H), 4.17 (s, 2H), 7.33 (dd, J=10.7, 8.5 Hz, 1H), 7.40-7.48 5 (m, 1H), 7.60 (dd, J=7.3, 1.8 Hz, 1H), 8.22 (dd, J=8.2, 5.8 Hz, 1H), 8.87 (d, J=8.2 Hz, 1H), 8.90 (d, J=5.5 Hz, 1H), 9.12 (s, 1H). EXAMPLE 40 4-(4-fluoro-3-pyridin-4-ylbenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one This example was prepared as the hydrochloride salt as described in EXAMPLE 39 '0 by substituting 4-pyridine boronic acid for 3-pyridine boronic acid. 1 H NMR (CD 3 0D) 61.68 1.84 (m, 4H), 2.46-2.64 (m, 4H), 4.15 (s, 2H), 7.35 (dd, J=11.0, 8.5 Hz, 1H), 7.48-7.53 (m, 1H), 7.69 (dd, J=7.2, 2.0 Hz, 1H), 8.32 (d, J=5.8 Hz, 2H), 8.91 (d, J=6.7 Hz, 2H). EXAMPLE 41 N,N-diethyl-2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-1,1'-biphenyl 25 2-carboxamide This example was prepared as the hydrochloride salt as described in EXAMPLE 39 by substituting (2-(N,N-diethylaminocarbonyl)phenyl)boronic acid for 3-pyridineboronic acid. 1H NMR (CD 3 0D) 60.83 (t, J=7.2 Hz, 3H), 0.93 (t, J=7.2 Hz, 3H), 1.72-1.83 (m, 4H), 2.51-2.66 (m, 4H), 2.73-3.01 (m, 2H), 3.02-3.25 (m, 2H), 4.11 (s, 2H), 7.13-7.17 (m, 1H), 30 7.17-7.19 (m, 1H), 7.26-7.31 (m, 1H), 7.38-7.41 (m, 2H), 7.47-7.50 (m, 1H), 7.51-7.54 (m, 1H). EXAMPLE 42 118 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -vl)methyl)phenvl)-3-piperidin- 1 vlpropanamide To 3-(1-piperidinyl)propionic acid (28 mg) in dichloromethane (3 mL) was added oxalyl chloride (24 ptL) and a drop of N,N-dimethylformamide. The mixture was stirred at 5 ambient temperature for 1 hour and concentrated. The concentrate was dissolved in dichloromethane (3 mL) and added to a solution of EXAMPLE 2C (50 mg) in tetrahydrofuran (3 mL). Triethylamine (31 ptL) was also added. The mixture was stirred at ambient temperature for 16 hours and was concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0 0 100% acetonitrile/water with 0.l1% trifluoroacetic acid). The product was dissolved in methanol/dichloromethane and treated with 1 M hydrochloric acid in diethyl ether and was concentrated to provide the title compound as the hydrochloride salt. 1 H NMR (CD 3 0D) 61.50-1.59 (m, 1H), 1.68-1.75 (m, 4H), 1.76-1.87 (m, 3H), 1.92-2.01 (m, 2H), 2.41-2.57 (m, 4H), 2.94-2.98 (m, 2H), 2.98-3.03 (m, 2H), 3.45 (t, J=6.9 Hz, 2H), 3.57 (d, J=12.2 Hz, 2H), 5 3.99 (s, 2H), 6.99-7.05 (m, 1H), 7.11 (dd, J=10.4, 8.5 Hz, 1H), 7.81 (dd, J=7.3, 1.8 Hz, 1H). EXAMPLE 43 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-(4 methylpiperazin- 1 -yl)propanamide This example was prepared as the hydrochloride salt as described in EXAMPLE 42 0 by substituting 3-(4-methylpiperazin-1-yl)propionic acid for 3-(1-piperidinyl)propionic acid. H NMR (CD 3 0D) 6 1.65-1.79 (m, 4H), 2.38-2.58 (m, 4H), 3.03 (s, 3H), 3.07 (t, J=6.7 Hz, 2H), 3.60-3.65 (m, 2H), 3.65-3.68 (m, 3H), 3.70-3.89 (m, 4H), 3.97-4.06 (m, 1H), 4.00 (s, 2H), 6.99-7.04 (m, 1H), 7.12 (dd, J=10.7, 8.5 Hz, 1H), 7.83 (dd, J=7.3, 1.8 Hz, 1H). EXAMPLE 44 25 2-amino-N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide A solution of EXAMPLE 2 (50 mg) and Boc-L-glycine N-hydroxysuccinimide ester (54 mg) in tetrahydrofuran (4 mL) was stirred at ambient temperature for 16 hours and was concentrated. To this solid in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) 30 and the mixture stirred at ambient temperature for 1 hour and concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.l1% trifluoroacetic acid) to provide the title compound as the trifluoroacetate salt. 1 H NMR (CD 3 0D) 6 1.65-1.74 (m, 4H), 2.38-2.55 (m, 119 4H), 3.89 (s, 2H), 3.96 (s, 2H), 7.00-7.06 (m, 1H), 7.09-7.16 (m, 1H), 7.87 (dd, J=7.4, 2.1 Hz, 1H). EXAMPLE 45 3-cyclohexyl-N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 vl)methyl)phenvll)propanamide This example was prepared as described in EXAMPLE 42 by substituting cyclohexanepropionic acid for 3-(1-piperidinyl)propionic acid. 1 H NMR (CD 3 0D) 6 0.90 1.00 (m, 2H) 1.16-1.33 (m, 4H) 1.53-1.61 (m, 2H) 1.63-1.68 (m, 1H) 1.70-1.74 (m, 5H) 1.74 1.82 (m, 3H) 2.39-2.46 (m, 4H) 2.48-2.51 (m, 2H) 3.94 (s, 2H) 6.96-7.01 (m, 1H) 7.07 (dd, 0 J=10.7, 8.5 Hz, 1H) 7.69 (dd, J=7.2, 1.7 Hz, 1H). EXAMPLE 46 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-vl)methyl)phenvll)piperidine-3 carboxamide This example was prepared as the trifluoroacetate salt as described in EXAMPLE 42 5 by substituting 1-(tert-butoxycarbonyl)-3-piperidine carboxylic acid for 3-(1 piperidinyl)propionic acid. 1 H NMR (CD 3 0D) 6 1.66-1.76 (m, 4H), 1.79-1.87 (m, 1H), 1.89 2.03 (m, 2H), 2.12 (dd, J=9.3, 4.9 Hz, 1H), 2.38-2.56 (m, 4H), 2.96-3.04 (m, 1H), 3.08-3.15 (m, 1H), 3.17-3.25 (m, 2H), 3.33-3.35 (m, 1H), 3.95 (s, 2H), 6.99-7.06 (m, 1H), 7.07-7.15 (m, 1H), 7.71 (dd, J=7.5, 2.0 Hz, 1H). 10 EXAMPLE 47 4-(4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 2 (200 mg) in dichloromethane (5 mL) was added 4 chlorobutanoylchloride (103 mg) and triethylamine (0.12 mL). The solution was stirred at ambient temperature for 16 hours and was concentrated. The concentrate was dissolved in 25 ethanol (2 mL) and added to a solution of 21 wt% sodium ethoxide in ethanol (0.47 mL). The mixture was stirred at ambient temperature for 16 hours, treated with 2M hydrochloric acid (1 mL) and concentrated. The concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.10% trifluoroacetic acid). 1 H NMR (CD 3 0D) 6 1.66-1.77 (m, 4H), 2.15-2.27 (m, 2H), 2.40-2.51 30 (m, 4H), 2.51-2.58 (m, 2H), 3.78-3.86 (m, 2H), 3.97 (s, 2H), 7.11-7.15 (m, 1H), 7.16-7.19 (m, 1H), 7.22-7.27 (m, 1H). EXAMPLE 48 120 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-3 carboxamide This example was prepared as the trifluoroacetate salt as described in EXAMPLE 42 by substituting 1-(tert-butoxycarbonyl)-3-azetidine carboxylic acid for 3-(1 5 piperidinyl)propionic acid. 1 H NMR (CD 3 0D) 6 1.64-1.78 (m, 4H), 2.40-2.49 (m, 2H), 2.47 2.55 (m, 2H), 3.81-3.93 (m, 1H), 3.96 (s, 2H), 4.20-4.33 (m, 4H), 6.99-7.06 (m, 1H), 7.07 7.15 (m, 1H), 7.87 (dd, J=7.3, 2.2 Hz, 1H). EXAMPLE 49 N-(2-(isopropylamino)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 0 yl)methyl)benzamide EXAMPLE 49A methyl 3-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H)-ylidene)methyl)benzoate This example was prepared as described in EXAMPLE IC by substituting methyl-3 formylbenzoate for 2-fluoro-5-formylbenzonitrile. 5 EXAMPLE 49B 3-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H)-ylidene)methyl)benzoic acid EXAMPLE 49A (6.09 g) in 1:1 tetrahydrofuran/water (60 mL) at ambient temperature was treated with lithium hydroxide monohydrate (1.8 g) and stirred for 16 hours. The mixture was acidified with 2N hydrochloric acid and partitioned between ethyl acetate '0 and brine. The organic layer was washed with water and concentrated, and the concentrate was purified by flash chromatography on silica gel with ethyl acetate. EXAMPLE 49C 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid This example was prepared as described in EXAMPLE 2C by substituting 25 EXAMPLE 49B for EXAMPLE 2B. EXAMPLE 49D N-(2-(isopropylamino)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide To a solution of EXAMPLE 49C (75 mg) in N,N-dimethylformamide (3 mL) was 30 added N-isopropylethylenediamine (27 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (50 mg), 1-hydroxybenzotriazole hydrate (35 mg) and triethylamine (0.11 mL). The mixture was stirred at ambient temperature for 16 hours and was partitioned between brine and water. The organics were washed with brine and concentrated. The 121 concentrate was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0-100% acetonitrile/water with 0.l1% trifluoroacetic acid) to provide the title compound as the trifluoroacetate salt. 1H NMR (CD 3 0D) 6 1.34 (d, J=6.7 Hz, 6H), 1.65-1.74 (m, 4H), 2.37-2.44 (m, 2H), 2.47-2.54 (m, 2H), 3.23 (t, J=5.9 Hz, 2H), 5 3.39-3.47 (m, 1H), 3.67 (t, J=5.9 Hz, 2H), 4.05 (s, 2H), 7.41-7.44 (m, 2H), 7.71-7.74 (m, 2H). EXAMPLE 50 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-morpholin-4 ylacetamide This example was prepared as the trifluoroacetate salt as described in EXAMPLE 41 0 by substituting morpholin-4-yl-acetic acid for 3-(1 -piperidinyl)propionic acid. 1 H NMR

(CD

3 0D) 6 1.65-1.73 (m, 4H), 2.38-2.46 (m, 2H), 2.46-2.52 (m, 2H), 3.34-3.52 (m, 4H), 3.90-4.03 (m, 6H), 4.19 (s, 2H), 7.03-7.09 (m, 1H), 7.10-7.17 (m, 1H), 7.85 (dd, J=7.3, 2.1 Hz, 1H). EXAMPLE 51 5 N-(2-morpholin-4-ylethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide EXAMPLE 51A 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid The title compound was prepared according to procedure for EXAMPLE 1 '0 substituting 3-formylbenzonitrile for 2-fluoro-5-formylbenzonitrile in EXAMPLE IC. MS

(DCI/NH

3 ) m/z 285 (M+H)*. EXAMPLE 51B N-(2-morpholin-4-ylethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide 25 To a solution of EXAMPLE 51 A (75 mg, 0.26 mmol) in anhydrous dichloromethane (5 mL) was added 4-(2-aminoethyl)morpholine (68 mg, 0.52 mmol), benzotriazol-1-yl oxytripyrrolidinophosphonium hexafluorophosphate (271 mg, 0.52 mmol), and N,N' diisopropylethylamine (0.18 mmol, 1.04 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 16 hours, and concentrated. The residue was separated by 30 HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.10% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 397 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.64 - 1.75 (m, 4H), 2.37 122 2.45 (m, 2H), 2.45 - 2.55 (m, 2H), 3.15 - 3.27 (m, 2H), 3.40 (t, J=5.80 Hz, 2H), 3.63 - 3.71 (m, 2H), 3.74 - 3.81 (m, 4H), 4.02 - 4.13 (m, 4H), 7.42 - 7.46 (m, 2H), 7.71 - 7.75 (m, 2H). EXAMPLE 52 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(2-pyrrolidin-1 5 ylethyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 51 substituting 1-(2-aminoethyl)pyrrolidine for 4-(2-aminoethyl)morpholine. MS (DCI/NH 3 ) m/z 381 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.65 - 1.74 (m, 4H), 1.97 2.08 (m, 2H), 2.13 - 2.22 (m, 2H), 2.39 - 2.45 (m, 2H), 2.46 - 2.54 (m, 2H), 3.10 - 3.20 (m, 0 2H), 3.42 (t, J=5.80 Hz, 2H), 3.73 (t, J=5.95 Hz, 2H), 3.75 - 3.82 (m, 2H), 4.05 (s, 2H), 7.42 7.46 (m, 2H), 7.70 - 7.74 (m, 2H). EXAMPLE 53 4-(3-((2-methylpyrrolidin-1-yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure 5 for EXAMPLE 51 substituting 2-methylpyrrolidine for 4-(2-aminoethyl)morpholine. MS

(DCI/NH

3 ) m/z 352 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 0.86 (d, J=6.41 Hz, 1H), 1.33 (d, J=6.41 Hz, 2H), 1.60 - 1.67 (m, 2H), 1.70 (d, J=2.75 Hz, 3H), 1.73 - 1.80 (m, 1H), 1.90 1.99 (m, 1H), 2.11 - 2.22 (m, 1H), 2.39 - 2.47 (m, 2H), 2.46 - 2.56 (m, 2H), 3.43 - 3.51 (m, 1H), 3.57 - 3.67 (m, 1H), 4.02 (s, 2H), 4.21 - 4.28 (m, 1H), 7.24 - 7.33 (m, 2H), 7.33 - 7.36 '0 (m, 1H), 7.37 - 7.42 (m, 1H). EXAMPLE 54 N-azepan-1-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 51 substituting 1 -aminohomopiperidine for 4-(2-aminoethyl)morpholine. MS 25 (DCI/NH 3 ) m/z 381 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.68 - 1.74 (m, 4H), 1.73 1.81 (m, 4H), 1.92 - 2.01 (m, 4H), 2.41 - 2.46 (m, 2H), 2.48 - 2.54 (m, 2H), 3.53 - 3.60 (m, 4H), 4.06 (s, 2H), 7.45 - 7.50 (m, 2H), 7.70 - 7.73 (m, 2H). EXAMPLE 55 4-(3-(piperazin-1-ylcarbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 30 EXAMPLE 55A tert-butyl 4-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoyl)piperazine-1 carboxylate 123 The title compound was prepared according to procedure for EXAMPLE 51 substituting tert-butyl 1 -piperazine carboxylate for 4-(2-aminoethyl)morpholine. MS

(DCI/NH

3 ) m/z 453 (M+H)*. EXAMPLE 55B 5 4-(3-(piperazin-1-ylcarbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 55A (480 mg, 1.76 mmol) in methylene chloride (10 mL) was added trifluoroacetic acid (5 mL). The solution was stirred at room temperature for 1 hour, and was concentrated. The residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic 0 acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS

(DCI/NH

3 ) m/z 353 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.68 - 1.74 (m, 4H), 2.43 2.48 (m, 2H), 2.48 - 2.54 (m, 2H), 3.19 - 3.29 (m, 3H), 3.67 - 3.97 (m, 5H), 4.04 (s, 2H), 7.30 - 7.33 (m, 1H), 7.33 - 7.36 (m, 1H), 7.36 - 7.39 (m, 1H), 7.44 (t, J=7.48 Hz, 1H). EXAMPLE 56 5 N-azetidin-3-yl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 55 substituting 3-amino-1-N-Boc-azetidine for tert-butyl 1-piperazine carboxylate. MS (DCI/NH 3 ) m/z 339 (M+H)*; H NMR (500 MHz, CD 3 0D): 6 1.63 - 1.76 (m, 4H), 2.37 - 2.45 (m, 2H), 2.46 - 2.55 (m, 2H), 4.05 (s, 2H), 4.28 - 4.37 (m, 4H), 4.76 '0 4.82 (m, 1H), 7.41 - 7.45 (m, 2H), 7.69 - 7.74 (m, 2H). EXAMPLE 57 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-piperidin-3-ylbenzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 55 substituting (+/-)-3 -amino-i -N-Boc-piperidine for tert-butyl 1 -piperazine 25 carboxylate. MS (DCI/NH 3 ) m/z 367 (M+H)*; H NMR (500 MHz, CD 3 0D): 6 1.68 - 1.72 (m, 4H), 1.72 - 1.77 (m, IH), 1.80 - 1.89 (m, IH), 2.02 - 2.15 (m, 2H), 2.37 - 2.46 (m, 2H), 2.47 - 2.54 (m, 2H), 2.85 - 3.00 (m, 2H), 3.33 - 3.39 (m, IH), 3.52 (dd, J=12.21, 4.27 Hz, IH), 4.04 (s, 2H), 4.18 - 4.26 (m, IH), 7.40 - 7.43 (m, 2H), 7.66 - 7.71 (m, 2H). EXAMPLE 58 30 N-(4-(dimethylamino)phenyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 51 substituting N,N-dimethyl- 1,4-phenylenediamine for 4-(2 124 aminoethyl)morpholine. MS (DCI/NH 3 ) m/z 403 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.67 - 1.73 (m, 4H), 2.42 - 2.48 (m, 2H), 2.47 - 2.55 (m, 2H), 3.28 (s, 6H), 4.08 (s, 2H), 7.43 - 7.45 (m, 1H), 7.45 - 7.49 (m, 1H), 7.55 (d, J=8.85 Hz, 2H), 7.77 - 7.80 (m, 1H), 7.79 - 7.82 (m, 1H), 7.89 - 7.93 (m, 2H). 5 EXAMPLE 59 N-(2-(4-methylpiperazin-1-yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 51 substituting 2-(4-methyl-piperazin- 1 -yl)-ethylamine for 4-(2 0 aminoethyl)morpholine. MS (DCI/NH 3 ) m/z 410 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.67 - 1.73 (m, 4H), 2.41 - 2.46 (m, 2H), 2.48 - 2.54 (m, 2H), 2.82 (t, J=6.41 Hz, 2H), 2.87 (s, 3H), 2.89 - 3.09 (m, 3H), 3.17 - 3.26 (m, 2H), 3.33 - 3.41 (m, 1H), 3.57 (t, J=6.26 Hz, 2H), 4.04 (s, 2H), 4.72 - 4.83 (m, 2H), 7.39 - 7.44 (m, 2H), 7.63 - 7.66 (m, 1H), 7.66 - 7.69 (m, 1H). 5 EXAMPLE 60 4-(3-((4-(isoxazol-5-ylcarbonyl)piperazin-1-yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one A solution of isoxazole-5-carboxylic acid (32 mg, 0.28 mmol) in a mixture of anhydrous N,N-dimethylformamide (2 mL) and pyridine (2 mL) was treated with 1,1' 0 carbonyldiimidazole (48 mg, 0.30 mmol) at 40 0 C for 2 hours. EXAMPLE 55 (50 mg, 0.14 mmol) was added and the reaction mixture was heated at 60 0 C for 3 hours. After cooling, the reaction mixture was concentrated on a rotary evaporator and the residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.10% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. 25 MS (DCI/NH 3 ) m/z 448 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.65 - 1.76 (m, 4H), 2.41 2.47 (m, 2H), 2.48 - 2.56 (m, 2H), 3.51 - 3.66 (m, 3H), 3.66 - 3.79 (m, 3H), 3.79 - 3.94 (m, 2H), 4.04 (s, 2H), 7.27 - 7.30 (m, 1H), 7.32 - 7.35 (m, 1H), 7.36 - 7.39 (m, 1H), 7.43 (t, J=7.48 Hz, 1H), 7.61 - 7.66 (m, 1H), 7.86 - 7.91 (m, 1H). EXAMPLE 61 30 4-(3-((4-phenylpiperidin-1-yl)carbonyl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 51 substituting 4-phenylpiperidine for 4-(2-aminoethyl)morpholine. MS

(DCI/NH

3 ) m/z 428 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.54 - 1.65 (m, 1H), 1.64 125 1.71 (m, 4H), 1.72 - 1.82 (m, 2H), 1.91 - 1.99 (m, 1H), 2.40 - 2.45 (m, 2H), 2.49 - 2.51 (m, 2H), 2.80 - 2.89 (m, 1H), 2.89 - 2.98 (m, 1H), 3.15 - 3.26 (m, 1H), 3.71 - 3.82 (m, 1H), 4.04 (s, 2H), 4.72 - 4.81 (m, 1H), 7.16 - 7.20 (m, 1H), 7.22 - 7.26 (m, 3H), 7.27 - 7.30 (m, 2H), 7.30 - 7.32 (m, 1H), 7.34 (d, J=7.93 Hz, 1H), 7.42 (t, J=7.63 Hz, 1H). 5 EXAMPLE 62 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(piperidin-2-ylmethyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 55 substituting tert-butyl 2-(aminomethyl)piperidine-1-carboxylate for tert butyl 1-piperazine carboxylate. MS (DCI/NH 3 ) m/z 381 (M+H)*; H NMR (500 MHz, 0 CD 3 0D): 61.46 - 1.56 (m, 2H), 1.60 - 1.78 (m, 6H), 1.79 - 1.93 (m, 2H), 2.38 - 2.47 (m, 2H), 2.47 - 2.55 (m, 2H), 3.14 (dd, J=13.27, 4.42 Hz, 2H), 3.46 - 3.52 (m, 1H), 3.55 - 3.64 (m, 1H), 4.04 (s, 2H), 4.91 - 5.05 (m, 1H), 7.27 - 7.32 (m, 1H), 7.35 - 7.40 (m, 2H), 7.43 (t, J=7.48 Hz, 1H). EXAMPLE 63 5 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(piperidin-4-ylmethyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 55 substituting 4-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester for tert-butyl 1-piperazine carboxylate. MS (DCI/NH 3 ) m/z 381 (M+H)*; H NMR (500 MHz, CD 3 0D): 6 1.40 - 1.52 (m, 2H), 1.64 - 1.74 (m, 4H), 1.91 - 2.03 (m, 3H), 2.37 - 2.47 '0 (m, 2H), 2.47 - 2.55 (m, 2H), 2.93 - 3.02 (m, 2H), 3.32 - 3.36 (m, 2H), 3.37 - 3.44 (m, 2H), 4.04 (s, 2H), 7.38 - 7.43 (m, 2H), 7.65 - 7.69 (m, 2H). EXAMPLE 64 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(2-piperidin-1-ylethyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure 25 for EXAMPLE 51 substituting 2-(piperidin-1-yl)ethanamine for 4-(2-aminoethyl)morpholine. MS (DCI/NH 3 ) m/z 395 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.50 - 1.58 (m, 1H), 1.67 1.73 (m, 4H), 1.76 - 1.88 (m, 3H), 1.97 (d, J=14.34 Hz, 2H), 2.38 - 2.47 (m, 2H), 2.46 - 2.54 (m, 2H), 2.93 - 3.04 (m, 2H), 3.32 - 3.37 (m, 2H), 3.68 (d, J=12.21 Hz, 2H), 3.74 (t, J=6.10 Hz, 2H), 4.05 (s, 2H), 7.42 - 7.45 (m, 2H), 7.70 - 7.74 (m, 2H). 30 EXAMPLE 65 N-(1-methylazetidin-3-yl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide 126 To a solution of EXAMPLE 56 (25 mg, 0.07 mmol) in methanol (2 mL) was added formaldehyde (37% in water, 16 ptL, 0.21 mmol) and triethylamine (10 ptL, 0.07 mmol). The mixture was stirred at room temperature for 2 hours before sodium cyanoborohydride (13 mg, 0.21 mmol) and zinc chloride (10 mg) were added. The reaction mixture was stirred at room 5 temperature for 16 hours, and concentrated. The residue was dissolved in 1:1 mixture of acetonitrile and water, and purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 353 (M+H)*; H NMR (500 MHz, CD 3 0D): 6 1.63 - 1.74 (m, 4H), 2.36 - 2.45 (m, 2H), 2.46 - 2.53 (m, 2H), 3.01 (d, 0 J=17.70 Hz, 3H), 4.06 (d, J=10.68 Hz, 2H), 4.21 - 4.28 (m, 1H), 4.31 (dd, J=11.44, 8.70 Hz, 1H), 4.56 - 4.66 (m, 2H), 5.51 (s, 1H), 7.41 - 7.44 (m, 1H), 7.44 - 7.48 (m, 1H), 7.70 - 7.78 (m, 2H). EXAMPLE 66 methyl 4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate 5 EXAMPLE 66A 3-((2-bromopyridin-4-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 2-bromo-pyridine-4-carbaldehyde for 2-fluoro-5-formylbenzonitrile. MS

(DCI/NH

3 ) m/z 307 (M+H)*. 10 EXAMPLE 66B 4-((2-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C substituting EXAMPLE 66A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 321 (M+H)*. EXAMPLE 66C 25 methyl 4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate A mixture of EXAMPLE 66B (800 mg, 2.5 mmol), dichloro(1,1' ferrocenylbis(diphenyl-phosphine))palladium(II) dichloromethane(125 mg, 0.15 mmol) and triethylamine (1 ml) in a mixture of methanol (40 ml) and N,N-dimethylformamide (16 ml) was heated at 110 0 C in a pressure vessel under 30 psi of carbon monoxide for 16 hours. 30 After cooling, the solid material was filtered off, and the filtrate was concentrated. The residual solid was washed with methanol, and dried to provide the title compound. MS

(DCI/NH

3 ) m/z 300 (M+H)*. EXAMPLE 67 127 N-methyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide A solution of EXAMPLE 66 (100 mg, 0.33 mmol) in methanol (5 ml) was treated with methylamine (2.0 N in methanol, 2 ml) at 50 0 C for 24 hours, and concentrated. The residue was washed with methanol, and dried to provide the title compound. MS (DCI/NH 3 ) 5 m/z 299 (M+H)*. EXAMPLE 68 4-((2-(methylthio)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1(2H)-one EXAMPLE 68A 3-((2-(methylthio)pyrimidin-4-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 0 The title compound was prepared according to the procedure for EXAMPLE IC, substituting 2-methylthio-4-pyrimidine-carboxyaldehyde for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 275 (M+H)*. EXAMPLE 68B 4-((2-(methylthio)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1(2H)-one 5 The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 68A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 289 (M+H)*. EXAMPLE 69 4-((2-(methylsulfonyl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one To a suspension of EXAMPLE 68 (280 mg, 1 mmol) in methylene chloride (5 mL) '0 was added m-chloroperoxybenzoic acid (256 mg, 1.5 mmol). The reaction mixture was stirred at room temperature for 4 hours, and concentrated. The residual solid was separated by flash chromatography on silica gel (80% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 321 (M+H); 1 H NMR (300 MHz, CD 3 0D): 6 1.61 - 1.89 (m, 4 H), 2.37 - 2.71 (m, 4 H), 3.32 (s, 3H), 4.29 (s, 2H), 7.65 (d, J=5.09 Hz, 1 H), 8.88 (d, 25 J=5.43 Hz, 1 H). EXAMPLE 70 4-((2-(methylsulfinyl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was isolated as a side product in EXAMPLE 69. MS (ESI) m/z 305 (M+H)*. 30 EXAMPLE 71 4-((3-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 71A 3-((3-bromopyridin-4-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 128 The title compound was prepared according to the procedure for EXAMPLE IC, substituting 3-bromoisonicotinaldehyde for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 306 (M+H)*. EXAMPLE 71B 5 4-((3-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 71A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 321 (M+H)*. EXAMPLE 72 4-((6-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 0 EXAMPLE 72A 3-((6-bromopyridin-3-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 6-bromonicotinaldehyde for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 306 (M+H)+. 5 EXAMPLE 72B 4-((6-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 72A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 321 (M+H)+. EXAMPLE 73 10 4-((2-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 73A 3-((2-bromopyridin-3-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 2-bromonicotinaldehyde for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 25 306 (M+H)+. EXAMPLE 73B 4-((2-bromopyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 72A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 321 (M+H)+. 30 EXAMPLE 74 methyl 6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate EXAMPLE 74A 3-((6-bromopyridin-2-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 129 The title compound was prepared according to the procedure for EXAMPLE IC, substituting 6-bromo-pyridine-2-carbaldehyde for 2-fluoro-5-formylbenzonitrile. MS

(DCI/NH

3 ) m/z 300 (M+H)*. EXAMPLE 74B 5 4-((6-bromopyridin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 74A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 321 (M+H)*. EXAMPLE 74C methyl 6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)picolinate 0 The title compound was prepared according to the procedure for EXAMPLE 66C, substituting EXAMPLE 74B for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 300 (M+H)*. EXAMPLE 75 N-ethyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, 5 substituting ethylamine for methylamine. MS (ESI) m/z 313 (M+H)*. EXAMPLE 76 N-isopropyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting isopropyl amine for methyl amine. MS (ESI) m/z 327 (M+H)*. 10 EXAMPLE 77 N-cyclohexyl-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting cyclohexanamine for methyl amine. MS (ESI) m/z 367 (M+H)*; 1 H NMR (300 25 MHz, dimethylsulfoxide-d 6 ): 6 1.23 - 1.45 (m, 6 H), 1.60 - 1.64 (m, 4 H), 1.65 - 1.86 (m, 5 H), 2.30 - 2.40 (m, 4 H), 4.03 (s, 2 H), 7.41 (dd, J=4.92, 1.86 Hz, 1 H), 7.86 (s, 1 H), 8.41 (d, J=8.82 Hz, 1 H), 8.53 (d, J=5.09 Hz, 1 H), 12.64 (s, 1 H). EXAMPLE 78 N-methyl-N-((1-methylpiperidin-2-yl)methyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 30 yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 65, substituting EXAMPLE 62 for EXAMPLE 56. MS (DCI/NH 3 ) m/z 409 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.47 - 1.57 (m, 1H), 1.58 - 1.67 (m, 1H), 1.67 130 1.77 (m, 6H), 1.77 - 1.87 (m, 1H), 1.85 - 1.95 (m, 1H), 2.43 - 2.51 (m, 2H), 2.53 - 2.63 (m, 2H), 2.99 (s, 3H), 3.08 (s, 3H), 3.26 (dd, J=13.73, 3.36 Hz, 2H), 3.51 - 3.61 (m, 1H), 3.95 (dd, J=13.27, 11.44 Hz, 1H), 4.13 (s, 2H), 5.11 - 5.24 (m, 1H), 7.35 - 7.40 (m, 2H), 7.41 7.47 (m, 2H). 5 EXAMPLE 79 N-((1 -methylpiperidin-4-yl)methyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 65, substituting EXAMPLE 63 for EXAMPLE 56. MS (DCI/NH 3 ) m/z 395 0 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.49 - 1.61 (m, 2H), 1.69 - 1.78 (m, 4H), 1.90 1.98 (m, 1H), 1.97 - 2.08 (m, 2H), 2.43 - 2.53 (m, 2H), 2.54 - 2.65 (m, 2H), 2.85 (s, 3H), 2.95 - 3.04 (m, 2H), 3.32 - 3.38 (m, 2H), 3.53 (dd, J=10.53, 1.98 Hz, 2H), 4.15 (s, 2H), 7.39 - 7.41 (m, 1H), 7.43 (t, J=7.63 Hz, 1H), 7.68 (s, 1H), 7.70 - 7.73 (m, 1H). EXAMPLE 80 5 N-methyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 74 for EXAMPLE 66. MS (ESI) m/z 299 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.61 - 1.81 (m, 4 H), 2.38 - 2.61 (m, 4 H), 2.95 (s, 3 H), 4.22 (s, 2 H), 7.41 (dd, J=7.46, 1.36 Hz, 1 H), 7.88 (t, J=7.63 Hz, 1 H), 7.91 - 7.98 (m, 1 H). 10 EXAMPLE 81 N-ethyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 74 for EXAMPLE 66, and ethylamine for methylamine. MS (ESI) m/z 313 (M+H)*. 25 EXAMPLE 82 N-isopropyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 74 for EXAMPLE 66, and isopropylamine for methylamine. MS (ESI) m/z 327 (M+H)*. 30 EXAMPLE 83 131 N-cyclopropyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 74 for EXAMPLE 66, and cyclopropylamine for methylamine. MS 5 (ESI) m/z 325 (M+H)*. EXAMPLE 84 N-cyclohexyl-6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2 carboxamide The title compound was prepared according to procedure for EXAMPLE 67, 0 substituting EXAMPLE 74 for EXAMPLE 66, and cyclohexylamine for methylamine. MS (ESI) m/z 367 (M+H)*. EXAMPLE 85 methyl 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate The title compound was prepared according to procedure for EXAMPLE 66C, 5 substituting EXAMPLE 73B for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 300 (M+H)*. EXAMPLE 86 methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxylate The title compound was prepared according to the procedure for EXAMPLE 66C, substituting EXAMPLE 72B for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 300 (M+H)*. 10 EXAMPLE 87 4-((5-bromothiophen-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 87A 3-((5-bromothiophen-2-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to procedure for EXAMPLE IC, 25 substituting 5-bromothiophene-2-carbaldehyde for 2-fluoro-5-formylbenzonitrile. MS

(DCI/NH

3 ) m/z 312 (M+H)*. EXAMPLE 87B 4-((5-bromothiophen-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, 30 substituting EXAMPLE 87A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 326 (M+H)*. EXAMPLE 88 4-((3-bromothiophen-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 88A 132 3-((3-bromothiophen-2-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran- 1 (3H)-one The title compound was prepared according to procedure for EXAMPLE IC, substituting 3-bromothiophene-2-carbaldehyde for 2-fluoro-5-formylbenzonitrile. MS

(DCI/NH

3 ) m/z 312 (M+H)*. 5 EXAMPLE 88B 4-((3-bromothiophen-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C substituting EXAMPLE 88A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 326 (M+H)*. EXAMPLE 89 0 4-(3-aminobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2, substituting 3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde in EXAMPLE 2A. MS

(DCI/NH

3 ) m/z 256 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.62 - 1.75 (m, 4H), 2.37 2.44 (m, 2H), 2.46 - 2.54 (m, 2H), 3.86 (s, 2H), 6.46 - 6.54 (m, 2H), 6.57 (dd, J=7.93, 1.98 5 Hz, 1H), 7.01 (t, J=7.73 Hz, 1H). EXAMPLE 90 4-(3-bromobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting 3-bromobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS (DCI/NH 3 ) m/z '0 256 (M+H)*; H NMR (300 MHz, CD 3 0D): 6 1.64 - 1.77 (m, 4H), 2.37 - 2.46 (m, 2H), 2.47 2.55 (m, 2H), 3.96 (s, 2H), 7.13 - 7.18 (m, 1H), 7.18 - 7.24 (m, 1H), 7.35 - 7.40 (m, 2H). EXAMPLE 91 4-(thien-2-ylmethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one A mixture of EXAMPLE 87 (100 mg, 0.31 mmol) and acetamide (1 g) was stirred at 25 180 0 C overnight. After cooling, the mixture was dissolved in methanol, and separated by HPLC (Zorbax@ C-8 packing material [Agilent Technologies, Santa Clara, CA]0. 1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound. MS (DCI/NH 3 ) m/z 247 (M+H)*. EXAMPLE 92 30 methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)thiophene-2-carboxylate The title compound was prepared according to the procedure for EXAMPLE 66C, substituting EXAMPLE 87 for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 305 (M+H)*. EXAMPLE 93 133 N-methyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 86 for 66. MS (ESI) m/z 299 (M+H)*, H NMR (300 MHz, dimethylsulfoxide-d): 6 1.51 - 1.73 (m, 4 H), 2.40 (d, J=14.92 Hz, 4 H), 2.81 (d, J=5.09 Hz, 5 3 H), 4.02 (s, 2 H), 7.75 (dd, J=7.97, 2.20 Hz, 1 H), 7.96 (d, J=8.14 Hz, 1 H), 8.49 (d, J=1.70 Hz, 1 H), 8.70 (d, J=4.75 Hz, 1 H), 12.60 (s, 1 H). EXAMPLE 94 N-ethyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, 0 substituting EXAMPLE 86 for EXAMPLE 66, and ethylamine for methylamine. MS (ESI) m/z 313 (M+H)*. EXAMPLE 95 N-methyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, 5 substituting EXAMPLE 85 for 66. MS (ESI) m/z 299 (M+H)*, H NMR (300 MHz, dimethylsulfoxide-d 6 ) 6 1.53 - 1.79 (m, 4 H), 2.29 - 2.44 (m, 4 H), 2.73 (d, J=5.16 Hz, 3 H), 4.35 (s, 2 H), 7.50 (dd, J=7.73, 4.56 Hz, 1 H), 7.66 (dd, J=7.93, 1.59 Hz, 1 H), 8.49 (dd, J=4.36, 1.59 Hz, 1 H), 8.65 (d, J=5.16 Hz, 1 H), 12.35 (s, 1 H). EXAMPLE 96 10 N-ethyl-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridine-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 85 for EXAMPLE 66, and ethylamine for methylamine. MS (ESI) m/z 313 (M+H)*. EXAMPLE 97 25 N,N-dimethyl-N'-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)sulfamide To a solution of EXAMPLE 89 (50 mg, 02 mmol) in dichloromethane (4 mL) was added dimethylsulfamoyl chloride (31 mg, 0.22 mmol) and pyridine (17 mL, 0.22 mol). The solution was stirred at room temperature for 16 hours, and was concentrated. The residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa 30 Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 363 (M+H)*; 1 H NMR (400 MHz, CD 3 0D): 6 134 1.64 - 1.76 (m, 4H), 2.37 - 2.46 (m, 2H), 2.47 - 2.54 (m, 2H), 2.72 (s, 6H), 3.95 (s, 2H), 6.91 - 6.96 (m, 1H), 7.02 - 7.06 (m, 2H), 7.19 - 7.24 (m, 1H). EXAMPLE 98 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-piperidin-1 5 ylpropanamide To a solution of 3-(piperidin-1-yl)propanoic acid (31 mg) in anhydrous dichloromethane (2 mL) was added oxalyl chloride (25.7 ptL) and a drop of N,N dimethylformamide. The solution was stirred for 1 hour, and was concentrated. The residue was re-dissolved in anhydrous dichloromethane (2 mL), and was quickly added to a solution 0 of EXAMPLE 89 (50 mg) in anhydrous tetrahydrofuran (2 mL). Triethylamine (32.8 piL) was added, and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated. The residue was partitioned between ethyl acetate and brine. The organic phase was washed with brine and concentrated. The residual solid was separated on HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% 5 trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 395 (M+H)*; 1 H NMR (400 MHz, CD 3 0D): 6 1.48 - 1.60 (m, 1H), 1.65 1.71 (m, 4H), 1.73 - 1.87 (m, 3H), 1.92 - 2.01 (m, 2H), 2.38 - 2.45 (m, 2H), 2.46 - 2.53 (m, 2H), 2.87 (t, J=6.60 Hz, 2H), 2.93 - 3.03 (m, 2H), 3.44 (t, J=6.75 Hz, 2H), 3.57 (d, J=12.58 Hz, 2H), 3.97 (s, 2H), 6.95 - 7.00 (m, 1H), 7.26 (t, J=7.83 Hz, 1H), 7.36 - 7.39 (m, 1H), 7.41 '0 - 7.48 (m, 1H). EXAMPLE 99 4-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)butanamide A solution of EXAMPLE 89 (150 mg, 0.59 mmol) and 4-chlorobutanoyl chloride (83 mg, 0.59 mmol) in dichloromethane (5 mL) was stirred at room temperature for 16 hours, and 25 was concentrated. The residue was partitioned between ethyl acetate and brine. The organic phase was washed with brine, and concentrated to provide the title compound. MS

(DCI/NH

3 ) m/z 360 (M+H)*; 1 H NMR (400 MHz, CD 3 0D): 6 1.66 - 1.73 (m, 4H), 2.07 2.15 (m, 2H), 2.40 - 2.46 (m, 2H), 2.48 - 2.51 (m, 2H), 2.50 - 2.56 (m, 2H), 3.63 (t, J=6.44 Hz, 2H), 3.96 (s, 2H), 6.93 (d, J=7.67 Hz, 1H), 7.21 - 7.26 (m, 1H), 7.36 (s, 1H), 7.38 - 7.46 30 (m, 1H). EXAMPLE 100 4-(3 -(2-oxopyrrolidin- 1 -yl)benzyl)-5 ,6,7,8-tetrahydrophthalazin- 1 (2H)-one 135 A suspension of EXAMPLE 90 (150 mg, 0.47 mmol), pyrrolidine-2-one (80 mg, 0.94 mmol), tris(dibenzylideneacetone)dipalladium(0) (43 mg, 0.05 mmol), Xantphos (4,5 bis(diphenylphosphino)-9,9-dimethylxanthene) (4,5-bis(diphenylphosphino)-9,9 dimethylxanthene) (41 mg, 0.07 mmol) and cesium carbonate (214 mg, 0.66 mmol) in 5 anhydrous dioxane (2 mL) was heated in a CEM Explorer@ microwave reactor (Matthews, NC) at 200 0 C for 30 minutes. After cooling, the reaction mixture was concentrated. The residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 324 (M+H)*; H NMR (400 0 MHz, CD 3 0D): 6 1.65 - 1.75 (m, 4H), 2.11 - 2.23 (m, 2H), 2.41 - 2.47 (m, 2H), 2.48 - 2.53 (m, 2H), 2.57 (t, J=7.98 Hz, 2H), 3.83 - 3.92 (m, 2H), 3.99 (s, 2H), 7.01 (d, J=7.67 Hz, 1H), 7.31 (t, J=7.98 Hz, 1H), 7.38 - 7.42 (m, 1H), 7.51 (t, J=1.69 Hz, 1H). EXAMPLE 101 4-((2-(2-oxoazetidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 5 A microwave tube was charged with tris(dibenzylideneacetone)dipalladium(0) (5.4 mg, 0.006 mmol), Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene) (5.4 mg, 0.01 mmol), EXAMPLE 103 (50 mg, 0.16 mmol), azetidin-2-one (53 mg, 0.62 mmol) and Cs 2

CO

3 (70 mg, 0.21 mmol). Anhydrous dioxane was added, and the suspension was heated in a CEM Explorer@ microwave reactor (Matthews, NC)at 200 0 C for 30 minutes. After '0 concentration, the residue was partitioned between ethyl acetate and brine. The organic phase was concentrated. The residual solid was separated by flash chromatography on silica gel (100% ethyl acetate) to provide the title compound. MS (DCI/NH 3 ) m/z 311 (M+H)*. EXAMPLE 102 4-((2-(2-oxopyrrolidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 25 The title compound was prepared according to procedure for EXAMPLE 101, substituting pyrroline-2-one for azetidin-2-one. MS (ESI) m/z 339 (M+H)*. EXAMPLE 103 4-((2-bromopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared as described in EXAMPLE 66B. MS (DCI/NH 3 ) 30 m/z 321 (M+H)*. EXAMPLE 104 4-((6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 136 The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 72 for EXAMPLE 103, and pyrroline -2-one for azetidin-2-one. MS (ESI) m/z 325 (M+H)*. EXAMPLE 105 5 4-((6-(2-oxoazetidin-1-yl)pyridin-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 72 for EXAMPLE 103. MS (ESI) m/z 311 (M+H)*. EXAMPLE 106 N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)benzamide 0 The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 72 for EXAMPLE 103, and benzamide for azetidin-2-one. MS (ESI) m/z 361 (M+H)*; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.48 - 1.70 (m, 4 H), 2.41 (d, J=17.29 Hz, 4 H), 3.92 (s, 2 H), 7.86 (t, J=1.86 Hz, 3 H), 7.86 - 7.90 (m, 2 H), 7.99 - 8.06 (m, 1 H), 8.12 (d, J=8.48 Hz, 1 H), 8.24 (d, J=2.37 Hz, 1 H), 10.72 (s, 1 H) 12.60 (s, 1 H). 5 EXAMPLE 107 N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)isonicotinamide The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 72 for EXAMPLE 103, and isonicotinamide for azetidin-2-one. MS (ESI) m/z 362 (M+H)*; H NMR (300 MHz, dimethylsulfoxide-d): 6 1.65 (d, J=5.09 Hz, 4 '0 H), 2.41 (d, J=16.28 Hz, 4 H), 3.93 (s, 2 H), 7.68 (dd, J=8.48, 2.37 Hz, 1 H), 7.90 - 8.00 (m, 2 H), 8.11 (d, J=8.48 Hz, 1 H), 8.27 (d, J=2.03 Hz, 1 H), 8.76 - 8.82 (m, 2 H), 11.12 (s, 1 H), 12.60 (s, 1 H). EXAMPLE 108 N-(5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)pyridin-2-yl)nicotinamide 25 The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 72 for EXAMPLE 103, and nicotinamide for azetidin-2-one. MS (ESI) m/z 362 (M+H)*. EXAMPLE 109 4-((5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-2,2'-bipyridin-5-yl)methyl) 30 5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was a side-product of EXAMPLE 108. MS (ESI) m/z 481 (M+H)*. EXAMPLE 110 137 N-methyl-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)thiophene-2-carboxamide The title compound was prepared according to procedure for EXAMPLE 67, substituting EXAMPLE 92 for 66. MS (ESI) m/z 304 (M+H)*; H NMR (300 MHz, dimethylsulfoxide-d): 6 1.63 (d, J=3.05 Hz, 4 H), 2.29 - 2.46 (m, 4 H), 2.72 (d, J=4.41 Hz, 3 5 H), 4.09 (s, 2 H), 6.88 (d, J=3.73 Hz, 1 H), 7.51 (d, J=3.73 Hz, 1 H), 8.31 (d, J=4.41 Hz, 1 H), 12.66 (s, 1 H). EXAMPLE 111 Nl-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)glycinamide A solution of EXAMPLE 89 (50 mg, 0.2 mmol) and 2,5-dioxopyrrolidin-1-yl 2-(tert 0 butoxycarbonylamino)acetate 59 mg, 0.22 mmol) in anhydrous tetrahydrofuran (4 mL) was stirred at room temperature for 16 hours, and concentrated. The residual solid was dissolved in dichloromethane (4 mL) and treated with trifluoroacetic acid (2 mL) at room temperature for 1 hour. The reaction mixture was concentrated and the residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% 5 trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 313 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.64 - 1.75 (m, 4H), 2.36 2.45 (m, 2H), 2.46 - 2.54 (m, 2H), 3.80 (s, 2H), 3.98 (s, 2H), 7.00 (d, J=7.80 Hz, 1H), 7.28 (t, J=7.97 Hz, 1H), 7.37 - 7.40 (m, 1H), 7.42 - 7.47 (m, 1H). EXAMPLE 112 10 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-2-carboxamide EXAMPLE 112A tert-butyl 2-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenylcarbamoyl)azetidine- 1 -carboxylate The title compound was prepared according to procedure for EXAMPLE 98, 25 substituting 1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid for 3-(piperidin-1 yl)propanoic acid. MS (DCI/NH 3 ) m/z 439 (M+H)+. EXAMPLE 112B N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-2-carboxamide A solution of EXAMPLE 112A (64 mg) in dichloromethane (4 mL) was treated with 30 trifluoroacetic acid (2 mL) at room temperature for 1 hour. The reaction mixture was concentrated and the residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide 138 the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 339 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.64 - 1.73 (m, 4H), 2.36 - 2.44 (m, 2H), 2.46 - 2.53 (m, 2H), 2.57 2.69 (m, 1H), 2.81 - 2.93 (m, 1H), 3.94 - 4.04 (m, 1H), 3.98 (s, 2H), 4.08 - 4.20 (m, 1H), 5.07 (dd, J=9.49, 7.80 Hz, 1H), 7.03 (d, J=8.14 Hz, 1H), 7.30 (t, J=7.80 Hz, 1H), 7.41 (t, J=1.70 5 Hz, 1H), 7.49 (dd, J=7.97, 1.53 Hz, 1H). EXAMPLE 113 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)azetidine-3-carboxamide The title compound was prepared according to procedure for EXAMPLE 112, substituting 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid for 1-(tert 0 butoxycarbonyl)azetidine-2-carboxylic acid. MS (DCI/NH 3 ) m/z 339 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 61.62 - 1.75 (m, 4H), 2.36 - 2.44 (m, 2H), 2.46 - 2.54 (m, 2H), 3.69 - 3.83 (m, 1H), 3.97 (s, 2H), 4.17 - 4.33 (m, 4H), 7.00 (dd, J=7.14, 1.19 Hz, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.40 (t, J=1.59 Hz, 1H), 7.45 - 7.51 (m, 1H). EXAMPLE 114 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)methanesulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting methanesulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) m/z 334 (M+H)*; H NMR (500 MHz, dimethylsulfoxide-d): 6 1.53 - 1.67 (m, 4H), 2.29 - 2.42 (m, 4H), 2.95 (s, 3H), 3.88 (s, 2H), 6.92 (d, J=7.63 Hz, 1H), 7.00 (s, 1H), 7.06 (dd, J=7.93, '0 1.22 Hz, 1H), 7.26 (t, J=7.78 Hz, 1H), 9.68 (br s, 1H), 12.63 (br s, 1H). EXAMPLE 115 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)propane-2-sulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting propane-2-sulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) m/z 25 362 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.19 (d, J=7.02 Hz, 6H), 1.53 1.66 (m, 4H), 2.25 - 2.33 (m, 2H), 2.34 - 2.41 (m, 2H), 3.08 - 3.22 (m, 1H), 3.87 (s, 2H), 6.88 - 6.91 (m, 1H), 7.01 (s, 1H), 7.08 (dd, J=8.24, 1.22 Hz, 1H), 7.23 (t, J=7.78 Hz, 1H), 9.68 (br s, 1H), 12.64 (br s, 1H). EXAMPLE 116 30 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzenesulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting benzenesulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) m/z 396 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.48 - 1.60 (m, 4H), 2.10 - 2.21 139 (m, 2H), 2.29 - 2.39 (m, 2H), 3.78 (s, 2H), 6.83 - 6.87 (m, 2H), 6.92 (dd, J=8.09, 1.37 Hz, 1H), 7.15 (t, J=7.78 Hz, 1H), 7.48 (t, J=7.78 Hz, 2H), 7.58 (t, J=7.48 Hz, 1H), 7.64 - 7.69 (m, 2H), 10.24 (br s, 1H), 12.64 (br s, 1H). EXAMPLE 117 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyridine-3-sulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting pyridine-3-sulfonyl chloride hydrochloride for dimethylsulfamoyl chloride. MS

(DCI/NH

3 ) m/z 397 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.50 - 1.61 (m, 4H), 2.12 - 2.21 (m, 2H), 2.33 - 2.40 (m, 2H), 3.80 (s, 2H), 6.85 (s, 1H), 6.92 (d, J=7.63 Hz, 0 1H), 6.96 (dd, J=7.93, 1.22 Hz, 1H), 7.19 (t, J=7.78 Hz, 1H), 7.55 (dd, J=8.09, 4.73 Hz, 1H), 8.02 - 8.06 (m, 1H), 8.75 (dd, J=4.88, 1.53 Hz, 1H), 8.77 (d, J=1.83 Hz, 1H), 10.43 (br s, 1H), 12.63 (br s, 1H). EXAMPLE 118 N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)furan-2-sulfonamide 5 The title compound was prepared according to the procedure for EXAMPLE 97, substituting furan-2-sulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) m/z 386 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.52 - 1.63 (m, 4H), 2.19 - 2.28 (m, 2H), 2.32 - 2.40 (m, 2H), 3.82 (s, 2H), 6.57 (dd, J=3.66, 1.83 Hz, 1H), 6.89 (d, J=1.53 Hz, 1H), 6.91 (d, J=7.63 Hz, 1H), 6.95 - 6.99 (m, 1H), 7.04 (d, J=3.36 Hz, 1H), 7.20 (t, '0 J=7.78 Hz, 1H), 7.90 (dd, J=1.83, 0.92 Hz, 1H), 10.60 (br s, 1H), 12.65 (br s, 1H). EXAMPLE 119 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-imidazole 4-sulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, 25 substituting 1-methyl-1H-imidazole-4-sulfonyl chloride for dimethylsulfamoyl chloride. MS

(DCI/NH

3 ) m/z 400 (M+H)*. 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.55 - 1.61 (m, 4H), 2.24 - 2.32 (m, 2H), 2.32 - 2.40 (m, 2H), 3.63 (s, 3H), 3.80 (s, 2H), 6.80 (d, J=7.93 Hz, 1H), 6.92 (s, 1H), 6.99 (dd, J=8.09, 1.37 Hz, 1H), 7.13 (t, J=7.78 Hz, 1H), 7.70 (d, J=1.22 Hz, 1H), 7.73 (d, J=1.22 Hz, 1H), 10.15 (br s, 1H), 12.64 (br s, 1H). 30 EXAMPLE 120 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-2-sulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting thiophene-2-sulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) 140 m/z 402 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.41 - 1.64 (m, 4H), 2.18 2.24 (m, 2H), 2.34 - 2.40 (m, 2H), 3.82 (s, 2H), 6.90 - 6.94 (m, 2H), 6.97 (d, J=7.93 Hz, 1H), 7.06 (dd, J=5.03, 3.81 Hz, 1H), 7.17 - 7.24 (m, 1H), 7.45 (dd, J=3.81, 1.37 Hz, 1H), 7.85 (dd, J=5.03, 1.37 Hz, 1H), 10.36 (br s, 1H), 12.65 (br s, 1H). 5 EXAMPLE 121 4-cyano-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzenesulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting 4-cyanobenzene-1-sulfonyl chloride for dimethylsulfamoyl chloride. MS 0 (DCI/NH 3 ) m/z 421 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.49 - 1.62 (m, 4H), 2.14 - 2.20 (m, 2H), 2.31 - 2.39 (m, 2H), 3.80 (s, 2H), 6.84 (s, 1H), 6.90 (d, J=7.63 Hz, 1H), 6.94 (dd, J=7.93, 1.22 Hz, 1H), 7.19 (t, J=7.93 Hz, 1H), 7.83 (d, J=8.85 Hz, 2H), 8.00 (d, J=8.54 Hz, 2H), 10.52 (br s, 1H), 12.65 (br s, 1H). EXAMPLE 122 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)naphthalene-1 sulfonamide The title compound was prepared according to the procedure for EXAMPLE 97, substituting naphthalene-1-sulfonyl chloride for dimethylsulfamoyl chloride. MS (DCI/NH 3 ) m/z 421 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.41 - 1.47 (m, 2H), 1.47 '0 1.56 (m, 2H), 2.00 - 2.10 (m, 2H), 2.30 - 2.39 (m, 2H), 3.71 (s, 2H), 6.75 - 6.80 (m, 2H), 6.83 - 6.89 (m, 1H), 7.07 (t, J=7.78 Hz, 1H), 7.50 - 7.56 (m, 1H), 7.64 (t, J=7.02 Hz, 1H), 7.67 7.72 (m, 1H), 8.04 (d, J=7.63 Hz, 1H), 8.06 - 8.10 (m, 1H), 8.18 (d, J=8.24 Hz, 1H), 8.67 (d, J=8.54 Hz, 1H), 10.65 (br s, 1 H), 12.64 (br s, 1H). EXAMPLE 123 25 4-((6-bromopyridin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared as described in EXAMPLE 74B. MS (DCI/NH 3 ) m/z 321 (M+H)*. EXAMPLE 125 4-((6-(2-oxopyrrolidin- 1 -yl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one 30 The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 123 for EXAMPLE 103, and pyrroline -2-one for azetidin-2-one. MS (ESI) m/z 325 (M+H)+. 141 EXAMPLE 126 N-(6-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)pyridin-2-yl)benzamide The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 123 for EXAMPLE 103, and benzylamide for azetidin-2-one. MS 5 (ESI) m/z 361 (M+H)*; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.63 (m, 4 H), 2.40 (m, 4 H), 4.02 (s, 2 H), 6.95 (d, J=7.46 Hz, 1 H), 7.38 - 7.54 (m, 2 H), 7.50 - 7.62 (m, 1 H), 7.67 7.84 (m, 1 H), 7.90 - 8.12 (m, 3 H), 10.69 (s, 1 H), 12.61 (s, 1 H). EXAMPLE 127 4-((3'-((isopropylamino)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 0 1(2H)-one EXAMPLE 127A 3'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)biphenyl-3-carbaldehyde A suspension of EXAMPLE 90 (500 mg, 1.57 mmol), 3-formylphenylboronic acid (352 mg, 2.35 mmol), dichlorobis(triphenylphosphine)palladium(II) (112 mg, 0.16 mmol) 5 and sodium carbonate (2M solution, 3.13 mmol, 1.6 mL) in a 7/3/3 mixture of 1,2 dimethoxyethane/water/ethanol (23 mL) was purged with nitrogen, and heated at 70 0 C for 16 hours. After cooling to room temperature, the reaction mixture was concentrated on a rotary evaporator. The crude solid was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide '0 the title compound. MS (DCI/NH 3 ) m/z 345 (M+H)*. EXAMPLE 127B 4-((3'-((isopropylamino)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure 25 for EXAMPLE 65, substituting EXAMPLE 127A for formaldehyde, and propan-2-amine for EXAMPLE 56. MS (DCI/NH 3 ) m/z 388 (M+H)*; 1 H NMR (500 MHz, CD 3 0D): 6 1.41 (d, J=6.71 Hz, 6H), 1.64 - 1.76 (m, 4H), 2.43 - 2.48 (m, 2H), 2.48 - 2.53 (m, 2H), 3.42 - 3.52 (m, 1H), 4.06 (s, 2H), 4.27 (s, 2H), 7.22 (d, J=7.93 Hz, 1H), 7.41 (t, J=7.63 Hz, 1H), 7.45 - 7.50 (m, 2H), 7.51 - 7.56 (m, 2H), 7.64 - 7.69 (m, 1H), 7.71 - 7.74 (m, 1H). 30 EXAMPLE 128 4-((3'-((cyclopentylamino)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one 142 The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 65, substituting EXAMPLE 127A for formaldehyde, and cyclopentanamine for EXAMPLE 56. MS (DCI/NH 3 ) m/z 414 (M+H)*. EXAMPLE 129 5 4-((3'-((2-methylpyrrolidin-1-yl)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 65, substituting EXAMPLE 127A for formaldehyde and 2-methylpyrrolidine for EXAMPLE 56. MS (DCI/NH 3 ) m/z 414 (M+H)*. 0 EXAMPLE 130 4-((3'-((cyclopropylamino)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure for EXAMPLE 65, substituting EXAMPLE 127A for formaldehyde, and cyclopropanamine 5 for EXAMPLE 56. MS (DCI/NH 3 ) m/z 386 (M+H)*. EXAMPLE 131 4-((3'-((cyclobutylamino)methyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared as a trifluoroacetic acid salt according to procedure '0 for EXAMPLE 65, substituting EXAMPLE 127A for formaldehyde, and cyclobutanamine for EXAMPLE 56. MS (DCI/NH 3 ) m/z 400 (M+H)*. EXAMPLE 132 4-((2-bromo- 1 -oxidopyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one A solution of EXAMPLE 103 (100 mg, 0.31 mmol) in dichloromethane (15 ml) was 25 treated with meta-chloroperoxybenzoic acid (100 mg, 0.58 mmol) at room temperature overnight, and concentrated. The residue was dissolved in methanol, and separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 336 (M+H)*. 30 EXAMPLE 133 4-((1 -oxido-2-(2-oxopyrrolidin- 1 -yl)pyridin-4-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one 143 The title compound was prepared according to procedure for EXAMPLE 132, substituting EXAMPLE 102 for EXAMPLE 103. MS (ESI) m/z 341 (M+H)*. EXAMPLE 134 methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)thiophene-3-carboxylate 5 EXAMPLE 134A 3-((4-bromothiophen-2-yl)methylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 5-bromothiophene-2-carbaldehyde for 2-fluoro-5-formylbenzonitrile. MS

(DCI/NH

3 ) m/z 312 (M+H)*. 0 EXAMPLE 134B 4-((4-bromothiophen-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C substituting EXAMPLE 134A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 326 (M+H)*. EXAMPLE 134C 5 methyl 5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)thiophene-3-carboxylate The title compound was prepared according to the procedure for EXAMPLE 66, substituting EXAMPLE 134B for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 305 (M+H)*. EXAMPLE 135 4-(3-((4-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-1,4-diazepan-1-yl)carbonyl)-4 10 fluorobenzyl)phthalazin- 1 (2H)-one EXAMPLE 135A tert-butyl 2-(2-(2-(4-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzoyl)- 1,4-diazepan- 1 -yl)ethoxy)ethoxy)ethylcarbamate To a solution of 2-(2-(-t-Boc-aminoethoxy)ethoxy)ethyl bromide (Toronto, 137 mg, 25 0.44 mmol) in N,N-dimethylformamide (4 mL) was added EXAMPLE 5 (84 mg, 0.22 mmol) and potassium carbonate (91 mg, 0.66 mmol). The reaction mixture was heated at 35 0 C overnight, and partitioned between ethyl acetate and brine. The organic phase was washed with brine, and concentrated. The residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 250x2.54 column, mobile phase 30 A: 0.10% trifluoroacetic acid in H 2 0; B: 0.10% trifluoroacetic acid in CH 3 CN; 0-100% gradient) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 612 (M+H)*. EXAMPLE 135B 144 4-(3-((4-(2-(2-(2-aminoethoxy)ethoxy)ethyl)- 1,4-diazepan- 1 -yl)carbonyl)-4 fluorobenzyl)phthalazin- 1 (2H)-one To a suspension of EXAMPLE 135A (43 mg, 0.06 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL) at room temperature. The solution remained at room 5 temperature for 1 hour, and was concentrated. The residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 250x2.54 column, mobile phase A: 0.1 % trifluoroacetic acid in H 2 0; B: 0.l1% trifluoroacetic acid in CH 3 CN; 0 100% gradient) to provide the title compound as a trifluoroacetic acid salt. The trifluoroacetic acid salt was dissolved in a mixture of methylene chloride and methanol, and 0 was treated with IM solution of HCl in ether. Removal of the volatiles afforded the title compound as a HCl salt. MS (DCI/NH 3 ) m/z 338 (M+H)*. EXAMPLE 136 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)cyclopropanecarboxamide 5 A solution of EXAMPLE 89 (20 mg, 0.08 mmol), 1-methylcyclopropanecarboxylic acid (10 mg, 0.096 mmol), HATU (2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium) (38 mg, 0.1 mmol) and triethylamine (20 mg, 0.2 mmol) in dimethylacetamide (2.5 mL) was stirred at room temperature for 18 hours, and concentrated. The residue was dissolved in a 1:1 mixture of dimethylsulfoxide/methanol, and '0 separated by HPLC (Waters Sunfire@ C-8 analytical column [Milford, MA], 0. 1% trifluoroacetic acid/water/CH 3 CN) to provide the title compound. MS (DCI/NH 3 ) m/z 338 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 0.57 - 0.69 (m, 2H), 1.02 - 1.10 (m, 2H), 1.38 (s, 3H), 1.57 - 1.65 (m, 4H), 2.29 - 2.44 (m, 4H), 3.87 (s, 2H), 6.89 (d, J=7.63 Hz, 1H), 7.23 (t, J=7.93 Hz, 1H), 7.42 (s, 1H), 7.46 (d, J=8.24 Hz, 1H). 25 EXAMPLE 137 2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)cyclopropanecarboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-methylcyclopropanecarboxylic acid for 1-methylcyclopropanecarboxylic acid. 30 MS (DCI/NH 3 ) m/z 338 (M+H)*. EXAMPLE 138 3-ethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)propanamide 145 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-ethoxypropanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 356 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 1 H NMR (500 MHz, Solvent) 6 1.08 (t, J=7.02 Hz, 3H), 1.54 - 1.64 (m, 4H), 2.32 - 2.42 (m, 4H), 2.51 5 (t, J=6.26 Hz, 2H), 3.43 (q, J=7.02 Hz, 2H), 3.64 (t, J=6.26 Hz, 2H), 3.88 (s, 2H), 6.90 (d, J=7.63 Hz, 1H), 7.24 (t, J=7.78 Hz, 1H), 7.36 (s, 1H), 7.48 (d, J=7.93 Hz, 1H). EXAMPLE 139 5-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-L-prolinamide The title compound was prepared according to the procedure for EXAMPLE 136, 0 substituting (S)-5-oxopyrrolidine-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 367 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 1 H NMR (500 MHz, Solvent) 6 1.56 - 1.66 (m, 4H), 1.93 - 2.03 (m, 1H), 2.14 - 2.27 (m, 2H), 2.32 - 2.43 (m, 5H), 3.96 (s, 2H), 4.19 (dd, J=8.70, 4.42 Hz, 1H), 6.94 (d, J=7.63 Hz, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.40 (s, 1H), 7.49 (d, J=7.93 Hz, 1H). 5 EXAMPLE 140 5-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-D-prolinamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting (R)-5-oxopyrrolidine-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 367 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 '0 1.56 - 1.66 (m, 4H), 1.93 - 2.02 (m, 1H), 2.13 - 2.25 (m, 2H), 2.32 - 2.42 (m, 5H), 3.89 (s, 2H), 4.18 (dd, J=8.70, 4.42 Hz, 1H), 6.94 (d, J=7.63 Hz, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.39 (s, 1H), 7.49 (d, J=8.24 Hz, 1H). EXAMPLE 141 N -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)cyclopropane-1,1 25 dicarboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1-carbamoylcyclopropanecarboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 367 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 1.35 - 1.44 (m, 4H), 1.55 - 1.67 (m, 4H), 2.31 - 2.44 (m, 4H), 3.88 (s, 2H), 6.91 (d, J=7.63 30 Hz, 1H), 7.26 (t, J=7.78 Hz, 1H), 7.40 (s, 1H), 7.43 (d, J=7.93 Hz, 1H). EXAMPLE 142 2-(benzyloxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)acetamide 146 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-(benzyloxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 404 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.64 (m, 4H), 2.32 - 2.42 (m, 4H), 3.89 (s, 2H), 4.06 (s, 2H), 4.60 (s, 2H), 6.93 (d, J=7.63 Hz, 1H), 5 7.26 (t, J=7.78 Hz, 1H), 7.31 - 7.34 (m, 1H), 7.36 - 7.42 (m, 5H), 7.50 (d, J=7.93 Hz, 1H). EXAMPLE 143 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-phenylpropanamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-phenylpropanoic acid for 1-methylcyclopropanecarboxylic acid. MS 0 (DCI/NH 3 ) m/z 388 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 - 1.65 (m, 4H), 2.32 - 2.42 (m, 4H), 2.60 (t, J=7.63 Hz, 2H), 2.89 (t, J=7.63 Hz, 2H), 3.87 (s, 2H), 6.89 (d, J=7.63 Hz, 1H), 7.18 (t, J=7.17 Hz, 1H), 7.21 - 7.26 (m, 3H), 7.28 (t, J=7.48 Hz, 2H), 7.32 (s, 1H), 7.45 (d, J=8.24 Hz, 1H). EXAMPLE 144 5 3-(2,5-dimethoxyphenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)propanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-(2,5-dimethoxyphenyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 448 (M+H)*. 10 EXAMPLE 145 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1 phenylcyclopropanecarboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1 -phenylcyclopropanecarboxylic acid for 1-methylcyclopropanecarboxylic acid. 25 MS (DCI/NH 3 ) m/z 400 (M+H)*. EXAMPLE 146 (2S)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-phenylbutanamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting (S)-2-phenylbutanoic acid for 1-methylcyclopropanecarboxylic acid. MS 30 (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 147 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-phenylbutanamide 147 The title compound was prepared according to procedure for EXAMPLE 136, substituting 4-phenylbutanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 148 5 2-(3-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-(m-tolyloxy)acetic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 404 (M+H)*. 0 EXAMPLE 149 2-(2-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-(o-tolyloxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS 5 (DCI/NH 3 ) m/z 404 (M+H)*. EXAMPLE 150 2-(4-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide The title compound was prepared according to procedure for EXAMPLE 136, '0 substituting 2-(p-tolyloxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 404 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.65 (m, 4H), 2.23 (s, 3H), 2.33 - 2.44 (m, 4H), 3.89 (s, 2H), 4.61 (s, 2H), 6.88 (d, J=8.54 Hz, 2H), 6.94 (d, J=7.63 Hz, 1H), 7.11 (d, J=8.24 Hz, 2H), 7.27 (t, J=7.78 Hz, 1H), 7.41 (s, 1H), 7.50 (d, J=8.24 Hz, 1H). 25 EXAMPLE 151 (2R)-2-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2 phenylacetamide The title compound was prepared according to procedure for EXAMPLE 136, substituting (R)-2-methoxy-2-phenylacetic acid for 1-methylcyclopropanecarboxylic acid. 30 MS (DCI/NH 3 ) m/z 404 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 1.66 (m, 4H), 2.29 - 2.44 (m, 4H), 3.35 (s, 3H), 3.87 (s, 2H), 4.81 (s, 1H), 6.91 (d, J=7.63 Hz, 1H), 7.25 (t, J=7.93 Hz, 1H), 7.33 - 7.36 (m, 1H), 7.39 (t, J=7.17 Hz, 2H), 7.45 - 7.49 (m, 3H), 7.52 (d, J=8.24 Hz, 1H). 148 EXAMPLE 152 (2S)-2-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2 phenylacetamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting (S)-2-methoxy-2-phenylacetic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 404 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 1.66 (m, 4H), 2.30 - 2.42 (m, 4H), 3.34 (s, 3H), 3.87 (s, 2H), 4.81 (s, 1H), 6.91 (d, J=7.63 Hz, 1H), 7.25 (t, J=7.93 Hz, 1H), 7.32 - 7.36 (m, 1H), 7.39 (t, J=7.17 Hz, 2H), 7.44 - 7.49 (m, 3H), 7.51 (d, J=8.24 Hz, 1H). 0 EXAMPLE 153 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-phenoxypropanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-phenoxypropanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 404 (M+H)*. 5 EXAMPLE 154 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-thien-2-ylbutanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 4-(thiophen-2-yl)butanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 408 (M+H)*. 10 EXAMPLE 155 1-acetyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)piperidine-4 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1 -acetylpiperidine-4-carboxylic acid for 1-methylcyclopropanecarboxylic acid. 25 MS (DCI/NH 3 ) m/z 409 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.36 1.46 (m, 1H), 1.52 - 1.67 (m, 5H), 1.79 (t, J=14.19 Hz, 2H), 2.02 (s, 3H), 2.30 - 2.43 (m, 4H), 2.56 - 2.63 (m, 1H), 3.06 (t, J=12.97 Hz, 1H), 3.85 - 3.90 (m, 2H), 3.97 (s, 2H), 4.39 (d, J=13.43 Hz, 1H), 6.89 (d, J=7.63 Hz, 1H), 7.24 (t, J=7.78 Hz, 1H), 7.38 (s, 1H), 7.48 (d, J=8.24 Hz, 1H). 30 EXAMPLE 156 2-(3,5-difluorophenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide 149 The title compound was prepared according to procedure for EXAMPLE 136, substituting 2-(3,5-difluorophenyl)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 410 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 - 1.67 (m, 4H), 2.31 - 2.42 (m, 4H), 3.67 (s, 2H), 3.88 (s, 2H), 6.91 (d, J=7.63 Hz, 1H), 7.04 (d, 5 J=6.41 Hz, 1H), 7.07 - 7.13 (m, 1H), 7.25 (t, J=7.93 Hz, 1H), 7.36 (s, 1H), 7.46 (d, J=8.24 Hz, 1H). EXAMPLE 157 2 N -acetyl-N 1 -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-L-leucinamide The title compound was prepared according to procedure for EXAMPLE 136, 0 substituting (S)-2-acetamido-4-methylpentanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 411 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 0.88 (d, J= 6.71 Hz, 3H), 0.90 (d, J= 6.71 Hz, 3H), 1.43 - 1.53 (m, 2H), 1.56 - 1.66 (m, 5H), 1.87 (s, 3 H), 2.29 - 2.43 (m, 4H), 3.88 (s, 2H), 4.39 (dd, J=9.61, 5.34 Hz, 1H), 6.91 (d, J=7.63 Hz, 1H), 7.25 (t, J=7.78 Hz, 1H), 7.38 (s, 1H), 7.49 (d, J=8.24 Hz, 1H). 5 EXAMPLE 158 N -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-N 2

,N

2 -dipropyl L-alaninamide The title compound was prepared according to procedure for EXAMPLE 136, substituting (S)-2-(dipropylamino)propanoic acid for 1-methylcyclopropanecarboxylic acid. '0 MS (DCI/NH 3 ) m/z 411 (M+H)*. EXAMPLE 159 4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4 phenylbutanamide The title compound was prepared according to procedure for EXAMPLE 136, 25 substituting 4-oxo-4-phenylbutanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 411 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 - 1.66 (m, 4H), 2.31 - 2.42 (m, 4H), 2.70 (t, J=6.26 Hz, 2H), 3.32 (t, J=6.26 Hz, 2H), 3.87 (s, 2H), 6.88 (d, J=7.63 Hz, 1H), 7.23 (t, J=7.93 Hz, 1H), 7.37 (s, 1H), 7.45 (d, J=8.24 Hz, 1H), 7.55 (t, J=7.63 Hz, 2H), 7.66 (t, J=7.32 Hz, 1H), 7.99 (t, J=6.41 Hz, 2H). 30 EXAMPLE 160 N-(2-oxo-2-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenylamino)ethyl)benzamide 150 The title compound was prepared according to procedure for EXAMPLE 136, substituting 2-benzamidoacetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 417 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 - 1.66 (m, 4H), 2.31 - 2.40 (m, 4H), 3.89 (s, 2H), 4.04 (s, 2H), 6.92 (d, J=7.93 Hz, 1H), 7.26 (t, 5 J=7.93 Hz, 1H), 7.38 (s, 1H), 7.47 (d, J=8.24 Hz, 1H), 7.49 - 7.54 (m, 2H), 7.58 (t, J=7.32 Hz, 1H), 7.85 - 7.90 (m, 2H). EXAMPLE 161 3-(3-methoxyphenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)propanamide 0 The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-(3-methoxyphenyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 418 (M+H)*. EXAMPLE 162 3-(4-methoxyphenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl)phenyl)propanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-(4-methoxyphenyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 418 (M+H)*. EXAMPLE 163 10 2-(3,4-dimethylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 2-(3,4-dimethylphenoxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 418 (M+H)*. 25 EXAMPLE 164 (2R)-2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4 phenylbutanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting (R)-2-hydroxy-4-phenylbutanoic acid for 1-methylcyclopropanecarboxylic acid. 30 MS (DCI/NH 3 ) m/z 418 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 1.65 (m, 4H), 1.80 - 1.90 (m, 1H), 1.95 - 2.03 (m, 1H), 2.31 - 2.44 (m, 4H), 2.69 (t, J=7.93 Hz, 2H), 3.88 (s, 2H), 3.96 (s, 1H), 4.01 (dd, J=8.09, 4.12 Hz, 1H), 6.91 (d, J=7.63 Hz, 1H), 151 7.17 - 7.23 (m, 3H), 7.25 (t, J=7.78 Hz, 1H), 7.29 (t, J=7.48 Hz, 2H), 7.49 (s, 1H), 7.53 (d, J=7.93 Hz, 1H). EXAMPLE 165 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-phenoxybutanamide 5 The title compound was prepared according to procedure for EXAMPLE 136, substituting 4-phenoxybutanoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 418 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 - 1.67 (m, 4H), 1.96 - 2.06 (m, 2H), 2.31 - 2.42 (m, 4H), 2.47 (t, J=7.48 Hz, 2H), 3.88 (s, 2H), 3.99 (t, J=6.26 Hz, 2H), 6.87 - 6.91 (m, 2H), 6.91 - 6.96 (m, 2H), 7.24 (t, J=7.78 Hz, 1H), 7.26 0 7.30 (m, 2H), 7.36 (s, 1H), 7.48 (d, J=8.24 Hz, 1H). EXAMPLE 166 4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-thien-2 ylbutanamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 4-oxo-4-(thiophen-2-yl)butanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 422 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 1.65 (m, 4H), 2.32 - 2.42 (m, 4H), 2.69 (t, J=6.41 Hz, 2H), 3.26 (t, J=6.41 Hz, 2H), 3.87 (s, 2H), 6.88 (d, J=7.63 Hz, 1H), 7.23 (t, J=7.93 Hz, 1H), 7.25 - 7.29 (m, 1H), 7.37 (s, 1H), 7.44 (d, J=8.24 Hz, 1H), 7.97 (d, J=4.88 Hz, 1H), 7.99 (d, J=2.75 Hz, 1H). 10 EXAMPLE 167 2-((4-methylpyrimidin-2-yl)thio)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 2-(4-methylpyrimidin-2-ylthio)acetic acid for 1-methylcyclopropanecarboxylic 25 acid. MS (DCI/NH 3 ) m/z 422 (M+H)*. EXAMPLE 168 3-(2-chlorophenyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)propanamide The title compound was prepared according to procedure for EXAMPLE 136, 30 substituting 3-(2-chlorophenyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 422 (M+H)*. EXAMPLE 169 152 3-(4-chlorophenyl)-N-(3 -((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-(4-chlorophenyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS 5 (DCI/NH 3 ) m/z 422 (M+H)*. EXAMPLE 170 3-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2 phenylpentanamide The title compound was prepared according to procedure for EXAMPLE 136, 0 substituting 3-methyl-2-phenylpentanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 430 (M+H)*. EXAMPLE 171 2-(4-chloro-2-methylphenoxy)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)acetamide 5 The title compound was prepared according to procedure for EXAMPLE 136, substituting 2-(4-chloro-2-methylphenoxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 438 (M+H)*. EXAMPLE 172 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-N'-phenylpentanediamide 10 The title compound was prepared according to procedure for EXAMPLE 136, substituting 5-oxo-5-(phenylamino)pentanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 445 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 1.65 (m, 4H), 1.84 - 1.94 (m, 2H), 2.31 - 2.42 (m, 8H), 3.87 (s, 2H), 6.89 (d, J=7.63 Hz, 1H), 7.05 (t, J=7.32 Hz, 1H), 7.24 (t, J=7.93 Hz, 1H), 7.30 (t, J=8.09 Hz, 2H), 7.36 (s, 1H), 7.48 25 (d, J=8.24 Hz, 1H), 7.57 (d, J=7.63 Hz, 2 H). EXAMPLE 173 4-(4-methoxyphenyl)-4-oxo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)butanamide The title compound was prepared according to procedure for EXAMPLE 136, 30 substituting 4-(4-methoxyphenyl)-4-oxobutanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 446 (M+H)+. EXAMPLE 174 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2,2-diphenylacetamide 153 The title compound was prepared according to procedure for EXAMPLE 136, substituting 2,2-diphenylacetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 450 (M+H)*. EXAMPLE 175 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3 (phenylsulfonyl)propanamide The title compound was prepared according to procedure for EXAMPLE 136, substituting 3-(phenylsulfonyl)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 452 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.52 - 1.70 0 (m, 4H), 2.29 - 2.42 (m, 4H), 2.66 (t, J=7.32 Hz, 2H), 3.59 (t, J=7.32 Hz, 2H), 3.87 (s, 2H), 6.90 (d, J=7.32 Hz, 1H), 7.20 - 7.26 (m, 2H), 7.37 (d, J=8.54 Hz, 1H), 7.66 (t, J=7.63 Hz, 2H), 7.74 (t, J=7.48 Hz, 1H), 7.91 (d, J=7.32 Hz, 2H). EXAMPLE 176 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-(3 5 phenoxyphenyl)acetamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-(3-phenoxyphenyl)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 466 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.65 (m, 4H), 2.29 - 2.42 (m, 4H), 3.60 (s, 2H), 3.87 (s, 2H), 6.86 - 6.92 (m, 2H), 6.98 - 7.03 (m, '0 3H), 7.10 (d, J=7.93 Hz, 1H), 7.16 (t, J=7.48 Hz, 1H), 7.24 (t, J=7.78 Hz, 1H), 7.32 - 7.37 (m, 2H), 7.38 - 7.42 (m, 2H), 7.46 (d, J=8.24 Hz, 1H). EXAMPLE 177 4-ethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 25 substituting 4-ethylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 388 (M+H)*. EXAMPLE 178 3-fluoro-2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide 30 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-fluoro-2-methylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 392 (M+H)*. EXAMPLE 179 154 5-fluoro-2-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 5-fluoro-2-methylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS 5 (DCI/NH 3 ) m/z 392 (M+H)*. EXAMPLE 180 3-fluoro-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 0 substituting 3-fluoro-4-methylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 392 (M+H)*. EXAMPLE 181 2,3-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 2,3-difluorobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 396 (M+H)*. EXAMPLE 182 2,4-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, '0 substituting 2,4-difluorobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 396 (M+H)*. EXAMPLE 183 2,5-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 25 substituting 2,5-difluorobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 396 (M+H)*. EXAMPLE 184 3,5-difluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 30 substituting 3,5-difluorobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 396 (M+H)*. EXAMPLE 185 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-propylbenzamide 155 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-propylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 186 5 4-isopropyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-isopropylbenzoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 402 (M+H)*. EXAMPLE 187 0 2-ethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-ethoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 404 (M+H)*. EXAMPLE 188 5 4-isopropoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-isopropoxybenzoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 418 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.30 (d, J=6.10 Hz, 6H), 1.53 - 1.67 (m, 4H), 2.33 - 2.46 (m, 4H), 3.91 (s, 2H), 4.67 - 4.80 (m, 1H), '0 6.94 (d, J=7.63 Hz, 1H), 7.02 (d, J=8.85 Hz, 2H), 7.29 (t, J=7.78 Hz, 1H), 7.55 (s, 1H), 7.62 (d, J=8.24 Hz, 1H), 7.89 (d, J=8.85 Hz, 2H). EXAMPLE 189 4-(diethylamino)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-(diethylamino)benzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 431 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d 6 ): 6 1.11 (t, J=7.02 Hz, 6H), 1.57 - 1.66 (m, 4H), 2.34 - 2.44 (m, 4H), 3.45 (q, J=7.02 Hz, 4H), 3.91 (s, 2H), 6.87 (d, J=8.85 Hz, 2H), 6.91 (d, J=7.63 Hz, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.55 (s, 1H), 30 7.62 (d, J=8.24 Hz, 1H), 7.85 (d, J=8.85 Hz, 2H). EXAMPLE 190 4-butoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide 156 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-butoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 432 (M+H)*. EXAMPLE 191 5 2-fluoro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-5 (trifluoromethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-fluoro-5-(trifluoromethyl)benzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 446 (M+H)*. 0 EXAMPLE 192 2-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-5 (trifluoromethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-chloro-5-(trifluoromethyl)benzoic acid for 1-methylcyclopropanecarboxylic 5 acid. MS (DCI/NH 3 ) m/z 461 (M+H)*. EXAMPLE 193 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-furamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting furan-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS '0 (DCI/NH 3 ) m/z 350 (M+H)*. EXAMPLE 194 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-furamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting furan-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS 25 (DCI/NH 3 ) m/z 350 (M+H)*. EXAMPLE 195 2,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-furamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2,5-dimethylfuran-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. 30 MS (DCI/NH 3 ) m/z 378 (M+H)*. EXAMPLE 196 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-2-carboxamide 157 The title compound was prepared according to the procedure for EXAMPLE 136, substituting thiophene-2-carboxylic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 366 (M+H)*. EXAMPLE 197 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting thiophene-3-carboxylic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 366 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.66 (m, 4H), 2.32 - 2.44 (m, 4H), 3.92 (s, 2H), 6.96 (d, J=7.63 Hz, 1H), 7.30 (t, J=7.93 Hz, 1H), 0 7.53 (s, 1H), 7.59 - 7.65 (m, 3H), 8.31 (dd, J=2.75, 1.53 Hz, 1H). EXAMPLE 198 3-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-2 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 3-methylthiophene-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 380 (M+H)*. EXAMPLE 199 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)thiophene-2 carboxamide 10 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 5-methylthiophene-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 380 (M+H)*. EXAMPLE 200 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-pyrrole-2 25 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting pyrrole-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 349 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.66 (m, 4H), 2.33 - 2.44 (m, 4H), 3.91 (s, 2H), 6.18 (dd, J=3.51, 2.29 Hz, 1H), 6.92 (d, J=7.63 30 Hz, 1H), 6.98 (d, J=1.53 Hz, 1H), 7.03 - 7.07 (m, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.53 (s, 1H), 7.60 (d, J=7.93 Hz, 1H). EXAMPLE 201 158 1-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-pyrrole-2 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1-methyl-i H-pyrrole-2-carboxylic acid for 1 -methylcyclopropanecarboxylic 5 acid. MS (DCI/NH 3 ) m/z 363 (M+H)*. EXAMPLE 202 2,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-pyrrole 3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, 0 substituting 2,5-dimethyl-1H-pyrrole-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 377 (M+H)*. EXAMPLE 203 1,2,5-trimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H pyrrole-3-carboxamide 5 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1-methyl-iH-pyrrole-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 363 (M+H)*. EXAMPLE 204 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-2 10 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting thiazole-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 367 (M+H)*. EXAMPLE 205 25 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-4 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting thiazole-4-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 367 (M+H)*. 30 EXAMPLE 206 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1,3-thiazole-5 carboxamide 159 The title compound was prepared according to the procedure for EXAMPLE 136, substituting thiazole-5-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 367 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.67 (m, 2H), 2.32 - 2.44 (m, 2H), 3.92 (s, 2H), 7.00 (d, J=7.63 Hz, 1H), 7.32 (t, J=7.93 Hz, 1H), 5 7.49 (s, 1H), 7.59 (d, J=8.24 Hz, 1H), 8.66 (s, 1H), 9.27 (s, 1H). EXAMPLE 208 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)isoxazole-5-carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting isoxazole-5-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS 0 (DCI/NH 3 ) m/z 351 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.68 (m, 4H), 2.33 - 2.45 (m, 4H), 3.93 (s, 2H), 7.03 (d, J=7.63 Hz, 1H), 7.22 (d, J=2.14 Hz, 1H), 7.34 (t, J=7.93 Hz, 1H), 7.54 (s, 1H), 7.63 (d, J=7.93 Hz, 1H), 8.77 (d, J=1.83 Hz, 1H). EXAMPLE 209 3,5-dimethyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)isoxazole-4 5 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3,5-dimethylisoxazole-4-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 379 (M+H)*. EXAMPLE 210 10 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)nicotinamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting nicotinic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 361 (M+H)*. EXAMPLE 211 25 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)isonicotinamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting isonicotinic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 361 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.57 - 1.68 (m, 4H), 2.33 2.45 (m, 4H), 3.94 (s, 2H), 7.04 (d, J=7.63 Hz, 1H), 7.36 (t, J=7.78 Hz, 1H), 7.56 (s, 1H), 30 7.66 (d, J=8.24 Hz, 1H), 8.10 (d, J=6.41 Hz, 2H), 8.90 (d, J=6.10 Hz, 2H). EXAMPLE 212 3-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyridine-2 carboxamide 160 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-hydroxypicolinic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 377 (M+H)*. EXAMPLE 213 5 2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)nicotinamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-hydroxynicotinic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 377 (M+H)*. EXAMPLE 214 0 6-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)nicotinamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 6-hydroxynicotinic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 377 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 - 1.65 (m, 4H), 2.32 - 2.43 (m, 4H), 3.91 (s, 2H), 6.45 (d, J=10.07 Hz, 1H), 6.95 (d, J=7.63 Hz, 1H), 5 7.29 (t, J=7.93 Hz, 1H), 7.46 (s, 1H), 7.57 (d, J=8.24 Hz, 1H), 7.98 (dd, J=9.76, 2.75 Hz, 1H), 8.16 (d, J=2.14 Hz, 1H). EXAMPLE 215 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-pyridin-2-ylacetamide The title compound was prepared according to the procedure for EXAMPLE 136, '0 substituting 2-(pyridin-2-yl)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 375 (M+H)*. EXAMPLE 216 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-pyridin-3-ylacetamide The title compound was prepared according to the procedure for EXAMPLE 136, 25 substituting 2-(pyridin-3-yl)acetic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 375 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.66 (m, 4H), 2.30 - 2.42 (m, 4H), 3.88 (s, 2H), 3.98 (s, 2H), 6.94 (d, J=7.32 Hz, 1H), 7.27 (t, J=7.93 Hz, 1H), 7.38 (s, 1H), 7.46 (d, J=8.85 Hz, 1H), 8.04 (dd, J=7.93, 5.80 Hz, 1H), 8.52 (d, J=8.24 Hz, 1H), 8.81 (d, J=5.49 Hz, 1H), 8.85 (s, 1H). 30 EXAMPLE 217 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrazine-2 carboxamide 161 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 5-methylpyrazine-2-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 376 (M+H)+; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 1.69 (m, 4H), 2.34 - 2.46 (m, 4H), 2.63 (s, 3H), 3.93 (s, 2H), 7.00 (d, J=7.63 Hz, 1H), 7.33 (t, 5 J=8.09 Hz, 1H), 7.68 - 7.74 (m, 2H), 8.68 (s, 1H), 9.13 (d, J=1.22 Hz, 1H). EXAMPLE 218 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1H-indole-3 carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, 0 substituting 1H-indole-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 399 (M+H)+. EXAMPLE 219 5-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1-phenyl-1H pyrazole-4-carboxamide 5 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid for 1 methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 440 (M+H)+. EXAMPLE 220 6-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2H-chromene 10 3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 6-chloro-2H-chromene-3-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 448 (M+H)+. EXAMPLE 221 25 N 3

,N

3 -dimethyl-N 1 -(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-beta alaninamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-(dimethylamino)propanoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 355 (M+H)+; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.55 - 1.66 30 (m, 4H), 2.30 - 2.43 (m, 4H), 2.77 - 2.93 (m, 10H), 3.93 (s, 2H), 6.74 (s, 1H), 6.90 (dd, J=8.09, 1.37 Hz, 1H), 7.06 (d, J=7.63 Hz, 1H), 7.37 (t, J=7.78 Hz, 1H). EXAMPLE 222 4-(2-(3-bromophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 162 EXAMPLE 222A 2-(3-bromophenyl)-N-methoxy-N-methylacetamide To a solution of 2-(3-bromophenyl)acetic acid (4.4 g, 20.56 mmol) in N,N dimethylformamide (125 ml) was successively added N,O-dimethylhydroxyamine (4.5 g, 5 46.26 mmol), triethylamine (10 ml), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (8.9 g, 46.26 mmol) and 1-hydroxybenzotriazole (6.24 g, 46.26 mmol). The reaction mixture was stirred at room temperature overnight, and partitioned between ethyl acetate and brine. The organic phase was washed with brine, and concentrated. The residue was purified by flash chromatography on silica gel (50% ethyl acetate in hexane) to provide 0 the title compound. MS (DCI/NH 3 ) m/z 258 (M+H)*. EXAMPLE 222B 2-(3-bromophenyl)acetaldehyde A solution of EXAMPLE 222A (2.5 g, 9.7 mmol) in anhydrous tetrahydrofuran (50 ml) was treated with LiAlH 4 (0.37 g, 9.7 mmol) at 0 0 C for 10 minutes, and quenched with 5 water. The mixture was partitioned between ethyl acetate and saturated ammonium chloride. The organic phase was washed with water and concentrated. The residue was purified by flash chromatography on silica gel (20% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 199 (M+H)*. EXAMPLE 222C 10 3-(2-(3-bromophenyl)ethylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting EXAMPLE 222B for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 319 (M+H)*. EXAMPLE 222D 25 4-(2-(3-bromophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 222C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 333 (M+H)*. EXAMPLE 223 4-(2-(3-bromo-4-fluorophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 30 EXAMPLE 223A 2-(3-bromo-4-fluorophenyl)acetaldehyde 163 The title compound was prepared according to the procedure for EXAMPLE 222, substituting 2-(3-bromo-4-fluorophenyl)acetic acid for 2-(3-bromophenyl)acetic acid in EXAMPLE 223B. MS (DCI/NH 3 ) m/z 216 (M+H)+. EXAMPLE 223B 5 4-(2-(3-bromo-4-fluorophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting EXAMPLE 223A for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 351 (M+H)+. EXAMPLE 224 0 4-(2,2,2-trifluoro-1-phenylethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 224A 3-(2,2,2-trifluoro-1-phenylethylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 2,2,2-trifluoro-1-phenylethanone for 2-fluoro-5-formylbenzonitrile. MS 5 (DCI/NH 3 ) m/z 295 (M+H)+. EXAMPLE 224B 4-(2,2,2-trifluoro-1-phenylethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 224A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 309 (M+H)+. 10 EXAMPLE 225 2-hydroxy-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-hydroxy-4-methylbenzoic acid for 1 -methylcyclopropanecarboxylic acid. MS 25 (DCI/NH 3 ) m/z 390 (M+H)+. EXAMPLE 226 4-acetyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-acetylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) 30 m/z 402 (M+H)+; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.69 (m, 4H), 2.34 - 2.46 (m, 4H), 2.64 (s, 3H), 3.93 (s, 2H), 6.99 (d, J=7.63 Hz, 1H), 7.32 (t, J=7.93 Hz, 1H), 7.57 (s, 1H), 7.65 (d, J=7.93 Hz, 1H), 8.01 - 8.05 (m, 2H), 8.05 - 8.10 (m, 2H). EXAMPLE 227 164 3-methoxy-4-methyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3-methoxy-4-methylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS 5 (DCI/NH 3 ) m/z 404 (M+H)*. EXAMPLE 228 4-ethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-ethoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) 0 m/z 404 (M+H)*. EXAMPLE 229 3-fluoro-4-methoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 3-fluoro-4-methoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 408 (M+H)*. EXAMPLE 230 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-1-naphthamide The title compound was prepared according to the procedure for EXAMPLE 136, '0 substituting 1-naphthoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 410 (M+H)*. EXAMPLE 231 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-naphthamide The title compound was prepared according to the procedure for EXAMPLE 136, 25 substituting 2-naphthoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 410 (M+H)*. EXAMPLE 232 5-chloro-2-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide 30 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-hydroxy-5-methylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 390 (M+H)*. EXAMPLE 233 165 4-tert-butyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-tert-butylbenzoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 416 (M+H)*. 5 EXAMPLE 234 4-(acetylamino)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-acetamidobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS 0 (DCI/NH 3 ) m/z 417 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 - 1.68 (m, 4H), 2.10 (s, 3H), 2.33 - 2.44 (m, 4H), 3.92 (s, 2H), 6.95 (d, J=7.93 Hz, 1H), 7.30 (t, J=7.93 Hz, 1H), 7.56 (s, 1H), 7.63 (d, J=7.63 Hz, 1H), 7.70 (d, J=8.85 Hz, 2H), 7.90 (d, J=8.85 Hz, 2H). EXAMPLE 235 5 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-propoxybenzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 4-propoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 418 (M+H)*. EXAMPLE 236 10 1-hydroxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2 naphthamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 1 -hydroxy-2-naphthoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 426 (M+H)*. 25 EXAMPLE 237 2-chloro-5-(methylthio)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-chloro-5-(methylthio)benzoic acid for 1-methylcyclopropanecarboxylic acid. 30 MS (DCI/NH 3 ) m/z 440 (M+H)*. EXAMPLE 238 3,4-diethoxy-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide 166 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 3,4-diethoxybenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 448 (M+H)*. EXAMPLE 239 5 2-benzyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-benzylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 450 (M+H)*. EXAMPLE 240 0 2-anilino-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared as a trifluoroacetic acid salt according to the procedure for EXAMPLE 136, substituting 2-(phenylamino)benzoic acid for 1 methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 451 (M+H)*; 1 H NMR (500 MHz,

D

2 0/dimethylsulfoxide-d): 6 1.55 - 1.68 (m, 4H), 2.31 - 2.45 (m, 4H), 3.91 (s, 2H), 6.91 5 6.99 (m, 3H), 7.13 (d, J=7.63 Hz, 2H), 7.27 - 7.34 (m, 4H), 7.38 - 7.42 (m, 1H), 7.49 (s, 1H), 7.58 (d, J=8.85 Hz, 1H), 7.71 - 7.75 (m, 1H). EXAMPLE 241 2-benzoyl-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared as according to the procedure for EXAMPLE 136, '0 substituting 2-benzoylbenzoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 464 (M+H)*. EXAMPLE 242 N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-(2 phenylethyl)benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 136, substituting 2-phenethylbenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 464 (M+H)*. EXAMPLE 243 5-bromo-2-chloro-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 30 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting 5-bromo-2-chlorobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 472 (M+H)*. 167 EXAMPLE 244 2-(4-methylbenzoyl)-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 2-(4-methylbenzoyl)benzoic acid for 1 -methylcyclopropanecarboxylic acid. MS

(DCI/NH

3 ) m/z 478 (M+H)*. EXAMPLE 245 2-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 0 substituting 2-iodobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 486 (M+H)*. EXAMPLE 246 3-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, 5 substituting 3-iodobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 486 (M+H)*. EXAMPLE 247 4-iodo-N-(3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 136, '0 substituting 4-iodobenzoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 486 (M+H)*. EXAMPLE 248 N-(2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-1,1'-biphenyl-3 yl)acetamide 25 The title compound was prepared as a free base according to the procedure for EXAMPLE 39, substituting 3-acetamidophenylboronic acid for 3-pyridineboronic acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 392 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.58 - 1.67 (m, 4H), 2.05 (s, 3H), 2.33 - 2.39 (m, 2H), 2.40 2.46 (m, 2H), 3.95 (s, 2H), 7.16 (d, J=7.02 Hz, 1H), 7.18 - 7.21 (m, 1H), 7.22 - 7.27 (m, 1H), 30 7.30 (dd, J=7.63, 2.14 Hz, 1H), 7.38 (t, J=7.93 Hz, 1H), 7.59 (d, J=7.32 Hz, 1H), 7.76 (s, 1H), 10.04 (br s, 1H), 12.61 (br s, 1H). EXAMPLE 249 168 4-((6-fluoro-3'-(methylsulfonyl)- 1,1 '-biphenyl-3-yl)methyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared as free base according to the procedure for EXAMPLE 39, substituting 3-(methylsulfonyl)phenylboronic acid for 3-pyridineboronic 5 acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 413 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.57 - 1.73 (m, 4H), 2.34 - 2.41 (m, 2H), 2.41 2.48 (m, 2H), 3.28 (s, 3H), 3.98 (s, 2H), 7.24 - 7.28 (m, 1H), 7.28 - 7.33 (m, 1H), 7.47 (dd, J=7.63, 2.14 Hz, 1H), 7.77 (t, J=7.78 Hz, 1H), 7.90 (d, J=7.93 Hz, 1H), 7.96 - 8.00 (m, 1H), 8.04 (s, 1H), 12.61 (br s, 1H). 0 EXAMPLE 250 4-((6-fluoro-3'-(pyrrolidin-1-ylcarbonyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared as free base according to the procedure for EXAMPLE 39, substituting 3-(pyrrolidine-1-carbonyl)phenylboronic acid for 3 5 pyridineboronic acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 432 (M+H)*. EXAMPLE 251 4-((6-fluoro-4'-(pyrrolidin-1-ylcarbonyl)-1,1'-biphenyl-3-yl)methyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one 10 The title compound was prepared as free base according to the procedure for EXAMPLE 39, substituting 4-(pyrrolidine-1-carbonyl)phenylboronic acid for 3 pyridineboronic acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 432 (M+H)*; H NMR (500 MHz, dimethylsulfoxide-d): 6 1.57 - 1.68 (m, 4H), 1.78 - 1.93 (m, 4H), 2.32 - 2.39 (m, 2H), 2.40 - 2.47 (m, 2H), 3.39 - 3.53 (m, 4H), 3.95 (s, 2H), 7.21 25 7.24 (m, 1H), 7.24 - 7.31 (m, 1H), 7.39 (dd, J=7.63, 1.86 Hz, 1H), 7.55 - 7.59 (m, 2H), 7.60 7.64 (m, 2H), 12.60 (br s, 1H). EXAMPLE 252 2'-fluoro-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-1,1'-biphenyl-3 carboxamide 30 The title compound was prepared as free base according to the procedure for EXAMPLE 39, substituting 3-carbamoylphenylboronic acid for 3-pyridineboronic acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 378 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.55 - 1.72 (m, 4H), 2.33 - 2.41 (m, 2H), 2.41 - 2.47 (m, 2H), 169 3.97 (s, 2H), 7.19 - 7.24 (m, 1H), 7.24 - 7.30 (m, 1H), 7.42 (dd, J=7.63, 2.14 Hz, 1H), 7.44 (s, 1H), 7.56 (t, J=7.78 Hz, 1H), 7.68 (d, J=7.63 Hz, 1H), 7.88 - 7.92 (m, 1H), 8.02 (s, 1H), 8.07 (s, 1H), 12.61 (s, 1H). EXAMPLE 253 5 2'-fluoro-N,N-dimethyl-5'-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)- 1,1' biphenyl-4-carboxamide The title compound was prepared as free base according to the procedure for EXAMPLE 39, substituting 4-(dimethylcarbamoyl)phenylboronic acid for 3-pyridineboronic acid, but eliminating the last HCl salt formation step. MS (DCI/NH 3 ) m/z 406 (M+H)*. 1 H 0 NMR (500 MHz, dimethylsulfoxide-d): 6 1.56 - 1.69 (m, 4H), 2.31 - 2.40 (m, 2H), 2.40 2.47 (m, 2H), 2.95 (s, 3H), 3.00 (s, 3H), 3.96 (s, 2H), 7.20 - 7.24 (m, 1H), 7.24 - 7.30 (m, 1H), 7.40 (dd, J=7.48, 1.98 Hz, 1H), 7.49 - 7.52 (m, 1H), 7.56 - 7.59 (m, 2H), 7.60 - 7.65 (m, 1H), 12.61 (br s, 1H). EXAMPLE 254 5 4-(3,3,3-trifluoro-2-phenylpropyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 254A 3-(1,1,1-trifluoro-3-phenylpropan-2-ylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 1,1,1-trifluoro-3-phenylpropan-2-one for 2-fluoro-5-formylbenzonitrile. MS '0 (DCI/NH 3 ) m/z 309 (M+H)*. EXAMPLE 254B 4-(3,3,3-trifluoro-2-phenylpropyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 254A for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 323 (M+H)*. 25 EXAMPLE 255 4-(2-phenylethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared as a side product according to the procedure for EXAMPLE 101, substituting EXAMPLE 222 for EXAMPLE 103. MS (DCI/NH 3 ) m/z 255 (M+H)*. 30 EXAMPLE 256 4-(2-(3-bromophenyl)propyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 256A 2-(3-bromophenyl)-N-methoxy-N-methylpropanamide 170 A solution of EXAMPLE 222A (3.5 g, 13.56 mmol) in anhydrous tetrahydrofuran (50 ml) was treated with IN sodium dicyanamide v solution in tetrahydrofuran (16 ml, 16.27 mmol) at - 78 0 C for 1 hour. lodomethane (3.85 g, 27.1 mmol) was added through a syringe, and the mixture was allowed to warm up to room temperature for 2 hours. The mixture was 5 concentrated, and the residue was partitioned between ethyl acetate and brine. The organic phase was concentrated, the residue was purified by flash column chromatography ( 30% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 273 (M+H)*. EXAMPLE 256B 2-(3-bromophenyl)propanal 0 The title compound was prepared according to the procedure for EXAMPLE 222B, substituting EXAMPLE 256A for EXAMPLE 222A. MS (DCI/NH 3 ) m/z 214 (M+H)*. EXAMPLE 256C 3-(2-(3-bromophenyl)propylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, 5 substituting 256B for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 334 (M+H)*. EXAMPLE 256D 4-(2-(3-bromophenyl)propyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 256C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 348 (M+H)*. 10 EXAMPLE 257 tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)piperazine-1-carboxylate EXAMPLE 257A 4-benzyl 1 -tert-butyl 2-(methoxy(methyl)carbamoyl)piperazine- 1,4-dicarboxylate The title compound was prepared according to the procedure for EXAMPLE 222A, 25 substituting 4-(benzyloxycarbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid for 2-(3-bromophenyl)acetic acid. MS (DCI/NH 3 ) m/z 408 (M+H)*. EXAMPLE 257B 4-benzyl 1 -tert-butyl 2-formylpiperazine- 1,4-dicarboxylate The title compound was prepared according to the procedure for EXAMPLE 222B, 30 substituting EXAMPLE 257A for EXAMPLE 222A. MS (DCI/NH 3 ) m/z 349 (M+H)+. EXAMPLE 257C 4-benzyl 1-tert-butyl 2-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H) ylidene)methyl)piperazine- 1,4-dicarboxylate 171 The title compound was prepared according to the procedure for EXAMPLE IC, substituting EXAMPLE 257B for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 469 (M+H)*. EXAMPLE 257D 5 4-benzyl 1 -tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)piperazine- 1,4 dicarboxylate The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 257C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 483 (M+H)*. EXAMPLE 257E 0 tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)piperazine-1-carboxylate A solution of EXAMPLE 257D ( 0.77 g, 1.6 mmol) in tetrahydrofuran (100 ml) was treated with 10% palladium on carbon (85 mg, 0.8 mmol) at room temperature under hydrogen (balloon) overnight. The catalyst was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography ( 0

-

15 % gradient of 5 methanol in CH 2 Cl 2 ) to provide the title compound. MS (DCI/NH 3 ) m/z 349 (M+H)*. EXAMPLE 258 4-benzyl 1 -tert-butyl 2-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -vl)methyl)piperazine- 1,4 dicarboxylate The title compound was prepared as described in EXAMPLE 257D. MS (DCI/NH 3 ) '0 m/z 483 (M+H)*. EXAMPLE 259 4-(2-(3-nitrophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 259A N-methoxy-N-methyl-2-(3-nitrophenyl)acetamide 25 The title compound was prepared according to the procedure for EXAMPLE 222A, substituting 3-nitrobenzoic acid for 2-(3-bromophenyl)acetic acid. MS (DCI/NH 3 ) m/z 225 (M+H)*. EXAMPLE 259B 2-(3-nitrophenyl)acetaldehyde 30 The title compound was prepared according to the procedure for EXAMPLE 222B, substituting EXAMPLE 259A for EXAMPLE 222A. EXAMPLE 259C 3-(2-(3-nitrophenyl)ethylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one 172 The title compound was prepared according to the procedure for EXAMPLE IC, substituting EXAMPLE 259B for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 286 (M+H)*. EXAMPLE 259D 5 4-(2-(3-nitrophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 259C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 300 (M+H)*. EXAMPLE 260 4-(2-(3-aminophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 0 A suspension of EXAMPLE 259 (110 mg, 0.17 mmol) in methanol (20 ml) was treated with Raney Nickel (20 mg) at room temperature under hydrogen (balloon) overnight. The solid material was filtered off, and the filtrate was concentrated to give the title compound. MS (DCI/NH 3 ) m/z 270 (M+H)*. EXAMPLE 261 5 4-(piperazin-2-ylmethyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one A solution of EXAMPLE 258 (35 mg, 0.1 mmol) in trifluoroacetic acid (5 ml) was stirred at room temperature for 1 hour, and was concentrated. The residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.10% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. '0 MS (DCI/NH 3 ) m/z 249 (M+H)*. EXAMPLE 262 4-(2-(3-(2-oxopyrrolidin-1-yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 260 (100 mg, 0.37 mmol) in methylene chloride (5 mL) was added 4-chlorobutyrlchloride (52.3 mg, 0.37 mmol) and triethylamine (0.12 mL, 0.45 25 mmol). The mixture was stirred at room temperature overnight, and was concentrated. The residue was dissolved in absolute ethanol (5 mL), and was treated with sodium ethoxide (0.2 mL, 21 wt% in ethanol) at room temperature for 16 hours. 1 mL of 2N HCl was added, and the mixture was concentrated. The residue was separated by HPLC (Zorbax@ C- 18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0. 1% trifluoroacetic 30 acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS

(DCI/NH

3 ) m/z 338 (M+H)*. EXAMPLE 263 N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)phenyl)-2-phenoxyacetamide 173 A solution of 2-phenoxyacetic acid (28 mg, 0.186 mmol) in anhydrous dichloromethane (3 ml) was treated with oxalyl chloride (35.3 mg, 0.186 mmol) and a drop of N,N-dimethylformamide at room temperature for 1 hour, and was concentrated. The residue was re-dissolved in anhydrous dichloromethane (5 ml). A suspension of EXAMPLE 260 (50 5 mg, 0.186 mmol) in anhydrous tetrahydrofuran (2 ml) was then added. The reaction mixture was stirred at room temperature overnight, and was concentrated. The residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 404 (M+H)*; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.60 0 1.70 (m, 4 H), 2.35 - 2.39 (m, 2 H), 2.42 - 2.50 (m, 2 H), 2.66 - 2.93 (m, 4 H), 4.68 (s, 2 H), 6.82 - 7.09 (m, 4 H), 7.23 (t, J=7.80 Hz, 1 H), 7.24 - 7.38 (m, 2 H), 7.40 - 7.60 (m, 2 H), 10.01 (s, 1 H) 12.54 (s, 1 H). EXAMPLE 264 4-(2-(6-fluoro-3'-(morpholin-4-ylcarbonyl)-1,1'-biphenyl-3-yl)ethyl)-5,6,7,8 5 tetrahydrophthalazin- 1 (2H)-one A microwave vial charged with EXAMPLE 223 (50 mg, 0.14 mmol), dichlorobis(triphenylphosphine)palladium (II) (10 mg, 0.014 mmol), 3-(morpholine-4 carbonyl)phenylboronic acid (40 mg, 0.17 mmol), a mixture of DME(7)/water(3) /ethanol(2) (3 ml), and sodium carbonate solution (2M, 0.1 ml) was heated in a CEM Explorer@ '0 microwave reactor (Matthews, NC) at 150 0 C for 15 minutes. After cooling, the reaction mixture was diluted with methanol (20 ml), and filtered. The filtrate was concentrated, and the residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound. MS (DCI/NH 3 ) m/z 462 (M+H)*; H NMR (300 MHz, dimethylsulfoxide-d 6 ): 6 25 1.60 - 1.67 (m, 4 H), 2.35 - 2.39 (m, 2 H), 2.44 - 2.50 (m, 2 H), 2.75 - 3.01 (m, 4 H), 3.44 3.73 (m, 8 H), 7.17 - 7.28 (m, 1 H), 7.27 - 7.34 (m, 1 H), 7.38 - 7.47 (m, 1 H), 7.50 - 7.67 (m, 4 H), 12.55 (s, 1 H). EXAMPLE 265 methyl 3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoate 30 The title compound was prepared according to the procedure for EXAMPLE 66, substituting EXAMPLE 222 for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 313 (M+H)*. EXAMPLE 266 methyl 3-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoate 174 The title compound was prepared according to the procedure for EXAMPLE 66, substituting EXAMPLE 256 for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 237 (M+H)*. EXAMPLE 267 4-(2-(6-fluoro-4'-(morpholin-4-ylcarbonyl)-1,1'-biphenyl-3-yl)ethyl)-5,6,7,8 5 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 264, substituting 4-(morpholine-4-carbonyl)phenylboronic acid for 3-(morpholine-4 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 462 (M+H)*. EXAMPLE 268 0 4-(2-(6-fluoro-2'-(pyrrolidin-1-ylcarbonyl)-1,1'-biphenyl-3-yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 264 substituting 2-(pyrrolidine-1-carbonyl)phenylboronic acid for 3-(morpholine-4 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 446 (M+H)*. 5 EXAMPLE 269 4-(2-(6-fluoro-3'-(pyrrolidin-1-ylcarbonyl)-1,1'-biphenyl-3-yl)ethyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 264, substituting 3-(pyrrolidine-1-carbonyl)phenylboronic acid for 3-(morpholine-4 '0 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 446 (M+H)+; H NMR (300 MHz, CDCl 3 ): 6 1.64 - 1.81 (m, 4 H), 1.83 - 2.03 (m, 4 H), 2.43 - 2.47 (m, 2 H), 2.56 - 2.59 (m, 2 H), 2.76 - 2.88 (m, 2 H), 2.93 - 3.06 (m, 2 H), 3.48 (t, J=6.54 Hz, 2 H), 3.67 (t, J=6.74 Hz, 2 H), 7.01 - 7.11 (m, 1 H), 7.11 - 7.21 (m, 1 H), 7.29 (dd, J=7.54, 2.38 Hz, 1 H), 7.39 - 7.54 (m, 2 H), 7.55 - 7.62 (m, 1 H), 7.69 (s, 1 H), 10.10 (s, 1 H). 25 EXAMPLE 270 N-cyclopropyl-2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting 3-(cyclopropylcarbamoyl)phenylboronic acid for 3-(morpholine-4 30 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 432 (M+H)+. EXAMPLE 271 N-(2-(dimethylamino)ethyl)-2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)- 1,1 '-biphenyl-3-carboxamide 175 The title compound was prepared according to the procedure for EXAMPLE 264, substituting 3-(2-(dimethylamino)ethylcarbamoyl)phenylboronic acid for 3-(morpholine-4 carbonyl)-phenylboronic acid. MS (DCI/NH 3 ) m/z 463 (M+H)*; H NMR (300 MHz, CDCl 3 ): 6 2.28 - 2.39 (m, 2 H), 2.35 (m, 3 H), 2.45 (s, 6 H), 2.60 - 2.69 (m, 2 H), 2.73 - 2.82 5 (m, 2 H), 2.87 (t, J=7.14 Hz, 2 H), 3.01 (t, J=7.14 Hz, 2 H), 3.54 - 3.64 (m, 1 H), 3.69 (q, J=5.29 Hz, 2 H), 6.95 - 7.10 (m, 1 H), 7.10 - 7.20 (m, 1 H), 7.35 - 7.53 (m, 2 H), 7.65 - 7.80 (m, 2 H), 7.79 - 7.88 (m, 1 H). EXAMPLE 272 2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 0 carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting 3-carbamoylphenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 392 (M+H)*; 1 H NMR (500 MHz, pyridine-ds): 6 1.54 (s, 4 H), 2.27 (s, 2 H), 2.70 (s, 2 H), 2.76 - 2.95 (m, 2 H), 2.98 - 3.21 (m, 2 H), 7.19 - 7.27 (m, 2 H), 5 7.31 (s, 1 H), 7.49 (d, J=7.02 Hz, 1 H), 7.82 (d, J=7.32 Hz, 1 H), 8.42 (d, J=7.63 Hz, 1 H), 8.47 (s, 1 H), 8.68 (s, 1 H), 9.02 (s, 1 H), 14.05 (s, 1 H). EXAMPLE 273 N-(2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 yl)methanesulfonamide 10 The title compound was prepared according to the procedure for EXAMPLE 264, substituting 3-(methylsulfonamido)phenylboronic acid for 3-(morpholine-4 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 442 (M+H)*; H NMR (300 MHz, CDCl 3 ): 6 2.31 - 2.48 (m, 4 H), 2.59 (m, 4 H), 2.77 - 2.96 (m, 4 H), 3.02 (t, J=7.80 Hz, 3 H), 6.92 - 7.03 (m, 1 H), 7.02 - 7.12 (m, 1 H), 7.10 - 7.22 (m, 2 H), 7.27 - 7.33 (m, 1 H), 7.32 25 7.47 (m, 2 H), 10.96 (s, 1 H). EXAMPLE 274 N-(2'-fluoro-5'-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 yl)acetamide The title compound was prepared according to the procedure for EXAMPLE 264, 30 substituting 3-acetamidophenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 406 (M+H)*; 1 H NMR (300 MHz, CDCl 3 ): 6 2.06 - 2.21 (m, 4 H), 2.25 (s, 3 H), 2.34 (m, 2 H), 2.58 (m, 2 H), 2.80 - 2.94 (m, 2 H), 2.92 - 3.06 (m, 2 H), 6.93 176 7.10 (m, 2 H), 7.10 - 7.19 (m, 1 H), 7.23 (d, J=4.36 Hz, 1 H), 7.27 - 7.33 (m, 1 H), 7.38 (t, J=7.73 Hz, 1 H), 7.67 - 7.76 (m, 1 H), 11.25 (s, 1 H). EXAMPLE 275 4-(2-(6-fluoro-3'-(morpholin-4-ylcarbonyl)-1,1'-biphenyl-3-yl)propyl)-5,6,7,8 5 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 264 substituting EXAMPLE 293 for EXAMPLE 223. MS (DCI/NH 3 ) m/z 476 (M+H)*. EXAMPLE 276 4-(2-(6-fluoro-3'-(pyrrolidin-1-ylcarbonyl)-1,1'-biphenyl-3-yl)propyl)-5,6,7,8 0 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 264 substituting EXAMPLE 293 for EXAMPLE 223, and 3-(pyrrolidine-1 carbonyl)phenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS

(DCI/NH

3 ) m/z 460 (M+H)*; 1 H NMR (300 MHz, CDCl 3 ): 6 1.36 (d, J=6.74 Hz, 3 H), 1.61 5 1.78 (m, 4 H), 1.76 - 2.06 (m, 4 H), 2.26 - 2.45 (m, 2 H), 2.49 - 2.67 (m, 2 H), 2.84 (m, 2 H), 3.21 - 3.36 (m, 1 H), 3.40 - 3.57 (m, 2 H), 3.59 - 3.83 (m, 2 H), 7.13 - 7.23 (m, 1 H), 7.36 (t, J=7.93 Hz, 1 H), 7.40 - 7.51 (m, 3 H), 7.55 - 7.64 (m, 1 H), 7.73 (s, 1 H) 9.98 (s, 1 H). EXAMPLE 277 N-cyclopropyl-2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl) '0 1,1 '-biphenyl-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 293 for EXAMPLE 223, and 3 (cyclopropylcarbamoyl)phenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 446 (M+H)*. 25 EXAMPLE 278 4-(3-amino-4-chlorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2, substituting 4-chloro-3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS (DCI/NH 3 ) m/z 290 (M+H)*. 30 EXAMPLE 279 4-(3-amino-4-methoxybenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 177 The title compound was prepared according to the procedure for EXAMPLE 2, substituting 4-methoxy-3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS

(DCI/NH

3 ) m/z 286 (M+H)*. EXAMPLE 280 5 4-(3-amino-4-hydroxybenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2, substituting 4-hydroxy-3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS

(DCI/NH

3 ) m/z 272 (M+H)*. EXAMPLE 281 0 4-(3 -amino-4-methylbenzyl)-5,6,7,8-tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 2, substituting 4-methyl-3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS (DCI/NH 3 ) m/z 270 (M+H)*. EXAMPLE 282 5 N-(2-(dimethylamino)ethyl)-3'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)ethyl)- 1,1 '-biphenyl-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 256 for EXAMPLE 223, and 3-(2 (dimethylamino)ethylcarbamoyl)phenylboronic acid for 3-(morpholine-4 '0 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 459 (M+H)*. EXAMPLE 283 3'-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, 25 substituting EXAMPLE 256 for EXAMPLE 223, and 3-carbamoylphenylboronic acid for 3 (morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 388 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.40 (d, J=7.14 Hz, 3 H), 1.53 - 1.81 (m, 4 H), 2.25 - 2.59 (m, 4 H), 2.91 (d, J=7.14 Hz, 2 H), 3.31 - 3.41 (m, 1 H), 7.23 (d, J=7.54 Hz, 1 H), 7.36 (t, J=7.93 Hz, 1 H), 7.42 - 7.51 (m, 2 H), 7.50 - 7.59 (m, 1 H), 7.73 (d, J=7.93 Hz, 1 H), 7.79 - 7.91 (m, 1 H), 30 8.09 (s, 1 H). EXAMPLE 284 N-(3'-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 yl)acetamide 178 The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 256 for EXAMPLE 223, and 3-acetamidophenylboronic acid for 3 (morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 402 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.40 (d, J=7.12 Hz, 3 H), 1.50 - 1.78 (m, 4 H), 2.16 (s, 3 H), 2.36 5 2.53 (m, 4 H), 2.83 (m, 1 H), 2.88 (d, J=7.46 Hz, 2 H), 7.16 - 7.23 (m, 1 H), 7.22 - 7.29 (m, 1 H), 7.29 - 7.36 (m, 2 H), 7.36 - 7.45 (m, 2 H), 7.47 - 7.67 (m, 1 H), 7.72 (t, J=1.86 Hz, 1 H). EXAMPLE 285 3'-(1-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3-carboxamide EXAMPLE 285A 0 1-bromo-3-(1-bromoethyl)benzene A solution of 3-bromoethyl benzene (2 g, 11 mmol), N-bromosuccinimide (91.9 g, 11 mmol) and azobisisobutyronitrile (10 mg, 0.06 mmol) in chloroform (30 ml) was stirred at 65 0 C under nitrogen for 18 hours. After cooling, the reaction mixture was concentrated, and the residue was partitioned between ethyl acetate and brine. The organic layer was washed with 5 brine, and was concentrated. The residue was separated by flash chromatography on silica gel (10% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 262 (M+H)*. EXAMPLE 285B (1 -(3 -bromophenyl)ethyl)triphenylphosphonium bromide 10 A solution of EXAMPLE 285A (1.0 g, 3.8 mmol) and triphenylphosphine (1.1 g, 4.2 mmol) in toluene (15 ml) was heated at 120 0 C under nitrogen for three days. After cooling to room temperature, the solid material was collected by filtration, washed with toluene, and dried to provide the title compound. EXAMPLE 285C 25 3-(1-(3-bromophenyl)ethylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one A suspension of EXAMPLE 285B (1.88g, 3.4 mmol) in tetrahydrofuran (100 ml) was treated with potassium t-butoxide (IN solution in tetrahydrofuran, 3.4 ml, 3.4 mmol) at -78 0 C for 1 hour, and was allowed to warm up to 0 0 C over 30 minutes. A solution of 4,5,6,7 tetrahydroisobenzofuran-1,3-dione (0.54 g, 3.4 mmol) in tetrahydrofuran (10 ml) was then 30 added. The reaction mixture was warmed up to room temperature, and stirred at room temperature for additional 4 hours. After quenching with water, the reaction mixture was partitioned between ethyl acetate and brine. The organic phase was washed with brine, and 179 concentrated. The residue was separated by flash chromatography (20% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 320 (M+H)*. EXAMPLE 285D 4-(1-(3-bromophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 285C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 334 (M+H)*. EXAMPLE 285E 3'-(1-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, 0 substituting EXAMPLE 285D for EXAMPLE 223, and 3-carbamoylphenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 374 (M+H)*; 1 H NMR (300 MHz, CD 3 0D): 6 1.59 (d, J=7.12 Hz, 3 H), 1.61 - 1.81 (m, 4 H), 2.10 - 2.22 (m, 1H), 2.39 - 2.55 (m, 2 H), 2.61 - 2.73 (m, 1H), 4.32 (q, J=6.78 Hz, 1 H), 7.08 - 7.21 (m, 1 H), 7.35 - 7.43 (m, 1 H), 7.48 - 7.59 (m, 3 H), 7.75 (d, J=7.80 Hz, 1 H), 7.80 - 7.87 (m, 1 H), 8.06 5 8.11 (m, 1 H). EXAMPLE 286 N-(3'-(1-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3-yl)acetamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 285D for EXAMPLE 223, and 3-acetamidophenylboronic acid for 3 '0 (morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 388 (M+H)'; 1 H NMR (300 MHz, CD 3 0D): 6 1.58 (d, J=7.12 Hz, 3 H), 1.60 - 1.82 (m, 4 H), 2.14 (s, 3 H), 2.10 2.23 (m, 1H), 2.47 - 2.55 (m, 2 H), 2.60 - 2.73 (m, 1H), 4.30 (q, J=6.78 Hz, 1 H), 7.15 (d, J=7.46 Hz, 1 H), 7.23 - 7.30 (m, 1 H), 7.31 - 7.40 (m, 2 H), 7.41 - 7.47 (m, 1 H), 7.47 - 7.56 (m, 1 H), 7.56 - 7.69 (m, 1 H), 7.77 (t, J=1.86 Hz, 1 H). 25 EXAMPLE 287 N-(2-(dimethylamino)ethyl)-3'-(1 -(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-carboxamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 285D for EXAMPLE 223, and 3-(2 30 (dimethylamino)ethylcarbamoyl)phenylboronic acid for 3-(morpholine-4 carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 445 (M+H)*. EXAMPLE 288 3-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)benzoic acid 180 A solution of EXAMPLE 266 (50 mg, 0.16 mmol) in tetrahydrofuran (10 ml) was treated with a solution of LiOH-H 2 0 (100 mg, 4 mmol) in water (4 ml) at 50 0 C overnight. The mixture was concentrated, and the residue was purified by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic 5 acid/CH 3

CN/H

2 0) to provide the title compound. MS (DCI/NH 3 ) m/z 313 (M+H)*. EXAMPLE 289 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-(4 methoxyphenyl)-4-oxobutanamide To a solution of 4-(4-methoxyphenyl)-4-oxobutanoic acid (29 mg, 0.14 mmol) in 0 dioxane (1.5 mL) was added 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU) (42 mg) and N,N'-diisopropylethylamine (32 [tL). The mixture was stirred at room temperature for 15 minutes, and EXAMPLE 2 (25 mg, 0.091 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours, and was concentrated. The crude was separated by HPLC (Zorbax@ C- 18 ODS packing 5 material [Agilent Technologies, Santa Clara, CA], 0. 1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS (DCI/NH 3 ) m/z 464 (M+H)'; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.53 - 1.66 (m, 4H), 2.29 - 2.40 (m, 4H), 2.74 (t, J=6.41 Hz, 2H), 3.25 (t, J=6.56 Hz, 2H), 3.84 (s, 2H), 3.85 (s, 3H), 6.88 - 6.96 (m, 1H), 7.05 (d, J=8.85 Hz, 2H), 7.12 - 7.20 (m, 1H), 7.74 (d, J=6.41 Hz, 1H), 7.97 (d, J=9.15 Hz, 2H), '0 9.75 (br s, 1H), 12.60 (br s, 1H). EXAMPLE 290 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3,4-dimethyl 1H-pyrrole-2,5-dione To a solution of EXAMPLE 2 (100 mg, 0.37 mmol) in acetic acid (8 mL) was added 25 3,4-dimethylfuran-2,5-dione (46 mg, 0.37 mmol). The reaction mixture was heated at 80 0 C for 16 hours, and concentrated. The residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0. 1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS

(DCI/NH

3 ) m/z 382 (M+H)*; 1 H NMR (500 MHz, dimethylsulfoxide-d): 6 1.56 - 1.68 (m, 30 4H), 1.98 (s, 6H), 2.30 - 2.43 (m, 4H), 3.93 (s, 2H), 7.18 (dd, J=7.02, 1.53 Hz, 1H), 7.31 7.35 (m, 2H), 12.63 (br s, 1H). EXAMPLE 291 181 3-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 azabicyclo(3.1.0)hexane-2,4-dione To a suspension of EXAMPLE 2 (210 mg, 0.77 mmol) in acetonitrile (8 mL) was added 3-oxabicyclo(3.1.0)hexane-2,4-dione (95 mg, 0.85 mmol) and stirred at 80 0 C for 16 5 hours. The reaction mixture was cooled and concentrated on a rotary evaporator. The residual solid was dissolved in dioxane (4 mL), and treated with O-(benzotriazol-1-yl, N, N, N', N'-tetramethyluronium hexafluorophosphate (380 mg, 0.99 mmol) and N,N' diisopropylethylamine (0.3 mL, 1.69 mmol) at room temperature for an additional 16 hours. The reaction mixture was concentrated, and separated by HPLC (Zorbax@ C-18 ODS 0 packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as a trifluoroacetic acid salt. MS

(DCI/NH

3 ) m/z 368 (M+H)*; 1 H NMR (400 MHz, dimethylsulfoxide-d): 6 1.57 - 1.64 (m, 4H), 1.66 - 1.72 (m, 2H), 2.32 - 2.41 (m, 4H), 2.75 (dd, J=7.82, 3.22 Hz, 2H), 3.91 (s, 1H), 7.16 (d, J=7.36 Hz, 1H), 7.27 - 7.29 (m, 1H), 7.29 - 7.32 (m, 1H), 12.61 (br s, 1H). 5 EXAMPLE 292 4-((4-(phenoxyacetyl)piperazin-2-yl)methyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one A solution of EXAMPLE 258 (138 mg, 0.29 mmol) in methylene chloride (10 ml) was treated with trifluoroacetic acid ( 2 ml) at 40 0 C for 2 hours, and concentrated. The residue was purified by HPLC (Zorbax@ C- 18 ODS packing material [Agilent Technologies, '0 Santa Clara, CA], 0. 1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as TFA salt. MS (DCI/NH 3 ) m/z 383 (M+H)*. EXAMPLE 293 4-(2-(3-bromo-4-fluorophenyl)propyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 293A 25 2-(3-bromo-4-fluorophenyl)-N-methoxy-N-methylacetamide The title compound was prepared according to the procedure for EXAMPLE 222A, substituting 2-(3-bromo-4-fluorophenyl)acetic acid for 2-(3-bromophenyl)acetic acid. MS

(DCI/NH

3 ) m/z 276 (M+H)*. EXAMPLE 293B 30 2-(3-bromo-4-fluorophenyl)-N-methoxy-N-methylpropanamide The title compound was prepared according to the procedure for EXAMPLE 256A, substituting EXAMPLE 293A for EXAMPLE 222A. MS (DCI/NH 3 ) m/z 291 (M+H)*. EXAMPLE 293C 182 2-(3-bromo-4-fluorophenyl)propanal The title compound was prepared according to the procedure for EXAMPLE 256B, substituting EXAMPLE 293B for EXAMPLE 256A. MS (DCI/NH 3 ) m/z 232 (M+H)*. EXAMPLE 293D 5 3-(2-(3-bromo-4-fluorophenyl)propylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE IC, substituting 293C for 2-fluoro-5-formylbenzonitrile. MS (DCI/NH 3 ) m/z 352 (M+H)*. EXAMPLE 293E 4-(2-(3-bromo-4-fluorophenyl)propyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 0 The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 293D for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 366 (M+H)*. EXAMPLE 294 4-oxo-N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)phenyl)-4 phenylbutanamide 5 A mixture of 4-oxo-4-phenylbutanoic acid (50 mg, 0.28 mmol), 2-(3H (1,2,3)triazolo(4,5-b)pyridin-3-yl)-1,1,3,3-tetramethylisouroniumhexafluorophosphate (V) (106 mg, 0.28 mmol) and Hunig's base (120 mg, 0.9 mmol) in anhydrous N,N dimethylformamide (0.5 ml) was stirred at room temperature for 10 minutes, and EXAMPLE 260 (50 mg, 0.18 mmol) was added in one portion. The reaction mixture was stirred at room '0 temperature for another 1 hour, and was diluted with 5 mL of methanol. The solid material was collected by filtration, washed with methanol, and dried to provide the title compound. MS (DCI/NH 3 ) m/z 430 (M+H)*. H NMR (300 MHz, dimethylsulfoxide-d): 6 1.54 - 1.77 (m, 4 H), 2.30 - 2.42 (m, 2 H), 2.42 - 2.49 (m, 2 H), 2.65 - 2.79 (m, 4 H), 2.79 - 2.89 (m, 2 H), 3.30 - 3.38 (m, 2 H), 6.90 (d, J=7.80 Hz, 1 H), 7.19 (t, J=7.80 Hz, 1 H), 7.38 - 7.49 (m, 2 25 H), 7.54 (t, J=7.46 Hz, 2 H), 7.61 - 7.69 (m, 1 H), 7.99 (t, J=6.61 Hz, 2 H), 9.96 (s, 1 H), 12.52 (s, 1 H). EXAMPLE 295 2'-fluoro-5'-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1'-biphenyl-3 carboxamide 30 The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 293 for EXAMPLE 223, and 3-carbamoylphenylboronic acid for 3 (morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 406 (M+H)*. EXAMPLE 296 183 N-(2'-fluoro-5'-(1 -methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)- 1,1' biphenyl-3-yl)acetamide The title compound was prepared according to the procedure for EXAMPLE 264, substituting EXAMPLE 293 for EXAMPLE 223, and 3-acetamidophenylboronic acid for 3 5 (morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 420 (M+H)*. EXAMPLE 297 N-((2'-fluoro-5'-(1-methyl-2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)ethyl)-1,1' biphenyl-3-yl)methyl)methanesulfonamide The title compound was prepared according to the procedure for EXAMPLE 264, 0 substituting EXAMPLE 293 for EXAMPLE 223, and 3 (methylsulfonamidomethyl)phenylboronic acid for 3-(morpholine-4-carbonyl)phenylboronic acid. MS (DCI/NH 3 ) m/z 470 (M+H)+. EXAMPLE 298 2-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)hexahydro-1H 5 isoindole-1,3(2H)-dione The title compound was prepared according to the procedure for EXAMPLE 291, substituting hexahydroisobenzofuran-1,3-dione for oxabicyclo(3.1.0)hexane-2,4-dione. MS

(DCI/NH

3 ) m/z 410 (M+H)+; 1 HNMR (300 MHz, dimethylsulfoxide-d): 6 1.31 - 1.53 (m, 5H), 1.57 - 1.68 (m, 4H), 1.66 - 1.78 (m, 3H), 1.76 - 1.92 (m, 2H), 2.29 - 2.43 (m, 4H), 3.93 '0 (s, 2H), 7.12 - 7.17 (m, 1H), 7.28 - 7.33 (m, 1H), 7.33 - 7.37 (m, 1H), 12.63 (br s, 1H). EXAMPLE 299 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3,3 dimethylpyrrolidine-2,5-dione The title compound was prepared according to the procedure for EXAMPLE 291, 25 substituting 3,3-dimethyldihydrofuran-2,5-dione for oxabicyclo(3.1.0)hexane-2,4-dione. MS

(DCI/NH

3 ) m/z 384 (M+H)+; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.31 (s, 6H), 1.54 - 1.70 (m, 4H), 2.30 - 2.44 (m, 4H), 2.78 (s, 2H), 3.94 (s, 2H), 7.19 (d, J=7.46 Hz, 1H), 7.30 7.33 (m, 1H), 7.35 (s, 1H), 12.62 (br s, 1H). EXAMPLE 300 30 4-(4-fluoro-3-(2-methyl-5-oxopyrrolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H) one EXAMPLE 300A 4-fluoro-3-(2-methyl-5-oxopyrrolidin-1-yl)benzaldehyde 184 A 100 mL round bottom flask was charged with 3-bromo-4-fluorobenzaldehyde (1.0 g, 4.93 mmol), tris(dibenzylideneacetone)dipalladium(0)(450 mg, 0.493 mmol), Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene) (428 mg, 0.739 mmol), and cesium carbonate (2.4 g, 7.39 mmol). The mixture was purged with nitrogen, and anhydrous dioxane 5 (15 mL), and 5-methylpyrrolidinone (0.586 g, 5.91 mmol) were added. The reaction mixture was purged with nitrogen again, and heated at 100 0 C for 20 hours. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and brine. The organic phase was dried over MgSO 4 , filtered and concentrated. The residue was separated by flash chromatography (50% ethyl acetate in hexane) to provide the title compound. MS 0 (DCI/NH 3 ) m/z 222 (M+H)*. EXAMPLE 300B 4-(4-fluoro-3-(2-methyl-5-oxopyrrolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H) one A solution of EXAMPLE 1B (486 mg, 1.16 mmol), EXAMPLE 300A (265 mg) and 5 triethylamine (0.16 mL) in dichloromethane (8 mL) was stirred at room temperature for 16 hours, and concentrated. The residue was dissolved in ethanol (5 mL) and treated with hydrazine monohydrate (0.11 mL) at 80 0 C for 2 hours. The mixture was allowed to cool and the precipitated solid was filtered and dried to provide the title compound. MS (DCI/NH 3 ) m/z 356 (M+H)*; 1 H NMR (400 MHz, dimethylsulfoxide-d): 6 1.02 (d, J=6.14 Hz, 3H), 1.57 '0 - 1.63 (m, 4H), 1.64 - 1.72 (m, 1H), 2.27 - 2.34 (m, 1H), 2.34 - 2.40 (m, 4H), 2.41 - 2.46 (m, 2H), 3.90 (s, 2H), 4.08 (q, J=6.44 Hz, 1H), 7.10 - 7.14 (m, 1H), 7.14 - 7.18 (m, 1H), 7.20 7.27 (m, 1H), 12.61 (s, 1H). EXAMPLE 301 4-(4-fluoro-3-(2-oxo-1,3-oxazolidin-3-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 25 EXAMPLE 301A 4-fluoro-3-(2-oxooxazolidin-3-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting oxazolidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 210 (M+H)*. EXAMPLE 301B 30 4-(4-fluoro-3-(2-oxo-1,3-oxazolidin-3-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 301A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 344 (M+H)'; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.55 - 1.75 (m, 4H), 2.30 - 2.45 (m, 4H), 3.90 (s, 185 2H), 3.98 (t, J=7.93 Hz, 2H), 4.45 (dd, J=8.72, 7.14 Hz, 2H), 7.11 - 7.17 (m, 1H), 7.25 (dd, J=10.91, 8.53 Hz, 1H), 7.36 (dd, J=7.54, 2.38 Hz, 1H), 12.61 (br s, 1H). EXAMPLE 302 4-(4-fluoro-3-(2-oxoazepan-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 EXAMPLE 302A 4-fluoro-3-(2-oxoazepan-1-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting azepan-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 236 (M+H)*. EXAMPLE 302B 0 4-(4-fluoro-3-(2-oxoazepan-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 302A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 370 (M+H)'; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.54 - 1.65 (m, 4H), 1.65 - 1.80 (m, 6H), 2.32 2.45 (m, 4H), 2.54 - 2.63 (m, 2H), 3.57 - 3.72 (m, 2H), 3.88 (s, 2H), 7.04 - 7.12 (m, 2H), 7.13 5 - 7.22 (m, 1H), 12.61 (br s, 1H). EXAMPLE 303 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)piperidine-2,6 dione The title compound was prepared according to the procedure for EXAMPLE 291, '0 substituting dihydro-2H-pyran-2,6(3H)-dione for oxabicyclo(3. 1.0)hexane-2,4-dione. MS

(DCI/NH

3 ) m/z 370 (M+H)*; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.53 - 1.69 (m, 4H), 1.84 - 1.97 (m, 1H), 1.98 - 2.11 (m, 1H), 2.29 - 2.42 (m, 4H), 2.75 (t, J=6.44 Hz, 4H), 3.90 (s, 2H), 7.04 (d, J=7.80 Hz, 1H), 7.24 (s, 1H), 7.26 (d, J=1.36 Hz, 1H), 12.63 (s, 1H). EXAMPLE 304 25 4-(4-fluoro-3-(2-oxoimidazolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 304A 4-fluoro-3-(2-oxoimidazolidin-1-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting imidazolidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 209 (M+H) . 30 EXAMPLE 304B 4-(4-fluoro-3-(2-oxoimidazolidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 304A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 343 (M+H)'; 1 H 186 NMR (300 MHz, dimethylsulfoxide-d): 6 1.55 - 1.69 (m, 4H), 2.31 - 2.44 (m, 4H), 3.39 (t, J=7.97 Hz, 2H), 3.75 - 3.83 (m, 2H), 3.86 (s, 2H), 6.86 (br s, 1H), 6.94 - 7.03 (m, 1H), 7.16 (dd, J=11.19, 8.48 Hz, 1H), 7.31 (dd, J=7.63, 2.20 Hz, 1H), 12.61 (br s, 1H). EXAMPLE 305 5 4-(3-(1,1-dioxidoisothiazolidin-2-yl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 2 (150 mg, 0.55 mmol) in dichloromethane (5 mL) was added 3-chloropropane-1-sulfonyl chloride (97 mg, 0.55 mmol), and the mixture stirred for 16 hours. The reaction mixture was concentrated, and the residual solid was dissolved in dioxane (3 mL). Sodium ethoxide (0.14 mL, 21 wt% in ethyl alcohol) was then added, and 0 the solution was heated at 80 0 C for 16 hours. After cooling, the reaction mixture was concentrated. The residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0.1% trifluoroacetic acid/CH 3

CN/H

2 0) to provide the title compound as free base. MS (DCI/NH 3 ) m/z 378 (M+H)*; H NMR (300 MHz, dimethylsulfoxide-d): 6 1.56 - 1.70 (m, 4H), 2.33 - 2.47 (m, 6H), 3.40 (t, J=7.29 Hz, 2H), 5 3.72 (t, J=6.44 Hz, 2H), 3.90 (s, 2H), 7.09 - 7.16 (m, 1H), 7.23 (d, J=8.48 Hz, 1H), 7.25 7.28 (m, 1H), 12.61 (br s, 1H). EXAMPLE 306 4-(4-fluoro-3-(2-oxoazetidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 306A 10 4-fluoro-3-(2-oxoazetidin-1-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting azetidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 194 (M+H)*. EXAMPLE 306B 4-(4-fluoro-3-(2-oxoazetidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 25 The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 306A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 328 (M+H)'. 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.55 - 1.68 (m, 4H), 2.31 - 2.43 (m, 4H), 3.11 (t, J=4.58 Hz, 2H), 3.82 (q, J=4.41 Hz, 2H), 3.86 (s, 2H), 6.86 - 6.94 (m, 1H), 7.18 (dd, J=1 1.87, 8.48 Hz, 1H), 7.74 (dd, J=7.63, 2.20 Hz, 1H), 12.60 (br s, 1H). 30 EXAMPLE 307 4-(4-fluoro-3-(2-oxopiperidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 307A 187 4-fluoro-3-(2-oxopiperidin- 1 -yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting piperidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 222 (M+H)*. EXAMPLE 307B 5 4-(4-fluoro-3-(2-oxopiperidin-1-yl)benzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 307A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 356 (M+H)'; 1 H NMR (300 MHz, dimethylsulfoxide-d): 6 1.54 - 1.67 (m, 4H), 1.77 - 1.93 (m, 4H), 2.31 2.44 (m, 6H), 3.44 - 3.53 (m, 2H), 3.88 (s, 2H), 7.10 - 7.14 (m, 1H), 7.15 (d, J=6.35 Hz, 1H), 0 7.17 - 7.23 (m, 1H), 12.62 (s, 1H). EXAMPLE 308 N-(3-furylmethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide EXAMPLE 308A methyl 3-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H)-ylidene)methyl)benzoate 5 A solution of EXAMPLE lB (25.8 g, 61.5 mmol), methyl-3-formylbenzoate (10.01 g, 61.0 mmol), and triethylamine (8.7 mL, 62.4 mmol) in dichloromethane (125 mL) was stirred at room temperature for 16 hours, and concentrated. The residue was stirred with a mixture of ethyl acetate and water. The precipitated solid was filtered, washed with water, and dried to provide the title compound. MS (DCI/NH 3 ) m/z 285 (M+H)*. 10 EXAMPLE 308B 3-((3-oxo-4,5,6,7-tetrahydroisobenzofuran-1(3H)-ylidene)methyl)benzoic acid A solution of EXAMPLE 308A (9.9 g, 35 mmol) in 1:1 mixture of tetrahydrofuran/water (100 mL) was treated with lithium hydroxide monohydrate (2.93 g, 70 mmol) at room temperature for 16 hours. Ethyl acetate was added (100 mL) and the mixture 25 washed with 2M HCl (100 mL). The combined organics were concentrated and dried under vacuum to provide the title compound. MS (DCI/NH 3 ) m/z 271 (M+H)*. EXAMPLE 308C 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoic acid A solution of EXAMPLE 308B (9.0 g, 33.33 mmol) in absolute ethanol (120 mL) was 30 heated with hydrazine monohydrate (3.3 mL, 66.66 mmol) at 80 0 C for 16 hours. After cooling to room temperature, the precipitated solid was filtered, and dried to provide the title compound. MS (DCI/NH 3 ) m/z 285 (M+H)*. EXAMPLE 308D 188 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzoyl chloride A solution of EXAMPLE 308C (2.73 g, 9.6 mmol) in anhydrous tetrahydrofuran (30 mL) was treated with oxalyl chloride (1.3 mL, 14.4 mmol) and a couple of drops of N,N dimethylformamide at room temperature for 10 minutes and at 50 0 C for 1 hour. The reaction 5 mixture was concentrated and dried to provide the title compound. MS (DCI/NH 3 ) m/z 303 (M+H)*. EXAMPLE 308E N-(3-furylmethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)benzamide A solution of EXAMPLE 308D (19 mg, 0.06mmol), furan-3-ylmethanamine (0.07 0 mmol) and triethylamine (14.6 mg, 0.14 mmol) in tetrahydrofuran (1.0 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated. The residue was dissolved in 1:1 mixture of dimethylsulfoxide/methanol and purified by HPLC (Waters Sunfire@ C-8 analytical column [Milford, MA]/0.1% trifluoroacetic acid/water/100%

CH

3 CN) to provide the title compound. MS (DCI/NH 3 ) m/z 363 (M+H)*; H NMR (500 5 MHz, D 2 0/dimethylsulfoxide-d): 6 1.54 - 1.69 (m, 4H), 2.32 - 2.45 (m, 4H), 3.96 (s, 2H), 4.29 (s, 2H), 6.41 - 6.49 (m, 1H), 7.32 - 7.37 (m, 1H), 7.41 (t, J=7.63 Hz, 1H), 7.52 - 7.60 (m, 2H), 7.64 - 7.72 (m, 2H). EXAMPLE 309 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(thien-2-ylmethyl)benzamide 10 The title compound was prepared according to the procedure for EXAMPLE 308, substituting thiophen-2-ylmethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 380 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.70 (m, 4H), 2.32 - 2.43 (m, 4H), 3.97 (s, 2H), 4.61 (s, 2H), 6.97 (dd, J=5.03, 3.51 Hz, 1H), 7.02 (d, J=2.44 Hz, 1H), 7.34 - 7.39 (m, 2H), 7.42 (t, J=7.63 Hz, 1H), 7.67 (s, 1H), 7.70 (d, J=7.93 Hz, 1H). 25 EXAMPLE 310 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(thien-3-ylmethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting thiophen-3-ylmethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 380 (M+H)*. 30 EXAMPLE 311 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(pyridin-3-ylmethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting pyridin-3-ylmethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 375 189 (M+H)*; 'H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.53 - 1.70 (m, 4H), 2.31 - 2.45 (m, 4H), 3.98 (s, 2H), 4.61 (s, 2H), 7.37 - 7.41 (m, 1H), 7.45 (t, J=7.63 Hz, 1H), 7.69 (s, 1H), 7.74 (d, J=7.63 Hz, 1H), 7.91 (dd, J=7.93, 5.49 Hz, 1H), 8.37 (d, J=7.93 Hz, 1H), 8.72 (d, J=5.19 Hz, 1H), 8.78 (s, 1H). 5 EXAMPLE 312 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(pyridin-4-ylmethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting pyridin-4-ylmethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 375 (M+H)*. 0 EXAMPLE 313 N-(2-(dimethylamino)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting N,N -dimethylethane-1,2-diamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) 5 m/z 355 (M+H)*; 1 H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.66 (m, 4H), 2.33 - 2.44 (m, 4H), 2.84 (s, 6H), 3.26 (t, J=5.95 Hz, 2H), 3.60 (t, J=5.95 Hz, 2H), 3.98 (s, 2H), 7.38 - 7.41 (m, 1H), 7.45 (t, J=7.63 Hz, 1H), 7.67 (s, 1H), 7.71 (d, J=7.93 Hz, 1H). EXAMPLE 314 N-(3-(dimethylamino)propyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 10 yl)methyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting N,N -dimethylpropane-1,3-diamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 369 (M+H)*. EXAMPLE 315 25 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(3-pyrrolidin-1 ylpropyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-(pyrrolidin-1-yl)propan-1-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 395 (M+H)*. 30 EXAMPLE 316 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-(3-piperidin-1 ylpropyl)benzamide 190 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-(piperidin-1-yl)propan-1-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 409 (M+H)*. EXAMPLE 317 5 N-(3-morpholin-4-ylpropyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-morpholinopropan-1-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 411 (M+H)*; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.56 - 1.68 (m, 4H), 1.87 0 1.97 (m, 2H), 2.31 - 2.45 (m, 4H), 3.08 (t, J=12.05 Hz, 2H), 3.11 - 3.17 (m, 2H), 3.33 (t, J=6.71 Hz, 2H), 3.42 (d, J=12.51 Hz, 2H), 3.65 (t, J=12.05 Hz, 2H), 3.96 - 4.02 (m, 2H), 3.97 (s, 2H), 7.35 - 7.39 (m, 1H), 7.43 (t, J=7.63 Hz, 1H), 7.65 (s, 1H), 7.69 (d, J=7.93 Hz, 1H). EXAMPLE 318 5 N-(2-(1H-indol-3-yl)ethyl)-3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(1H-indol-3-yl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 427 (M+H)+. 10 EXAMPLE 319 3-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)-N-1,3-thiazol-2-ylbenzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting thiazol-2-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 367 (M+H)+; H NMR (500 MHz, D 2 0/dimethylsulfoxide-d): 6 1.59 - 1.68 (m, 4H), 2.35 - 2.46 (m, 4H), 25 4.01 (s, 2H), 7.28 (d, J=3.66 Hz, 1H), 7.45 - 7.48 (m, 1H), 7.50 (t, J=7.48 Hz, 1H), 7.56 (d, J=3.66 Hz, 1H), 7.87 (s, 1H), 7.93 (d, J=7.63 Hz, 1H). EXAMPLE 320 benzyl 2-oxo-2-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)ethyl)phenylamino)ethylcarbamate 30 The title compound was prepared according to the procedure for EXAMPLE 294, substituting 2-(benzyloxycarbonylamino)acetic acid for 4-oxo-4-phenylbutanoic acid. MS

(DCI/NH

3 ) m/z 461 (M+H)+. EXAMPLE 321 191 4-oxo-N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)ethyl)phenyl)-4-(4 phenoxyphenyl)butanamide The title compound was prepared according to the procedure for EXAMPLE 294, substituting 4-oxo-4-(4-phenoxyphenyl)butanoic acid for 4-oxo-4-phenylbutanoic acid. MS 5 (DCI/NH 3 ) m/z 522 (M+H)*. EXAMPLE 322 benzyl 3-[({3-[2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)ethyl]phenyl} amino)carbonyl]piperidine- 1 -carboxylate The title compound was prepared according to the procedure for EXAMPLE 294, 0 substituting 1-(benzyloxycarbonyl)piperidine-3-carboxylic acid for 4-oxo-4-phenylbutanoic acid. MS (DCI/NH 3 ) m/z 515 (M+H)+. EXAMPLE 323 2-(4-methylphenoxy)-N-{3-[2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)ethyl]phenyl} acetamide 5 The title compound was prepared according to the procedure for EXAMPLE 294, substituting 2-(p-tolyloxy)acetic acid for 4-oxo-4-phenylbutanoic acid. MS (DCI/NH 3 ) m/z 418 (M+H)+. EXAMPLE 324 2-(4-methoxyphenoxy)-N-(3-(2-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 10 yl)ethyl)phenyl)acetamide The title compound was prepared according to the procedure for EXAMPLE 294, substituting 2-(4-methoxyphenoxy)acetic acid for 4-oxo-4-phenylbutanoic acid. MS

(DCI/NH

3 ) m/z 434 (M+H)+. EXAMPLE 325 25 4-[4-fluoro-3-(3-methyl-2-oxoimidazolidin-1-yl)benzyl]-5,6,7,8-tetrahydrophthalazin-1(2H) one EXAMPLE 325A 4-fluoro-3-(3-methyl-2-oxoimidazolidin-1-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, 30 substituting 1-methylimidazolidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 223 (M+H)+. EXAMPLE 325B 192 4-[4-fluoro-3-(3-methyl-2-oxoimidazolidin- 1 -yl)benzyl]-5,6,7,8-tetrahydrophthalazin- 1 (2H) one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 325A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 357 (M+H)'; 1 H 5 NMR (300 MHz, DMSO-d): 6 1.54 - 1.69 (m, 4H), 2.32 - 2.43 (m, 4H), 2.74 (s, 3H), 3.39 3.44 (m, 2H), 3.67 - 3.76 (m, 2H), 3.86 (s, 2H), 6.97 - 7.05 (m, 1H), 7.17 (dd, J=11.19, 8.48 Hz, 1H), 7.31 (dd, J=7.63, 2.20 Hz, 1H), 12.60 (s, 1H). EXAMPLE 326 4-[4-fluoro-3-(2-oxotetrahydropyrimidin-1(2H)-yl)benzyl]-5,6,7,8-tetrahydrophthalazin 0 1(2H)-one EXAMPLE 326A 4-fluoro-3-(2-oxotetrahydropyrimidin-1(2H)-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting tetrahydropyrimidin-2(1H)-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 5 223 (M+H)*. EXAMPLE 326B 4-[4-fluoro-3-(2-oxotetrahydropyrimidin-1(2H)-yl)benzyl]-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, '0 substituting EXAMPLE 326A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 357 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.57 - 1.68 (m, 4H), 1.87 - 2.00 (m, 2H), 2.33 - 2.43 (m, 4H), 3.23 (t, J=5.76 Hz, 2H), 3.44 - 3.52 (m, 2H), 3.86 (s, 2H), 6.60 (s, 1H), 7.00 - 7.07 (m, 1H), 7.09 - 7.18 (m, 2H), 12.61 (s, 1H). EXAMPLE 327 25 4-[3-(3-tert-butyl-2-oxoimidazolidin-1-yl)-4-fluorobenzyl]-5,6,7,8-tetrahydrophthalazin 1(2H)-one EXAMPLE 327A 3-(3-tert-butyl-2-oxoimidazolidin-1-yl)-4-fluorobenzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, 30 substituting 1-tert-butylimidazolidin-2-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 265 (M+H)*. EXAMPLE 327B 193 4-[3-(3-tert-butyl-2-oxoimidazolidin- 1 -yl)-4-fluorobenzyl]-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 327A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 399 (M+H)'; 1 H 5 NMR (300 MHz, DMSO-d): 6 1.3 (s, 9H), 1.53 - 1.68 (m, 4H), 2.31 - 2.45 (m, 4H), 3.43 3.48 (m, 2H), 3.58 - 3.69 (m, 2H), 3.86 (s, 2H), 6.95 - 7.02 (m, 1H), 7.15 (dd, J=11.36, 8.31 Hz, 1H), 7.28 (dd, J=7.46, 2.03 Hz, 1H), 12.59 (s, 1H). EXAMPLE 328 4-{4-fluoro-3-[(1S,4R)-3-oxo-2-azabicyclo[2.2.1]hept-2-yl]benzyl}-5,6,7,8 0 tetrahydrophthalazin- 1 (2H)-one EXAMPLE 328A 4-fluoro-3-((iS,4R)-3-oxo-2-azabicyclo[2.2.1]heptan-2-yl)benzaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting (1 S,4R)-2-azabicyclo [2.2.1 ]heptan-3 -one for 5 -methylpyrrolidinone. MS 5 (DCI/NH 3 ) m/z 234 (M+H)*. EXAMPLE 328B 4-{4-fluoro-3-[(1S,4R)-3-oxo-2-azabicyclo[2.2.1]hept-2-yl]benzyl}-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one The title compound was prepared according to the procedure for EXAMPLE 300B, '0 substituting EXAMPLE 328A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 368 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.49 - 1.56 (m, 2H), 1.57 - 1.65 (m, 4H), 1.69 - 1.76 (m, 1H), 1.79 - 1.86 (m, 1H), 1.89 - 1.96 (m, 1H), 1.97 - 2.03 (m, 1H), 2.32 - 2.45 (m, 4H), 2.74 - 2.82 (m, 1H), 3.87 (s, 2H), 4.25 (s, 1H), 7.01 - 7.08 (m, 1H), 7.16 - 7.23 (m, 1H), 7.23 - 7.28 (m, 1H), 12.59 (br s, 1H). 25 EXAMPLE 329 N-(2-ethylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-ethylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 388 (M+H)*. EXAMPLE 330 30 N-(3-ethylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-ethylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 388 (M+H)*. EXAMPLE 331 194 N-(4-ethylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-ethylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 388 (M+H)*. EXAMPLE 332 5 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-propylphenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-propylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 333 N-(2-isopropylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-isopropylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 334 N-(4-isopropylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 4-isopropylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*; IH NMR (500 MHz, D 2 0/DMSO-d): 6 1.20 (d, J=7.02 Hz, 6H), 1.55 - 1.72 (m, 4H), 2.34 2.47 (m, 4H), 2.82 - 2.96 (m, 1H), 4.01 (s, 2H), 7.23 (d, J=8.24 Hz, 2H), 7.39 (d, J=7.63 Hz, 1H), 7.47 (t, J=7.63 Hz, 1H), 7.63 (d, J=8.54 Hz, 2H), 7.74 (s, 1H), 7.80 (d, J=7.93 Hz, 1H). EXAMPLE 335 10 N-(3-tert-butylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-tert-butylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 416 (M+H)*. EXAMPLE 336 N-(4-tert-butylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-tert-butylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 416 (M+H)*. EXAMPLE 337 N-1,1'-biphenyl-4-yl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 30 substituting biphenyl-4-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 436 (M+H)*; IH NMR (500 MHz, D 2 0/DMSO-d 6 ): 6 1.57 - 1.70 (m, 4H), 2.34 - 2.48 (m, 4H), 4.02 (s, 2H), 7.36 (t, J=7.32 Hz, 1H), 7.42 (d, J=7.93 Hz, 1H), 7.45 - 7.48 (m, 2H), 7.49 - 7.52 (m, 1H), 7.66 - 7.71 (m, 4H), 7.78 (s, 1H), 7.81 - 7.87 (m, 3H). 195 EXAMPLE 338 N-(2-fluoro-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 2-fluoro-4-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 392 (M+H)*. EXAMPLE 339 N-(3-fluoro-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-fluoro-4-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 392 (M+H)*. EXAMPLE 340 N-(4-fluoro-2-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-fluoro-2-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 392 (M+H)*. EXAMPLE 341 10 N-(4-fluoro-3-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-fluoro-3-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 392 (M+H)*. 25 EXAMPLE 342 N-(3-chloro-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-chloro-4-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 408 30 (M+H)*. EXAMPLE 343 N-(4-chloro-3-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 196 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-chloro-3-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 408 (M+H)*. EXAMPLE 344 5 N-(3-bromo-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-bromo-4-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 452 (M+H)*. 0 EXAMPLE 345 N-(4-bromo-3-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-bromo-3-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 452 5 (M+H)*. EXAMPLE 346 N-(3-fluoro-4-methoxyphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 3-fluoro-4-methoxyaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 408 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.55 - 1.69 (m, 4H), 2.33 - 2.49 (m, 4H), 3.83 (s, 3H), 4.01 (s, 2H), 7.16 (t, J=9.31 Hz, 1H), 7.40 (d, J=7.93 Hz, 1H), 7.44 - 7.50 (m, 2H), 7.69 (dd, J=13.58, 2.59 Hz, 1H), 7.73 (s, 1H), 7.79 (d, J=7.93 Hz, 1H). EXAMPLE 347 25 N-[3-methoxy-5-(trifluoromethyl)phenyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-methoxy-5-(trifluoromethyl)aniline for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 458 (M+H)*. 30 EXAMPLE 348 N-(2-hydroxy-6-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 197 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-amino-3-methylphenol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 390 (M+H)*. EXAMPLE 349 5 N-(3-hydroxy-2-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-amino-2-methylphenol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 390 (M+H)*. 0 EXAMPLE 350 N-(3-hydroxy-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-amino-5-methylphenol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 390 5 (M+H)*. EXAMPLE 351 N-(2-methoxy-5-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 2-methoxy-5-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 404 (M+H)*. EXAMPLE 352 N-(3-methoxy-4-methylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 5-methoxy-2-methylaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 404 (M+H)*. EXAMPLE 353 N-(3-hydroxy-4-methoxyphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 30 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 5-amino-2-methoxyphenol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 406 (M+H)*. 198 EXAMPLE 354 N-(2-ethoxyphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-ethoxyaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 404 (M+H)*. 5 EXAMPLE 355 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(4-propoxyphenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-propoxyaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 418 (M+H)*. EXAMPLE 356 0 N-(5-tert-butyl-2-methoxyphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 5-tert-butyl-2-methoxyaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 446 (M+H)*. 5 EXAMPLE 357 N-[5-(acetylamino)-2-methoxyphenyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting N-(3-amino-4-methoxyphenyl)acetamide for furan-3-ylmethanamine. MS '0 (DCI/NH 3 ) m/z 447 (M+H)*. EXAMPLE 358 N-2,3-dihydro-1,4-benzodioxin-6-yl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 25 substituting 2,3-dihydrobenzo[b][1,4]dioxin-6-amine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 418 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.56 - 1.68 (m, 4H), 2.34 - 2.48 (m, 4H), 4.00 (s, 2H), 4.15 - 4.32 (m, 4H), 6.84 (d, J=8.85 Hz, 1H), 7.16 (dd, J=8.85, 2.44 Hz, 1H), 7.34 (d, J=2.44 Hz, 1H), 7.38 (d, J=7.93 Hz, 1H), 7.46 (t, J=7.63 Hz, 1H), 7.72 (s, 1H), 7.77 (d, J=7.63 Hz, 1H). 30 EXAMPLE 359 N-(5-chloro-2,4-dimethoxyphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 199 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 5-chloro-2,4-dimethoxyaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 454 (M+H)*. EXAMPLE 360 5 N-[3-(methylthio)phenyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-(methylthio)aniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 406 (M+H)*. EXAMPLE 361 0 N-[4-(methylthio)phenyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-(methylthio)aniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 406 (M+H)*. EXAMPLE 362 5 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(4-piperidin-1 ylphenyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-(piperidin-1-yl)aniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 443 (M+H)*. 10 EXAMPLE 363 N-(4-morpholin-4-ylphenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-morpholinoaniline for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 445 25 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.57 - 1.68 (m, 4H), 2.34 - 2.46 (m, 4H), 3.15 - 3.23 (m, 4H), 3.79 - 3.82 (m, 4H), 4.01 (s, 2H), 7.10 (d, J=9.15 Hz, 2H), 7.39 (d, J=7.63 Hz, 1H), 7.45 - 7.50 (m, 1H), 7.66 (d, J=9.15 Hz, 2H), 7.72 - 7.77 (m, 1H), 7.80 (d, J=7.93 Hz, 1H). EXAMPLE 364 30 N-(2-anilinophenyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting Nl-phenylbenzene-1,2-diamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 451 (M+H)*; H NMR (500 MHz, D 2 0/DMSO-d): 6 1.54 - 1.69 (m, 4H), 2.31 - 2.44 (m, 200 4H), 3.95 (s, 2H), 6.78 (t, J=7.32 Hz, 1H), 6.86 (d, J=7.63 Hz, 2H), 7.02 - 7.09 (m, 1H), 7.15 - 7.23 (m, 3H), 7.28 - 7.32 (m, 1H), 7.35 - 7.39 (m, 1H), 7.42 (t, J=7.63 Hz, 1H), 7.59 (d, J=7.32 Hz, 1H), 7.63 (s, 1H), 7.69 (d, J=7.63 Hz, 1H). EXAMPLE 365 5 N-{4-[(4-methoxyphenyl)amino]phenyl}-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting Nl-(4-methoxyphenyl)benzene-1,2-diamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 481 (M+H)*. 0 EXAMPLE 366 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-quinolin-6-ylbenzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting quinolin-7-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 411 (M+H)*; H NMR (500 MHz, D 2 0/DMSO-d 6 ): 6 1.57 - 1.72 (m, 4H), 2.36 - 2.49 (m, 4H), 4.04 (s, 5 2H), 7.44 - 7.50 (m, 1H), 7.54 (t, J=7.63 Hz, 1H), 7.82 (s, 1H), 7.88 (dd, J=8.24, 5.19 Hz, 2H), 8.19 (d, J=9.15 Hz, 1H), 8.27 (dd, J=9.15, 2.14 Hz, 1H), 8.74 (d, J=2.44 Hz, 1H), 8.88 (d, J=7.93 Hz, 1H), 9.04 (d, J=4.88 Hz, 1H). EXAMPLE 367 N-(5-hydroxy-1-naphthyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 10 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 5-aminonaphthalen-1-ol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 426 (M+H)*. EXAMPLE 368 25 N-1H-indazol-6-yl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1H-indazol-6-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 400 (M+H)*. EXAMPLE 369 30 8-(4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one EXAMPLE 369A methyl 2-(2-(4-fluorophenyl)acetyl)nicotinate 201 To a solution of dimethyl pyridine-2,3-dicarboxylate (1.0 g, 5.1 mmol) in tetrahydrofuran (50 ml) was added (4-fluorobenzyl)magnesium chloride (0.25 M in tetrahydrofuran, 20 ml, 5.1 mmol) through a syringe at -78 0 C. The reaction mixture was stirred at the same temperature for 30 minutes and was quenched with addition of water. 5 After warming up to room temperature, the reaction mixture was partitioned between ethyl acetate and brine. The organic phase was washed with brine and concentrated. The residue was purified by flash chromatography (150% ethyl acetate in hexane) to give the title compound. MS (DCI/NH 3 ) m/z 274 (M+H)*. EXAMPLE 369B 0 8-(4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one A solution of EXAMPLE 369A (0.46 g, 1.68 mmol) in ethanol (20 ml) was treated with hydrazine (108 mg, 3.37 mmol) at room temperature for 5 hours. The reaction mixture was concentrated to about 5 mL. The solid was collected by filtration, washed with ethanol and dried to provide the title compound. MS (DCI/NH 3 ) m/z 256 (M+H)*. 5 EXAMPLE 370 8-(3-chloro-4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one EXAMPLE 370A methyl 2-(2-(3-chloro-4-fluorophenyl)acetyl)nicotinate The title compound was prepared according to the procedure for EXAMPLE 369A, '0 substituting (2-chloro-4-fluorobenzyl)magnesium chloride for (4-fluorobenzyl)magnesium chloride. MS (DCI/NH 3 ) m/z 308 (M+H)*. EXAMPLE 370B 8-(3-chloro-4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one The title compound was prepared according to the procedure for EXAMPLE 369B, 25 substituting EXAMPLE 370A for EXAMPLE 369A. MS (DCI/NH 3 ) m/z 290 (M+H)*. EXAMPLE 371 (3aR)-8-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-2,3,3a,4-tetrahydro-1H pyrrolo[2, 1-c][1,4]benzoxazin-1-one EXAMPLE 371A 30 (R)-1-oxo-2,3,3a,4-tetrahydro-lH-benzo[b]pyrrolo[1,2-d] [1,4]oxazine-8-carbaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, substituting (R)-5-(hydroxymethyl)pyrrolidin-2-one for 5-methylpyrrolidinone. MS

(DCI/NH

3 ) m/z 232 (M+H)*. 202 EXAMPLE 371B (3aR)-8-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-2,3,3a,4-tetrahydro-1H pyrrolo[2,1-c] [1,4]benzoxazin-1-one The title compound was prepared according to the procedure for EXAMPLE 300B, 5 substituting EXAMPLE 371A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 352 (M+H)*; 1 H NMR (300 MHz, DMSO-d): 6 1.54 - 1.63 (m, 4H), 1.64 - 1.72 (m, 1H), 2.13 - 2.22 (m, 1H), 2.23 - 2.31 (m, 1H), 2.33 - 2.44 (m, 4H), 2.54 - 2.64 (m, 1H), 3.72 (t, J=10.17 Hz, 1H), 3.78 3.84 (m, 2H), 3.91 - 4.05 (m, 1H), 4.48 (dd, J=10.51, 3.05 Hz, 1H), 6.77 - 6.82 (m, 1H), 6.84 - 6.89 (m, 1H), 8.26 (d, J=2.03 Hz, 1H), 12.58 (br s, 1H). 0 EXAMPLE 372 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-N methylmethanesulfonamide EXAMPLE 372A N-(2-fluoro-5-formylphenyl)-N-methylmethanesulfonamide 5 The title compound was prepared according to the procedure for EXAMPLE 300A, substituting N-methylmethanesulfonamide for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 232 (M+H)+. EXAMPLE 372B N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-N 10 methylmethanesulfonamide The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 372A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 366 (M+H)+; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.57 - 1.71 (m, 4H), 2.34 - 2.47 (m, 4H), 3.13 (s, 6H), 3.93 (s, 2H), 7.25 (dd, J=8.33, 1.98 Hz, 1H), 7.51 (d, J=7.93 Hz, 1H), 7.58 (d, J=1.98 Hz, 1H), 12.62 25 (br s, 1H). EXAMPLE 373 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-2-hydroxy-2 methylpropanamide EXAMPLE 373A 30 N-(2-fluoro-5-formylphenyl)-2-hydroxy-2-methylpropanamide The title compound was prepared according to the procedure for EXAMPLE 300A, substituting 5,5-dimethyloxazolidine-2,4-dione for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 226 (M+H)+. 203 EXAMPLE 373B N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-2-hydroxy 2-methylpropanamide The title compound was prepared according to the procedure for EXAMPLE 300B, 5 substituting EXAMPLE 373A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 360 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.34 (s, 6H), 1.53 - 1.70 (m, 4H), 2.29 - 2.45 (m, 4H), 3.87 (s, 2H), 6.85 - 7.02 (m, 1H), 7.20 (dd, J=10.91, 8.53 Hz, 1H), 7.91 (dd, J=7.54, 1.98 Hz, 1H), 9.24 (s, 1H), 12.62 (s, 1H). EXAMPLE 374 0 (3aS)-8-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-2,3,3a,4-tetrahydro-1H pyrrolo[2, 1-c][1,4]benzoxazin-1-one EXAMPLE 374A (S)-1-oxo-2,3,3a,4-tetrahydro-lH-benzo[b]pyrrolo[1,2-d][1,4]oxazine-8-carbaldehyde The title compound was prepared according to the procedure for EXAMPLE 300A, 5 substituting (S)-5-(hydroxymethyl)pyrrolidin-2-one for 5-methylpyrrolidinone. MS

(DCI/NH

3 ) m/z 232 (M+H)*. EXAMPLE 374B (3aS)-8-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-2,3,3a,4-tetrahydro-1H pyrrolo[2, 1-c][1,4]benzoxazin-1-one 10 The title compound was prepared according to the procedure for EXAMPLE 300A, substituting EXAMPLE 374A for EXAMPLE 300B. MS (DCI/NH 3 ) m/z 352 (M+H)'; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.54 - 1.62 (m, 4H), 1.63 - 1.76 (m, 1H), 2.13 - 2.22 (m, 1H), 2.23 - 2.31 (m, 2H), 2.32 - 2.40 (m, 4H), 3.72 (t, J=10.31 Hz, 1H), 3.81 (s, 2H), 3.90 - 4.04 (m, 1H), 4.48 (dd, J=10.71, 3.17 Hz, 1H), 6.77 - 6.83 (m, 1H), 6.84 - 6.91 (m, 1H), 8.26 (d, 25 J=1.98 Hz, 1H), 12.58 (br s, 1H). EXAMPLE 375 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-phenylethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-phenylethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 388 30 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.56 - 1.69 (m, 4H), 2.33 - 2.45 (m, 4H), 2.84 (t, J=7.48 Hz, 2H), 3.43 - 3.51 (m, 2H), 3.96 (s, 2H), 7.21 (t, J=7.17 Hz, 1H), 7.23 - 7.26 (m, 2H), 7.27 - 7.32 (m, 2H), 7.32 - 7.36 (m, 1H), 7.40 (t, J=7.63 Hz, 1H), 7.60 (s, 1H), 7.64 (d, J=7.93 Hz, 1H). 204 EXAMPLE 376 N-[2-(2-methylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 2-o-tolylethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 377 N-[2-(3-methylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-m-tolylethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 378 N-[2-(4-methylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-p-tolylethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*. EXAMPLE 379 10 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-pyridin-2-ylethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(pyridin-2-yl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 389 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.57 - 1.68 (m, 4H), 2.31 - 2.43 (m, 4H), 3.24 (t, J=6.56 Hz, 2H), 3.69 (t, J=6.41 Hz, 2H), 3.95 (s, 2H), 7.33 - 7.37 (m, 1H), 7.40 (t, 25 J=7.63 Hz, 1H), 7.53 (s, 1H), 7.57 (d, J=7.63 Hz, 1H), 7.86 - 7.89 (m, 1H), 7.90 - 7.94 (m, 1H), 8.40 - 8.49 (m, 1H), 8.75 (d, J=4.88 Hz, 1H). EXAMPLE 380 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-pyridin-3-ylethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 30 substituting 3-(pyridin-2-yl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 389 (M+H)*. EXAMPLE 381 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-pyridin-4-ylethyl)benzamide 205 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 4-(pyridin-2-yl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 389 (M+H)*. EXAMPLE 382 5 N-[2-(2-methoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2-methoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 418 (M+H)*. 0 EXAMPLE 383 N-[2-(3-methoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 3-(2-methoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) 5 m/z 418 (M+H)*. EXAMPLE 384 N-[2-(4-methoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 4-(2-methoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 418 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.55 - 1.68 (m, 4H), 2.32 - 2.45 (m, 4H), 2.77 (t, J=7.48 Hz, 2H), 3.37 - 3.47 (m, 2H), 3.71 (s, 3H), 3.96 (s, 2H), 6.83 - 6.88 (m, 2H), 7.14 - 7.20 (m, 2H), 7.32 - 7.36 (m, 1H), 7.40 (t, J=7.63 Hz, 1H), 7.61 (s, 1H), 7.64 (d, J=7.63 Hz, 1H). 25 EXAMPLE 385 N-[2-(2-fluorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2-fluorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 30 406 (M+H)+. EXAMPLE 386 N-[2-(3-fluorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 206 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3-fluorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 406 (M+H)+. EXAMPLE 387 5 N-[2-(4-fluorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(4-fluorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 406 (M+H)+. 0 EXAMPLE 388 N-[2-(2-chlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2-chlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 5 422 (M+H)+. EXAMPLE 389 N-[2-(3-chlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 2-(3-chlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 422 (M+H)+. EXAMPLE 390 N-[2-(4-chlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(4-chlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 422 (M+H)+. EXAMPLE 391 N-[2-(3-bromophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 30 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3-bromophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 467 (M+H)+. 207 EXAMPLE 392 N-[2-(4-bromophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 2-(4-bromophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 467 (M+H)*. EXAMPLE 393 N-[2-(1,1'-biphenyl-4-yl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(biphenyl-4-yl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 464 (M+H)*; H NMR (500 MHz, D 2 0/DMSO-d): 6 1.54 - 1.67 (m, 4H), 2.30 - 2.44 (m, 4H), 2.89 (t, J=7.48 Hz, 2H), 3.52 (t, J=7.32 Hz, 2H), 3.96 (s, 2H), 7.33 - 7.37 (m, 4H), 7.41 (t, J=7.63 Hz, 1H), 7.44 - 7.50 (m, 2H), 7.59 (d, J=8.24 Hz, 2H), 7.64 (d, J=8.24 Hz, 2H), 5 7.64 - 7.68 (m, 2H). EXAMPLE 394 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-{2-[3 (trifluoromethyl)phenyl] ethyl} benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 2-(3-(trifluoromethyl)phenyl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 456 (M+H)*. EXAMPLE 395 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-{2-[4 (trifluoromethyl)phenyl] ethyl} benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(4-(trifluoromethyl)phenyl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 456 (M+H)*. EXAMPLE 396 3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-[2-(4 30 phenoxyphenyl)ethyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(4-phenoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 480 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.55 - 1.66 (m, 4H), 2.32 - 2.43 208 (m, 4H), 2.83 (t, J=7.32 Hz, 2H), 3.48 (t, J=7.32 Hz, 2H), 3.96 (s, 2H), 6.91 - 6.94 (m, 2H), 6.96 (d, J=7.63 Hz, 2H), 7.12 (t, J=7.48 Hz, 1H), 7.26 (d, J=8.54 Hz, 2H), 7.32 - 7.35 (m, 1H), 7.35 - 7.38 (m, 2H), 7.38 - 7.43 (m, 1H), 7.62 (s, 1H), 7.64 (d, J=7.63 Hz, 1H). EXAMPLE 397 5 N-[2-(3,4-dimethylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3,4-dimethylphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 416 (M+H)*. 0 EXAMPLE 398 N-[2-(2,4-dimethylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2,4-dimethylphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) 5 m/z 416 (M+H)*. EXAMPLE 399 N-[2-(2,5-dimethylphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting 2-(2,5-dimethylphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 416 (M+H)*. EXAMPLE 400 N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3-ethoxy-4-methoxyphenyl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 462 (M+H)*. EXAMPLE 401 N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 30 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(4-ethoxy-3-methoxyphenyl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 462 (M+H)*. 209 EXAMPLE 402 N-[2-(2,3-dimethoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 2-(2,3-dimethoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 448 (M+H)*. EXAMPLE 403 N-[2-(2,4-dimethoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2,4-dimethoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 448 (M+H)*. EXAMPLE 404 N-[2-(2,5-dimethoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2,5-dimethoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 448 (M+H)*. EXAMPLE 405 10 N-[2-(3,4-dimethoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3,4-dimethoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 448 (M+H)*. 25 EXAMPLE 406 N-[2-(3,5-dimethoxyphenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3,5-dimethoxyphenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) 30 m/z 448 (M+H)*. EXAMPLE 407 N-[2-(1,3-benzodioxol-5-yl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 210 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(benzo[d][1,3]dioxol-5-yl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 432 (M+H)*; 1 H NMR (500 MHz, D 2 0/DMSO-d): 6 1.54 - 1.72 (m, 4H), 2.32 - 2.44 (m, 4H), 2.75 (t, J=7.32 Hz, 2H), 3.43 (t, J=7.32 Hz, 2H), 3.96 (s, 2H), 5.94 (s, 5 2H), 6.70 (dd, J=7.93, 1.53 Hz, 1H), 6.80 (s, 1H), 6.81 - 6.83 (m, 1H), 7.32 - 7.36 (m, 1H), 7.40 (t, J=7.63 Hz, 1H), 7.61 (s, 1H), 7.64 (d, J=7.93 Hz, 1H). EXAMPLE 408 N-[2-(2,3-dichlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2,3-dichlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 457 (M+H)*. EXAMPLE 409 N-[2-(3,4-dichlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3,4-dichlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 457 (M+H)*. EXAMPLE 410 10 N-[2-(2,6-dichlorophenyl)ethyl]-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2,6-dichlorophenyl)ethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 457 (M+H)*. 25 EXAMPLE 411 (3aS,4R,7S,7aR)-5- {2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]phenyl} -2,2-dimethyltetrahydro-4,7-methano[1,3]dioxolo[4,5-c]pyridin-6(3aH) one EXAMPLE 41 1A 30 3-[(3aS,4R,7S,7aR)-2,2-dimethyl-6-oxotetrahydro-4,7-methano[1,3]dioxolo[4,5-c]pyridin 5(4H)-yl]-4-fluorobenzaldehyde 211 The title compound was prepared according to the procedure for EXAMPLE 300A, substituting (IS, 2R, 6S, 7R)-4,4-dimethyl-3,5-dioxa-8-azatricyclo[5.2.1.0(2,6)]decan-9-one for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 306 (M+H)*. EXAMPLE 411B 5 (3aS,4R,7S,7aR)-5- {2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]phenyl} -2,2-dimethyltetrahydro-4,7-methano[1,3]dioxolo[4,5-c]pyridin-6(3aH) one The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 41 1A for EXAMPLE 300B. MS (DCI/NH 3 ) m/z 440 (M+H)'; 1 H 0 NMR (300 MHz, DMSO-d): 6 1.29 - 1.34 (m, 3H), 1.42 (s, 3H), 1.55 - 1.67 (m, 4H), 2.01 2.11 (m, 1H), 2.12 - 2.21 (m, 1H), 2.32 - 2.45 (m, 4H), 2.77 - 2.84 (m, 1H), 3.88 (s, 2H), 4.16 - 4.24 (m, 1H), 4.58 - 4.64 (m, 1H), 4.64 - 4.69 (m, 1H), 7.02 - 7.09 (m, 1H), 7.22 (dd, J=11.19, 8.48 Hz, 1H), 7.31 (dd, J=7.46, 2.03 Hz, 1H), 12.59 (s, 1H). EXAMPLE 412 5 4-(1-(3-bromo-4-fluorophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 412A 1-(3-bromo-4-fluorophenyl)ethanol A solution of 1-(3-bromo-4-fluorophenyl)ethanone (15.0 g, 69 mmol) in tetrahydrofuran (200 mL) was treated with sodium borohydride (5.3 g, 138 mmol) at 0 0 C. '0 After the addition, the ice bath was removed, and the mixture was stirred at room temperature for 30 minutes and at reflux overnight. After cooling, IN HCl (10 mL) was slowly added and the reaction mixture was concentrated. The residue was partitioned between ethyl acetate and brine. The organic phase was washed with water, and concentrated. The residue was purified by flash chromatography (30% ethyl acetate in hexane) to provide the title 25 compound. MS (DCI/NH 3 ) m/z 220 (M+H)*. EXAMPLE 412B 2-bromo-4-(1 -bromoethyl)- 1 -fluorobenzene To a solution of EXAMPLE 412A (1.5 g, 6.8 mmol) and triphenyl phosphine (1.9 g, 7.2 mmol) in dimethylformamide (20 ml) was added bromine (1.1 g, 6.8 mmol) through a 30 syringe. After the addition, the reaction mixture was stirred at room temperature for additional 15 minutes, and partitioned between water (100 ml) and ethyl acetate (200 ml). The organic phase was washed with brine and concentrated. The residue was purified by 212 flash chromatography (2.6% ethyl acetate in hexane) to provide the title compound. MS

(DCI/NH

3 ) m/z 282 (M+H)*. EXAMPLE 412B (1 -(3 -bromo-4-fluorophenyl)ethyl)triphenylphosphonium bromide 5 The title compound was prepared according to the procedure for EXAMPLE 285B, substituting EXAMPLE 412A for EXAMPLE 285A. EXAMPLE 412C 3-(1-(3-bromo-4-fluorophenyl)ethylidene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one The title compound was prepared according to the procedure for EXAMPLE 285C, 0 substituting EXAMPLE 412B for EXAMPLE 285B. MS (DCI/NH 3 ) m/z 338 (M+H)*. EXAMPLE 412D 4-(1-(3-bromophenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 2C, substituting EXAMPLE 412C for EXAMPLE 2B. MS (DCI/NH 3 ) m/z 352 (M+H)*. 5 EXAMPLE 413 4-(1-(4-fluoro-3-(2-oxopyrrolidin-1-yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 412 for EXAMPLE 103, and pyrroline-2-one for azetidin-2-one. MS (ESI) m/z 356 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.42 (d, J=6.74 Hz, 3 H), 1.46 '0 - 1.70 (m, 4 H), 1.93 - 2.16 (m, 4 H), 2.29 - 2.67 (m, 6 H), 4.25 (q, J=6.74 Hz, 1 H), 7.07 7.15 (m, 1 H), 7.18 (s, 1 H), 7.19 - 7.29 (m, 1 H), 12.70 (s, 1 H). EXAMPLE 414 8-(4-fluorobenzyl)-1,2,3,4-tetrahydropyrido[3,2-d]pyridazin-5(6H)-one A mixture of EXAMPLE 369 (150 mg, 0.6 mmol), 5% platinum on carbon (30 mg), 25 concentrated aqueous HCl (50 tL) and dimethylformamide (5 ml) in a pressure vessel was stirred at room temperature under 50 psi of hydrogen for 16 hours. The mixture was filtered, and the filtrate was concentrated. The residual solid was purified by HPLC (Zorbax@ C- 18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0. 1% TFA/CH 3

CN/H

2 0) to provide the title product as TFA salt. MS (ESI) m/z 260 (M+H)*. 30 EXAMPLE 415 8-(3-bromo-4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one EXAMPLE 415A methyl 2-(2-(3-bromo-4-fluorophenyl)acetyl)nicotinate 213 A mixture of magnesium turnings (880 mg, 37 mmol) and 2-bromo-4-(bromomethyl) 1-fluorobenzene (1.0 g, 3.7 mmol) in anhydrous diethyl ether (15 ml) was treated with a piece of iodine. The mixture was then heated to gentle reflux until the color of the mixture disappeared, after which the heating continued for additional hour. The suspension was 5 cooled to room temperature, and cannulated into a solution of dimethyl pyridine-2,3 dicarboxylate (1.0 g, 5.1 mmol) in tetrahydrofuran (50 ml) at - 78 0 C. The reaction mixture was maintained at the same temperature for 30 minutes, and was quenched with addition of water. After warming up to room temperature, the reaction mixture was partitioned between ethyl acetate and brine. The organic phase was washed with brine and concentrated. The 0 residue was purified by flash chromatography (150% ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 353 (M+H)*. EXAMPLE 415B 8-(3-bromo-4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one The title compound was prepared according to the procedure for EXAMPLE 369B 5 substituting EXAMPLE 415A for EXAMPLE 369A. MS (DCI/NH 3 ) m/z 335 (M+H)*. EXAMPLE 418 N-[2-(dimethylamino)ethyl]-N-ethyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, '0 substituting N -ethyl-N 2

,N

2 -dimethylethane-1,2-diamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 383 (M+H)*. EXAMPLE 419 N-[2-(diethylamino)ethyl]-N-methyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 25 The title compound was prepared according to the procedure for EXAMPLE 308, substituting N,N -diethyl-N 2 -methylethane- 1,2-diamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 397 (M+H)*. EXAMPLE 420 N-benzyl-N-ethyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 30 The title compound was prepared according to the procedure for EXAMPLE 308, substituting N-benzylethanamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 402 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 0.97 - 1.11 (m, 3H), 1.36 - 1.57 (m, 4H), 214 2.22 - 2.30 (m, 2H), 2.50 - 2.66 (m, 2H), 3.27 - 3.45 (m, 2H), 3.98 (s, 2H), 4.61 - 4.74 (m, 2H), 7.26 - 7.31 (m, 1H), 7.32 - 7.40 (m, 6H), 7.42 - 7.47 (m, 1H), 7.52 (s, 1H). EXAMPLE 421 N-benzyl-N-isopropyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 5 The title compound was prepared according to the procedure for EXAMPLE 308, substituting N-benzylpropan-2-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 416 (M+H)*. EXAMPLE 422 N-benzyl-N-butyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 0 The title compound was prepared according to the procedure for EXAMPLE 308, substituting N-benzylbutan-1-amine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 430 (M+H)*. EXAMPLE 423 N,N-dibenzyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzamide 5 The title compound was prepared according to the procedure for EXAMPLE 308, substituting dibenzylamine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 464 (M+H)*. EXAMPLE 424 N-benzyl-N-(2-hydroxyethyl)-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]benzamide 10 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(benzylamino)ethanol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 418 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.40 - 1.54 (m, 4H), 2.21 - 2.33 (m, 2H), 2.50 - 2.61 (m, 2H), 3.62 - 3.78 (m, 2H), 3.89 - 4.02 (m, 2H), 3.96 (s, 2H), 4.82 - 4.97 (m, 2H), 7.25 - 7.29 (m, 1H), 7.30 - 7.36 (m, 5H), 7.36 - 7.43 (m, 1H), 7.43 - 7.47 (m, 1H), 7.50 25 (d, J=7.32 Hz, 1H). EXAMPLE 426 N-methyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]-N-(2-pyridin-2 ylethyl)benzamide The title compound was prepared according to the procedure for EXAMPLE 308, 30 substituting N-methyl-2-(pyridin-2-yl)ethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 403 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-d): 6 1.42 - 1.52 (m, 4H), 2.24 - 2.34 (m, 2H), 2.51 - 2.62 (m, 2H), 2.97 (s, 3H), 3.07 - 3.21 (m, 2H), 3.83 - 3.94 (m, 215 2H), 3.99 (s, 2H), 7.12 (dd, J=7.32, 5.49 Hz, 1H), 7.14 - 7.20 (m, 1H), 7.28 - 7.32 (m, 2H), 7.32 - 7.37 (m, 1H), 7.37 - 7.45 (m, 1H), 7.57 (t, J=7.63 Hz, 1H), 8.55 (d, J=3.66 Hz, 1H). EXAMPLE 427 N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 5 yl)methyl]benzamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(3,4-dimethoxyphenyl)-N-methylethanamine for furan-3-ylmethanamine. MS

(DCI/NH

3 ) m/z 462 (M+H)*. EXAMPLE 428 0 4-{3-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting piperidin-4-ol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 368 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.42 - 1.52 (m, 4H), 1.63 - 1.75 (m, 2H), 1.87 - 1.98 (m, 2H), 2.27 - 2.35 (m, 2H), 2.54 - 2.62 (m, 2H), 3.25 - 3.40 (m, 2H), 4.01 (s, 2H), 4.01 5 4.04 (m, 2H), 4.05 - 4.07 (m, 1H), 7.35 (t, J=7.17 Hz, 1H), 7.37 - 7.40 (m, 1H), 7.40 - 7.44 (m, 1H), 7.51 (s, 1H). EXAMPLE 429 1- {3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzoyl}piperidine-3 carboxamide 10 The title compound was prepared according to the procedure for EXAMPLE 308, substituting piperidine-3-carboxamide for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 395 (M+H)*. EXAMPLE 430 1-{3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzoyl}piperidine-4 25 carboxamide The title compound was prepared according to the procedure for EXAMPLE 308, substituting piperidine-4-carboxamide for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 395 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-d): 6 1.41 - 1.55 (m, 4H), 1.82 - 1.97 (m, 4H), 2.27 - 2.37 (m, 2H), 2.54 - 2.61 (m, 2H), 2.63 - 2.73 (m, 1H), 2.94 - 3.06 (m, 2H), 4.00 (s, 30 2H), 4.16 - 4.32 (m, 2H), 7.32 - 7.36 (m, 1H), 7.36 - 7.40 (m, 2H), 7.48 - 7.51 (m, 1H). EXAMPLE 434 4-(3-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]carbonyl}benzyl)-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one 216 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 484 (M+H)*. EXAMPLE 435 5 4-{3-[(4-methylpiperazin-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-methylpiperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 367 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-d): 6 1.46 - 1.52 (m, 4H), 2.24 (s, 3H), 2.29 2.34 (m, 2H), 2.37 - 2.42 (m, 4H), 2.54 - 2.62 (m, 2H), 3.61 - 3.73 (m, 4H), 4.02 (s, 2H), 7.35 0 - 7.39 (m, 1H), 7.39 - 7.43 (m, 2H), 7.51 (s, 1H). EXAMPLE 436 4-{3-[(4-ethylpiperazin-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-ethylpiperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 381 (M+H)*. 5 EXAMPLE 437 4-{3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]benzoyl}piperazine-1 carbaldehyde The title compound was prepared according to the procedure for EXAMPLE 308, substituting piperazine-1-carbaldehyde for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 381 '0 (M+H)*. EXAMPLE 438 4-{3-[(4-acetylpiperazin-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-(piperazin-1-yl)ethanone for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 395 25 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.44 - 1.57 (m, 4H), 2.09 (s, 3H), 2.28 2.39 (m, 2H), 2.51 - 2.66 (m, 2H), 3.39 - 3.73 (m, 8H), 4.03 (s, 2H), 7.36 - 7.39 (m, 1H), 7.43 (t, J=7.02 Hz, 2H), 7.54 (s, 1H). EXAMPLE 439 4-(3-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}benzyl)-5,6,7,8-tetrahydrophthalazin 30 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(piperazin-1-yl)ethanol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 397 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.42 - 1.55 (m, 4H), 2.27 - 2.37 (m, 2H), 217 2.50 - 2.62 (m, 6H), 2.69 (t, J=5.80 Hz, 2H), 3.54 - 3.75 (m, 4H), 3.89 (t, J=5.80 Hz, 2H), 4.02 (s, 2H), 7.35 - 7.38 (m, 1H), 7.39 - 7.43 (m, 2H), 7.50 (s, 1H). EXAMPLE 440 4- {3-[(4-phenylpiperazin-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-phenylpiperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 429 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-d): 6 1.44 - 1.57 (m, 4H), 2.27 - 2.42 (m, 2H), 2.52 - 2.66 (m, 2H), 3.08 - 3.20 (m, 4H), 3.68 - 3.83 (m, 4H), 4.04 (s, 2H), 6.91 (t, J=7.32 Hz, 1H), 6.98 (d, J=7.93 Hz, 2H), 7.28 - 7.34 (m, 2H), 7.37 - 7.41 (m, 1H), 7.44 (t, J=7.48 Hz, 0 1H), 7.46 - 7.49 (m, 1H), 7.57 (s, 1H). EXAMPLE 441 4- {3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]benzyl} -5,6,7,8-tetrahydrophthalazin-1(2H) one The title compound was prepared according to the procedure for EXAMPLE 308, 5 substituting 1-(pyridin-2-yl)piperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 430 (M+H)*; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.46 - 1.55 (m, 4H), 2.29 - 2.40 (m, 2H), 2.52 - 2.65 (m, 2H), 3.53 - 3.63 (m, 4H), 3.64 - 3.78 (m, 4H), 4.03 (s, 2H), 6.66 (dd, J=6.71, 4.58 Hz, 1H), 6.73 (d, J=8.54 Hz, 1H), 7.37 - 7.41 (m, 1H), 7.43 (d, J=7.63 Hz, 1H), 7.45 7.48 (m, 1H), 7.49 - 7.54 (m, 1H), 7.57 (s, 1H), 8.29 (dd, J=4.88, 1.22 Hz, 1H). 10 EXAMPLE 442 4- {3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]benzyl} -5,6,7,8-tetrahydrophthalazin-1(2H) one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(piperazin-1-yl)pyrimidine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 25 431 (M+H)*; H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.42 - 1.59 (m, 4H), 2.26 - 2.40 (m, 2H), 2.50 - 2.66 (m, 2H), 3.62 - 3.74 (m, 4H), 3.82 - 3.91 (m, 4H), 4.03 (s, 2H), 6.55 (t, J=4.73 Hz, 1H), 7.38 (d, J=5.80 Hz, 1H), 7.40 - 7.45 (m, 1H), 7.45 - 7.49 (m, 1H), 7.57 (s, 1H), 8.38 (d, J=4.88 Hz, 2H). EXAMPLE 443 30 4-[3-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)benzyl]-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one 218 The title compound was prepared according to the procedure for EXAMPLE 308, substituting 2-(2-(piperazin-1-yl)ethoxy)ethanol for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 441 (M+H)*. EXAMPLE 444 5 4-(3- { [4-(2-fluorophenyl)piperazin-1-yl]carbonyl}benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-(2-fluorophenyl)piperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 447 (M+H)+. 0 EXAMPLE 445 4-(3- {[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-(4-fluorophenyl)piperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 5 447 (M+H)+; H NMR (500 MHz, D 2 0/pyridine-d): 6 1.44 - 1.56 (m, 4H), 2.30 - 2.39 (m, 2H), 2.53 - 2.63 (m, 2H), 3.02 - 3.12 (m, 4H), 3.68 - 3.81 (m, 4H), 4.05 (s, 2H), 6.93 - 6.97 (m, 2H), 7.04 - 7.09 (m, 2H), 7.37 - 7.41 (m, 1H), 7.44 (t, J=7.32 Hz, 1H), 7.46 - 7.51 (m, 1H), 7.57 (s, 1H). EXAMPLE 446 10 4-(3- {[4-(2-chlorophenyl)piperazin-1-yl]carbonyl}benzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-(2-chlorophenyl)piperazine for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 463 (M+H)+. 25 EXAMPLE 447 4- {3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]benzyl}-5,6,7,8-tetrahydrophthalazin-1(2H)-one The title compound was prepared according to the procedure for EXAMPLE 308, substituting 1-methyl-4-(piperazin-1-yl)azepane for furan-3-ylmethanamine. MS (DCI/NH 3 ) m/z 381 (M+H)+; 1 H NMR (500 MHz, D 2 0/pyridine-ds): 6 1.44 - 1.48 (m, 1H), 1.48 - 1.51 30 (m, 4H), 1.92 - 2.01 (m, 2H), 2.28 - 2.36 (m, 2H), 2.51 - 2.55 (m, 2H), 2.58 (s, 3H), 2.64 (t, J=5.65 Hz, 1H), 2.84 - 2.94 (m, 2H), 3.64 - 3.71 (m, 3H), 3.88 - 3.92 (m, 1H), 4.01 (s, 2H), 7.33 - 7.39 (m, 1H), 7.39 - 7.41 (m, 1H), 7.41 - 7.45 (m, 1H), 7.51 (s, 1H). EXAMPLE 448 219 4-[3-(1,1 -dioxido- 1,2-thiazinan-2-yl)-4-fluorobenzyl]-5,6,7,8-tetrahydrophthalazin- 1 (2H) one EXAMPLE 448A 3-(1,1-dioxido-1,2-thiazinan-2-yl)-4-fluorobenzaldehyde 5 The title compound was prepared according to the procedure for EXAMPLE 300A, substituting 1,4-butanesultam for 5-methylpyrrolidinone. MS (DCI/NH 3 ) m/z 258 (M+H)*. EXAMPLE 448B 4-[3-(1,1-dioxido-1,2-thiazinan-2-yl)-4-fluorobenzyl]-5,6,7,8-tetrahydrophthalazin-1(2H) one 0 The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 448A for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 392 (M+H)'; 1 H NMR (300 MHz, DMSO-d): 6 1.57 - 1.71 (m, 4H), 1.75 - 1.87 (m, 2H), 2.13 - 2.24 (m, 2H), 2.34 - 2.46 (m, 4H), 3.16 - 3.28 (m, 2H), 3.46 - 3.58 (m, 2H), 3.92 (s, 2H), 7.23 (dd, J=8.13, 2.18 Hz, 1H), 7.48 (d, J=7.93 Hz, 1H), 7.57 (d, J=1.59 Hz, 1H), 12.61 (br s, 1H). 5 EXAMPLE 449 8-[4-fluoro-3-(2-oxoazetidin-1-yl)benzyl]pyrido[2,3-d]pyridazin-5(6H)-one The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 415 for EXAMPLE 103. MS (ESI) m/z 325 (M+H)*. EXAMPLE 450 10 8-(3-chloro-4-fluorobenzyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one The title compound was prepared as TFA salt according to procedure for EXAMPLE 414, substituting EXAMPLE 370 for EXAMPLE 369. MS (ESI) m/z 294 (M+H)*. EXAMPLE 451 4-(1-(4-fluoro-3-(2-oxoazetidin-1-yl)phenyl)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 25 The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 412 for EXAMPLE 103. MS (ESI) m/z 342 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 1.41 (d, J=7.12 Hz, 3 H), 1.44 - 1.67 (m, 4 H), 1.84 - 2.08 (m, 1 H), 2.34 (m, 2 H), 2.53 - 2.74 (m, 1 H), 3.11 (t, J=4.58 Hz, 2 H), 3.72 - 3.88 (m, 2 H), 4.22 (q, J=6.78 Hz, 1 H), 6.81 - 6.95 (m, 1 H), 7.18 (dd, J=11.87, 8.48 Hz, 1 H), 7.76 (dd, J=7.46, 2.37 Hz, 1 30 H), 12.70 (s, 1 H). EXAMPLE 452 1- {3-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}pyrrolidine-2,5-dione 220 The title compound was prepared according to the procedure for EXAMPLEs 2, 3 and 4, substituting 3-nitrobenzaldehyde for 4-fluoro-3-nitrobenzaldehyde. MS (DCI/NH 3 ) m/z 256 (M+H)*. EXAMPLE 453 5 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-2-(2 oxopyrrolidin- 1 -yl)acetamide The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 2 for EXAMPLE 89, and 2-(2-oxopyrrolidin-1 yl)acetic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 356 (M+H)*. 0 MS (DCI/NH 3 ) m/z 399 (M+H)*; H NMR (300 MHz, DMSO-d): 6 1.53 - 1.67 (m, 4H), 1.89 - 2.06 (m, 2H), 2.26 (t, J=7.97 Hz, 2H), 2.31 - 2.43 (m, 4H), 3.39 - 3.47 (m, 2H), 3.86 (s, 2H), 4.07 (s, 2H), 6.93 - 6.99 (m, 1H), 7.18 (dd, J=10.85, 8.48 Hz, 1H), 7.71 (dd, J=7.46, 2.03 Hz, 1H), 9.82 (br s, 1H), 12.61 (br s, 1H). EXAMPLE 454 5 N- {2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-5-methyl-1 phenyl- 1 H-pyrazole-4-carboxamide The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 2 for EXAMPLE 89, and 5-methyl-1-phenyl-1H pyrazole-4-carboxylic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z '0 356 (M+H)*. MS (DCI/NH 3 ) m/z 458 (M+H)*. EXAMPLE 455 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-5 oxohexanamide The title compound was prepared as TFA salt according to the procedure for 25 EXAMPLE 136, substituting EXAMPLE 2 for EXAMPLE 89, and 5-oxohexanoic acid for 1 methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 386 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.53 - 1.65 (m, 4H), 1.67 - 1.80 (m, 2H), 2.08 (s, 3H), 2.28 - 2.34 (m, 2H), 2.34 - 2.41 (m, 4H), 2.42 - 2.49 (m, 2H), 3.85 (s, 2H), 6.82 - 6.96 (m, 1H), 7.15 (dd, J=10.85, 8.48 Hz, 1H), 7.67 (dd, J=7.46, 1.70 Hz, 1H), 9.60 (br s, 1H), 12.61 (br s, 1H). 30 EXAMPLE 456 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-3 methoxypropanamide 221 The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 2 for EXAMPLE 89, and 3-methoxypropanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 360 (M+H)*; H NMR (300 MHz, DMSO-d): 6 1.55 - 1.66 (m, 4H), 2.30 - 2.43 (m, 4H), 2.60 (t, J=6.10 Hz, 2H), 3.23 (s, 5 3H), 3.59 (t, J=6.27 Hz, 2H), 3.86 (s, 2H), 6.85 - 6.99 (m, 1H), 7.16 (dd, J=10.85, 8.48 Hz, 1H), 7.74 (dd, J=7.46, 1.70 Hz, 1H), 9.64 (br s, 1H), 12.61 (br s, 1H). EXAMPLE 457 N-{2-fluoro-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl]phenyl}-N' phenylpentanediamide 0 The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 2 for EXAMPLE 89, and 5-oxo-5 (phenylamino)pentanoic acid for 1-methylcyclopropanecarboxylic acid. MS (DCI/NH 3 ) m/z 463 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.55 - 1.67 (m, 4H), 1.83 - 1.94 (m, 2H), 2.31 - 2.40 (m, 6H), 2.40 - 2.45 (m, 2H), 3.85 (s, 2H), 6.89 - 6.96 (m, 1H), 6.98 - 7.06 (m, 5 1H), 7.15 (dd, J=10.85, 8.48 Hz, 1H), 7.24 - 7.32 (m, 2H), 7.59 (d, J=7.46 Hz, 2H), 7.71 (dd, J=7.97, 1.53 Hz, 1H), 9.67 (br s, 1H), 9.88 (br s, 1H), 12.62 (br s, 1H). EXAMPLE 458 benzyl 2-(dimethylamino)-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl]phenylcarbamate 10 EXAMPLE 458A 4-(dimethylamino)-N-methoxy-N-methyl-3-nitrobenzamide To a solution of 4-fluoro-3-nitrobenzoic acid (5 g, 27.0 mmol) in dimethylformamide (100 mL) was added N,O-dimethylhydroxylamine hydrochloride (5.93 g, 60.8 mmol) and triethylamine (17.0 mL, 122 mmol). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 25 hydrochloride (11.65 g, 60.8 mmol) and hydroxybenzotriazole (9.31 g, 60.8 mmol) were added and the reaction mixture was stirred at room temperature for 3 days. The reaction mixture was concentrated and partitioned between ethyl acetate (150 mL) and brine (150 mL). The organics were concentrated on rotary evaporator and the crude was purified by flash chromatography eluting with 40% ethyl acetate in hexanes to provide the title product. 30 MS (DCI/NH 3 ) m/z 254 (M+H)*. EXAMPLE 458B 3-amino-4-(dimethylamino)-N-methoxy-N-methylbenzamide 222 A solution of EXAMPLE 458A (2.34 g, 9.24 mmol) in tetrahydrofuran (40 mL) was treated with Raney Ni (2.0 g, Raney 2800, slurry in water) at room temperature under a hydrogen (balloon) for 16 hours. The catalyst was filtered off, and the filtrate was concentrated. The residue was used the subsequent step without further purification. 5 EXAMPLE 458C benzyl 2-(dimethylamino)-5-(methoxy(methyl)carbamoyl)phenylcarbamate To a solution of EXAMPLE 458B in a mixture of tetrahydrofuran (20 mL) and water (20 mL) was added cesium carbonate (6.02 g, 18.58 mmol) and benzyl chloroformate (1.5 mL, 10.16 mmol). The reaction mixture was stirred at room temperature for 16 hours, and 0 concentrated. The residue was partitioned between ethyl acetate (100 mL) and brine (75 mL). The organic layer was washed with brine, and concentrated. The residual oil was purified by flash chromatography eluting with 40% ethyl acetate in hexanes to provide the title product. MS (DCI/NH 3 ) m/z 358 (M+H)*. EXAMPLE 458D 5 benzyl 2-(dimethylamino)-5-formylphenylcarbamate A solution of EXAMPLE 458C (2.89 g, 8.1 mmol) in anhydrous tetrahydrofuran (20 mL) was treated with lithium aluminum hydride (1.0 M solution in tetrahydrofuran, 8.1 mL, 8.1 mmol) at 0 0 C for 10 minutes. The reaction was quenched with water, and the mixture was partitioned between ethyl acetate and diluted HCl solution. The organic layer was '0 washed with brine, and concentrated on a rotary evaporator. The residual oil was purified by flash chromatography eluting with 20% ethyl acetate in hexanes to provide the title product. MS (DCI/NH 3 ) m/z 299 (M+H)*. EXAMPLE 458E benzyl 2-(dimethylamino)-5-[(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 25 yl)methyl]phenylcarbamate The title compound was prepared according to the procedure for EXAMPLE 300B, substituting EXAMPLE 458D for EXAMPLE 300A. MS (DCI/NH 3 ) m/z 433 (M+H)*. EXAMPLE 459 8-(4-fluoro-3-(2-oxoazetidin-1-yl)benzyl)-1,2,3,4-tetrahydropyrido[3,2-d]pyridazin-5(6H) 30 one The title compound was prepared according to procedure for EXAMPLE 414, substituting EXAMPLE 449 for EXAMPLE 369. MS (ESI) m/z 329 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.61 - 1.76 (m, 2 H), 2.33 (t, J=6.35 Hz, 2 H), 3.12 (t, J=4.56 Hz, 2 H), 223 3.17 (m, 2 H), 3.77 (s, 2 H), 3.81 (q, J=4.36 Hz, 2 H), 6.32 (s, 1 H), 6.87 - 7.01 (m, 1 H), 7.17 (dd, J=11.90, 8.33 Hz, 1 H), 7.78 (dd, J=7.54, 2.38 Hz, 1 H), 11.80 (s, 1 H). EXAMPLE 460 4-(3-bromo-4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 EXAMPLE 460A 3-(3-bromo-4-fluorophenyl)-3-methoxy-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one To a solution of 2-bromo-1-fluoro-4-iodobenzene (13.23 g, 44 mmol) in anhydrous tetrahydrofuran (30 mL) was added isopropylmagnesium chloride (2.0 M solution in tetrahydrofuran, 24.18 mL, 48.4 mmol) at - 20 0 C. After the addition, the reaction mixture 0 was stirred at 0 0 C for 3 hours, and was added to a solution of 3,4,5,6-tetrahydrophthalic anhydride (6.08 g, 40 mmol) in anhydrous tetrahydrofuran (60 mL) at -78 0 C. The mixture was stirred for 2 hours, and a saturated aqueous ammonium chloride solution was added to the reaction mixture, which then was stirred at room temperature for 30 minutes. Anhydrous magnesium sulfate was added to the reaction mixture, and the mixture was filtered. The 5 filtrate was concentrated. Thionyl chloride (10.4 mL, 142 mol) was added dropwise to methanol (40 mL) at -10 0 C., and the solution was stirred at 0 0 C for 30 minutes. To the thionyl chloride solution was then added the residue from the filtrate in anhydrous methanol (15 mL). The reaction mixture was stirred at room temperature overnight, and was concentrated. The residue was dissoved in methylene chloride (40 mL), and was treated with 0 triethylamine (5.58 mL) at 0 0 C for 1 hour. Water was added, and the mixture was washed with sodium bicarbonate, brine and water. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was separated by flash chromatography (10 35% gradient ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 341, 343 (M+H)*. 25 EXAMPLE 460B 4-(3-bromo-4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one A solution of EXAMPLE 460A (9.5 g, 27.8 mmol) and hydrazine monohydrate (1.76 mL, 36.2 mmol) in ethanol (70 mL) was heated under reflux for 4 hours. After cooling to room temperature, the solids were collected by filtration, washed with ethanol and dried to 30 provide the title compound. MS (DCI/NH 3 ) m/z 323, 325 (M+H)*; 1 H NMR (300 MHz,

DMSO-D

6 ): 6 1.57 - 1.65 (m, 2 H), 1.66 - 1.74 (m, 2 H), 2.34 (t, J=5.75 Hz, 2 H), 2.45 (t, J=6.15 Hz, 2 H), 7.45 (t, J=8.72 Hz, 1 H), 7.49 - 7.55 (m, 1 H), 7.80 (dd, J=6.74, 2.38 Hz, 1 H), 12.85 (br s, 1H). 224 EXAMPLE 461 4-[4-fluoro-3-(2-oxoazetidin-1-yl)phenyl]-5,6,7,8-tetrahydrophthalazin-1(2H)-one EXAMPLE 461A 2-(benzyloxymethyl)-4-(3-bromo-4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 To a solution of EXAMPLE 460 (2.0 g, 6.19 mmol) in anhydrous dimethylformamide (30 mL) was added potassium t-butoxide (1 M solution in tetrahydrofuran, 6.50 mL, 6.5 mmol). The solution was stirred at room temperature for 30 minutes, and benzyl chloromethylether (1.163 g, 7.43 mmol) was added. The reaction mixture was stirred at room temperature overnight. After quenching with water, the reaction mixture was partitioned 0 between water and ethyl acetate. The organic phase was washed with water, and concentrated. The residue was separated by flash chromatography (20-60% gradient ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 443 (M+H)*. EXAMPLE 461B 2-(benzyloxymethyl)-4-(4-fluoro-3-(2-oxoazetidin-1-yl)phenyl)-5,6,7,8-tetrahydrophthalazin 5 1(2H)-one A microwave reactor tube was charged with EXAMPLE 461A (137 mg, 0.309 mmol), tris(dibenzylideneacetone)dipalladium(0) (28.3 mg, 0.031 mmol), 4,5 bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (26.9 mg, 0.046 mmol), 2 azetidinone (44 mg, 0.619 mmol), and potassium phosphate tribasic (98 mg, 0.464 mmol). '0 Anhydrous dioxane (3 mL) was added. The suspension was purged with nitrogen, and was capped with a microwave septum. The reaction mixture was heated in a CEM Explorer@ microwave reactor (Matthews, NC) at 200 0 C for 50 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and brine. The organic phase was washed with water, and concentrated. The residue was separated by flash chromatography ( 2 0

-

7 0 % 25 gradient ethyl acetate in hexane) to provide the title compound. MS (DCI/NH 3 ) m/z 434 (M+H)*. EXAMPLE 461C 4-[4-fluoro-3-(2-oxoazetidin-1-yl)phenyl]-5,6,7,8-tetrahydrophthalazin-1(2H)-one To a solution of EXAMPLE 461B (140 mg, 0.323 mmol) in methanol (10 mL) was 30 added 20% palladium hydroxide on carbon (80 mg) under nitrogen. This suspension was purged with hydrogen, and stirred under hydrogen (balloon) at 50 0 C for 4 hours. The mixture was filtered, and the filtrate was concentrated. The residue was recrystallized from methanol (4 mL) to provide the title compound. The mother liquor was separated by HPLC 225 (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 250x2.54 column, Mobile phase A: 0.10% TFA in H 2 0; B: 0.1 % TFA in CH 3 CN; 0-100% gradient) to provide additional title compound. MS (DCI/NH 3 ) m/z 314 (M+H)*; 1 H NMR (400 MHz, DMSO-d 6 ), 6 1.57 - 1.63 (m, 2 H), 1.67 - 1.74 (m, 2 H), 2.33 (t, J=5.83 Hz, 2 H), 2.45 (t, 5 J=6.14 Hz, 2 H), 3.14 - 3.18 (m, 2 H), 3.86 - 3.90 (m, 2 H), 7.16 - 7.21 (m, 1 H), 7.34 (dd, J=1 1.66, 8.59 Hz, 1 H), 7.93 (dd, J=7.52, 2.30 Hz, 1 H), 12.89 (s, 1 H). EXAMPLE 462 2-fluoro-5-[(5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-8-yl)methyl]benzamide EXAMPLE 462A 0 methyl 2-fluoro-5 -((5 -oxo-5,6-dihydropyrido [3,2-d]pyridazin-8-yl)methyl)benzoate The title compound was prepared according to the procedure for EXAMPLE 66C, substituting EXAMPLE 415 for EXAMPLE 66B. MS (DCI/NH 3 ) m/z 314 (M+H)*. EXAMPLE 462B 2-fluoro-5-[(5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-8-yl)methyl]benzamide 5 A solution of EXAMPLE 462A (1 g, 3.2 mmol) in 7N ammonia in methanol (5 ml) was heated at 70 0 C overnight, and cooled to room temperature. The solid was collected by filtration, washed with methanol and dried to provide the title compound. MS (DCI/NH 3 ) m/z 299 (M+H)*. EXAMPLE 463 10 8-(3-amino-4-fluorobenzyl)pyrido[2,3-d]pyridazin-5(6H)-one A mixture of 1.5 N aqueous KOH solution (2 ml) and 3 g of ice was treated with bromine (80 mg, 0.5 mmol) at -10 0 C for 10 minutes. EXAMPLE 462 (100 mg, 0.3 mmol) was added. The reaction mixture was stirred at -10 0 C for an additional 10 minutes, and was then allowed to warm up to 65 0 C for 1 hour. After cooling, the mixture was partitioned 25 between ethyl acetate and brine. The organic phase was washed with brine, and concentrated to about 10 mL. The solid was collected by filtration, washed with methanol, and dried to provide the title compound. MS (DCI/NH 3 ) m/z 271 (M+H)*. EXAMPLE 464 8-[4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl]-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H) 30 one EXAMPLE 464A 6-(benzyloxymethyl)-8-(3-bromo-4-fluorobenzyl)pyrido[3,2-d]pyridazin-5(6H)-one 226 A solution of EXAMPLE 415 (1 g, 3 mmol) in anhydrous dimethylformamide (100 ml) was treated with potassium t-butoxide (IN solution in tetrahydrofuran, 3 mL, 3 mmol) at room temperature for 30 minutes. Benzyloxychloromethane (0.6 g, 3.6 mmol) was then added, and the mixture was stirred at room temperature overnight. After quenching with 5 water, the reaction mixture was partitioned between ethyl acetate and brine. The organic layer was washed with brine, and concentrated. The residue was purified by flash chromatography (85% ethyl acetate in hexane) to provide the title compound. MS

(DCI/NH

3 ) m/z 454 (M+H)*. EXAMPLE 464B 0 6-(benzyloxymethyl)-8-(4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl)pyrido[3,2-d]pyridazin 5(6H)-one The title compound was prepared according to procedure for EXAMPLE 101, substituting EXAMPLE 464A for EXAMPLE 103. MS (ESI) m/z 459 (M+H)*. EXAMPLE 464C 5 8-[4-fluoro-3-(2-oxopyrrolidin-1-yl)benzyl]-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H) one A mixture of EXAMPLE 464B (130 mg, 0.28 mmol), 5% platinum on carbon (25 mg), 5% Pd(OH) 2 on carbon (25 mg), concentrated aqueous HCl (66 tL) and dimethylformamide (10 ml) was stirred in a pressure vessel at room temperature under 40 psi '0 of hydrogen for 48 hours. The volatiles were removed, the residue was separated by HPLC (Zorbax@ C-18 ODS packing material [Agilent Technologies, Santa Clara, CA], 0. 1%

TFA/CH

3

CN/H

2 0) to provide the title product as TFA salt. MS (ESI) m/z 343 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.57 - 1.81 (m, 2 H), 2.01 - 2.18 (m, 2 H), 2.26 - 2.46 (m, 4 H), 3.17 (m, 2 H), 3.72 (t, J=6.94 Hz, 2 H), 3.84 (s, 2 H), 6.39 (s, 1 H), 7.16 - 7.19 (m, 1 H), 25 7.18 - 7.25 (m, 1 H), 7.29 (dd, J=7.54, 1.98 Hz, 1 H), 11.89 (s, 1 H). EXAMPLE 465 methyl 2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 yl)methyl]benzoate The title compound was prepared as TFA salt according to procedure for EXAMPLE 30 414, substituting EXAMPLE 462A for EXAMPLE 369. MS (ESI) m/z 318 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.61 - 1.75 (m, 2 H), 2.34 (t, J=6.15 Hz, 2 H), 3.17 (m, 2 H), 3.44 (s, 3 H), 3.84 (s, 2 H), 6.39 (s, 1 H), 7.27 (dd, J=10.91, 8.53 Hz, 1 H), 7.46 - 7.56 (m, 1 H), 7.76 (dd, J=7.14, 2.38 Hz, 1 H), 11.84 (s, 1 H). 227 EXAMPLE 467 8-(3-amino-4-fluorobenzyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one The title compound was prepared as TFA salt according to procedure for EXAMPLE 414, substituting EXAMPLE 463 for EXAMPLE 369. MS (ESI) m/z 275 (M+H)'; H NMR 5 (300 MHz, DMSO-d 6 ): 1.62 - 1.74 (m, 2 H), 2.35 (t, J=6.27 Hz, 2 H), 3.10 - 3.23 (m, 2 H), 3.69 (s, 2 H), 4.91 (s, 2 H), 6.25 (s, 1 H), 6.45 - 6.54 (m, 1 H), 6.64 (dd, J=8.82, 2.03 Hz, 1 H), 6.92 (dd, J=1 1.53, 8.48 Hz, 1 H), 11.93 (s, 1 H). EXAMPLE 468 2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]benzoic acid 0 The title compound was prepared according to procedure for EXAMPLE 288, substituting EXAMPLE 465 for EXAMPLE 266. MS (ESI) m/z 304 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.61 - 1.77 (m, 2 H), 2.34 (t, J=6.10 Hz, 2 H), 3.06 - 3.25 (m, 2 H), 3.84 (s, 2 H), 6.36 (s, 1 H), 7.22 (dd, J=10.85, 8.48 Hz, 1 H), 7.39 - 7.52 (m, 1 H), 7.73 (dd, J=7.12, 2.37 Hz, 1 H), 11.82 (s, 1 H) 13.19 (s, 1 H). 5 EXAMPLE 470 N-ethyl-2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 yl)methyl]benzamide The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and ethylamine for 1-(3 ,0 dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 331 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 1.09 (t, J=7.14 Hz, 3 H), 1.58 - 1.74 (m, 2 H), 2.34 (t, J=6.15 Hz, 2 H), 3.12 - 3.20 (m, 2 H), 3.20 - 3.29 (m, 2 H), 3.82 (s, 2 H), 6.39 (s, 1 H), 7.19 (dd, J=10.31, 8.33 Hz, 1 H), 7.30 - 7.38 (m, 1 H), 7.47 (dd, J=6.74, 2.38 Hz, 1 H), 8.17 - 8.29 (m, 1 H), 11.88 (s, 1 H). 25 EXAMPLE 471 N-cyclobutyl-2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 yl)methyl]benzamide The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and cyclobutanamine for 1-(3 30 dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 357 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.56 - 1.77 (m, 4 H), 1.90 - 2.10 (m, 2 H), 2.12 - 2.28 (m, 2 H), 2.33 (t, J=6.35 Hz, 2 H), 3.05 - 3.25 (m, 2 H), 3.81 (s, 2 H), 4.27 - 4.45 (m, 1 H), 6.35 (s, 1 H), 7.18 228 (dd,J=10.31, 8.33 Hz, 1 H), 7.26 - 7.37 (m, 1 H), 7.42 (dd,J=6.74, 2.38 Hz, 1 H), 8.49 (d, J=7.54 Hz, 1 H), 11.84 (s, 1 H). EXAMPLE 472 2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]-N-(2 5 pyrrolidin- 1 -ylethyl)benzamide The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and 2-(pyrrolidin-1-yl)ethanamine for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 400 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.63 - 1.76 (m, 2 H), 1.76 - 1.93 (m, 2 H), 1.93 - 2.10 (m, 2 H), 2.34 (t, 0 J=6.10 Hz, 2 H), 2.61 - 2.76 (m, 2 H), 2.96 - 3.12 (m, 2 H), 3.12 - 3.22 (m, 2 H), 3.25 - 3.40 (m, 2 H), 3.52 - 3.68 (m, 2 H), 3.84 (s, 2 H), 6.35 (s, 1 H,) 7.25 (dd, J=10.85, 8.48 Hz, 1 H), 7.33 - 7.49 (m, 1 H), 7.57 (dd, J=7.12, 2.37 Hz, 1 H), 8.31 - 8.50 (m, 1 H), 11.84 (s, 1 H). EXAMPLE 473 8-(4-fluoro-3- {[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]carbonyl}benzyl)-2,3,4,6 5 tetrahydropyrido[2,3-d]pyridazin-5(1H)-one The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and morpholino(piperazin-1 yl)methanone for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 485 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.60 - 1.78 (m, 2 H), 2.35 (t, J=6.15 Hz, 2 H), '0 3.05 - 3.28 (m, 12 H), 3.51 - 3.58 (m, 4 H), 3.60 - 3.70 (m, 2 H), 3.82 (s, 2 H), 6.41 (s, 1 H), 7.16 - 7.29 (m, 2 H), 7.29 - 7.37 (m, 1 H), 11.92 (s, 1 H). EXAMPLE 474 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-N' phenylpentanediamide 25 The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 5-oxo-5 (phenylamino)pentanoic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 464 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.62 - 1.75 (m, 2 H), 1.81 - 1.96 (m, 2 H), 2.34 (t, J=7.12 Hz, 4 H), 2.42 (t, J=8.14 Hz, 2 H), 3.09 - 3.22 (m, 2 H), 3.77 (s, 2 H), 6.30 (s, 1 H), 30 6.93 - 7.07 (m, 1 H), 7.14 (dd, J=10.85, 8.48 Hz, 1 H), 7.22 - 7.34 (m, 3 H), 7.59 (d, J=7.80 Hz, 2 H), 7.68 - 7.77 (m, 1 H), 9.62 (s, 1 H), 9.87 (s, 1 H), 11.82 (s, 1 H). EXAMPLE 475 229 1-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 yl)methyl]phenyl}pyrrolidine-2,5-dione EXAMPLE 475A 4-(2-fluoro-5-((5-oxo-5,6-dihydropyrido[3,2-d]pyridazin-8-yl)methyl)phenylamino)-4 5 oxobutanoic acid The title compound was prepared according to procedure for EXAMPLE 3, substituting EXAMPLE 463 for EXAMPLE 2. MS (ESI) m/z 371 (M+H)*. EXAMPLE 475B 1-(2-fluoro-5-((5-oxo-5,6-dihydropyrido[3,2-d]pyridazin-8-yl)methyl)phenyl)pyrrolidine-2,5 0 dione The title compound was prepared according to procedure for EXAMPLE 4, substituting EXAMPLE 475A for EXAMPLE 3. MS (ESI) m/z 353 (M+H)*. EXAMPLE 475C 1-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 5 yl)methyl]phenyl}pyrrolidine-2,5-dione The title compound was prepared according to procedure for EXAMPLE 414, substituting EXAMPLE 475B for EXAMPLE 369. MS (ESI) m/z 357 (M+H)'; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.58 - 1.78 (m, 2 H), 2.33 (t, J=6.27 Hz, 2 H), 2.72 - 2.90 (m, 4 H), 3.07 - 3.23 (m, 2 H), 3.84 (s, 2 H), 6.34 (s, 1 H), 7.13 (dd, J=6.95, 2.20 Hz, 1 H), 7.27 - 7.37 '0 (m, 1 H), 7.37 - 7.43 (m, 1 H), 11.83 (s, 1 H). EXAMPLE 476 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-3 methoxypropanamide The title compound was prepared as TFA salt according to the procedure for 25 EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 3-methoxypropanoic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 361 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.63 - 1.74 (m, 2 H), 2.33 (t, J=6.15 Hz, 2 H), 2.60 (t, J=6.15 Hz, 2 H), 3.09 - 3.21 (m, 2 H), 3.24 (s, 3 H), 3.59 (t, J=6.15 Hz, 2 H), 3.77 (s, 2 H), 6.33 (s, 1 H), 6.93 7.05 (m, 1 H), 7.14 (dd, J=10.91, 8.53 Hz, 1 H), 7.69 - 7.80 (m, 1 H), 9.63 (s, 1 H), 11.85 (s, 30 1 H). EXAMPLE 477 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-5 oxohexanamide 230 The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 5-oxohexanoic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 387 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 1.64 - 1.80 (m, 4 H), 2.08 (s, 3 H), 2.27 - 2.39 (m, 4 H), 2.42 - 2.50 (m, 2 H), 5 3.10 - 3.23 (m, 2 H), 3.77 (s, 2 H), 6.34 (s, 1 H), 6.94 - 7.04 (m, 1 H), 7.13 (dd, J=10.85, 8.48 Hz, 1 H), 7.66 - 7.71 (m, 1 H), 9.58 (s, 1 H), 11.86 (s, 1 H). EXAMPLE 478 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-3 0 phenoxypropanamide The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 3-phenoxypropanoic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 423 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.55 - 1.74 (m, 2 H), 2.33 (t, J=6.15 Hz, 2 H), 2.84 (t, J=6.15 Hz, 2 H), 5 3.08 - 3.21 (m, 2 H), 3.78 (s, 2 H), 4.24 (t, J=6.15 Hz, 2 H), 6.36 (s, 1 H), 6.88 - 6.96 (m, 3 H), 6.97 - 7.05 (m, 1 H), 7.16 (dd, J=10.91, 8.53 Hz, 1 H), 7.25 - 7.31 (m, 2 H), 7.77 (dd, J=7.54, 1.98 Hz, 1 H), 9.79 (s, 1 H), 11.89 (s, 1 H). EXAMPLE 479 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-4 10 oxo-4-phenylbutanamide The title compound was prepared according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 4-oxo-4-phenylbutanoic acid for 1 methylcyclopropanecarboxylic acid. MS (ESI) m/z 435 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.63 - 1.73 (m, 2 H), 2.32 (t, J=5.95 Hz, 2 H), 2.75 - 2.79 (m, 2 H), 3.08 - 3.19 25 (m, 2 H), 3.27 - 3.36 (m, 2 H), 3.75 (s, 2 H), 6.27 (s, 1 H), 6.91 - 7.04 (m, 1 H), 7.14 (dd, J=10.91, 8.53 Hz, 1 H), 7.54 (t, J=7.54 Hz, 2 H), 7.59 - 7.69 (m, 1 H), 7.70 - 7.77 (m, 1 H), 7.94 - 8.03 (m, 2 H), 9.74 (s, 1 H), 11.78 (s, 1 H). EXAMPLE 481 2-[4-(benzyloxy)phenoxy]-N- {2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3 30 d]pyridazin-8-yl)methyl]phenyl} acetamide The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 2-(4 (benzyloxy)phenoxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 231 515 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 6 1.53 - 1.81 (m, 2 H), 2.22 - 2.39 (m, 2 H), 3.07 - 3.21 (m, 2 H), 3.78 (s, 2 H), 4.66 (s, 2 H), 5.04 (s, 2 H), 6.34 (s, 1 H), 6.83 - 6.99 (m, 4 H), 7.02 - 7.10 (m, 1 H), 7.14 - 7.23 (m, 1 H), 7.30 - 7.37 (m, 2 H), 7.37 - 7.46 (m, 3 H), 7.65 (dd, J=7.54, 1.98 Hz, 1 H), 9.77 (s, 1 H), 11.84 (s, 1 H). 5 EXAMPLE 483 N-{2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]phenyl}-2 (4-methoxyphenoxy)acetamide The title compound was prepared as TFA salt according to the procedure for EXAMPLE 136, substituting EXAMPLE 467 for EXAMPLE 89, and 2-(4 0 methoxyphenoxy)acetic acid for 1-methylcyclopropanecarboxylic acid. MS (ESI) m/z 438 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 1.63 - 1.75 (m, 2 H), 2.33 (t, J=6.27 Hz, 2 H), 3.08 - 3.24 (m, 2 H), 3.70 (s, 3 H), 3.79 (s, 2 H), 4.66 (s, 2 H), 6.35 (s, 1 H), 6.84 - 6.96 (m, 4 H), 7.01 - 7.11 (m, 1 H), 7.18 (dd, J=10.85, 8.48 Hz, 1 H), 7.66 (dd, J=7.63, 2.20 Hz, 1 H), 9.73 (s, 1 H), 11.85 (s, 1 H). 5 EXAMPLE 484 N-cyclopropyl-2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8 yl)methyl]benzamide The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and cyclopropanamine for 1-(3 ,0 dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 343 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 0.44 - 0.59 (m, 2 H), 0.63 - 0.76 (m, 2 H), 1.60 - 1.78 (m, 2 H), 2.34 (t, J=6.35 Hz, 2 H), 2.74 - 2.90 (m, 1 H), 3.09 - 3.22 (m, 2 H), 3.81 (s, 2 H), 6.39 (s, 1 H), 7.03 7.25 (m, 1 H), 7.25 - 7.37 (m, 1 H), 7.42 (dd, J=6.74, 2.38 Hz, 1 H), 8.33 (d, J=3.97 Hz, 1 H), 11.89 (s, 1 H). 25 EXAMPLE 485 8-(3- {[4-(2-ethoxyethyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)-2,3,4,6 tetrahydropyrido[2,3-d]pyridazin-5(1H)-one The title compound was prepared as TFA salt according to procedure for EXAMPLE 48, substituting EXAMPLE 468 for EXAMPLE 48C, and 1-(2-ethoxyethyl)piperazine for 1 30 (3-dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 444 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 1.09 (t, J=9.0 Hz, 3 H), 1.61 - 1.76 (m, 2 H), 2.56 - 2.69 (m, 2 H), 3.01 3.11 (m, 2 H), 3.11 - 3.24 (m, 4 H), 3.35 - 3.43 (m, 4 H), 3.43 - 3.61 (m, 4 H), 3.82 (s, 2 H), 6.35 (s, 1 H), 7.18 - 7.26 (m, 1 H), 7.28 - 7.34 (m, 1 H), 7.34 - 7.41 (m, 1 H), 11.84 (s, 1 H). 232 EXAMPLE 486 2-fluoro-5-[(5-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-d]pyridazin-8-yl)methyl]-N-(2-piperidin 1 -ylethyl)benzamide The title compound was prepared according to procedure for EXAMPLE 48, 5 substituting EXAMPLE 468 for EXAMPLE 48C, and 2-(piperidin-1-yl)ethanamine for 1-(3 dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 414 (M+H)*; H NMR (300 MHz, DMSO-d 6 ): 1.33 - 1.49 (m, 2 H), 1.50 - 1.64 (m, 4 H), 1.62 - 1.75 (m, 2 H), 2.33 (t, J=6.35 Hz, 2 H), 2.54 - 2.82 (m, 4 H), 3.10 - 3.20 (m, 2 H), 3.20 - 3.35 (m, 2 H), 3.37 - 3.55 (m, 2 H), 3.82 (s, 2 H), 6.35 (s, 1 H), 7.20 (dd, J=10.51, 8.53 Hz, 1 H), 7.33 - 7.44 (m, 1 H), 0 7.53 (dd, J=7.14, 2.38 Hz, 1 H), 8.51 (dd, J=4.36, 1.59 Hz, 1 H,) 11.83 (s, 1 H). EXAMPLE 487 2-fluoro-5-((5-oxo-1,2,3,4,5,6-hexahydropyrido[3,2-d]pyridazin-8-yl)methyl)-N-(2-oxo-2 (piperidin- 1 -yl)ethyl)benzamide The title compound was prepared according to procedure for EXAMPLE 48, 5 substituting EXAMPLE 468 for EXAMPLE 48C, and 2-amino-1-(piperidin-1-yl)ethanone for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. MS (ESI) m/z 428 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 1.44 (m, 2 H), 1.48 - 1.65 (m, 4 H), 1.65 - 1.79 (m, 2 H), 2.33 (t, J=6.27 Hz, 2 H), 3.10 - 3.24 (m, 2 H), 3.34 - 3.42 (m, 2 H), 3.41 - 3.50 (m, 2 H), 3.84 (s, 2 H), 4.13 (d, J=5.09 Hz, 2 H), 6.00 - 6.50 (m, 1 H), 7.05 - 7.28 (m, 1 H), 7.32 - 7.53 (m, 1 H), 7.63 (dd, '0 J=7.12, 2.37 Hz, 1 H), 8.17 (q, J=5.09 Hz, 1 H), 11.82 (s, 1 H). EXAMPLE 490 4- {4-fluoro-3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]benzyl}-5,6,7,8 tetrahydrophthalazin- 1 (2H)-one To a solution of EXAMPLE 1 (100 mg, 0.33 mmol) in dimethlyacetamide (5 mL) was 25 added 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU) (126 mg, 0.33 mmol) and triethylamine (92 tL, 0.66 mmol) and stirred for 20 minutes at room temperature. (Piperazin-1-yl)pyrimidine dihydrochloride (78 mg, 0.33 mmol) was then added and the reaction mixture was stirred at room temperature for 16 hours. After concentration, the residual oil was purified by HPLC (Zorbax@ C-18 ODS 30 packing material [Agilent Technologies, Santa Clara, CA], 0.1% TFA/CH 3

CN/H

2 0) to provide the title product. MS (DCI/NH 3 ) m/z 449 (M+H)*; 1 H NMR (300 MHz, DMSO-d 6 ): 6 1.53 - 1.71 (m, 4H), 2.32 - 2.44 (m, 4H), 3.24 - 3.39 (m, 2H), 3.67 - 3.78 (m, 4H), 3.79 233 3.88 (m, 2H), 3.93 (s, 2H), 6.67 (t, J=4.75 Hz, 1H), 7.21 - 7.23 (m, 1H), 7.24 - 7.28 (m, 1H), 7.30 - 7.35 (m, 1H), 8.39 (d, J=4.75 Hz, 2H), 12.62 (br s, 1H). EXAMPLE 491 4-(4-fluoro-3-(2-oxopyrrolidin-1-yl)phenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 5 The title compound was prepared according to the procedure for EXAMPLE 461, substituting 2-pyrrolidinone for 2-azetidinone in EXAMPLE 461B. MS (DCI/NH 3 ) m/z 328 (M+H)*; 1 H NMR (400 MHz, CD 3 0D): 6 1.73 - 1.79 (m, 2 H), 1.83 - 1.90 (m, 2 H), 2.22 2.29 (m, 2 H), 2.55 - 2.60 (m, 4 H), 2.69 (t, J=5.83 Hz, 2 H), 3.91 (t, J=7.06 Hz, 2 H), 7.35 7.41 (m, 1 H), 7.48 - 7.52 (m, 1 H), 7.60 - 7.64 (m, 1 H). 0 The foregoing is meant to be illustrative of the invention and not meant to limit it to disclosed embodiments. Variations and changes obvious to one skilled in the art are intended to be within the scope and nature of the invention as defined in the appended claims. 234

Claims (10)

1. A compound having formula (1k), 0 NH N R"0 R1R1 R 10 5 R 103 R1 04 (1k), or a pharmaceutically acceptable salt thereof, wherein R1 01 , R ' 04 , and R10' are H; R. 0 3 is F; R'o 2 is NHC(O)R"; R"1 is R 2 , R 13 , R 1 4 or R1; R is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R1 3 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R1 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 5 is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Rio, OR 16 , SR16, S(O) 2 R 16 , C(O)OH, NH 2 , 235 NHR 1N(R 6)2, C(O)R 6, C(O)NH 2 , C(O)NHR 6, C(O)N(R 6)2, NHC(O)R 6, NR 6C(O)R 1, NHC(O)OR 1, NR 6C(O)OR 6, OH, F, Cl, Br or I; wherein each R 6 is R or R17A R is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with one or two of independently selected Ri, C(O)OH, NH 2 , NHR1 or N(Ri)2, C(O)R18 C(O)NH 2 , C(O)NHRi, C(O)N(R1)2, NHC(O)R1, NRiC(O)R 18, F, Cl, Br or I; R17A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein each R18 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; 12 13 14 17A 18 wherein each of the moieties represented by R , R , R , R , and R are independently unsubstituted or substituted with one or two or three or four of 19 19 1 91 91 independently selected R , OR , SR 9, S(O)R 9, SO 2 R 9, C(O)R 9, CO(O)R 9, OC(O)R 9, OC(O)OR 9, NH 2 , NHR 9, N(R 9) 2 , NHC(O)R 9, NR 1C(O)R 9, NHS(O) 2 R19, NR S(O) 2 R 9, NHC(O)OR 9, NR 1C(O)OR 9, NHC(O)NH 2 , NHC(O)NHR 9, NHC(O)N(R 9) 2 , NR 1C(O)NHR 9, NR 1C(O)N(R 9)2, C(O)NH 2 , C(O)NHR 9, C(O)N(R 9)2, C(O)NHOH, C(O)NHOR 9, C(O)NHSO 2 R 9, C(O)NR 9SO 2 R , SO 2 NH 2 , SO 2 NHR 9, SO 2 N(R 9)2, C(O)H, C(O)OH, C(N)NH 2 , C(N)NHR 9, C(N)N(R 9)2, CNOH, CNOCH 3 , OH, (0), CN, N 3 , NO 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, Cl, Br or I; 19 20 21 22 23 wherein each R is R2, R , R or R R20 is phenyl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R21 is heteroaryl which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R22 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, 236 heterocycloalkane or heterocycloalkene; each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R23 is alkyl, alkenyl or alkynyl; each of which is unsubstituted or substituted with 241 4 24 24 one or two of independently selected R , OR , SR2, S(O) 2 R , C(O)OH, NH 2 , 24 24 24 24 24 2 NHR N(R )2, C(O)R , C(O)NH 2 , C(O)NHR , C(O)N(R )2, NHC(O)R24 NR 24C(O)R 24, NHC(O)OR 24, NR 24C(O)OR2, NHS(O) 2 R2, NR 24S(O) 2 R 24, OH, F, Cl, Br or I; wherein each R24 is R24A or R24B R24A is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 24 is alkyl, alkenyl or alkynyl each of which is unsubstituted or substituted with 25 25 25 25 one or two of independently selected R , OR , SR , S(O) 2 R , C(O)OH, NH 2 , 25 25 25 25 25 25 NHR N(R )2, C(O)R , C(O)NH 2 , C(O)NHR , C(O)N(R )2, NHC(O)R NR 2C(O)R 2, NHC(O)OR 2, NR 2C(O)OR 2, OH, F, Cl, Br or I; wherein each R is alkyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; each of which is unsubstituted or substituted with NH 2 , NH(CH 3 ), N(CH 3 ) 2 , OH or OCH 3 ; 20 21 22 24A wherein each of the moieties represented by R , R , R , and R are 26 independently unsubstituted or substituted with one or two of independently selected R 26 OR , alkenyl, alkynyl, phenyl, OH, (0), C(O)OH, CN, CF 3 , OCF 3 , CF 2 CF 3 , F, Cl, Br or I; and R26 is alkyl.

2. The compound of claim 1, wherein R" is R 5 , wherein R 5 is alkyl, unsubstituted 16 16 16 16 or substituted with one or two of independently selected R , OR , SR , S(O) 2 R 16 16 16 16 16 16 C(O)OH, NH 2 , NHR N(R )2, C(O)R , C(O)NHR , NHC(O)R , NHC(O)OR , OH or Cl; wherein each R 6 is R or R17A R is alkyl, which is unsubstituted or substituted with one or two of independently selected R18 237 R17A is phenyl, heteroaryl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl each of which is unfused or fused with benzene or heterocycloalkane; wherein each R18 is phenyl or heterocycloalkyl; wherein each of the moieties represented by R17A and R18 are independently unsubstituted or substituted with one or two or three or four of independently selected 19 19 1 91 9 1 91 R , OR , SR 9, SO 2 R 9, C(O)R 9, CO(O)R 9, NHR 9, N(R 9)2, NHC(O)R 9, NHS(O) 2 R 9, C(O)NH2, C(O)NHR 9, C(O)N(R 9)2, C(O)H, OH, (0), CN, CF 3 , F, Cl, Br or I; 19 20 21 22 23 wherein each R is R2, R , R or R R20 is phenyl which is unused; R21 is heteroaryl which is unfused; R22 is cycloalkyl or heterocycloalkyl; each of which are unfused or fused with benzene; R23 is alkyl, which is unsubstituted or substituted with one or two of 241 4 2 24 24 independently selected R , OR2, NHR2N(R )2, NHS(O) 2 R or OH; wherein each R24 is R24A or R24B R24A is unsubstituted phenyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with heterocycloalkane; R 24 is alkyl, which is unsubstituted or substituted with one or two of independently selected OR or OH; wherein each R is alkyl unsubstituted or substituted with NH 2 ; wherein each R20 is unsubstituted or substituted with one or two of independently 26 26 selected R , OR (0), F or Cl; and R26 is alkyl; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 selected from

4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)amino)-4-oxobutanoic acid; 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin 1(2H)-one; 238 N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-3 piperidin- 1 -ylpropanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-3-(4 methylpiperazin- 1 -yl)propanamide; 2-amino-N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)acetamide; 3-cyclohexyl-N-(2-uoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 yl)methyl)phenyl)propanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl) piperidine-3-carboxamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophihalazin-1 yl)methyl)phenyl)azetidine-3-carboxamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 morpholin-4-ylacetamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-4-(4 methoxyphenyl)-4-oxobutanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-2 hydroxy-2-methylpropanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-2-(2 oxopyrrolidin- 1 -yl)acetamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-5 methyl-1-phenyl- 1H-pyrazole-4-carboxamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)-5 oxohexanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophihalazin-1-yl)methyl)phenyl)-3 methoxypropanamide; N-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin- 1 -yl)methyl)phenyl)-N' phenylpentanediamide; 4-(4-fluoro-3-((4-pyrimidin-2-ylpiperazin- 1 -yl)carbonyl)benzyl)-5,6,7,8 tetrahydrophthalazin-1(2H)-one; or 239 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophihalazin-1 yl)methyl)phenyl)amino)-4-oxobutanoic acid. 4. The compound 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8 tetrahydrophthalazin-1(2h)-one; or a pharmaceutically acceptable salt thereof.

5. The compound 4-((2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1 yl)methyl)phenyl)amino)-4-oxobutanoic acid; or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition having poly(ADP-ribose)polymerase (PARP) inhibitory activity comprising a compound of any of claims 1-5 and pharmaceutically acceptable excipient.

7. A method of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of any of claims 1-5.

8. A method for decreasing tumor volume in a mammal comprising administering thereto a therapeutically acceptable amount of any of claims 1-5.

9. A method according to claim 8 additionally comprising radiotherapy.

10. A method according to claim 8 additionally comprising administering a chemotherapeutic agent selected from temozolomide, dacarbazine, cyclophosphamide, carmustine, melphalan, lomustine, carboplatin, cisplatin, 5-FU +/- leucovorin, gemcitabine, methotrexate, bleomycin, irinotecan, camptothecin, or topotecan. AbbVie Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON 240